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Chapter One: Introduction 
1.1. Hepatitis B virus 
1.1.1. History 
Viral hepatitis was first described by Lurman in 1885, who reported the development of 
jaundice in 15% of 1,289 shipyard workers in Bremen after their vaccination with human 
derived smallpox vaccine (Fields Virology). Blumberg detected Australia Antigen, in 
1963 in serum from an Australian aborigine that reacted with an antibody in the serum of 
an American haemophiliac. Electron microscopy of sera with Australia antigen showed 
Dane particles, which are hepatitis B virus (HBV) and its surface component; hepatitis B 
surface antigen (HBsAg) (Dane et al., 1970). 
1.1.2. Classification of Hepadna Viruses 
The Hepadnaviridae family are DNA viruses infecting humans and other primates, 
rodents and avian hosts targeting the liver (fig.1-1, table1-1) (Kidd- Ljunggren; 2002). 
1.1.3. Definition of Hepatitis 
Hepatitis is inflammation of the liver tissues. This can be caused by a variety of 
aetiologies, including metabolic, toxic as alcohol, and viral infections.  Several systemic 
viral infections may affect the liver; such as cytomegalovirus, haemorrhagic fevers, and 
hepatotropic viruses; hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D  
virus, hepatitis E virus, hepatitis G virus HGV/GBV-C, and TTV (table 1-2). 
1.1.4. Hepatitis B Virus Structure 
Hepatitis B virus (HBV) is the prototype virus for the Hepadnaviridae family. HBV is a 
42 nm double-shelled particle that consists of an outer envelope of HBsAg and an inner 
core antigen (HBcAg) and DNA polymerase enzyme (fig.1-2). 
1.1.5. HBV Genome 
The genome consists of circular partially double stranded DNA. Hepatitis B viral genome 
has four open reading frames S, Core, Pol and X-genes, and four promoters; S1, S2, Core 
promoter, and X-promoter. There are two enhancer elements; Enhancer I and II (Kreutz, 
2002). The preS region is divided into Pre-S1 and Pre-S2 (fig.1-3).  
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Figure1-1: Phylogenetic tree of different human and simian HBV genotypes. HBV 
genotypes A to G, and animal hepatitis viruses infecting chimpanzee, gorilla, orangutan, 
and gibbon (Kidd- Ljunggren; 2002). 
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Table1-1: Members of the Hepadnaviridae family; infecting humans, primates as chimpanzee, gorilla, gibbon, wood- 
chuck, ground and arctic squirrel, wooley monkey, avian Hepadnaviridae, duck, heron and Stork hepatitis B virus. 
Virus Host Identity  
to HBV 
Genome 
Size ( bp)  
Remarks Surface 
Proteins 
X-gene 
I-Orthohepadnaviridae 
Hepatitis B virus HBV 
Human genotypes A-H 
Primate strains 
 
Humans 
Primates: 
Chimpanzee, Gorilla, 
orangutan (Pongo 
pygmeaeus)  
 
100%  
90%  
 
3215 
Partially 
double 
stranded 
 
Cirrhosis, HCC. 
Replicates in liver, 
kidney, pancreas and 
WBC 
 
3 
 
Present 
Gibbon HBV Gibbon > 80%    3 Present 
Woodchuck hepatitis virus WHV Woodchucks 
Marmota monax  
70%  3300 High incidence of HCC 3 Present 
Ground squirrel hepatitis virus 
GSHV 
Ground squirrels 
(Spermophilus 
beecheyi), 
Woodchucks, 
chipmunks 
55%  3300 More related to WHV 
(80%),  
HCC 
3 Present 
Arctic squirrel hepatitis virus 
ASHV 
Spermophilus parryi 
kannicotti 
  84% identity to GSHV 
and WHV 
3 Present 
Wooley monkey B hepatitis virus 
WMHBV 
Lagothrix lagotricha   hepatitis 3 Present 
II-Avian Hepadnaviridae 
Duck hepatitis B virus DHBV 
 
Geese, Pekin ducks 
 (Anas domesticus)  
 
40%  
 
3000 
Fully  
double 
stranded 
 
 
 
2: PreS1, 
PreS2 
 
Absent 
Heron hepatitis B virus HHBV German grey herons 
 (Ardea cinerea)  
  78% related to DHBV 1 PreS Absent 
Stork hepatitis B virus SHBV Stork   Related to HHBV 1 PreS Absent 
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The precore region (nt. 1814±1900) precedes the core region (nt. 1901-2449). The basal 
core promoter (BCP) (nt. 1742-1813) and regulatory sequences are essential for the 
synthesis of the pregenomic and precore mRNA, which is the template for HBV genome 
replication and control synthesis of the core protein. 
1.1.6. Structural Protein 
1.1.6.1. Hepatitis B surface antigen  
Envelope polypeptides are encoded by the combination of the pre S and S gene regions. 
The major protein of hepatitis B surface antigen (HBsAg) particles is the smallest gene 
product (SHBs) (fig.1-4). The middle protein (MHBs) contains the pre-S2/S component. 
The large surface protein (LHBs) contains pre-S1, pre-S2 and HBsAg, and is 
incorporated in intact virus particles (Reifenberg et al., 2006). In viraemic carriers, MHBs 
and SHBs products predominate in the liver, whereas in non-viraemic carriers, LHBs 
products predominate. LHBs show direct toxic or immunomodulatory effect and 
interaction with cytokines (Ayada et al., 2006) which may result in massive 
hepatocellular necrosis, regeneration and the eventual development of HCC. 
 
HBsAg (fig.1-2) is produced in excess amounts that circulate in the blood as empty 22 
nm spherical, tubular and filamentous sub viral particles. S protein and pre-S1 of HBsAg 
binds to lymphocytes and human liver cell plasma membranes associated endonexin II 
affecting virus infectivity (de Bruin et al., 1996). Pre-S2 sequences bind to polymerised 
human serum albumin (PHSA) receptors correlate with the presence of virus in serum 
and maintenance of chronic infection (Kondo et al., 2002). The `a` determinant is part of 
the major hydrophilic region (MHR) of HBsAg, comprising positions 100-169. The 
cysteine web model of MHR accounts for S-S bridges (positions 124-147) (fig.1-5) 
(Francois et al., 2001).  
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Table 1-2: Comparison of different hepatotropic viruses; hepatitis A, B, C, D, E, GBV, TTV and SEN viruses. 
Virus Family  Nucleic    
acid 
Distribution Structural 
Proteins  
Transmission I.P* Acute  
Disease 
Chronicity Mortality 
Hepatitis A 
virus 
Picorna virus 
Hepavirus 
 
ssRNA  
1ORF 
Developing 
countries 
VP1-4 Faecal-oral 15-
60d 
<5% children 
>20% adults 
No 0.1-2%  
Hepatitis B 
virus 
Hepadnaviridae Incomplet
e dsDNA 
4 ORFs 
Worldwide HBcAg 
HBsAg 
Parenteral 
vertical 
Sexual 
45-
120
d 
<5% children 
>20% adults 
>70% 
children 
<10% adults 
Acute1%  
Chronic  1-
10%  
Hepatitis C 
virus 
Flaviviridae 
Hepacivirus 
ssRNA 
1ORF 
Worldwide E1 
 (gp35) 
E2 
 (gp70) 
Parenteral 
Vertical 
2-52 
wk 
Rare up to 80 %  1-10% long 
term 
Hepatitis D 
virus 
Viroid ssRNA 
1ORF 
Mediterranian, 
Amazon 
HDAg 
 (HBsAg) 
Parenteral 3-13 
wk 
Common High 2-20%  
Hepatitis E 
virus 
Caliciviridae 
 
ssRNA 
3ORFs 
Indian sub-
continent 
ORF2 
 (ORF3) 
products 
Faecal-oral 3-9 
wk 
Common No 1-2%  
20-30% in 
pregnancy 
GB virus C 
(GBV-C)  
enveloped 
Flaviviridae 
family 
positive-
sense 
ssRNA  
Worldwide. 
6genotypes:  
1:West Africa,  
2 : Europe,  
America 
3: Asia,  
4: Southwest 
Asia,  
5 : South 
Africa  
 6: Indonesia. 
 Parenteral  No common none 
TTV Circinoviridae DNA Japan, 
worldwide 
 Parenteral  No common none 
SEN virus 2variants :SENV-
D, SENV-H 
DNA worldwide  
China 
 Parenteral  No  none 
*IP: Incubation period
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Figure 1-2: Electron micrograph of hepatitis B virus (HBV) 
showing the double-shelled virion (Dane particles), and excess HBsAg in tubular and 
spherical forms. 
 
 
Figure 1-3: HBV genome organization;  
Circular HBV genome partially double-stranded dsDNA indicated in black lines .The overlapping 
four open reading frames (ORFs)  Pre-S/S(Pink line), PreC/Core (blue), Pol (blue), and X-
genes(Beige line)(Kidd-Ljunggren et al., 2002).  
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Genome: nt. 2848                nt. 3172           nt. 155                                                    nt. 833 
Genotype: A/B/C/F               119aa              55aa                                                       226aa 
                       D                   108aa              55aa                                                       226aa   
                     G/E                 118aa              55aa                                                       226aa 
 
 
 
 
 
 
 
 
 
Figure 1-4: Pre-S/S-gene and its products;  
HBV surface gene encoding the three hepatitis B surface antigen (HBsAg) proteins shown; large 
HBsAg (LHB), middle HBsAg (MHB) and small HBsAg (SHB). Amino acid numbering restarts 
at the first methionine of each the subparts as shown in each HBV genotype. The number of 
amino acids (aa) of Pre S1 is constant at 119 in genotypes A, B, C and F, but is 108 aa in 
genotype D and 118 in genotypes E and G. The number of amino acids in Pre S2 and S-gene is 
constant in all HBV genotypes at 55 and 226, respectively. PHSA: polymerized human serum 
albumin binding site. 
 
Figure 1-5: The double loop structure of `a`determinant of HBsAg (Kao and Chen, 
2005); including the cysteines at positions 124, 137, 139 and 147 with S-S bridges (dotted lines). 
The amino acids 122 and 160 determine the HBsAg serotype as d or y and w or r respectively.  
PreS1 region            PreS2                     S-gene (684nt) 
 (357nt)   (165nt) 
pHSA 
binding site Major S-Antigen (SHB) (226aa) 
Middle S-Antigen (MHB) (281aa) 
                                        Large S-Antigen (LHB) (389-400aa) 
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1.1.6.2.   Core Proteins 
The hepatitis B core antigen (HBcAg) (25 kD) is assembled into the capsid, which is 
essential for viral packaging. Its synthesis is restricted to liver tissues, and is an important 
target for immune recognition in chronic infection. Soluble Hepatitis B e antigen 
(HBeAg) (21kD) peptide is released into the circulation, and is a reliable marker for 
actively replicating virus, and hence, for high infectivity (fig.1-6) (Wu et al., 2007). 
Seroconversion from HBeAg to anti-HBe is commonly associated with the clearance of 
wild type (wt) HBV and the resolution of acute liver disease.  
 
1.1.7. Nonstructural Proteins 
1.1.7. 1. HBV Polymerase Enzyme 
The HBV polymerase is a 56 to 70kD polypeptide. HBV polymerase has the following 
domains; the amino-terminal region; terminal protein (tp) which acts as a prime promoter 
for synthesis of the minus strand cDNA, spacer domain, the RNA-dependent DNA 
polymerase (reverse transcriptase), and the RNase H domain at the carboxy-terminus 
(fig.1-7). Mutation of polymerase affecting its activity will affect the amount of virus 
produced, as well as the number of templates available to encode viral proteins.  
1.1.7.2. X-gene 
The X gene protein (154 amino acids (aa.)) encoded by the X gene (nt. 1372-1834), 
exhibits numerous activities affecting intracellular signal transmission, gene transcription, 
cell proliferation, DNA repair, and apoptosis (Francois et al., 2001). HBx trans-activates 
and upregulates viral and cellular genes as the transcriptional expression of human 
telomerase l; reverse transcriptase (hTERT) (Qu et al., 2005), through activation of 
transcription factors, modulation of cell signalling pathways, RNA stabilization, and 
alteration of nucleocytoplasmic translocation and inhibition of serine protease activity 
(aa. 67-69 and 135-138 (Blackberg and Kidd-Ljunggren; 2003) (fig.1-7).  
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     Genotype:        Precore                        Core (start) 
             A               1814                             1901                                                                                                  (185 aa) 2455 
          B to F, H     1814                             1901                                                                                                   (183 aa) 2449    
            G               1814                             1901                                                                                                   (197 aa) 2485    
        aa                    0                               28  29                                                            
        1736-44                  1824-1834                    
 
                                             1858        G1896A 
 
(QFDSVLGDWLRQVLJQDOİ 
   1858     HBeAg (-)                                G1896A                                      183 aa 
 
 
 
 
 
 
 
                                                                                       159 aa (19-29 PC and 149 from core sequence)                    
 
 
 
 
 
Figure 1-6: The organization of the HBV core gene in different HBV genotypes.  
Starting with the core promoter (nt. 1742-1849), then the precore (PC) region (nt. 1814-1900) and the core region (1901-2449). The Direct 
Repeat (DR1) (nt. 1824-1834) is the origin of replication of the virus overlapping the precore region. The core genome length varies in 
different HBV genotypes in the core region only, but neither in the core promoter nor the precore regions. Precore mutants have stop codon 
(AUG) at G1896A in codon 28, results in HBeAg-negative phenotype (as shown by the bold arrow) CURS: Core upstream regulatory 
sequence (1645-1744) (modified from Stuyver et al., 2000). 
Core                               Pre      Precore                                                Core Gene 
Promoter 
                                                                        Structural HBcAg 
                                                 Secreted HBeAg 
DRI CURS
Signal sequence                                                   HBcAg 
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Genome: nt. 2357                          2738         3215/0  130                                                                      1162                             
1621 
 
 
Polymerase Protein (832aa) 
 
                                                                                 F       A             B     C         D        E 
rt37-47   75-91     163-189  197-210  230-241  247-257 
Genotype: A                              179aa              348 (169)                                                             692 (344)                      845 (153)   
               B/C/F                          177aa              346 (169)                                                             690 (344)                      843 (153)   
                   D                             177aa              335 (158)                                                             679 (344)                      832 (153)     
                 G/E                            177aa              345 (168)                                                             689 (344)                      842 (153)  
 
Figure 1-7: HBV Pol-gene (nt. 2357-1621). The polymerase protein has four domains;  
Terminal protein (tp), spacer region, reverse transcriptase (rt) (RNA-dependent DNA polymerase), and ribonuclease H (RNase H). The 
currently used numbering system of HBV polymerase for each genotype i.e. the total length of the protein is outlined at each domain, and 
the standardized numbering system with three starting points at tp, spacer domain and rt.  The domain`s amino acids (aa) number are 
indicated between brackets (modified from Stuyver; 2001). The rt and the RNAase H domains of the polymerase are constant in length in 
all genotypes mounting to 344, and 153 amino acids respectively. Within RT, six catalytic functional units are characterized; A, B, C, D, E 
and F are shown according to the RT numbering. 
Terminal protein (tp)     Space (169aa)   R  ever    se   tran  scriptase (rt) (344aa)          RNase H (153aa) 
Pol-gene 
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1.1.8. HBV replication 
During infection, HBV penetrates into the cells after surface binding, then the virus is 
transported into the nucleus without processing, where replication starts by unwinding 
circular DNA which is converted into a covalently closed circular DNA (cccDNA) that 
acts as a template for transcription of HBV pregenomic, and messenger RNAs (Beck and 
Nassal, 2007). 
Transcription starts from the core promoter to yield the 3.5 kb pregenomic RNA, which is 
packaged with polymerase into immature core particles, and then serves as a template for 
reverse transcription and negative strand DNA synthesis. The incomplete positive strand 
DNA is then synthesized. The mature core particles are packed into HBsAg and pre-S 
proteins in the endoplasmic reticulum then are exported from the cell (fig.1-8) (more on 
replication). 
1.1.9. Immune Responses in HBV Infections  
1.1.9.1. Humoral Immunity 
The `a`determinant epitopes in HBsAg triggers protective neutralizing antibodies that 
prevent viral spread and subsequently eliminate circulating virus. The presence of anti-
envelope antibodies denotes the resolution of acute hepatitis B (Jung and Pape; 2001). 
Their biological effects are dependent on the conformation (fig.1-5). The excessive 
production of HBsAg and the high viral replication induce immunological anergy or 
tolerance by the exhaustion of antiviral antibodies and CTLs. The virus also affects the 
immune system directly by infecting the lymphocytes.  
1.1.9.2. Cell Mediated Immunity  
Cell Mediated Immunity (CMI) is triggered by acute HBV infection yielding polyclonal 
specific cellular response (Jung and Pape; 2001) (fig.1-9). HBcAg contains also helper T 
cell epitopes (table 1-3), which might result from the diverse distribution of HLA 
antigens in different geographical areas (Jazayeri et al., 2004). HBcAg is an immunologic 
target of cytotoxic T lymphocytes (CTL), and immune recognition and elimination of  
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Figure 1-8: Hepatitis B virus life-cycle 
The enveloped hepatitis B viral particle infects the cell by binding to host cell via envelope 
protein HBsAg interaction with host receptors. Uncoating of the envelope occur and entry into 
cell releasing the nucleocapsid into the cytoplasm. HBV DNA is transported to the nucleus, 
Replication inside the nucleus proceeds via cccDNA intermediate. Transcription of cccDNA by 
RNA polymerase II produces mRNAs and pregenomic RNA. Translation of viral proteins occurs 
in the cytoplasm and assembly of the core. Envelope forms during budding through the 
endoplasmic reticulum and virus release. Pregenomic RNA is encapsidated, together with P 
protein, and reverse transcribed inside the nucleocapsid. Part of these capsids is recycled to 
amplify the pool of intracellular cccDNA and the others are enveloped and released as virions. 
(www.infekt.ch/updown/ images/hbv_cycl.gif). 
replicating HBV in chronic infection, as cytotoxicity that enhance viral clearance, and 
inhibit HBV gene expression through the secretion of antiviral cytokines. Remarkably, 
the CTLs also purge HBV replicative intermediates from the liver by secreting type 1 
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inflammatory cytokines thereby limiting virus spread to uninfected cells and reducing the 
degree of immunopathology required to terminate the infection (Chisari et al., 2010). 
HBeAg is strictly T-cell dependent (fig.1-9). Because HBcAg and HBeAg have cross-
reactive T-cell epitopes, the production of HBeAg may partially or totally block the 
cellular immune responses against HBcAg and promote virus persistence (Jung and Pape; 
2001) (table 1-3).  
Persistent HBV infection is characterized by a weak adaptive immune response, thought 
to be due to inefficient CD4+ T cell priming early in the infection and subsequent 
development of a quantitatively and qualitatively ineffective CD8+ T cell response. Other 
factors that could contribute to viral persistence are immunological tolerance, mutational 
epitope inactivation, T cell receptor antagonism, incomplete down-regulation of viral 
replication and infection of immunologically privileged tissues. However, these pathways 
become apparent only in the setting of an ineffective immune response, which is, 
therefore, the fundamental underlying cause. Persistent infection is characterized by 
chronic liver cell injury, regeneration, inflammation, widespread DNA damage, and 
insertional deregulation of cellular growth control genes, which collectively lead to 
cirrhosis of the liver and hepatocellular carcinoma (Chisari et al., 2010). 
HBV flourishes in an immunologically deprived haven. Hepatocytes present antigens 
poorly, as they do not express HLA class I and II molecules, except during inflammation. 
T-cells induce anergy upon exposure to viral antigens due to the absence of costimulation 
(Chen et al., 2005). Most activated lymphocytes die within the liver, thereby inactivating 
an essential arm of the immune response. In perinatal infections, the soluble HBeAg and 
HBxAg may cross the placenta, tolerize the immature neonatal immune system including 
the T-cells and favour the establishment of chronic HBV carrier state in 90% of cases. 
Such individuals may have high level of viraemia or clinical manifestations of chronic 
active hepatitis (CAH). Mature efficient T-cells are required to prevent chronic carrier 
state (Cacciola et al., 2002).  
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Figure 1-9: Interaction of the immune system against HBV infection  
(NK: natural killer cells; CTL: cytotoxic lymphocytes, CD4: T-helper cells and macrophages) 
(Jung and Pape; 2001).  Hepatocellular injury starts with antigen recognition by class I restricted 
HBV- specific cytotoxic T- lymphocytes (CTL) with induction of apoptosis in infected 
hepatocytes. CTL then recruit nonspecific inflammatory cells as macrophages, neutrophils, and 
lymphocytes, thereby forming necroinflammatory hepatocellular damage. 
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Table1-3: Immunological B-cell and T-cell epitopes within HBV proteins and the 
Human leucocyte antigens (HLA) activated by them (Caselmann and Koshy; 1998) 
(Kreutz, 2002) (Jazayeri et al., 2004). 
ORF Nucleotide Residues LS no. () Properties HLA 
Class 
HLA Type 
Pre S1 2878 10-17 Cytotoxic T cells Class I A11 
2878 10-19 CD4+ cells Class II DQ5 
 58-100 Viral clearance   
Pre S2  109-123(1-10) Cytotoxic T cells Class I A3 
 109-123 (1-10)  
CD4+ cells 
 
Class II DR2 
HBsAg 
Polymerase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Core 
 182-191 (20-29) Class II DPw4 
 182-196 (20-33) Class II DR2w15 
 215-260 (41-49)  
 
 
 
Cytotoxic T cells 
 
 
Class I  
 250-258 (88-96) Class I A2 
 260-269 (97-106) Class I A2 
 335-343 (172-180) Class I A2 
 348-357 (185-194) Class I A2 
 455-463 (rt 107-115) Class I A2 
 551-559 (rt 203-211) Class I A2 
 575-583 (rt 227-235) Class I A2 
 655-663 (rt 307-363) Class I A2 
 773-782 (rt 425-434) Class I A2 
 816-824 (rt 468-576) Class I A2 
1901- 1960 1-20 CD4+ cells Class II ND 
1954-1981 18-27 Cytotoxic T cells 
Conserved 
Class I A2 
1984-2041 28-47  
CD4+ cells 
Class II DR7, DP0402 / 
DP0201 
2050-2107 48-69 Class II ND 
2122-2152 74-83 HBeAg/conformation 
determinant of HBc 
antigenicity 
B cell  
2128-2167 76-89 Linear determinant of 
HBe antigenicity 
B cell  
2155-2203 84-101 CD8/Cytotoxic T cells / 
deletions 
Class I Riedl et al., 
2009) 
2221-2254 107-118 Determinant of HBc 
antigenicity 
  
2251-2293 117-131 Conserved Class II DRw52/ DR6 
2260-2317 120-139 conformation 
determinant of HBe 
antigenicity 
Class II DR1 
2278-2305 126-135 HBeAg B cell  
2323-2353 141-151 Cytotoxic T cells Class I A31/ Aw68 
ORF: Open Reading Frame  *The amino acid numbers of the large S protein are shown; 
while the amino acid numbers of the corresponding segment appear between brackets.        
nt. : Nucleotide 
   Chapter 1 - Introduction 
16 
 
Mutant HBV induces more severe immune disorders in host, resulting in the activation of 
lymphocyte and release of cytokines; TNF-alpha, IFN-gamma, IL-6 and IL-8 were higher 
in patients with severe than those in acute hepatitis B. The ratio of CD4+/CD8+ was 
higher in mutant than in wild-type HBV. Ultimately liver damage is more prominent 
(Wang and Liu; 2003). The cellular over expression of the immunogenic HBcAg in 
precore  mutants during virus replication may have direct cytopathic effect, and trigger 
vigorous T cell-mediated immune response to core that contributes to the development of 
fulminant hepatitis (Chen et al., 2003). 
1.1.10. Pathogenesis 
The interaction between viral factors as infectivity, viral replication and mutations with 
host factors as immunity, results in different disease severity and outcome (table 1-4). 
HBV is not cytopathic, hepatocellular inflammation and damage occurs, as evidenced by 
the development of clinical hepatitis and elevated aminotransferases. 
HBV viral genome integrates into multiple sites of host DNA, which may be 
accompanied by mutation in viral (and cellular) genes. The integrated template produces 
S and pre-S polypeptide that displays trans-activation properties, which may have a role 
in hepatocarcinogenesis mediated by topoisomerase (Brechot et al., 2004).  
Viral integrants may contain cis-acting sequences other than viral promoters, such as 
enhancers and glucocorticoid-responsive elements (nt. 364-374). HBV can integrate into 
retinoic acid receptors gene and cyclin A gene thereby influencing their expression. X-
gene products and other proteins provide transcriptional transactivating function, which 
interferes with cellular DNA repair processes of cells genotoxically damaged (fig.1-10) 
by environmental agents like aflatoxin. At the same time, the inhibition of p53 by HBx 
would allow regeneration of liver cells and inhibit apoptosis of DNA damaged cells. In 
this way, mutations would be allowed to accumulate, eventually leading to malignant 
transformation of the hepatocytes. HCV carcinogenesis develops through different 
mechanisms (fig.1-10).  
1.1.11. Clinical Picture 
Hepatitis B virus can cause a variety of liver diseases including acute and chronic 
hepatitis, cirrhosis, and hepatocellular carcinoma. 
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1.1.11.1. Acute infections:  
After an incubation period of six weeks to six months, which is inversely proportional to 
the infective dose of the virus. The spectrum of the acute infection varies from mild to 
severe attacks. Clinically, acute infections manifest by fever, anorexia, nausea, malaise, 
vomiting, jaundice, dark urine, clay coloured stools, and abdominal pain. 1 to 2 % of 
acute disease results in fulminant hepatitis, with a case fatality ratio of 63 to 93 % 
(Bracho et al., 2006). Viraemia may reach up to 1010  virions per ml. HBV replicates in 
extrahepatic tissues, and particularly in peripheral blood mononuclear cells (PBMCs), 
which may serve as a reservoir for the maintenance of infection (Mazet-Wagner et al., 
2006). Extra-hepatic manifestations of HBV infection occur in acute cases, and less 
frequently in chronic mild infections. The symptoms include fever, symmetric arthralgia, 
arthritis, urticaria, haematological abnormalities as lymphocytosis, mild or aplastic 
anaemia, and thrombocytopenia, as well as bradycadia, hypertension, pleural effusions, 
and respiratory infections, vasculitis, polyarteritis and glomerulonephritis. Less 
frequently neuropsychatric manifestations are encountered as depression, insomnia and 
headache (Fileds Virology; 2005). Acute exacerbations of infection may develop in 
chronically infected patients (table 1-5). 
1.1.11.2.   Chronic Hepatitis B:  
Chronic HBV infection (CHB) may present in one of the four phases of infection: 
immune tolerance, immune clearance HBeAg-positive chronic hepatitis B, inactive 
carrier state, and reactivation (HBeAg-negative CHB). Chronic HBV carriers as defined 
by the persistence of HBsAg for more than six months or the absence of anti-HBc IgM 
antibodies. Chronic liver inflammation may occur with abnormal levels of liver enzymes. 
Such carriers have initial high levels of viraemia that decline gradually become 
undetectable after years or decades (fig.1-11). 
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Figure 1-4: Hepatitis B virus virulence factors and host factors, their interaction 
affect the clinical presentation, progression and outcome of infection. 
Viral Virulence Factors Host Factors 
Immune escape mutants: Age at infection 
Vaccine escape mutants Immune status 
Altered surface protein,  
 T-cell epitopes and CTL- epitopes 
Tolerance 
Precore mutants Coinfection with HCV, HIV etc. 
Viral genotypes  Nutrition 
HBsAg serotypes  Alcohol and hepatotoxins 
Viral persistence  
Viral integration into host genome  
Occult or silent infection.   
 
 
Table 1-5: Causes of acute flares and reactivation in chronic hepatitis (Kao; 2002). 
Aetiology of Acute Flares in Chronic Hepatitis B 
Spontaneous reactivation of chronic hepatitis B 
Reactivated hepatitis due to immunosuppressive medications 
         Cancer chemotherapy 
         Antirejection drugs 
         Corticosteroids 
Resulting from antiviral therapy 
         Interferon 
         Nucleoside analogues 
         Corticosteroid withdrawal  
Induced by HBV genotypic variation 
          Precore mutant 
          Core promoter mutant 
          HBV DNA polymerase mutant 
Due to superimposed infections with other hepatotropic viruses 
          Hepatitis A virus 
          Hepatitis C virus 
          Hepatitis delta virus 
Caused by interaction with HIV infection 
          Reactivated hepatitis 
          Effect of immune reconstition therapy 
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Figure 1-10: Mechanism of HBV and HCV-mediated carcinogenesis.  
In the cytoplasm, HBx transactivates several cytoplasmic signaling pathways. Which include 
protein kinase C (PKC), JAK/STAT, PI3K, stress-activated protein kinase (SAPK)/c-Jun NH2-
terminalkinase (JNK), ras-raf-MAPK, and reactive oxidative intermediate (ROI)-dependent 
mechanisms to stimulate gene expression through activator protein-1 (AP1), AP-2, nuclear factor-
țB (NF-țB), Smad and Wnt, and by binding to nuclear transcription factors, including cAMP 
response element binding (CREB), activating transcription factor 2 (ATF-2), Oct-1 and TATA 
box binding protein (T BP). UGT1A1, UGT2B10 and GPX2 expression was preferentially 
repressed in HBV-HCCs, but not  HCV-HCCs. E-cadherin and GSTP1 were preferentially 
methylated in HBV-HCC compared with HCV-HCC (Su et al., 2007). TNF-Į-863A genotype, 
IL-1B-511C allele, C-A haplotype of IL-10 gene andXRCC1 Gln allele at codon 399, í509CĺT 
polymorphism in the TGF-ȕ1 gene promoter are all associated with HCC in chronic HBV 
carriers. HCV increased expression of genes encoding phase I enzymes CYP2E, AKR1C4, 
EPHX1 and FMO3 exclusively in HCV positive HCCs (Tsai and Chung, 2010) 
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Figure 1-11: Serological markers in chronic HBV infection.  
After the incubation period of 4 to 6 weeks, HBsAg and HBeAg start to increase and persist for 
more than 6 months. HBeAg seroconversion to anti-HBe occurs later during the course of 
disease.  
 
 
 
Table1-6: Risk groups for HBV infections 
Individuals at increased risk of HBV infection 
Family contacts of HBV infected individuals 
Infants born to HBV infected mothers 
Institutionalised individuals (e.g., prisoners, mentally  handicapped) 
Health care and public safety workers 
Recipients of multiple blood transfusions 
Haemodialysis patients 
Infants and children  of immigrants from areas with high rates of HBV 
infection 
Individuals with multiple sexual partners 
Sexual contacts of infected person 
Homosexual males 
Parenteral drug abusers                
>6 months Years 
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The risk of developing chronic infection varies inversely with age and is highest (up to 
90%) in infants infected in the perinatal period. Between 25 and 50% of children infected 
between 1 and 5 years, and 6 to 10% of acutely infected older children and adults become 
chronically infected and 33 to 50% of adults are symptomatic. The risk of developing 
chronic infections is increased by host factors as renal failure, HIV infection and diabetes 
(Mphahlele et al., 2006).  
Chronic hepatitis B infection substantially predisposes to complications such as chronic 
liver disease, cirrhosis and hepatocellular carcinoma (fig.1-12). Death occurs in 15-25 % 
of chronically infected persons. Up to 25% of persons acquiring HBV as infants and 
young children develop either cirrhosis or HCC, compared to 15% of young adults who 
acquire chronic HBV infection. Histologically, liver biopsy shows chronic persistent 
hepatitis, chronic active hepatitis, and cirrhosis (Ahn et al., 2005). Approximately 0-10% 
of infected individuals become chronic carriers of HBV. Chronic carriers are 
symptomless, but may have histological evidence of hepatocellular damage from mild 
inflammation to cirrhosis and hepatocellular carcinoma HCC. 
1.1.11.3.   Hepatocellular Carcinoma: 
Hepatocellular carcinoma (HCC) is one of the 10 most common cancers in man.  The 
annual incidence is 250 000 worldwide. Risk factors are; HBV and HCV infections 
especially those acquired early in life or after prolonged course, cirrhosis, male sex, 
aflatoxin and smoking, peak incidence in 30-50 year age group. The relative risk of 
developing HCC is over 200-fold for HBsAg carriers over matched controls. Whilst most 
HCC arise in cirrhotic liver, this is not always the case (Liu et al., 2006). 
1.1.12. Epidemiology 
Approximately 5 % of the world`s population reaching 350 millions, have chronic HBV 
infection, which is the leading cause of chronic hepatitis, cirrhosis and HCC worldwide. 
It is estimated that 500, 000- to 1000, 000 persons die annually from HBV related liver 
disease (Hou et al., 2005). Most infections occur at birth or during early childhood. 
Infections usually cluster in households of chronically infected patients. 
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Figure 1-12: Clinical outcome of HBV infection
 
Acute 
Hepatitis 25%  
Subclinical 
Infections 65%  
 
Acute HBV 
Infection 
Cirrhosis 
10-30%  
Chronic 
Hepatitis 
Hepatocellular 
Carcinoma Dysplasia 
 
Death 
 
Resolution 
Chronic 
Infection 10%  
Fulminant 
Hepatitis 1%  
Asymptomatic 
Chronic Carrier 
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1.1.12.1.  Geographical Distribution 
Areas of high endemicity where prevalence is > 8% are China, Indian subcontinent and 
Africa. Intermediate endemicity areas show prevalence of 2 to 7 % in North Africa, India 
and Russia. Low endemicity < 2 % seen in Western Europe and North America (Fig. 4-
3). In areas of high endemicity, the lifetime risk of HBV infection is > 60 % . 
1.1.12.2.  Routes of Transmission 
Transmission of HBV is by percutaneous route or mucosal exposure to infectious body 
fluids, sexual contact or perinatally from infected mothers.  HBV is highly infectious, 
especially in HBeAg positive individuals, up to 50 to 100 times more infectious than 
HIV. Risk groups for contracting HBV are listed in table 1-6.  
1.1.12.3.  Vertical Transmission 
HBeAg among pregnant women increases the risk of perinatal infections up to 70 to 90% 
in the absence of immunoprophylaxis, whereas only 5 to 20 % of infants born to HBsAg 
positive and HBeAg negative mothers become infected (table 1-6). Postnatal early 
childhood transmission is also common in endemic areas. 
1.1.13. Diagnosis 
The development of sensitive and specific tests to detect HBV infections allowed the 
study of its natural history and epidemiology to prevent its transmission.  
1.1.13.1.  Serological Tests 
Serological tests are the main stay of diagnosing and differentiating the various viruses 
causing hepatitis, and for blood bank screening, as they are quick, cheap, and detect 
HBsAg carriers. Acute HBV is characterized by the presence of HBsAg in serum and the 
development of IgM core antibodies (anti-HBc IgM), which may be the only marker in 
active hepatitis, and it correlates with inflammatory activity. In the convalescent stage, 
HBsAg and HBeAg are cleared with the development of anti-HBs, anti-HBe and anti-
HBc antibodies. Anti-HBs is also elicited by vaccine.  
In chronic HBV infections, HBsAg generally persists for life. Total anti-HBc tests for 
both IgM and IgG antibodies to HBV core protein, they indicate current or past infection 
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by HBV respectively. IgM anti-HBc disappears six months after the acute infection. The 
IgG anti-HBc appears shortly after HBsAg in acute disease and persists for life (fig.1-13). 
Different methods  exist for detection of HBsAg as immunodiffusion, reverse passive 
haemagglutination assays, and the more sensitive enzyme linked immunoassays ELISA 
and radioimmunoassays with detection limit of = > 0.1 ng /ml of HBsAg. 
Ordinary serological tests may not detect mutant HBsAg and would therefore give rise to 
false negative results. New immunoassays are designed for the detection of hepatitis B 
surface escape mutants, and are specifically useful in the monitoring of liver transplant 
recipients on HBIG prophylaxis (Ijaz et al., 2001).   
 
1.1.13.2. Molecular Biology Techniques 
Different molecular techniques have been used to detect HBV DNA (table 1-7). HBV 
DNA is detectable in serum by slot or dot blot hybridization assays (Shao et al., 2007) 
with detection limit of 1.5 pg per ml (4.0 x105 genomes/ml). PCR detects 103 pg /ml 
(approximately 100 to 1000 genomes). However, the high sensitivity of PCR is limited 
by the increased risk of false positive results. Clinical significance of HBV PCR is the 
same as detection of HBsAg and indicates current HBV infection. HBV DNA monitoring 
and quantitative PCR are essential in determining the response and follow up of chronic 
HBV infection to treatment. Nucleic acid sequence analysis is used to identify genetic 
variants of the virus, and to epidemiologically type nosocomial transmission of HBV 
(Gunson et al., 2006).  
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Figure 1-13: Serological, virological and clinical patterns of chronic hepatitis B infection 
(Jung and Pape; 2002). 
 
 
Figure 1-14: Four possible sites of action of lamivudine in HBV replicative cycle; 
(1) inhibit reverse transcriptase enzyme, (2) inhibits DNA polymerase, (3 and 4) inhibits 
cccDNA formation cell entry and in replication (Yuen and Lai, 2001). 
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1.1.14. Treatment 
1.1.14.1. Clinical Management 
Supportive and symptomatic therapy is the mainstay of management of acute HBV 
infections. Interferon is an immunomodulatory cytokine that increases the expression of 
HLA class-I molecules, thereby increasing the cytotoxic lymphocytes (CTL) elimination 
of virus infected cells. It aims to clear markers of HBV replication, and to improve the 
liver disease by normalization of alanine aminotransferase (ALT) levels and liver 
histologic changes (Hannoun et al., 2002). 
Several drugs are used in different combination to treat hepatitis B infections. As in cases 
of active viral replication, high viral load, and HBeAg positivity, elevations in serum 
aminotransferases, persistent HBsAg, chronic hepatitis and compensated liver disease 
(table 1-9). The mainstay of therapy in chronic hepatitis B is inhibition of the replicative 
cycle of HBV in hepatocytes, aiming at complete suppression of serum HBV DNA using 
reverse transcriptase inhibitors as lamivudine (3`-thiocytidine) (fig.1-15). (Yuen and Lai 
2001). Viral breakthrough, defined as an abrupt or continuous increase in serum HBV 
DNA levels after a period of persistent suppression, occurs with non compliance to 
therapy or lamivudine resistant mutants (Kennedy et al., 2008). 
1.1.14.2.  Immunoglobulins 
Blood with anti-HBs was used for the preparation of hepatitis B immune globulin 
(HBIG), which was effective in preventing or modifying the course of HBV infections 
(table 1-9), and as post-exposure prophylaxis (table 1-10).  
1.1.15. Prevention 
1.1.15.1. Virus Inactivation 
The immunogenicity and antigenicity of HBsAg are retained after exposure to ether, acid, 
and heat, while the virus is inactivated by boiling for two minutes, autoclaving at 121oC 
for 20 minutes, or dry heat at 160oC for one hour as well as sodium hypochlorite 0.5% for 
10 minutes, 0.1 to 2% gluteraldehyde, and 70% isopropyl alcohol for 2 minutes.  
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Table 1-7: Comparison of molecular techniques for the diagnosis of HBV 
Dot blot hybridisation Branched DNA  assay 
(bDNA) 
Polymerase chain 
reaction (PCR) 
Quantitative real-time 
PCR 
Monitoring antiviral 
therapy 
Easy for bulk testing Monitoring antiviral 
therapy 
Monitoring antiviral 
therapy 
Less sensitive than PCR Less sensitive than 
PCR 
Little correlation with 
disease activity 
Little correlation with 
disease activity 
Detect 105 copies/ml 
(0.1-1pg) 
Detect 2.5-3.5x105 
copies/ml 
Detect 102 copies/ml Detect 12IU/ml 
Qualitative  Semiquantitative  Prone to contamination Less contamination 
 
 
Table 1-8: Current or proposed therapeutic agents for chronic HBV infection (Yuen 
and Lai 2001). 
Category Agents 
Immunomodulators Interferon alfa (recombinant, pegylated) 
Thymosin alfa1 
Levamisol 
Passive Immunity hepatitis B immunoglobulins HBIG 
Antiviral Agents  
A. Nucleoside/nucleotide 
Analogues 
Lamivudine 
Adefovir dipivoxil 
Tenofovir 
Entacavir 
Emtricitabine 
Beta-L-2`-deoxythymidine 
Famciclovir 
B. Glycosylation Inhibitors Inhibit viral assembly 
C. Gene Therapy Antisense, ribozyme, targeted drug delivery, etc. 
    IV.  Combination Therapy Lamivudine  plus Interferon alfa 
Lamivudine plus therapeutic vaccines 
Steroid priming followed by Lamivudine  or Interferon alfa 
Lamivudine  plus famciclovir or adefovir dipivoxil 
    V.   Therapeutic Vaccines PreS/S vaccines (preS2, preS1) 
Core lipopeptide 
HBs-DNA vaccine 
HBsAg-anti-HBs antibody complex 
CTL epitope vaccine 
Cell based: Adoptive immune transfer 
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Table 1-9: Strategies to prevent HBV transmission: 
Extended program of childhood immunization (EPI) 
HBV vaccination of risk groups and health care workers 
Standard precautions against blood and body fluids 
Proper use and disposal of sharps  
Screening of blood and organ donors 
Monitoring of haemodialysis patients 
Screening of pregnant mothers 
HBIG and vaccination at birth to infants of infected mothers 
Avoid sharing of personal items as razors and tooth brushes 
Care with tattoo and body piercing as potential source of infection 
Avoid sharing of needles in IV drug users 
Use of condoms and safe sex practice 
 
Table1-10: Indications of Hepatitis B immunoglobulins (HBIG) 
Infants of HBsAg positive mothers 
Percutaneous or mucus membrane exposure to HBsAg positive blood or body fluids 
Sexual exposure to HBsAg positive person 
Protect patients from severe recurrent HBV infection after liver transplantation  
 
Table 1-11: HBV Prophylaxis for Reported Exposure Incidents 
 
HBV status of person 
exposed 
Significant Exposure (Source Patient) Non- significant Exposure 
HBsAg* Positive Unknown 
source 
HBsAg 
negative 
Continued 
risk 
No further 
risk 
=<1dose HBV vaccine pre-
exposure 
Accelerated HBV 
vaccination**,  
HBIG x 1 
Accelerated 
vaccination 
Initiate HBV 
vaccination 
Initiate 
HBV 
vaccination 
No HBV 
prophylaxis 
Reassure 
=<1dose HBV vaccine pre-
exposure 
 (anti-HBs not known) 
Two doses of 
vaccine one 
month  apart 
One dose of 
vaccine 
Finish course 
of vaccine 
Finish 
course of 
vaccine 
No HBV 
prophylaxis 
Reassure 
Known responder to HBV 
vaccine 
 (anti-HBs>10miU/ml) 
Consider booster 
dose of vaccine 
Consider 
booster dose 
of vaccine 
Consider 
booster dose 
of vaccine 
Consider 
booster 
dose of 
vaccine 
No HBV 
prophylaxis 
Reassure 
Known non-responder to 
two full courses of vaccine 
(anti-HBs>10mIU/ml) 1-2 
months post immunization 
HBIG x2 one 
month apart 
HBIG x2 one 
month apart 
No HBIG No HBIG No HBV 
prophylaxis 
Reassure 
Known non-responder to 
one full course of vaccine 
(anti-HBs>10miU/ml) 1-2 
months post immunization 
HBIG x 1, Start 
the second full 
course of vaccine 
Exclude HBV 
infection as the 
cause of non-
responsiveness 
HBIG x 1, 
Start the 
second full 
course of 
vaccine 
No HBIG 
Start the 
second full 
course of 
vaccine 
No HBIG 
Start the 
second full 
course of 
vaccine 
No HBV 
prophylaxis 
Reassure, 
consider a 
second full 
course of 
vaccine 
* Accelerated HBV vaccination consists of doses spaced at 0, 1, 2, and 12 months 
Modified from CDR Review 1992:2; R97-R101, PHLS Hepatitis Subcommittee (CDC; 2001).   
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HBV retains its infectivity when stored at 4oC for six months and when frozen at  ±20oC 
for 15 years (Fields Virology; 2005) 
1.1.15.2. Infection Control 
Nosocomial transmission of HBV has occurred in several situations in medical care 
settings (Kramer et al., 2006). Characterization of HBV strains by subtype or genotype 
has been used to detect the prevalent strains, and to investigate chains of nosocomial 
infection. Haemodialysis is a recognized risk procedure for nosocomial HBV 
transmission (Kondili et al., 2006), although this problem has been largely controlled by 
the introduction of prolonged HBV vaccination schedule to haemodialysis patients. 
Guidelines recommend the institution of infection control practices specifically designed 
for the haemodialysis setting, including routine serologic testing, surveillance and 
education and training of staff to reduce the opportunities for patient-to-patient 
transmission of infectious agents directly or indirectly via contaminated devices, 
equipments and supplies, environmental surfaces and hands of personnel (CDC; 2001).    
1.1.15.3.   Immunoprophylaxis 
Passive immunization with neutralizing anti-HBs may provide protection from acute 
clinical hepatitis B and chronic HBV infection if given soon after the exposure. HBIG is 
prepared by Cohn Onely fractionation procedure from serum containing high titres of 
anti-HBs, and is standardized to 100, 000 IU of anti-HBs per ml. HBIG has several 
indications (table 1-11), and is used in combination with HBV vaccine to prevent 
perinatal infection in infants born to HBsAg positive mothers. 
 
1.1.16. Accidental Exposure/Needle Stick Injury 
In health care settings, significant exposure to HBV infected or suspected source carries a 
risk of transmission of the infection. Several guidelines have been published to handle 
such situations and to minimize the possibility of transmitting the infection (table 1-12). 
(Guidance for Clinical HCW prophylaxis in UK: Protection against Infection with blood 
borne viruses. www.open.gov.uk/doh/chcguid1.htm) 
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Table 1-12: HBV Prophylaxis for Reported Exposure Incidents Groups for whom 
hepatitis B immunization is recommended 
 
 
A. Professional Risk:  
I- Staff in: Renal dialysis facilities 
Clinical laboratories 
Mental handicap hospitals 
Infectious diseases units 
Sexually transmitted diseases units 
Oral surgery departments 
Accidents and emergency departments 
Operation rooms, delivery rooms 
Ambulance/police /prisons personnel 
General hospitals: offered to all medical/ nursing disciplines dealing 
with hazard situations, e.g. needle stick exposure 
B. Contact Risks:  
I-Patients In adult institutions 
In mental handicap hospitals  
Before  haemodialysis programmes  
Before  organ transplantation   
Before multiple transfusion of blood or blood products 
Household and sexual contacts of known HBsAg patients 
Household and sexual contacts of known HBsAg carriers 
Intravenous drug abusers 
II-Infants Of infected mothers, particularly where these women are HBeAg 
positive 
All infants in high risk areas 
III- Individuals International travellers to endemic areas 
Refugees 
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1.1.17. Vaccines 
HBV vaccine is safe, immunogenic even in neonates, highly effective, and is the first 
vaccine that prevents cancer. HBV vaccine contains highly purified HBsAg, generated 
from either plasma or recombinant plasmids containing the S gene with or without the 
pre-S1 and/or preS2 gene.  
 
The development of anti-HBs antibodies: titres of >10 mIU per ml are 100% protective 
against clinical illness and chronic infection. Two-dose vaccine is introduced by the 
:+2WRIDFLOLWDWHDGROHVFHQW¶VFRPSOLDQFH2WKHUKRVW IDFWRUVDIIHFWLQJ WKHUHVSRQVH WR
vaccine are age, smoking, obesity, chronic disease, dialysis, and HIV infection. 
Vaccination against HBV is recommended to several risk groups preferably before 
exposure to the virus (table 1-13). A booster dose of vaccination and doubling of vaccine 
dose might be required in the second decade after vaccination, especially in 
immunosuppresed, haemodialysis and liver transplant patients (Gunther, 2006).  
The new DNA vaccines provide a vaccination strategy that is less expensive and easier to 
produce than antigenic proteins.  In addition DNA immunization induces a strong CTL as 
well as T-helper and antibody response to the expressed proteins (Mancini-Bourgine et 
al., 2006), which is directed against expressed and processed viral epitopes. 
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Chapter Two: Occult HBV Infection  
2.1. Introduction 
Occult hepatitis B infection (OBI) has been referred to as `inapparent hepatitis B virus 
(HBV) infection` and `serologically silent hepatitis B`(Raimondo et al., 2007). In 2008, 
the European Association for the study of the liver (EASL) defined OBI as the "presence 
of HBV DNA in the liver (with detectable or undetectable HBV DNA in the serum) of 
individuals testing HBsAg-negative by currently available assays" with or without the 
presence of anti core (anti-HBc) and/or anti-HBs antibodies (Ocana et al., 2011) (fig.2-1, 
table 2-1). 
 
OBI may have underlying liver disease indicating that viral replication may result in 
hepatocellular injury. OBI is associated with low HBV DNA levels and higher immune 
responses (Allain et al., 2009). HBV reactivation may appear upon immunosuppression 
or exposure to chemotherapy (Leaw et al., 2004), and can transmit the virus through liver 
transplant (Shetty et al., 2008). 
Several possibilities were hypothesized as the mechanisms of OBI infection including 
mutations or integration of HBV DNA into host's chromosomes or as episomal DNA, 
formation of immune complex containing HBV, altered host immune response or 
interaction of HBV with other viruses. The mean percentage of HBV-infected 
hepatocytes was significantly lower in patients with OBI than in HBsAg chronic carriers. 
Patients with chronic hepatitis B have HBV DNA in their peripheral blood mononuclear 
cells (PBMCs) while this occurred less in cases with OBI (Mazet-Wagner et al., 2006).  
 
Different clinical situations have been associated with OBI (table 2-1). OBI may follow 
recovery from infection, displaying anti-HBs and persistent low-level viraemia, escape 
mutants undetected by the HBsAg assays, or healthy carriage with anti-HBe and anti-
HBc. Over time, in the latter situation, anti-HBe and, later, anti-HBc may become 
undetectable, but in most cases the explanation is probably the low level of viral 
replication (Jeantet et al., 2004).  
 Chapter 2-Occult Hepatitis B Infection 
33 
 
 
Figure 2-1: Serological profile and viral DNA in occult HBV infections (Thorbinson 
and Thomas; 2002). 
Table 2-1: Anti-HBc states 
Different clinical presentations showing their hepatitis markers and HBV viral loads 
(Torbenson and Thomas, 2002). 
 Clinical State Anti-HBs Anti-HBe Anti-HBc HBsAg HBeAg HBV DNA 
Early window phase - - + IgM + -/+ + 
Late HBV immunity + + + - - - 
Unresolved HBV 
infection 
- - + + + +, >105 
copies/ml 
Low grade chronic 
infection 
- -/+ + + +/- +, >105 
copies/ml 
Asymptomatic carriers - + + +/- - +, <105 
copies/ml 
OBI -/+ -/+ -/+ - -/+ +, <103 
copies/ml 
 
Table 2-2: Clinical groups at risk for occult hepatitis B (Torbenson and Thomas, 2002) 
Clinical group OBI prevalence DNA 
concentration 
Chronic HCV with hepatocellular carcinoma High >50%   
Liver transplant recipients from core antibody 
positive donors 
High >50%   
Chronic hepatitis C, positive for anti-HBc Moderate 10-49%   
Cryptogenic cirrhosis/advanced fibrosis Moderate 10-49%   
Intravenous drug users Moderate 10-49%   
HIV, positive for hepatitis B core antibody Moderate 10-49%   
Routine blood donors Low <10%  2.2pg/ml 
HBsAg-negative mutants   
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OBIs carry the potential risk of HBV transmission in immunocompromised individuals as 
HIV (Nebbia et al., 2007), haemodialysis (Jain and Nijhawan; 2008), cancer 
chemotherapy and liver transplantation, or bone marrow transplant recipients (Shetty et 
al., 2008). In immunocompetent recipients, there is no evidence that anti-HBc antibody 
positive blood with anti-HBs antibody even at low titre, are infectious. Second, it may 
serve as the cause of cryptogenic liver disease, and contribute to acute exacerbation of 
chronic hepatitis B or chronic HCV. Third, it is associated with development of 
hepatocellular carcinoma. Fourth, OBI may affect disease progression and treatment 
response of chronic hepatitis C (Raimondo et al., 2007). 
Clinicians should consider testing for OBI in certain situations for diagnosing and 
management of such cases as flares of OBI can occur and are treatable (table 2-2). OBI 
should be suspected in patients with risk factors in whom immunosuppression is 
expected, refugee and pregnant women in endemic areas. Also in patients with 
unexplained active liver disease; either unexplained elevations in liver enzymes or 
cirrhosis or with isolated anti-HBc in whom the presence of OBI would affect the clinical 
decisions such as suitability for organ donation. Other risk groups of OBI are HBV 
vaccination non-responders and patients with HCV resistant to interferon or ribavirin 
therapy or with rapid progression of liver disease (Rodriguez-Torres et al., 2007). OBI 
may contribute to the unfavourable IFN response in chronic HCV by down regulation of 
IFN receptor gene expression in the liver (Fukuda et al., 2001). Patients with anti-HBc 
antibodies might develop immune tolerance against HCV, with less advanced hepatolysis 
and necroinflammation even in the presence of HCV viraemia with sustained ALT 
normalization. 
Prevalence of OBI depends on the prevalence of HBV in a population, and the prevalence 
of immunosupressed subjects particularly among individuals coinfected with HCV or 
HIV (Mphahlele et al., 2006). Screening of HIV-infected patients for OBI may have 
implications in terms of antiretroviral therapy and risk of immune reconstitution-
associated flares (Shire et al., 2004). 
 
The frequency of OBI diagnosis depends on the relative sensitivity of both HBsAg and 
accuracy of HBV DNA assays. It also depends on the prevalence of HBV infection in the 
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population. Anti-HBc antibodies estimation is recommended before HBV vaccination, in 
blood donors, organ donations especially Liver donors, and in relevant clinical situations. 
Confirmation of OBI is by HBV DNA testing, and monitoring of ALT elevation (Li et 
al., 2007). 
2.2. Aim 
The aim of occult HBV study is: 
To detect the presence and prevalence of HBV DNA in anti-HBc positive blood donors 
from Saudi Arabia, and to evaluate the safety of anti-HBc-positive blood.  
To check whether OBI is related to specific HBV genotypes or is host determined  
To evaluate HBV infection in asymptomatic individuals as a control group to the liver 
disease group studied in next chapters. 
To evaluate the prevalence of OBI in hepatitis C virus (HCV) patients in Saudi Arabia. 
To investigate the prevalence of OBI in hepatocellular carcinomas in Saudi Arabia. 
2.3. Patients and Blood Donors 
2.3.1. Patients 
5 groups of Saudi individuals were studied 
Group-I :consisted of sera collected from 199 voluntary Saudi blood donors HBsAg-
negative and anti-HBc IgG antibodies positive tested during the time period March 2002 
to June 2005. Donors filled questionnaires for history of liver disease, previous tattooing, 
transfusions or drug addiction, to exclude risk factors for blood-borne infections. Those 
were divided into two subgroups 
Ia : 104 anti-HBs antibody positive  
Ib : 95 anti-HBs antibody negative 
Group-II: 30 HBsAg-positive and anti-HBc IgG positive Saudi blood donors 
Group-III: 250 Saudi blood donors negative for HBsAg, anti-HBc IgG and anti-HBs as 
control.  
Group-IV: Hepatitis C patients. Serum samples were collected from 25 Saudi cases with 
positive HCV antibodies, anti-HBc antibodies positive and HBsAg negative. Inclusion 
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Group-V: Hepatocellular carcinoma: Liver biopsies were obtained from 15 Saudi 
patients with hepatocellular carcinoma to test for HBV DNA. All were HBsAg negative, 
four were anti-HBc positive. 
2.3.2.    Serological Tests 
Serum samples were tested for HBsAg, total anti-HBc antibody, antibody to hepatitis C 
virus, HIV antibodies and P24, HTLV antibodies by ELISA technique using Murex kits. 
Negative and positive controls were included. Cutoff levels were calculated according to 
kits instructions.RPR was also done. All the HBsAg negative with anti-HBc positive 
units were checked for anti-HBsAg antibodies.  
2.3.3.    DNA Extraction from Sera 
DNA was extracted from 200µl serum by QIAamp kits (Qiagen) into 100 µl sterile water 
(Sigma). 
2.3.4.    DNA Extraction from archival material 
Liver biopsy archival specimens were cut into 3mm thick sections collected from each 
paraffin wax block in a microtube. A small section (not more than 25mg) of paraffin-
embedded tissue was placed in a 2ml micro-centrifuge tube containing 1200µl of xylene, 
and vigorously vortexed. The tissue was then pelleted by centrifugation at 13000 rpm 
(10000 x g) for 5 minutes at room temperature. The supernatant was removed by 
pipetting, and the pellet washed twice with 1200µl absolute ethanol (100%) to remove 
any residual xylene. The pellet was then incubated at 37°C for 15 minutes in order to 
evaporate the ethanol. DNA was extracted with the QIAmp DNA tissue kit (Qiagen) 
DFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV'1$ZDVPHDVXUHGE\VSHFWURSKRWRPHWU\ 
2.3.5.    Amplification of Precore/core Gene 
Amplification of the core promoter region of genomic HBV DNA by the Polymerase 
Chain Reaction (PCR), using primers PC1 and PC3 (De Castro et al., 2001) (table 2-3). 
The standard PCR mixture contains 0.15µl of hot start Taq polymerase (Qiagen), 
5pmolof each primer (MWG-Biotech Ltd), 2.5µl 10x buffer (containing 15mMMgCl2, 
Qiagen), 100nM of each of four deoxyribonucleoside triphosphates (dNTPs) (Roche) and 
2µl DNA template giving a total volume of 25µl in sterile distilled water (Sigma). 
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Positive and at least 3 negative controls were included in each run.  The amplification 
started with 95oC for 10 minutes; cycle conditions were shown in table: 2-4 (PT-200 
Peltier Thermal Cycler). 4µl of PCR products (296 bp) were loaded into a 2% agarose gel 
(Helena Biosciences). Electrophoresis was done at 90 Volts, then stained with ethidium 
bromide and visualized under UV light. 
2.3.6.    Nested Core PCR 
Amplification of core gene was done using a modified semi-nested PCR. The outer 
primers were C1 and C2 (Kurosaki et al., 1996). The standard PCR reaction mix was as 
described in precore PCR. Primer sequences are shown in table 2-3.  Product size was 
374 bp. The second PCR was done using the inner primers: C3 (sense) and C2 (antisense) 
and 2µl of the first reaction products per tube under the conditions specified in table 2-4; 
the product size was 364 bp. 
2.3.7.    Extended Core PCR 
Amplification of core gene was done using a modified PCR. The outer primers were C1 
(Kurosaki et al., 1996) and PC3. The standard PCR reaction mix was the same, under the 
following conditions: 95oC for 10 minutes, then 50 cycles of 94oC for 1 minute, 60oC 
for 1 minute, 72oC for 3 minute. The product size was 475 bp. 
2.3.8.    Amplification of Surface Gene 
The surface gene (S-ORF) from genomic HBV DNA was amplified by nested PCR 
(Fagan and Harrison; 1994) using the following outer primers: HBV-S1and HBV-S2 
under the following conditions; 95oC for 10 minutes, then 40 cycles of 94oC for 1.5 
minutes, 47oC for 1.5 minutes and72oC for 3 minutes. A final extension was done for 7 
minutes at 72oC. The product size was 359 bp. 
The second PCR was done using the inner primers: HBV-S3 and HBV-S4. Standard 
reaction mix have the same other components as first round PCR and 2µl first round PCR 
product giving a total volume of 25µl. The PCR conditions were as follows; 95oC for 10 
minutes, then 40 cycles of 94oC for 1.5 minutes, 45oC for 1.5 minutes, 72oC for 3 
minutes. The product size was 294 bp. 
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2.3.9.    Short PCR of S-gene  
Amplification of the S-gene was done as previously described (Brechtbuehl et al., 2001). 
The 25 µl PCR mixture contains 5 pmol of each primer HBVfr (sense nt. 376-395) and 
HBVrv (antisense nt. 656-637) (primers from MWG-Biotech Ltd) and 2µl DNA. The 
PCR conditions were shown in table 2-4. These primers were also used for real-time 
PCR. The product size was 281 bp. 
2.3.10.    RFLPs PCR 
Using PCR to amplify conserved region in the S-gene, a seminested PCR (Mizokami et 
al., 1999) was performed with the first-round sense primer F1 and antisense primer R2, in 
standard master mix. The thermal cycler program was 95oC for 10 minutes; followed by 
40 cycles of 94oC for 15 seconds (denaturation), 60oC for 45 seconds (annealing) 72oC 
for 45 seconds (extension); followed by further extension at 72oC for 7 minutes. The 
product size was 676 bp. The second round inner sense primer F3, and the antisense 
primer R2were amplified under the same conditions. The product size was 492 bp. 
2.3.11      HBV Multiplex Genotyping PCR 
See genotyping chapter. 
2.3.12.    Optimization for Occult HBV detection 
4µl of template DNA were used instead of 2µl in all the above PCRs. Total reaction 
volume was 25µl by decreasing sterile water volume from 18.5µl to 16.5µl per tube.  
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Table 2-3: List of different HBV PCR used, their primers  and their thermal cycle conditions 
PCR Primers  
Pairs 
Nucleotide 
Position 
 (nt.) 
Produc
t 
 ( bp) 
Primer Sequence Ref. PCR cycles Conditions (temperature/time) 
Denaturati
on  
/94oC  
Annealin
g  
Extensio
n 
72oC  
Number  
Core Gene: 
Pre-core (PC) PCR 
PC1  
 PC3 
1781-1803 
2075-2056 
296 5`-GGCTGTAGGCAT AAATTGGTCTG-3`  
5`- TTGCCTGAGTGC AGTATGGT-3`  
(De Castro 
et al., 2001) 
45 sec 55 x 
1min 
3 min 50 
X gene/Extended 
core (EC) 
C1 
PC3 
1601-1620 
2075-2056) 
475 
 
5`-ACGTCGCATGG AGACCACCG-3`  
5`- TTGCCTGAGTG CAGTATGGT-3` 
Kurosaki et 
al., 1996 
1 min 60 x 1 
min 
3 min 50 
Nested Core : first 
round C1 
C1  
C2 
1601-1620 
1974-1954 
374 5`-ACGTCGCATGG AGACCACCG-3`  
5`-GGAAAGAAGTC AGAAGGCAAA-3` 
Kurosaki et 
al., 1996 
1 min 55 x 1 
min 
3 min 40 
Nested core 
second round C2 
C3  
C2 
1611-1630 
1974-1954 
364 5`-GAGACCACCG TGAACGCCCA-3` 
5`-GGAAAGAAGT CAGAAGGCAAA-3` 
1 min 60 x 1 
min 
1 min 40 
S-gene: 
Mx-S PCR* 
HBVFr  
HBVRv 
376-395 
656-637 
 
2. 
5`-GATGTGTCTGC GGCGTTTTA-3` 
5`-CTGAGGCCCAC TCCCATAGG-3` 
Brechtbuehl 
et al., 2001 
30 sec 55 x 1:30 
min 
3 min 40 
Nested S-PCR first 
round S1 
S1 
S2 
418-433 
776-761 
359 5`-GCGCTGCAGCT ATGCCTCATCTTC-3`   
5`-GCGAAGCTTGC TGTACAGACTTGG-3`  
Fagan and 
Harrison; 
1994) 
1:30 min 47 x 1:30 
min 
3 min 40 
Second round S2 S3  
S4 
455-470 
748-734  
294 5`-GCGCTGCAGCA AGGTATGTTGCCCG-3` 
5`-GCGAAGCTTCAT CATCCATATAGC-3`  
1 min 45 x 1:30 
min 
3 min 40 
Nested RFLP PCR 
First round R1 
F1  
R2  
nt. 57-77 
nt. 732-711 
676 5`-Y (C/T)CCTGCTGG TGGCTCCAGTTC-3`,  
5`-AAGCCANACA 
R (A/G)TGGGGGAAAGC-3`  
 
Mizokami 
et al., 1999 
15 sec 
 
60 x 1 
min 
3 min 40 
Second round R2 F3 
R2  
nt. 245-
270) 
nt. 732-711 
492 5`-GTCTAGACTCG TGGTGGACTTCTCTC-
3` 
5`-AAGCCANACARTGGGGGAAAGC-3` 
Genotyping nested 
P1 
P1 
S2 
 1097 5`-TCACCATATTCTTGGGAACAAGA3` 
5`-CGAACCACTGAACAAATGGC-3` 
 
Naito et al., 
2001 
30 sec 55 x 1 
min 
3 min 40 
2nd round (Mix A) 
multiplex  
B3N  
A4, R5, C6 
(antisenses) 
 178, 
389, 
230 
# 20 sec 
 
20 sec 
58 x 20 
sec 
 
60 x 20 
sec 
1 min 
1 min 
25 then 
at  
30 
addition
al cycles 
2nd round (Mix B) 
multiplex  
D7, E8, F9 
(sense) 
R11 
(antisense) 
 200, 
225, 
147 
# 
* :Those primers were also used for real-time QPCR. Y: C or T, R: A or G, N: A or G or C or T. 
#  See table 4-2.  
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2.4.    Results: 
2.4.1 Evaluation of Different HBV PCRs 
2.4.1.1   Optimized extended core PCR 
Optimization was done using different combination of primers C1 and PC3, C3 and PC3 
to cover this important region of the core promoter, precore and the beginning of the core 
gene. Variation of primers and PCR conditions led to the development of X 
gene/Extended core PCR (EC) with product size 475 bp. Primers C1 and PC3 were used.  
2.4.1.2.   Comparison of the detection limits and sensitivities of eight 
different PCRs of HBV core and S/pol genes 
To test for occult HBV infections, first the most sensitive PCR method must be specified 
for two different genes, the core gene and the S-genes of HBV to test sera with low HBV 
DNA levels. The detection limits of each of different HBV PCRs were assessed by 
testing serial 10-fold dilution of the WHO standard and another four specimens whose 
HBV DNA level was low, around 104/ml as previously determined using Amplicor kits 
(table 2-4). These specimens were tested using eight different HBV PCRs. At first, the 
concentrations of 104, 103 and 102 copies/ml were entered into the different PCR 
reactions. Some were nested as core C2, S-gene PCR S-2, RFLPs PCR and the multiplex 
nested genotyping assay. In the nested PCR, both first and second round products were 
examined by gel electrophoresis. The precore (PC) PCR showed a sensitivity of 1.9 x 102 
IU/ml (equivalent to 1.0 x 103 copies/ml) (fig.2-2). 
X gene/Extended core (EC) PCR showed less sensitivity as only 3 out of 4 specimens 
with 103  copies per ml were seen, two with faint bands. Nested core PCR (C2) detected 
also 3/4 specimens but their bands were more intense. The single round precore (PC) 
PCR was the most sensitive assay of the core gene, of equal sensitivity to the nested core 
PCR. The extended core PCR was less sensitive  
For S-gene, short S (Mx) PCR showed 4/4 positive of 103 copies/ml (fig.2-3). Unlike 
RFLPs nested PCR which were much less sensitive and gave only 2/4 positives (fig.2-3). 
The nested S-gene PCR (S2) gave 4/4 positive of our panel at 103 copies/ml, thus its  
 Chapter 2-Occult Hepatitis B Infection 
41 
 
 
                    M      1       2       3       4        5       6       7       8      9      10      11 
 
Figure 2-2: Precore (PC) PCR dilution 
2% Agarose gel electrophoresis showing PCR products visualized under UV light; M: 
100 bp DNA ladder, lane 1: Negative control. Lanes 2, 3 and 4:WHO standard; lane 2: 
104 IU/ml, lane 3: 103 IU/ml, lane 4: 102 IU/ml, lanes 5, 6, and 7; Specimen N14, lane 5: 
104 copies per ml, lane 6: 103 copies per ml, lane 7: 102 copies per ml, lanes 8, 9, and 
10: specimen N17; lane 8: 104 copies per ml, lane 9: 103 copies per ml, lane 10: 102 
copies per ml, lane 11: negative control. 
  
                             1       2      3       4      5     M      6      7       8      9     10    11  
 
Figure 2-3: S-gene PCR, and RFLPs (R2) PCR 
S-gene PCR:lanes 1-5; Lane 1; WHO standard 1:100 dilution (104 IU/ml), Lane 2; N14 
1:10 (103 copies/ml), Lane 3; N17 1:10 (103 copies/ml), Lane 4; 1-50 1:100 (102 
copies/ml) Lane 5; 1-56 1:10 (103 copies/ml), Lane 6; negative control. Nested RFLPs 
(R2) PCR: lanes 7-11; Lane 7; WHO standard 1:100 dilution (104 IU/ml), Lane 8; N14 
1:10 (103 copies/ml) showing bands of both first and second round PCR, Lane 9; N17 
1:10 (103 copies/ml), Lane10; 1-50 1:100 (102 copies/ml) Lane 11; 1-56 1:10 (103 
copies/ml). 
300 bp 
300 bp 
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Table 2-4: Sensitivity and detection limit of different HBV PCRs in  copies/ml.  
The number of positive PCR is indicated in relation to the panel tested of dilutions of WHO 
standard and samples with known HBV DNA level by Cobas Amplicor quantitative PCR. 
PCR WHO standard Sample N14 Sample N17 Sample 1-56 
104 103 102 104 103 102 104 103 102 104 103 102 
Core Gene: 
Pre-core (PC)  
4/4 4/4 2/4 4/4 4/4 3/4 4/4 4/4 3/4 4/4 4/4 2/4 
X gene/Extended core 
(EC) 
4/4 2/4 0/4 4/4 2/4 0/4 4/4 2/4 0/4 4/4 2/4 0/4 
Nested Core : first 
round C1 
0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 
Nested core second 
round C2 
4/4 2/4 0/4 4/4 3/4 0/4 4/4 2/4 0/4 4/4 2/4 0/4 
S-gene:  
Short-S PCR 
4/4 4/4 2/4 4/4 4/4 2/4 4/4 4/4 2/4 4/4 4/4 2/4 
Nested S-PCR first 
round S1 
0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 04 0/4 
second round S2 4/4 2/4 0/4 4/4 2/4 0/4 4/4 3/4 0/4 4/4 2/4 0/4 
Nested RFLP first 
round R1 
0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 
2nd round R2 1/4 1/4 0/4 ¼ 1/4 0/4 2/4 1/4 0/4 2/4 1/4 0/4 
Genotyping first round 
P1 
0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 0/4 
2nd round multiplex  4/4 2/4 0/4 4/4 2/4 0/4 4/4 2/4 0/4 4/4 2/4 0/4 
 
Table 2-5: Results of HBV PCR in different blood donors and patient groups 
Groups Hepatitis Markers Number HBV DNA 
positive (%) 
P value 
 
 
 
Blood Donors 
 
Ia HBsAg -negative  
anti-HBc +/ anti-HBs + 
104 6 (5.8%) 0.004 
Ib HBsAg  -negative  
anti-HBc +/ anti-HBs -ve 
95 22 (23.2%) 0.004 
II  HBsAg +  30 25 (83.3%)  
III HBsAg -negative  
anti-HBc -ve/ anti-HBs-ve 
250 1 (0.4%) 0.001 
Chronic Liver 
Disease Patients 
 HCV coinfected  
HBsAg -negative  
anti-HBc +/ HCV-Ab + 
25 4 (16%)  
Liver Biopsy of 
Hepatocellular 
Carcinoma (HCC) 
patients 
 HBsAg -negative  
/ anti-HBc +* 
 
15 2 (13.3%) 0.15 
*Only 4 had anti HBc-antibodies 
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sensitivity is comparable to Mx PCR. The Mx PCR was the most sensitive PCR of the 
HBV S-gene. The RFLPs PCR showed the least detection level of 104 copies/ml. The 
multiplex genotyping PCR was performed on the same sera and results showed 4/4 
positives. 
 
2.4.1.3. Screening of Anti-HBc only Blood Donors for occult HBV infection 
Sera from blood bank were screened by highly sensitive PCRs spanning two different 
genes of the HBV genome; precore PCR, which amplify a 268 bp region of the core gene, 
and S-gene (Mx) PCR that amplify a different region spanning the S-gene. Only twenty 
eight cases out of 199 (14.07%) blood donors showed positive HBV DNA. Most of them 
had a faint band of the expected size. This suggests a low viral load as expected. In 
addition, a third PCR; the extended core PCR with detection limit of more than 103 HBV 
DNA  copies per ml, showed only one positive case (no.1-71), confirming the low HBV 
DNA of 103 or lower in most OBI cases. The real time quantitative PCR further 
confirmed that these cases have low HBV DNA level of = or < 103. The alanine 
aminotransferase (ALT) level in our cases with OBI was normal in most of blood donors 
with mean of 48 IU/ml. Abnormal ALT was seen in 16 cases from 52 to 128 IU/ml. 
 
HBV DNA was detected in two out of 15 (13.3%) cases of HCC by precore PCR and S-
gene (MX) PCR. The HBV genotypes of HBsAg blood donors were genotype A 6/25 
(24%), C 1/25 (4%) and D 18/25 (72%).5 were ungenotypable. 
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2.5.    Discussion 
The choice of a highly sensitive, quantitative molecular test of HBV DNA at low viral 
loads is crucial for the diagnosis of OBI. The frequency and detection efficiency of OBI 
not only depends on the relative sensitivity of both HBsAg and HBV DNA assays, but 
also depends on the prevalence of HBV infection in the population (Allain; 2006). Hence, 
the type of assay used and its sensitivity must be specified (Said et al., 2009). As HBV 
DNA level in OBI is below 104 copies/ml or less (Valsamakis, 2007), the yield of PCR in 
OBI depends on the detection limit of the used test and thereby explains the variation in 
their detection rates. It also depends on the efficiency of DNA extraction, the amount of 
input DNA, the PCR primers, and assay conditions (Banerjee et al., 2007).  In sensitive 
PCR assays, there is pronounced risk of false positive results from contamination or 
amplification of non-HBV DNA targets. We prefer single round PCR to decrease the 
possibility of contamination, though it has lower detection limit drawback of the test 
compared to nested PCRs.  
Different regions of the HBV genome were amplified using two independent PCRs 
targeting the surface gene and the precore/core region of HBV. Amplifying different 
regions spanning the HBV genome serves as an independent double check of the HBV 
DNA positivity and to confirm the reliability of the results (Kew et al., 2008). That was 
recommended by other workers to confirm the results, and to rule out contamination by 
PCR products (Sagnelli et al., 2008). In our results the precore PCR was more sensitive 
than the S-gene PCRs except when the S-gene PCR amplifying a short segment of the S-
gene was equally sensitive. Nevertheless, both tests must have comparable detection 
limits to enable proper evaluation. The detection limit was estimated at 200 genome 
copies/ml for both assays using samples with previously known HBV DNA levels. Our 
results were in agreement with other workers (Fabris et al., 2004) who found that PCR of 
the HBV core gene was more sensitive than the S-gene in serum and in the liver tissues. 
Possibly, due to better relaxing the double stranded HBV DNA at the core region near to 
the origin of replication. In contradiction, other groups experienced more sensitive PCRs 
of the S gene (Kew et al., 2008). 
In our assay, the input  4Pl template of the 100Pl of DNA that was originally extracted 
from 200Pl of serum. Therefore, when we can detect 1-2 copies of HBV per reaction, 
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amounting to about 125-250 copies of HBV DNA/ml of serum. This detection limit still 
needs to be improved to below 100 copies of HBV DNA/ml; to avoid the undesired risk 
of permitting infectious dose of 5x104 HBV copies per unit of 500 ml transfused blood. 
Some workers claim the detection of up to 10copies per ml of serum by real-time PCR 
(Allice et al., 2007), which is equivalent to 3500-5000 HBV copies in a unit of 500 ml 
transfused blood. In a study by Torbenson et al., (2004), semi-nested PCR (detection 
limit, 15 HBV  copies per ml) detected HBV DNA in 81 of 180 (45%) of anti-HBc 
positive individuals using. The other implication of the very low viral load in OBI is the 
importance of validating a suitable molecular test to detect OBI in blood transfusion 
services, as HBV nucleic acid amplification technology (NAT). There is no standardized 
method to detect OBI, and assays vary in their sensitivities, ranging from 1-3 viral 
particles/ml of serum by nested PCR and 50  copies/ml in single round PCR coupled with 
hybridisation (De Maria et al., 2000) to 10 IU per ml in TaqMan assay (Allice et al., 
2007). Whereas the specificity of the results is checked by sequencing of the amplicon, or 
hybridization with labelled DNA probes. Both rule out sample contamination, (Sagnelli 
et al., 2008). 
In most Saudi cases, the HBV DNA was mostly at or below 103 copies/ml. At these 
levels, NAT is likely to be ineffective and its cost-effectiveness is questionable, 
particularly when used with plasma pools, and cause false sense of security by relying on 
a test of inadequate detection limit. HBV NAT needs either extreme sensitivity or use on 
individual donations to eliminate HBV DNA-containing units, although some groups 
recommended the exclusion of anti-HBc positive units (Alhababi et al., 2003). As in OBI, 
HBV DNA is usually below 104 and can be less than 351 IU/ml (Katsoulidou et al., 
2009), making testing of plasma pools unsuitable unless the sensitivity of NAT 
significantly increases by genome enrichment or test improvement. In addition, such 
plasma pools must be screened first to exclude HBsAg positive units, because units with 
high HBV DNA levels can give misleading results.  As HBV DNA is detected in up to 
81.8% (18/22) of HBsAg positive blood donors, with a mean level of 3.67 (+/-1.77) 
log10 copies/ml (Hasegawa et al., 2006).  
Generally, there is an increasing NAT positivity with increasing anti-HBc titres from 26 
to 212 . As prevalence of anti-HBc decreases below the age of 40, an alarming increase 
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of HBV DNA occurs in this age group (75.8% vs.21.5%) (Yugi et al., 2006). . An 
increasing incidence of OBI is expected with the implementation of massive HBV 
vaccination (Chang; 2006). Thus, the need for highly sensitive DNA testing of donated 
blood will be increasing by time.  
The main purpose of studying Saudi blood donor group is to check the prevalence of 
positive HBV DNA in the donated blood in an endemic area as Saudi Arabia. Our results 
showed the presence of HBV DNA in 14.1% of anti-HBc positive, HBsAg negative 
Saudi blood donors. Although HBVDNA ratio is not very high, it is still more than 
described from other parts of the world (Alhababi et al., 2003). This can be explained by 
the higher prevalence of HBV infections in Saudi Arabia, as it is an endemic area with an 
incidence of 1.9%, 4.1 % to 5.1% of HBsAg in the general population in Eastern, Central 
and Southern provinces, respectively (Panhotra et al., 2005) (Al Traif et al., 2004) 
(Ayoola et al., 2003). Clearly these rates are significantly lower than the HBsAg 
prevalence of 12% reported in 1985, and much lower HBsAg in vaccinated children 2 of 
229 (0.9%), indicating a major decline even from the rate of 8.8% observed early in this 
decade (Ayoola et al., 2003).  
Rates of isolated anti-HBc positive, anti-HBs negative in Saudi blood donors reached 
853/26, 606 (3.2%) (Zekri et al., 2002). Taking into consideration that the prevalence of 
anti-HBc / anti-HBs positive 271/2687 (10.1%) to 194/1051 (18.46%) reported in Eastern 
and Western province, respectively (Panhotra et al., 2005) (Zekri et al., 2002). Donations 
from the first group are discarded according to blood bank regulations. While the anti-
HBc /antiHBs positive group reaching 17.1% of total donations, may have positive 
HBVDNA in 5.8%.  HBsAg-negative Anti-HBc prevalence varies in other neighboring 
countries ranging from 20.5% in Oman, (Kaminski et al., 2006), 17.28% in Pakistan 
(Bhatti et al., 2007), 10.96% in Egypt (El-Zayadi et al., 2008), and 7.1% in Lebanon 
(Ramia et al., 2008). 
According to our results, the estimated prevalence of HBVDNA to 0.19 to 0.99% of total 
blood donations, which comprise a risk of HBV transmission from blood and 
consequently considered infectious. As HBV DNA was present in 5.8% of anti-
HBc/antiHBs positive donors, donations carrying anti-HBc antibodies only and HBV 
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DNA can be infectious and this removes a threat where anti-HBc is not screened. Anti-
HBc screening identifies most OBI but not all. Despite that serological loss of viral 
antigens and appearance of anti-HBs is generally believed to signify viral clearance. Our 
data agree with Fabris et al., 2004) that the seroconversion to anti-HBs is not always 
accompanied by the complete elimination of the virus. In another study of anti-HBc 
positive blood donors from Saudi Arabia, HBVDNA was detected in much lower rate at 
only 1.25% of sera (Zekri et al., 2002), possibly due to difference in detection limit of the 
tests used. Allain (2004) has pointed that carriers of anti-HBs or anti-HBc only were 
mainly infectious in immunosuppressed organ or bone marrow transplant recipients. In 
such cases, the risk of transmitting HBV justifies a specific prophylaxis in liver 
recipients. Up to 55% of recipients presented some degree of immunodeficiency 
including age. Under these circumstances, it is possible that the threshold of infectivity of 
antibody-complexed virions is significantly decreased (Allain 2006). In 
immunocompetent recipients, there is little evidence that anti-HBs-containing 
components are infectious.  
The critical question is whether OBI is infectious by transfusion. While most infectious 
blood units are removed by screening for HBsAg, there is clear evidence that 
transmission by HBsAg-negative blood occurs, in part, during the serologically negative 
window period, but more so during the late stages of infection with isolated detection of 
anti-HBc, but positive for HBVDNA, with or without the presence of anti-HBs antibodies 
(Allain et al., 2004). However, HBV presents a much higher residual risk of transmission 
by transfusion than HCV or HIV in endemic areas (Velati et al., 2008).  
 
Acute post transfusion HBV was not reported in our Saudi patients, although one case of 
the liver disease group has documented blood transfusion as the source of infection. The 
calculated window period reflects the incidence in the donor population (Kleinman and 
Busch; 2006).Our results agree with Yugi et al., (2006) that anti-HBc positive blood may 
still contain low level of HBVDNA. Therefore, the ideal strategy to prevent the residual 
risk of transfusion transmitted HBV infection relies mostly on serological screening of 
blood donors for anti-HBc by highly sensitive tests, and to eliminate all the positive 
donations. Preferably in conjunction with NAT to detect donors in the window period of 
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HBV infection. Despite the significant decline in anti-HBc positivity over the last decade, 
isolated anti-HBc positive leads to high rejection rate of collected blood units without 
completely covering the residual risk of HBV transmission by transfusion (Panhotra et 
al., 2005). 
We found one case with positive HBV DNA despite completely negative HBV serology. 
This can be explained by either early infection or OBI following an old infection with 
negative serology. Low level of HBV DNA remains detectable in serum (Arase et al., 
2007) and liver tissue in some patients who cleared HBsAg from either acute self-limited 
or chronic HBV infection or even after a successful anti-HBV therapy (Said et al., 2009). 
Rare cases of HBVDNA without any serological HBV marker has been reported, and can 
be associated with infectivity as the virus persists in the liver and is accompanied by 
abnormal liver histology for a decade after complete clinical recovery (Yuki et al., 2003). 
The HBV genotypes of HBsAg blood donors were genotype A 6/25 (24%), C 1/25 (4%) 
and D 18/25 (72%). 5 were ungenotypable. HBV genotype D was common in Saudi 
Arabia (Al Traif et al., 2004) (Abdo et al., 2006). The predominant anti-HBe serology 
needs to be considered. The other cases were ungenotypable because of their low viral 
load characteristic of most OBI infections. The genotype of occult infection reflects the 
geographical distribution of HBV genotypes. In a study by (Alhababi et al., 2003), HBV 
DNA of genotypes A, E and G was detected in 6/151 (4%), all of which had HBV 
DNA<400 copies per ml.  
The alanine aminotransferase (ALT) level in our cases with OBI was mostly normal. 
Blendis et al., (2003), found no association between serum aspartate aminotransferase 
(AST), activity grade, or stage of liver disease and the presence of OBI. Serum ALT 
levels were slightly higher in patients without OBI (46 vs. 35 IU/L).  
In Saudi Arabia, an intermediate HBV endemic country, some patients may have 
persistent viral infection after the loss of HBsAg (Al Traif et al., 2004). OBI with positive 
HBV DNA was detected in 3 of 25 (12%) liver disease patients with anti-HBc only 
(Helmy and Al-Sebayel; 2006).  OBI cannot be explained totally by mutations in the 
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HBV "a" determinant. However, it is appropriate to monitor the emergence of HBsAg 
negative mutants in vaccinated individuals (Chang; 2006).  
Although OBI cases with HBV DNA in serum in the absence of HBsAg is common in 
chronic hepatitis C, the prevalence and the impact of OBI in patients with chronic 
hepatitis C infection is still a matter of some controversy. In Saudi patients with chronic 
HCV infection, anti-HBc alone was frequently reported, and is significantly more 
common in those with CAH than those with cirrhosis at 71 (64.5%) and 14 (23.7%) 
respectively (Helmy and Al-Sebayel; 2006). A proper follow up of HCV patients is 
needed to evaluate the effect of OBI on the progress of their disease and the outcome of 
therapy in different HBV genotypes.  
Our results showed the presence of HBV DNA in only 4/25 (16 %) of HCV patients, who 
have both anti-HCV antibodies and anti-HBc antibodies. Our low level of HBV DNA in 
patients coinfected with HCV is consistent with the results of Kao et al., (2002) who 
found 31 of the 210 patients (14.8%) had HBV DNA in their sera, as did 15 of the 100 
HBsAg-negative healthy controls (15%). In contrast, our rates of OBI in HCV patients 
are much higher than that found by Fabris et al., (2004), where he detected HBV DNA in 
only one of 51 (1.9%) serum samples. Higher prevalences of OBI in Greek HCV patients 
were reported by Georgiadou et al., (2004), with HBV DNA reaching 26.2% of 187 
HCV-infected patients. HBV DNA was not associated with HBV markers, nor with the 
clinical status of HCV and non-HCV patients. This rate of coinfection suggests a 
common source of infection in a high-risk group as IV drug users. Another factor 
affecting the prevalence of OBI is significant increase in those who are HCV-RNA 
positive rather than negative (Said et al., 2009). Despite a reciprocal inhibition between 
both viruses leading to fluctuating HBV viraemia, HBV and HCV frequently coexist in 
liver tissue (Coppola et al., 2008). 
HBV DNA was detected in two out of 15 (13%) Saudi cases of HCC, lower than 15/51 
(29.4%) of liver tissue specimens from chronic HCV cases reported by Fabris et al., 
(2004), possibly integrated or have low level replication. The level of HBV DNA may 
not be sufficient to cause progressive liver disease (Hui et al., 2006). Ayoola and Gadour 
(2004) reported that the prevalence of HBsAg in 118 HCC Saudi patients (67%) was 
significantly higher than the rate (6.7%) in the controls.  Dual HBV and HCV infections 
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occurred in only 3.4% and were associated with only a moderate increase in the risk of 
HCC. In 24.6% of the cases no virus was identified as the etiologic factor. Suggesting 
that HBV constitutes a major risk factor and HCV contributes a less significant role in the 
development of HCC in Saudi patients. A tight association of HBV and HCC was 
demonstrated with or without HCV (Geo et al., 2005, Ohaba et al., 2004). 
2.6.  Conclusion: 
Anti-HBc/anti-HBs positive blood is of questionable safety in HBV endemic areas. 
Policy for checking the collected blood unit by 3 tests for anti-HBc, anti-HBs and HBsAg 
should be re-evaluated, in favour of HBV DNA testing by PCR, to possibly achieve the 
zero risk goal of transfusion transmitted HBV infection. 
 
2.7. Future Direction: 
We need to investigate the prevalence of OBI in UK blood donors with positive anti -
HBc antibodies, and in HCV patients in UK and its association of with pathological or 
clinical findings. To investigate OBI in HIV coinfected Saudi individuals. And to test for 
HBV transcripts integration by covalently closed circular HBV (cccDNA) genomes. 
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Chapter Three: Real-Time Quantitative PCR of HBV Genotypes 
3.1 Introduction 
The laboratory diagnosis of hepatitis B virus (HBV) infection is based traditionally on 
serological assays. Yet the detection and quantitation of viral DNA is necessary when 
addressing directly the question of infectivity. Serial measurements of HBV DNA are 
required to assess non-responsiveness to antiviral drugs (Kennedy et al., 2008). Viral 
breakthrough occurs with inadequate dosage or noncompliance to therapy and in resistant 
mutants. Adefovir add-on therapy used for lamivudine resistant mutants, treatment 
algorithms are likely to consist of entecavir and tenofovir (Kennedy et al., 2008). Real-
time assays are used for large-scale nucleic acid testing (NAT) for validation of blood 
products (Yugi et al., 2006). Multiplex real-time quantitative PCR assays were developed 
for simultaneous detection, genotyping and quantification of HBV (Liu et al., 2006). 
Quantitation of cccDNA evaluates replication and pathogenesis of the virus (Takkenberg 
et al., 2009). 
Different methods are used to quantify HBV DNA e.g. competitive PCR (Payan et al., 
1997), hybridization with labelled probes in the Amplicor monitor (Roche)(Yuan et al., 
2004), branched-chain DNA signal amplification assay (bDNA) (Dai et al., 2004), and 
transcription mediated amplification (TMA). Standard hybridization assays allow for 
exact quantitation, but their sensitivity is limited from 103 to106 viral genomes per ml of 
serum. Real-time assays include minor groove binders and fluorescent energy transfer 
probes (FRET) for single nucleotide polymorphism (SNP) detection (Aliyu et al., 2004), 
intercalating dyes as SYBR green and the dual labelled TaqManTM probes which 
combines the sensitivity of PCR amplification and the quantitation of hybridization tests 
(table 3-1) (Allice et al., 2007). Fluorescent labelled primers as Scorpion primersTM, or 
molecular beacons, which are single-stranded, highly specific fluorophore-labeled nucleic 
acid probes that generate a fluorescent signal only in the presence of target, allowed 
quantitative real-time multiplex detection of PCR products (Gunson et al., 2006).  
Quantitative methods based on real-time continuous monitoring of the exponential phase 
of PCR amplification are rapid, more accurate with greater dynamic range than those 
based on end determination. The end assays are influenced by limiting the concentration 
 Chapter 3ȂQuantitative PCR of HBV 
52 
 
of reagents, small differences in reaction components, or cycling conditions. In addition, 
they are unable to quantify the whole dynamic range over which HBV DNA should be 
measured, requiring serum dilutions for estimation of high HBV DNA levels (Gunson et 
al., 2006).  
Most standardized technologies show divergent results with high inter-assay variations. 
This necessitates serial measurements using the same assay to achieve proper 
interpretation of results (Gunson et al., 2006). High specificity depends on selection of 
primers, probes and assay conditions. There are different detection limits of different 
quantitative techniques. The enhanced sensitivity and specificity are valuable for both 
diagnostic and epidemiological work. Different strategies have been attempted to 
optimise QPCR for detection of low copy number target DNA and to decrease primer 
dimer formation e.g. bovine serum albumin, HDL, RNase, tRNA, anti-Tag antibody and 
glycerol (Teo et al., 2002).   
3.2.  Hypothesis 
We need quantitative HBV assay to give an insight about HBV infections and the viral 
activity. HBV genotypes may have different replication efficiencies and consequently can 
affect disease progression. The relation of the HBV DNA quantity to the genotype 
present can show this.  
3.3. Aim 
The aims of this study are:  
To establish the reliability of SYBR Green I real-time PCR method in comparison to 
Amplicor kits. 
To compare the performance of different HBV PCRs with the quantity of HBV DNA 
present.  
To measure the amount of HBV DNA in Saudi and UK specimens. 
To assess the relation of HBV DNA level to the HBeAg, and liver disease status.  
To explore the natural history of infection with different HBV genotypes, and which 
genotype is associated with high viral replication.  
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Table 3-1: Comparison of quantitative molecular techniques for DNA and RNA viruses (Valsamakis 2007) 
Features Limiting 
dilution 
PCR 
Branched 
DNA 
 (bDNA) 
NASBA     
/TMA 
Co- 
amplification of 
reference  
template PCR 
Competitive 
PCR 
QcPCR 
Real-time Detection 
Fluorogenic 
Dye:SYBR 
Green I 
TaqMan 
(5`nuclease 
assay 
Molecular 
beacons 
Labelled 
primers 
Scorpions 
Sunrise  
Detection 
method 
Serial 
dilutions 
PCR in 
duplicate
s 
Chemilumine
-scence 
Signal 
Amplification 
Electroche
milumines
cence  
for RNA 
viruses, IS 
Gel 
electrophoresis 
or colorimetric 
1 IS single copy 
cellular gene or 
transcript 
Colorimetric 
Ratio of 
product to 
competitor IS 
Monitoring 
Fluorescence 
upon binding to 
dsDNA 
Use on large 
regions 
Fluorescent 
generated on 
degradation 
of  probes  
Hairpin- 
shaped oligos 
fluoresce on 
binding to  
target 
Stem loop 
tail with 
integral tail 
 
Dynamic range 
( copies/ml) 
100-100, 
000 
500-106 
(version2.0).    
50-50, 
000000 
(version 3.0) 
80-107  400-750, 000 
(standard) 
50-50, 000 
ultrasensitive) 
100-1010 10-1010   
Intra-assay SD 
(log10 
copies/ml) 
High 0.12-0.32 0.13-0.23 variables affect 
both templates 
0.15-0.33 
    
Contamination Intermedi
ate 
Low Low Low low Low low low low 
Specificity  High 
  
High Intermediate Highest Highest  
Comment Impractic
al, low 
precision. 
large no.  
of PCR 
/sample 
Low 
sensitivity 
  
Internal 
standard have 
similar primer 
binding, size, 
and base 
composition  
Primer-dimer  
Variable melting 
peaks 
High sensitivity 
Less false 
negatives in 
probe 
mismatch 
High 
sensitivity 
False 
negatives in 
probe 
mismatch 
Primer-
dimer 
formation 
Strict 
design 
criteria 
NASBA: Nucleic acid based amplification. TMA: Transcription mediated amplification, IS: Internal standard. 
No. : Number.
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3.4. Principle of Real-time QPCR Using SYBR Green 
In real-time quantitative PCR, amplification of DNA with continuous detection of the 
product is achieved by monitoring the fluorescence emitted from SYBR Green ITM, 
which is activated by binding to the minor groove in double stranded DNA. Fluorescence 
ceases when the dsDNA dissociates and thereby depends on the melting temperature 
(Tm) of the target product; this is measured in the dissociation curves. The initial amount 
of HBV DNA can be measured during real-time PCR based on the cycle threshold (Ct), 
which is inversely proportional to the log of the initial copy number. Ct is defined as the 
cycle at which fluorescence is determined to be statistically significant above the 
background. Simultaneous monitoring of significant photon emission of both 
fluorophores SYBR Green I dye (FAM) and the control dye (ROX) is then correlated 
with the input copy number (-dF/dT versus T) (Wilkening et al., 2004). 
3.5. Materials and Methods 
3.5.1 Patients and Blood Donors: 
Quantitative PCR was done on sera from 85 UK patients, 127 Saudi patients. Patients 
were not vaccinated for HBV. Liver function tests as ALT levels and serological hepatitis 
B markers tests were done by Murex ELISA kits. Liver ultrasonography and liver biopsy. 
Liver disease include Inactive hepatitis B, chronic hepatitis, cirrhosis and hepatocellular 
carcinoma (HCC). 
3.5.1.1. UK Patients Information 
The UK patients were mostly Caucasians, one Live in Taiwan. Other nationalities were 7 
Chinese, 3 Pakistani, one of Bangladesh, Philippines, Vietnamese, Thai, Nigeria and 
Bulgaria. 19 patients were from the Virus reference laboratory, Colindale (London). The 
mean age of UK was 37 years. History of tattoo, ear and body piercing. One nurse. There 
were two cases presenting with acute hepatitis, one case had HCC with elevated AFP492 
and HDV1991. Inactive hepatitis and liver disease in 2 and 21 UK patients. All have 
HBsAg. Liver biopsy showed 4 minimal activity, 5 mild portal fibrosis, 3 Bridging 
fibrosis, 2 Fibrosis score 3, Steato hepatitis 
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3.5.1.2. Saudi Patients Information 
Saudi patients were attending gastroenterology, renal and surgical clinics and 10 Saudi 
blood donors. The mean age of was 43 years. HBsAg was positive; their clinical data 
include liver disease and other clinical diagnoses. ALT levels and serological tests as 
HBeAg and anti-HBe were done on most of those patients. HBsAg positive blood donors, 
asymptomatic carrier, inactive hepatitis and liver disease in 13 and 43 Saudi patients, 
respectively.  Acute hepatitis, 3 HBeAg conversion, chronic carrier. 4 ENT patients; 2 
Chronic sinusitis, otitis media, mastoiditis, one had history of blood transfusion. 3 
rheumatic heard disease, 2 congestive heart failure, 2 cerebrovascular accidents, 1 SLE, 3 
tuberculosis-one died. 4 Dental, 4 diabetics. 3 chronic renal failure patients, two kidney 
transplant, one nephrotic syndrome, one renal stone. 
4 Orthopedic patients: 2 fracture, Head injury, laminectomy. General surgical patients; 
appendicitis, gastritis, cholecystectomy, one Gilbert`s disease. 
Piles, perianal abcess, 2 addicts, 1 septicaemia, one VDRL positive, 2 detected in 
screening for marriage, pregnancy. Diabetes mellitus, breast carcinoma, carcinoma of 
glottis, pancreatic carcinoma, obstructive jaundice, lymphoma-diffuse B-cell. One had 
sickle cell disease, whose father died with HBV. 2 hepatitis D virus (HDV) 
Upper gastrointestinal bleeding, 2 jaundice, Helicobacter pylori infection. 
 
Liver biopsy showed  CHILD classification 8 chronic hepatitis; Albumin 2.8. Fibrosis in 
2/4 chronic hepatitis 2/4, chronic hepatitis grade1, chronic hepatitis 2/4 stage 0/4, 2/4 
stage 0/4, stage 3 grade4, Grade4 and CAH-piecemeal fibrosis. 4 patients were treated by 
lamivudine,  2  by adefovir.  
 
Every serum was aliquoted then stored at -80 oC. All sera were positive for HBsAg. 
DNA was extracted from 200µl serum by QIA amp kits (Qiagen) and their HBV DNA 
levels were estimated by two different assays using an MX 4000 machine (Stratagene). 
HBV multiplex genotyping PCR was done on 90 Saudi and 82 UK patients that were 
tested by quantitative PCR assays. 
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3.5.2.  Preparation of HBV Plasmid Standards 
HBV standards were prepared from plasmid encoded HBV S-gene. PCR products using 
the above primers were cloned in TOP10 Escherichia coli using TOPO cloning Kit 
(Invitrogen, Leek, Netherland). The plasmid`s DNA concentration was determined by 
fluorimetric method, then the copy number of the plasmid was calculated according to the 
standard equation. 
Mass of 1 plasmid in ng = (vector size bp + insert size bp) x 662 x1.6605655x10-15ng 
(Avogadro`s constant).      
Plasmid  copies per µl=   concentration of plasmid in ng /µl 
                                        mass of 1 plasmid in ng 
3.5.3. Real-time PCR 
Amplification of the S-gene was done, the PCR product size is 281 bp. Each real-time 
PCR reaction mixture contained 12.5 µl of the Brilliant® Strategene® SYBR Green 
QPCR Master Mix (no.600548), 0.75 µl of each of the forward primer (HBVfr) and 
reverse primer (HBVrv)(5pmol/µl) (MWG-Biotech) (Brechtbuehl et al., 2001) (table 2-
3). 0.325 µl of a control dye (ROX) (1:500 dilution), 9.635 water and 1µl DNA template, 
were added to final volume of 25 µl. 
The control dye (ROX) was added to each PCR reaction tube as a reference to calibrate 
the detection of fluorescence by the machine. ROX has excitation and emission maxima 
of 584 nm and 612 nm respectively. SYBR Green I dye (FAM) has different excitation 
and emission maxima of 497 nm and 520 nm, respectively. Serial dilutions of cloned 
plasmid encoded HBV S-gene segment (see fig. 3-4). Standards were added to each run 
in duplicates. 
Our assay was evaluated using a 10-fold dilution series of a quantified WHO standard 
HBV DNA from the National Institute for Biological Standards and Controls (NIBSC, 
Hertfordschire, UK. code 98/780) and the sensitivity compared with Amplicor Monitor 
kits. Several negative controls were included to check the background fluorescence, 
which may be present in the reagents.  
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3.5.4.  Real-time PCR Thermal Cycling Conditions 
The real-time machine; Stratagene Mx 4000 machine (Stratagene, La Jolla, CA) was 
calibrated initially to the following PCR conditions; 95oC for 15 minutes (Hot start), then 
40 cycles of denaturation at 94oC for 30 seconds, annealing at 55oC for 30 seconds, and 
extension at 72oC for 30 seconds, and a final ascent from 55oC to 95oC at 30 seconds per 
degree (dissociation curve), followed by a cold soak at 4oC.  
3.5.5.  Optimized real-time PCR conditions 
Later the real-time PCR conditions were modified to increase the sensitivity of the test by 
increasing the standards and template DNA to 2µl, and increasing the annealing time to 
1:30 minutes and the extension time to 2 minutes.  
 
3.5.6. The HBV MONITOR assay 
The HBV MONITOR assay (Roche) has a quantitative dynamic range from 200 to 2 x 
105  copies/ml. A 104- bp fragment of the precore and core gene is amplified together 
with an internal standards (IS) DNA. Followed by hybridization to enzyme labelled 
probes. The signal was detected by ELISA. The amount of HBV DNA is calculated from 
the ratio of the HBV-specific well to the IS-specific well according to a standard curve. 
 
3.6. Quantitative real-time PCR Results 
3.6.1.    In-house quantitative Real-time PCR Results 
Real-time QPCR was done the HBV S-gene. Verification of the size of the PCR product 
was achieved by gel electrophoresis. Each of the plasmid standards amplified as 
expected. Several negative control sera and two water blanks were included in each run, 
to measure the background fluorescence above which threshold is calculated. 
Background fluorescence varies from -100 to +100 R (T), but it is negligible as 
fluorescence of true positives reached 950 to 1200 R (T). Non-template negative controls 
did not produce fluorescence that breaks the threshold. 
 
 Chapter 3ȂQuantitative PCR of HBV 
58 
 
The amplification curve measures a different parameter of fluorescence, the corrected 
normalized fluorescence (dRn) against the cycles of real-time PCR (Graph.3-2). The 
threshold fluorescence cut-off is above the base-line fluorescence, the latter was 
calculated from background fluorescence emitted from the negative specimens. Cycle 
threshold (Ct) of standards and specimens is the cycle number at which the fluorescence 
exceeded the fluorescence threshold. Analytical specificity was determined by the 
inclusion of several negative controls. The overall specificity was 99% .  
 
The SYBR green I dissociation curve on raw fluorescence reading data (Graph 3-1), and 
on processed data (Graph 3-3) plotted against the temperature showed clear peaks at 
80.5-81.7oC. The peak correlates with melting temperature (Tm). Single peak signifies 
the presence of a single type of PCR product. Primer dimers are not present in this graph, 
they usually generate low level fluorescence represented by smaller peaks, but their 
melting temperature is below 75oC. 
 
A standard graph was established, in which the cycle threshold (Ct) of serial dilutions of 
known quantity of cloned HBV S-gene was plotted against the concentration of the virus 
in each dilution (Graph 3-4). Duplicates of each concentration of the following: 108, 107, 
106, 105, 104, 103 and 102 HBV S gene plasmid  copies per ml were tested. The line of 
`best fit` was drawn according to these measurements to correlate the HBV plasmid 
concentration with the cycle thresholds (Ct). All the negative controls (NC) showed  
complete absence of fluorescence thereby confirming the absence of contamination in 
this PCR reaction. Quantitative range of SYBR green method as defined by the lowest 
and highest concentrations of HBV DNA was detectable with acceptable accuracy and 
precision.  
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Graph 3-1: The dissociation curves of plasmid-cloned HBV S-gene DNA standards and 
DNA extracted from patients sera.  
A separate line on the dissociation curve denotes the fluorescence generated from each PCR 
reaction, fluorescence is monitored against different temperatures. Y-axis: Fluorescence; where R 
is the fluorescence reading against the temperature variation within the reaction. Background 
fluorescence is constant in the negative controls (NC); this baseline is also reached by the 
dissociated double stranded (ds) DNA of the amplicons into single stranded DNA in the 
denaturation step of the PCR after heating over 82oC. 
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Graph 3-2: A graph to show amplification curves of MX4000 real-time quantitative PCR 
using plasmid-cloned HBV DNA standards and DNA extracted from patient`s sera. 
The x-axis denotes the number of the PCR cycles at which the fluorescence was detected plotted 
against baseline corrected normalized fluorescence (dRn) in they-axis.  Fluorescence from each 
PCR reaction is represented by a separate line where amplified amplicon from either a plasmid-
cloned HBV DNA standard (STD), a clinical specimen, or a negative template control (NTC). 
The threshold is the line above the negative reactions` base-line fluorescence, above which the 
reaction is considered positive. The cycle threshold (Ct) is the cycle at which fluorescence is 
determined to be statistically significant above the background. 
 
108 Standard 
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specimens  
Threshold 
107 Standard 
106 Standard 
105 Standard 
104 Standard 
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Some specimens showed a steep rise in fluorescence starting at 78oC, indicating gradual 
build up of dsDNA with the increase in temperature due to primer annealing and 
formation of the new DNA amplicons. No smaller peaks were noticed at lower 
temperatures, denoting the absence of primer dimers that can give low-grade fluorescence 
by their binding to SYBR green I in some occasions. 
 
Analytical accuracy (linearity) which is the expected values versus observed log10 
copies/ml mean quantitative values for each QC/standard panel were observed. The linear 
regression plot had a slope of Y= -3.589 log (X) +44.64 with a correlation coefficient 
(R2) of 0.99. Thus, good linearity was observed throughout the quantitative range of 2 to 
8 log10 copies/ml. The quantitative efficiency was near 100% which further validate the 
results. 
 
The HBV DNA was measured for each specimen in duplicates, and the mean was 
calculated and compared to the results generated using the light cycler. The World Health 
Organization (WHO) standard with HBV concentration of 1000, 000 IU (equivalent to 
5.2 x 105 copies/ml) per ml gave a mean concentration of 7.07x105 copies/ml. The 
sensitivity of the assay was assessed by comparing the observed and the expected Ct of 
plasmid standards. The mode of standard deviation of the cycle thresholds (Ct) of 
plasmid-cloned standards and specimens was 2.73. The standard deviation of cycle 
threshold (Ct) of specimens showed a small range between 0.06 and 0.68. Therefore, 
analytical precision (reproducibility) was high as measured by low  % CV within run and 
between runs. 
 
The validity and accuracy of this test in the lower ranges of HBV DNA was verified by 
testing serial dilutions of both the WHO standard, and dilutions of samples containing  
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Graph 3-3: The dissociation curves of plasmid-cloned HBV DNA standards dilutions and 
'1$ H[WUDFWHG IURP SDWLHQW¶V VHUD A separate line on the dissociation curve denotes the 
fluorescence generated from each PCR reaction, where detected fluorescence is monitored against 
different temperatures. Y-axis: Fluorescence; where ±Rn` (T) is the first derivative of the 
normalized fluorescence reading multiplied by ±1. Background ±Rn` (T) (-100 to+100) is 
constant in the negative controls (NC), this baseline is also reached by the dissociated dsDNA of 
the amplicons after heating over 82oC. Those thermal denaturation profiles which showed peak 
fluorescence at 80.5 - 81.7oC (one arrow for each temperature) due to melting of the target PCR 
products, belonging to two different genotypes. 
 
 
 
 
 
 
 
Standards 
and 
unknown 
specimens 
 Chapter 3ȂQuantitative PCR of HBV 
63 
 
High HBV DNAs. As well as repeated testing of samples with low concentrations of 
HBV DNA, using the optimized method showed better low detection limit. Accordingly, 
we doubled the reaction volume to 2µl, the PCR conditions were also modified (see 
methods). HBV DNA was measured by two methods, Amplicor and SYBR green QPCR 
method. 
 
Comparison between HBV DNA quantitative PCR results done by both 
Amplicor and SYBR green QPCR methods. 
The mean measured by SYBR green method which was slightly lower than by the 
Amplicor at 4.58 and 5.18 log10  copies/ml, respectively. SYBR green method showed 
less variation as measured by the standard deviation and the standard error of the mean 
(table 3-2).  
 
Comparative analysis of the quantitative values of plasmid standards and sera from 
SYBR green versus Amplicor results. The difference in HBV DNA measurement 
between the two methods was 0.595 with a 95% CI of 0.10-1.094 (table 3-2). The slope 
was slightly different from a value of 1 indicating a less linear relationship between the 
two assays.  
 
After the observation of many negative results in sera with low HBV DNA by SYBR 
green methods, we introduced modification (see methods). Optimization showed 
significantly better correlation with Amplicor at low HBV DNA levels (table 3-4), and 
even better detected the  
WHO standard diluted  at 104 IU per ml (equivalent to 1.9 x 103  copies per ml) as 1.53 x 
103 compared to the manufacturer`s  value. The Amplicor test showed less concordance 
at higher HBV DNA levels of plasmid standards than the optimized method. Analytical 
sensitivity, which is number of replicate samples with HBV DNA quantitative values 
above the detection cut-off, was determined. 
 
Mean HBV DNA level was significantly higher in UK than Saudi patients at 5.09 (95% 
CI 1.43-8.75) and 4.52 (95% CI 0.14-8.90) log10 copies/ml, respectively (p: 0.007) (table 
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Graph 3-4: Standard curve graph in copies per ml, which is acceptable. Plot of MX4000 
real-time quantitative PCR using plasmid-cloned HBV DNA standards and 10clinical 
specimens.  
Quantitative PCR standard curve is a plot of the initial template HBV DNA concentration added 
to standard wells in copies per ml on the x-axis versus the cycle threshold (Ct) at the end of each 
cycle on they-axis. Each reaction is indicated by a square on the graph; the WHO standard 
(106IU/ml) is also shown. The full squares indicate the plasmid-encoded standards using the 
SYBR Green I (FAM) fluorescent dye. The empty squares indicate unknown clinical specimens 
where their HBV DNA levels are extrapolated from the standard curve plot according to their Ct 
values. dRn is the baseline corrected normalized fluorescence. The slope of the curve was 
calculated as: Y= -3.589 log (X) +44.64 
 
 
Table 3-2: Paired differences of HBV DNA results done by comparing both Amplicor and 
SYBR green quantitative PCR methods t: 2.451, p: 0.021 
Method SYBR Green 
QPCR assay 
Cobas Amplicor 
Kits 
Mean difference between 
the two methods 
Mean HBV DNA level 
 (log10  copies/ml) 
4.58 5.18 0.6 
Standard deviation (SD) 2.15 2.79 0.64 1.26 
Standard Error of the Mean 0.41 0.54 0.13 0.243 
95% confidence interval of the 
difference 
  0.10-1.094 
 
WHO 
Standard 
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3-3). Mean HBV DNA  in patients with HBeAg was 7.18 and 6.44 log10  copies/ml, while 
anti-HBe positive patients had 3.84 and 4.11 log10  copies/ml in UK and Saudi patients, 
respectively. That was 2.4 to 3.3 log10 less than the HBeAg positive group (table 3-4). 
Saudi HBeAg-negative patients had higher HBV DNA than UK patients. 
 
3.6.2. Clinical presentation of HBV 
Inactive hepatitis in Saudi patients was associated with low HBV DNA (table 3-5), have 
very low or undetectable HBV DNA =<103 copies/ml in their sera. On the other hand, 
active liver disease was associated with low, intermediate and high HBV DNA levels. 
Within the liver disease group, 53/92 (57.6%) Saudi and 42/66 (63.6%) UK patients have 
high HBV DNA of >5 log10, whereas a much smaller proportion show moderate or low 
HBV DNA levels.  
 
The correlations of HBV DNA levels with liver disease as acute hepatitis, chronic 
hepatitis, and cirrhosis and hepatocellular carcinoma in UK and Saudi patients are shown 
in table 3-4. 
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Table 3-3: Concordance between HBV DNA quantitative PCR by Amplicor and our in-
house real-time assay before and after optimization (p0.014) 
Cobas Amplicor results In-house Q-
PCR 
Optimized in-house Q-PCR 
<=3 log10 copies/ml 
 (concordance within group) 
5/0 4/6 
3-<5 log10 copies/ml 
 (concordance within group) 
0/5 6/7 
=>5 log10 copies/ml 
 (concordance within group) 
9/11 
 (81.8%) 
3/6 
Total  concordance 9/16 (56.3%) 13/19 (68.5%) 
 
 
 
Table 3-4: Mean HBV DNA in UK and Saudi patients and correlation between HBV DNA 
and serum HBeAg status, and the clinical presentation of  age matched patients. 
Clinical 
Manifestations 
No. of Saudi Patients  
in log10  copies/ml 
Mean HBV 
DNA (no. of 
patients) 
No. of UK Patients  
In log10  copies/ml 
Mean HBV 
DNA (no. of 
patients) <=3 >3-<5  =>5  Total <=3  >3-<5  =>5  Total 
HBeAg 0 4 17 21 6.44 (21) 0 1 30 31 7.18 (31) 
Anti-HBe 32 32 42 106 4.11 (106) 13 29 12 54 3.84 (54) 
Mean (no. of 
patients)  95% CI 
 4.52 (127) 
0.14-8.90 
 5.09 (85) 
1.43-8.75 
Inactive Hepatitis  15 12 -  2.8 (27) 7 11 -  2.43 (18) 
Liver Disease 16 23 53  4.9 (92) 6 19 42  5.8 (66) 
-Acute hepatitis  
 
-Chronic hepatitis 
-cirrhosis  
 
-HCC  
- 
 
11 
 
5 
1 
 
17 
 
4 
 
1 
7 
 
40 
 
2 
 
4 
 6.9 (8) 
 
 4.9 (68) 
 
4 (13) 
 
5.8 (5) 
- 
 
4 
 
1 
 
1 
1 
 
15 
 
3 
 
- 
2 
 
34 
 
6 
 
- 
 6.4 (3) 
 
6 (52) 
 
5.3 (10) 
 
2 (1) 
Total  31 35 53   13 30 42 85  
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3.7. Discussion 
Real-time PCR is increasingly used as a molecular diagnostic procedure within clinical 
laboratories, not only because it better evaluates viral activity and replication, but for its 
rapidity, reliability, and low contamination rates.  
 
The use of fresh specimens of known HBV marker status was essential to avoid 
deterioration of viral count by repeated freeze and thaw cycles, to ensure proper 
comparison with other quantitative methods used simultaneously, and to exclude 
preanalytical causes of inter-test variations (Gunson et al., 2006). Specimens containing 
low viral load produce false negative or unreliable genotyping results. This can be proved 
by quantitation of HBV DNA using a sensitive real-time assay, with lower limit of 
detection range below 500copies per ml.  
 
Our use of SYBR green standardized master mix for real-time PCR leaves the input DNA 
as the only unknown factor, thereby increasing the accuracy of the reaction. The 
inclusion of internal markers, and selection of appropriate sample preparation devices and 
methods further increase reliability and limit susceptibility to contamination, interference, 
or inhibitory factors than conventional HBV DNA quantification method (Gunson et al., 
2006) (Olioso et al., 2007). 
 
In an amplification plot (fig.3-2) of specimens and standards with high HBV DNA levels 
have lower threshold cycle (Ct) of 14-15, and consume their reagents quickly, so end 
point measurements will miss the true initial concentration, and will give rise to 
inaccuracies. Lower viral concentrations showed higher Ct values, but the amount of 
fluorescence (dRn), and possibly the amount of PCR product can reach higher magnitude 
by the end of the 38-40 amplification cycles. Because of the higher availability of 
reagents giving the robustness of the late starting reaction despite low initial template 
concentration, this would further confuse the end point measurements. All such variables 
are conveniently monitored and controlled by the real-time technology. This 
amplification plot proves the inherent accuracy and precision of the method, as well as 
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obviating the need for a separate detection step using gels or ELISA. Thus, further 
increasing their speed and throughput, removing possible interference by other variables. 
 
This assay was evaluated for its specificity, efficacy, reproducibility and accuracy. 
Positive signals of HBV DNA were observed in sera from chronic hepatitis B patients 
tested but not in individuals negative for HBV markers. Quantitative measuring of 
sequential levels of HBV DNA in plasmid standards and in serum specimens was done in 
duplicates.  
 
There were two melting temperatures (Tm) of 80.5 and 81.7oC in the dissociation curve 
of HBV genotype A (including specimens and plasmid standards) and genotype B 
respectively (Graph3-3). Which are clear-cut for each reaction on its own, indicating the 
presence of pure product. But possibly small differences in the product sequences due 
genotype related variations, or to mutations, resulting in the observed slight differences in 
the Tm. Sequencing of any aberrant PCR product will verify the presence of different 
size product and will show the mutations, recombination, deletion, or insertion if present. 
Gel electrophoresis of these PCR reaction products did not show any variation in their 
sizes. Payungporn et al., (2004) demonstrated significant differences in the melting 
temperature (Tm) of HBV genotype B lower than genotype C. The GC content of HBV 
genotypes A, B, C and D were 56.61, 58.24, 55.86 and 57.24, respectively. Genotype D 
has a 33- bp deletion in the PreS1 that may also affect the Tm. The Tm was used as a 
method to determine HBV genotype (Liu et al., 2006). 
 
Regarding the dynamic range, a linear standard curve was obtained between 102 and 108 
DNA copies/reaction. Thereby this test is capable of quantifying serum HBVDNA, 
covering the range of naturally replicating virus as well as occult hepatitis B infections. 
The standard deviation of cycle threshold (Ct) of specimens showed a small range 
between 0.06 and 0.68. The coefficient of variation (CV) both within and between 
experiments indicated remarkable reproducibility. CV was lowest in the middle of the 
standard curve at 105-106, denoting the area of highest precision. Lower precision was 
seen at both extremes of 102 and 108 copies/ml. Other studies of HBV quantitation 
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demonstrated a median coefficient of variation of inter experimental variability of 1.5% 
to 26.2% and 1.8% to 5.5% for Cobas Monitor and Cobas TaqMan assays, respectively 
(Laperche et al., 2006), while b-DNA tests showed total CV variation from 10.6 to 26.5% 
over the dynamic range (Yao et al., 2004). Differences in amplification efficiency and 
lower reproducibility will therefore affect more the weaker samples (Brechtbuehl et al., 
2001). The inclusion of serial dilution of standardized quality control material is essential 
to validate our assay in the lower detection range. Accuracy achieved was tested by the 
accurate detection of the WHO standard to control reliability and validity of the test.  
 
The mean difference between the SYBR green and the Amplicor measurements was 
significantly 0.595 log10  copies/ml lower than the SYBR green method (p: 0.021) (table 
3-3), with a range of 0.10 to 1.094. This is not a big difference, as a minimum of 2 log10  
copies/ml is required to define a clinically significant change of HBV DNA 
measurements. Nevertheless, necessitates using the same method for serial measurement 
of HBV DNA levels.  
 
However, in samples at the lower part of the range i.e. below 103, larger differences 
between duplicate measurements were seen. The lower limit of 102 was not as accurate as 
was claimed by the test (Ho et al., 2003). Because its Ct of 34.4 cycles was so low as the 
final limit of the test was 38 cycles, after which non-specific results can occur from 
negative controls. This is to be expected since more amplification cycles are required 
before the threshold is crossed for these samples.  
 
In our assay, the actual lower detection limit is one to two copies of HBV DNA in the 
minute volume of template per reaction. The low sensitivity for the HBV concentration 
can be explained by the very low amount of DNA; 0.1 copy in the 102 standard, which 
can be inaccurate, and its measurement is unreliable. The input DNA was later increased 
from 1 µl to 2µl out of100 µl DNA extracted from 200 ml of serum, which is equivalent 
to 500 and 250 HBV DNA copies/ml, respectively. To improve the test detection limit, a 
minimum of 10 to 20 µl of the template DNA can be added to the reaction containing 1-2 
copies of the HBVDNA, as used in some real-time methods. Although some studies have 
 Chapter 3ȂQuantitative PCR of HBV 
70 
 
claimed the detection limit of 1 HBV DNA copy/reaction (Paraskevis et al., 2002), even 
10 HBV DNA  copies per ml detected in the more sensitive TaqMan assay (Allice et al., 
2007). However, in the latter assay, input DNA extracted from whole 1ml plasma. 
 
Meanwhile, major drawback of increasing the template volume can be the production of 
excessive amount of fluorescence from DNA in the higher concentration standards of 106 
to 108 copies/ml, thereby compromising the upper detection limits in an effort to improve 
the lower detection cut-off. The alternative is to tailor the test according to individual 
requirement with second nested PCR run to confirm low HBV DNA cases as described 
by Brechtbuehl et al., (2001). Another strategy is to repeat testing of all sera with low 
HBV DNA  to confirm the specificity of assays with wide detection range (Gunson et al., 
2006).  
 
This can be balanced depending on the clinical diagnostic priorities. Low HBV DNA 
below 103 copies/ml, is important for determining response to therapy, and deciding to 
stop treatment without risking relapse for false negative HBV DNA assay. Patients with 
higher HBV DNA may also need specification, to determine changes of 1-3 log10 as a 
measure of clinical responsiveness to therapy. 
 
Clinical presentation and implications HBV viral loads 
Mean HBV DNA level was significantly higher in UK than Saudi patients at 5.09 (95% 
CI 1.43-8.75) and 4.52 (95% CI 0.14-8.90) log10 copies/ml, respectively (p: 0.007) (table 
3-2). This difference reflected the lower viral replication of HBV in Saudi patients, which 
may be related to viral genotype or mutants present.  
 
Hepatitis markers may correlate with and influence the interpretation of HBV DNA 
measurements in relation to the clinical information. Significantly higher HBV DNA 
levels were detected in patients with HBeAg positivity 7.18 and 6.44 log10 copies/ml in 
UK than Saudi patients, respectively. Conversely, HBeAg-negative UK patients had 
lower HBV DNA than Saudi patients at 3.84 and 4.11 log10  copies/ml, respectively (table 
3-3 and graph 3-4). Possibly reflecting a more acute presentation of HBV in UK patients 
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as compared to vertical transmission or more chronic disease in Saudi patients with or 
without HBeAg-negative mutants (see core chapter). Is the mode of transmission or 
genotype responsible solely for this variation in the HBV epidemiology and biological 
behaviour, or are there differences in HBV replication and immunogenicity. 
 
Generally, patients with HBeAg positivity had HBV DNA level above105 copies/ml. 
While those with negative HBeAg had around 104copies/ml, that is 102 to 103 copies/ml 
less than the HBeAg positive group, which is consistent with the knowledge that HBeAg 
positivity is associated with higher viral replication and infectivity. A significant drop in 
HBV DNA is required for HBeAg seroconversion (Chan; et al., 2003). In contrast, Saudi 
HBeAg-negative patients had higher HBV DNA than UK patients. Here, anti-HBe 
positive sera were associated with full range from undetectable to high HBV DNA levels. 
Possibly due to HBeAg-negative mutants. Hence, HBeAg-negative state does not exclude 
active HBV replication, and therefore serological monitoring cannot be relied upon in the 
management of HBV patients in Saudi Arabia.  
 
Clinically, the HBV DNA cut-off level of below 4 log10 copies/ml was associated with 
anti-HBe antibody positivity, and previously was indicative of inactive liver disease in 
HBeAg negative or seroconversion patients (Martinot-Peignoux et al., 2002). While 
HBV DNA levels of => 5 log10  copies/ml in HBeAg positive patients were consistent 
with the results of Chan et al., (2003) who described that HBV DNA levels of 104 to 105 
copies/ml was a grey zone to predict disease activity because of the overlap in DNA 
levels between patients with remission and those with reversion of HBeAg. This further 
necessitates accurate monitoring of the proposed cut-off level of 104 instead of 105 and 
correlating it to a wider range of anti-HBe positive patients either during the natural 
history of the disease or after manipulation by therapy especially in Saudi patients. In 
support to our findings, recent guidelines have approved the limits of 2000-20000 IU/ml 
for tailoring therapy (Keeffe et al., 2008) (Kennedy et al., 2008).  
 
HBV Saudi patients with active liver disease had low, intermediate and high HBV DNA 
levels. Hence, liver disease patients may have low or undetectable HBV DNA. This 
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indicates that factors other than HBV DNA level and active replication are associated 
with the degree of liver damage (Wiegand et al., 2008). Inactive hepatitis was associated 
with low HBV DNA in most patients (table 3-4). The low viral replication in chronic 
HBV infection in Saudi patients. Inactive hepatitis or carrier status is consistent with such 
DNA levels and low infectivity. These results indicate that in Saudi asymptomatic 
carriers, up to 19% can have high HBV DNA levels. Some patients have high HBV DNA 
levels despite the absence of both HBeAg and ALT elevation (Chan et al., 2002). On the 
other hand, Gandhe et al., (2003) reported that HBV DNA PCR positivity among 
asymptomatic HBsAg-positive carriers was lower than in chronic hepatitis B. Although 
HBV DNA levels were reported to decrease in patients with cirrhosis or HCC 
(Payungporn et al., 2004). 
 
High HBV DNA was a major factor for the development of cirrhotic complications, 
which continued to develop in 24.5% of patients with HBV DNA levels below 104 
copies/ml (Yuan et al., 2004). However, persistent active viral replication is strongly 
associated with the progression of fibrosis in HBeAg-negative chronic hepatitis (Kumar 
et al., 2008).Our patients with high HBV DNA of more than 5log10copies/ml are 
associated with more severe liver disease, and a much more prone to hazardous 
complications as cirrhosis and HCC. This necessitates greater care and more aggressive 
therapy for such patients, with clear aims of either suppressing the HBV DNA levels 
completely, or at least decreasing it to the moderate level of 3-5 log10 copies/ml to hinder 
the progression of liver disease (Payungporn et al., 2004).  
Quantitative determination of serum HBV DNA concentration is the most important 
measure for an estimation of the infectivity of an HBV positive carrier as health care 
worker and the basis for the decision whether he or she is allowed to perform exposure 
prone procedures (EPP) (Buster et al., 2007). Thus, questions are raised on how reliable 
quantitative assays are at or below 103 copies per ml, and how stable is the HBV DNA 
concentration is in a healthy chronic HBV carrier. Regular follow up is essential, and 
should be interpreted with some caution as they fluctuate widely in chronic carriers 
(Chen et al., 2009). Over repetition of QPCR in short intervals can be time consuming, 
and wasteful of resources. Proper designing of the frequency of QPCR monitoring needs 
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to be standardized in clinical guidelines for patients on therapy after proper clinical 
studies on HBV viral kinetics and chronology of the development of drug resistance 
(Punia et al., 2004). In a study by Ide et al., (2003), response to therapy depends on the 
pre-treatment HBV DNA levels. Virological breakthroughs, were observed at 31 to 67 
weeks in most patients, and in at 107 and 115 weeks in patients with low HBV DNA (< 
2.6 log10 copies/ml).  
          3.8. Conclusion 
The use of SYBR green I kits (Stratagene) showed high sensitivity, accuracy, and 
reproducibility in quantitative HBV DNA assay. This method had a dynamic range from 
2.5x102 to 108 HBV DNA copies/ml. However, we found out that improvement is 
required to increase sensitivity and accuracy at lower detection limit and to increase the 
QPCR yield at lower viral concentrations. Therefore, it was generally suitable for 
quantitative PCR assays, and provides the required test range for monitoring HBV 
infected patients. Titres obtained with this method show good correlation and wider 
dynamic range than those obtained with the AMPLICOR HBV MONITOR test. 
Mean HBV DNA level was significantly higher in UK than Saudi patients at 5.09 (95% 
CI 1.43-8.75) and 4.52 (95% CI 0.14-8.90) log10 copies/ml, respectively (p: 0.007). Mean 
HBV DNA in patients with HBeAg was 7.18 and 6.44 log10 copies/ml.  Saudi HBeAg-
negative patients had higher HBV DNA than UK patients at 4.11 log10 and 3.84 
copies/ml, respectively.  
 3.9. Future Directions 
To study the HBV DNA quantity as a measure of replication in various HBV genotypes 
at different clinical stages of the infection.  
To determine the HBV DNA levels in different mutations in relation to HBV genotypes 
as a measure of viral replication and activity.  
To develop a real time assay to genotype HBV and another one to detect important 
mutations in the S, Pol and core genes, in order to conduct large molecular epidemiology 
study. 
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Chapter Four: Hepatitis B Genotypes 
4.1. Introduction 
4.1.1. HBsAg Serological Subtypes 
Serological subtypes of HBsAg depend upon the antigenic structure of `a`determinant 
which is located within the amino acids 120 -147 domain, containing a double loop 
structure projecting from the surface of the virus (Fig.4-1). Bouvier (1975) first detected 
HBsAg subtype determinants d and y in 1971, then w and r.  All combinations of these 
determinants exist in nine subtypes; ayw1, ayw2, ayw3, ayw4, ayr, adw2, adw4, adrq- 
and adrq- (Liu et al., 2002), which are specified by amino acid lysine or argnine at 
positions 122 and 160 of HBsAg (Kao and Chen, 2005). Other subtype determinants 
were mapped to amino acid positions 127, 144, 145, 158, 159, 177 and 178(Kramvis et 
al., 2008). Serotyping of HBV was used for epidemiological purposes, or to predict 
disease progression. The adw strains had a 20-fold higher risk of lamivudine resistance 
more than ayw strains (Zollner et al., 2004).  
4.1.2. HBV Genotypes 
4.1.2.1. HBV genotypes A to H 
Genotypes of HBV are defined as strains that had DNA sequences with more than 8% 
divergence between the groups (Okamoto et al., 1988). Eight genotypes (A to H) of HBV 
have been described (Arauz-Ruiz et al., 2002). The rate of genomic nucleotide 
substitutions of HBV is 105 to 104 per position per year. Accordingly, genotypes diverged 
less than 600 years ago (Fares and Holmes; 2002). Changes occur from evolutionary 
drift, recombination, or as a consequence of a long-term adaptation of HBV to genetic 
determinants of specific host populations (Gunther; 2006). Genotyping is a more 
appropriate epidemiological tool to track common sources of infection and to investigate 
viral evolution. The correlation between different genotypes and related serotypes is 
shown in table 4-1 (Kramvis et al., 2008) (Kidd-Ljunggren et al., 2002). 
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Figure 4-1: Genotype related variations within HBsAg. 
Hypothetical model of the amino acids substitutions in the HBsAg including the `a`determinant  in 
different HBV genotypes A to H. Conserved amino acid residues are shown in black. Non-
conserved residues are shown in grey. If residues are varying subtype specially the minor genotype 
is indicated in bold beside of the amino acid. The position of the frequently described variant 
G145- R is shown in white. Residue 122 and 160 which confer subtype change from d/y  and r, 
respectively, are indicated in black and white.  W4- reactivity is determined by L127;I126 
abolishes reactivity with w-antisera and is linked to the r- subdeterminant. The figure is based on 
an alignment of 166 SHBs- sequences translated from 166 wild type-HBV genomes from 
GenBank (Schaefer; 2005). 
 
4.1.2.2. Relationship between HBV genotypes 
There are structural, functional, infectivity and clinical differences between genotypes. 
Such differences include prognosis, progression of disease, complications as cirrhosis and 
hepatocellular carcinoma, as well as response to antiviral therapy. Structurally, HBV 
genotypes differ in the length of their genomes. The numbering of HBV genome from the 
EcoRI site leads to difficulties in comparing nucleotide positions between genotypes, 
unlike the numbering system, which is based on Bartholomeusz and Schaefer (2004). 
Functionally, the preS region that is important for virus attachment and cell entry, show 
significant differences between genotypes. Genotype A differs mainly in sequence of the 
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preS2 region, and has insertion of six nucleotides in the terminal protein portion of the 
polymerase gene overlapping the core gene, and shares some structural features with 
genotype F. Genotype D genome is most similar to Genotype E, especially in the X-gene. 
Differences in RNA splicing folding between genotypes could be predicted (van Hemert 
et al., 2008). 
4.1.2.3. HBV Genotypes, recombinations and co-infection 
Infection by multiple HBV genotypes or reinfection can exist, especially in high-risk 
individuals such as IV drug users (Olinger et al., 2007). In addition, recombination 
between genotypes has been reported as genotypes A with D (Sugauchi et al., 2004) 
(Schaefer, 2007), A with C and B with C (Sugauchi et al., 2003). The latter recombinant 
HBV (Ba) is a chimera in which the majority of the genetic framework is genotype B 
(fig.4-2), except for the basal core promoter (BCP), precore and core regions which 
correspond to genotype C. Coinfection with genotypes A and G exist (Zaaijer et al., 
2011). Such events can increase as different genotypes circulate in the same region. 
4.1.2.4. Geographical Distribution of HBV genotypes 
There is a defined geographical distribution of different HBV genotypes (table: 4-1, fig.4-
4), that reflect the evolution of the disease and is related to patterns of travel which lead 
to interaction between HBV genotypes. Genotype A in Northwestern Europe possibly 
reflects the immigration to North America and South Africa especially over the last 
century. In New Zealand and Australia genotype A, D and C are contributed by 
immigration from Southeast Asia and the Pacific Islands (Bartholomeusz and Schaefer; 
2004). Genotypes A and D predominate in UK (Dervisevic et al., 2007). Although 
genotype D is the most widely distributed universally, with highest prevalence in a belt 
stretching from Southern Europe and Africa to India (see fig.4-3). Behavioural patterns 
also change the prevailing genotype as homosexual men co-infected with HIV harbour 
genotype A instead of C or B in Japan (Koibuchi et al., 2001), genotype E in West and 
South Africa, and Genotype G in Caucasians males(Bartholomeusz and Schaefer, 2004). 
Studies are needed to examine possible long-term changes in HBV genotypes within any 
region.
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Figure 4-2: Phylogenetic analysis of HBV genotypes and sub genotypes.  
Phylogenetic tree of 188 complete HBV genomes from Gene Bank aligned using Clustal 
W in the program DNASTAR. The alignment was further analyzed by boot-strapping 
using the neighbor-joining method contained in MEGA version 2.1. HBV genotypes A to 
H and sub genotypes A-Africa (A afr), chimeric genotype B and C (Ba), B-Japan (Bj), C-
Australia (C aus), Chimpanzee strain (HBV cpz), Orgutan strain (HBV org), Gibbon 
strain (HBVgbn) (Bartholomeusz and Schaefer; 2004)  
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Figure 4-3: Geographical distribution of HBV genotypes and subgenotypes A, A Africa (A afr), B, C, C Australia (C aus), D, E, F, G 
and H (Bartholomeusz and Schaefer; 2004)  
 Chapter 4ȂHBV Genotypes 
79 
 
Table 4-1: Relationship between HBV genotypes and serotypes and their geographical distribution 
HBV serotypes are designated according to the antigenic constitution of HBsAg determinants d or y and r or w. Different HBV 
genotypes can have the same HBsAg serotype, while a single genotype can be associated with several HBsAg serotypes. 
Differences in HBeAg seroconversion rate and age are also shown (Weber; 2005) (Allain; 2006).   
Geno -
type 
Associated 
Serological 
Subtypes 
Distribution Main mode of 
transmission 
% Chronic 
infection 
% HBeAg Median age 
of HBe 
seroconversion 
% Viral load 
>104  
copies/ml 
A Adw2, ayw1 North Western Europe, USA, Argentina, Japan, 
Philippines, Hong Kong, Australia, Central and 
South Africa, and India 
Sexual 
IVDU 
<1 25-80 20 40.3 
A`  South Africa (Bowyer et al., 1997)       
B1 Adw, adw2,  Vietnam Vertical 1-12 12-53 40 64.3 
B2 ayw1 Southeast Asia      
C adw2, adrq+, 
adrq-, ayr, 
adr 
East Asia, China, Japan, Korea, Vietnam, USA 
Polynesia, Southeast Asia, south Pacific islands 
and Australia 
Vertical 1-10 50-69 30 64.3 
D Ayw2, 
ayw3, ayw4 
Mediterranean area, Middle East, Southern 
Europe, Russia, Australia, India, Africa, USA, 
and in IVDU worldwide  
Vertical, 
sexual, 
nosocomial 
<1-5 33-58 20  
E ayw4 (adw2) West and South Africa Horizontal, 
nosocomial 
3-25 21.5-29 <10 27.5 
F adw4q, 
adw2, ayw4 
South and Central America, West and South 
Africa, Polynesia 
Sexual, 
vertical 
1 90 unknown  
G adw2 Europe, U.S.A. Central America homosexuals     
H adw4 Central and South America (Arauz-Ruiz et al., 
2002)  
     
I        
J        
IVDU: Intravenous drug users 
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HBV genotypes have distinct sub genotypes according to their geographical distribution 
and rates of progression. Genotype A has Aa (Africa/Asia) and Ae (Europe) (Sugauchi et 
al., 2004) (A1, A2). Genotype B is divided into B1 to B4. There is also chimeric 
genotype B and C; Ba and genotype Bj for Japanese strains (Norder et al., 2004). Huy et 
al., (2004) divided genotype C into C1 (Cs) from Southeast Asia including Vietnam, and 
Thailand, and genotype C2 (Ce) from Far East Asia including Japan, Korea and China. 
Sub genotypes C3, C4 and D1-D4 had been described (Norder et al., 2004). Genotype C 
has an Australian strain, Caus as well (Bartholomeusz and Schaefer, 2004). Other 
recombinations between different HBV genotypes have been described (Schaefer, 2005) 
(Kramvis et al., 2008). 
 
4.1.2.5. Clinical Characteristics 
The clinical course of HBV infection varies depending on the patient`s age, 
immunological response, and viral genotype. HBV genotypes may evolve from a 
research tool into an essential diagnostic test, as HCV genotyping did. Specific genotypes 
of HBV are associated with particular clinical presentations and viral mutations. Chronic 
hepatitis in genotype A is more prevalent than in genotype D, whereas the opposite 
situation is found in patients with acute hepatitis and drug addicts. On the other hand, 
Genotype A patients were less likely to develop HBV recurrence or die after liver 
transplant compared with genotype D patients (Girlanda et al., 2004), biochemical 
remission, clearance of HBV DNA and clearance of HBsAg are more common in 
genotype A than D (Payungporn et al., 2004). In addition, genotype A infections had a 
better prognosis than the more aggressive genotype C. Fulminant hepatitis occurs in 
genotype B (ayw and adw2), sub genotype Bj (41%) (Sugauchi et al., 2006). Genotype B 
may have motifs that bind to HLA class I molecules, thereby activating stronger immune 
response (Imamura et al., 2003). Genotype C (subtype adr) is more common in cirrhotic 
patients and hepatocellular carcinoma (HCC) patients older than 50 years (Chen et al., 
2004). Genotype Care more resistant to interferon therapy than genotype A (Suzuki et al., 
2004) or genotype B. Although subgenotype Ba shows a poorer response to therapy than 
Bj (Akuta and Kumada, 2005). However, vaccination with HBsAg from different HBV 
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sero/genotypes can prime cross-reactive, specific CD8 (+) T-cell immunity that breaks 
tolerance to HBsAg (Schirmbeck et al., 2003). 
 
4.1.2.6. Genotyping Methods 
Sequencing of specific genes or even the whole genome is the gold standard for HBV 
genotyping. Genotyping is also done by restriction endonuclease digestion of HBV PCR 
products of the S gene, i.e. restriction fragment length polymorphism (RFLPs) 
(Mizokami et al., 1999) (Lindh et al., 1998); Post-PCR hybridization or line probe assays 
(Grandjacques et al., 2000); Multiplex PCR (Naito et al., 2001) using genotype specific 
primers; Simultaneous HBV genotyping and quantitation by real-time PCR (Payungporn 
et al., 2004). Usuda et al., (1999) raised genotype-specific monoclonal antibodies. 
Cloning can assist in the study of different HBV genotypes and mutants especially in 
patients with coinfection and mixed viral populations. 
 
4.2. Hypothesis 
Saudi Arabia is an HBV endemic area. Whether HBV genotypes influence viral 
characteristics and clinical presentation. The natural history of HBV disease, as well as 
factors affecting disease progression remains to be explored. HBV patients from UK, a 
low incidence country were included for comparison.  
 
Certain sequence differences occur between genotypes that determine the specificity the 
primer binding sites, and hence validate the genotyping PCR. 
 
4.3. Aim 
The aim is to gain insight into the molecular epidemiology, prevalence and distribution of 
HBV genotypes in Saudi Arabia and UK. 
To analyze genotype associated HBeAg seroconversion, clinical presentations and liver 
disease.  
To validate the genotype specificity of the primers used in genotyping assay.  
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To clone different HBV genotypes to provide high concentration of each genotype as 
reliable pure controls for both the multiplex genotyping PCR and the RFLPs genotyping 
assay.  
To verify infections with multiple genotypes, to confirm whether these had more than one 
viral genotype. 
To assess whether HBV DNA level interferes with the outcome of HBV genotyping 
methods.  
4.4. Patients and Methods 
4.4.1.  Patients Details (see chapter 3;  3.5.1.1.and 3.5.1.2.) 
DNA was extracted from sera of 130 Saudi and 105 UK patients. 
 
4.4.2.  HBV Multiplex Genotyping PCR 
A nested multiplex PCR to detect conserved regions of the pre-S1 and S-gene was 
established for the purpose of genotyping HBV in clinical samples (Naito et al., 2001); 
the first-round PCR using outer pair universal primers P1 (sense) and S2 (antisense) 
(table 4-2 and fig.4-4) product size (1,097 bases). The reaction mixture contains  0.125µl 
of hot start Taq polymerase (Qiagen), 5pmol of each primer (MWG-Biotech Ltd), 2.5µl 
10x buffer (containing 15mM Mg Cl2, Qiagen), 100 nM of each of four deoxynucleoside 
triphosphate (dNTPs) (Roche) and 2µl DNA template giving a total volume of 25µl in 
sterile distilled water (Sigma). The amplification program had a hot start at 95oC for 15 
minutes, followed by 40 cycles of 94oC for 20 seconds (denaturation), 55oC for 20 
seconds (annealing) 72oC for 1 minute (extension); followed by further extension at 72oC 
for 10 minutes, after  that the product was kept at 4oC.  The second-round PCRs were 
performed for each specimen using primers (inner pairs) in two different combinations; 
mix A for genotypes A, B, and C; using universal primer B3 (sense) and A4 (genotype A-
specific, antisense), R5 (genotype B-specific, antisense), and C6 (genotype C specific, 
antisense). Mix B for genotypes D, E, and F, using primer R10 (antisense) and D7 
(genotype D-specific, sense), E8 (genotype E specific, sense, and F9 (genotype F-
specific, sense). 2µl of the first PCR product was added to each mix and the same 
components as the first reaction. These were amplified for 40 cycles with the following 
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parameters: mixture contains 0.125µl of hot start Taq polymerase (Qiagen), 5 pmol of 
each primer (MWG-Biotech Ltd), 2.5µl 10x buffer (containing 15mM MgCl2, Qiagen), 
100nM of each of four deoxyribonucleoside triphosphates (dNTPs) (Roche) and 2µl 
DNA template giving a total volume of 25µl in sterile distilled water (Sigma). The 
thermal cycler program starts with 95oC for 15 minutes, followed by 20 cycles of 94oC 
for 20 seconds (denaturation), 58oC for 20 seconds (annealing) 72oC for 30 seconds 
(extension). Then an additional 20 cycles of 94oC for 20 seconds, 60oC for 20 seconds, 
72oC for 30 seconds; followed by further extension at 72oC for 10 minutes (PT-200 
Peltier Thermal Cycler). The PCR product was kept at 4oC. 9µl of the products of this 
second round PCR were electrophoresed on 2% agarose gel, and are differentiated by the 
size of genotype-specific bands compared to DNA marker (Roche molecular weight 
Marker XIV(100 bp ladder)(11721933001). 
 
4.4.2.1.   Optimization of the Multiplex Genotyping PCR 
Many factors can influence the efficiency of a PCR reaction; these include the 
concentration of the DNA, the magnesium concentration, the number of cycles in the 
reaction and primer design, which includes related factors such as annealing temperature. 
Cycle numbers were modified in some of the PCR programs to obtain perfect 
amplification products from PCR reaction. Optimization of PCR conditions was 
performed by the modification of some of these factors to achieve best amplicon yield. 
4.4.2.1.1.   Optimization of the first round PCR  
The PCR conditions were altered to improve final PCR bands as follows: annealing at 
55oC for 1 minute instead of 20 seconds, extension at 72oC for 3 minutes instead of 1 
minute 
4.4.2.1. 2.  Optimization of the second round genotyping PCR   
Q-solution (QIAGEN) was added 5µl per reaction to increase the stringency of the PCR. 
The amplification cycle was modified to 25 cycles of 94oC for 20 seconds (denaturation), 
58oC for 20 seconds (annealing) 72oC for 1 minute (extension); and an additional 30 
cycles  of 94oC for 20 seconds, 60oC for 20 seconds, 72oC for 1 minute; followed by 
further extension at 72oC for 10 minutes. 
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Table 4-2: Primers of multiplex PCR for HBV genotyping (Naito et al., 2001). 
Primer Sequence Position  Polarity Specificity Product  
size 
New 
product 
size  
Melting 
Temp.Tm 
First 
round 
PCR 
P1 
 
5`-TCACCATATTCTTGGGAACAAGA3` 
 
nt. 2823-2845 
 
Sense 
 
universal 
 
 
1097 bp 
  
57.1oC 
S2 5`-CGAACCACTGAACAAATGGC-3` nt. 704-685 Antisense universal  57.3oC 
B22 5`-CAAT (A/T)C (G/T) (C/T) TGACA 
(A/G/C/T) ACTTTCCAAT-3` 
nt. 996-977 Antisense Universal 1389 bp 
 (P1 and 
B22)  
  
64.2oC 
Second 
round 
PCR: Mix 
A 
B3 
 
 
5`-GGCTCM (A/C)AGTTCM 
(A/C)GGAACAGT-3` 
 
 
nt. 67-86  
 
 
Sense 
 
 
Universal  
 
 
 
 
 
 
 
 
59.4oC 
A4 5`-CTCGCGGAGATTGACGAGATGT-3` nt. 134-113 Antisense  Genotype A-
specific 
68 bp 178 bp 62.1oC 
R5 5`-CAGGTTGGTGAGTGACTGGAGA-3` nt. 345-324 Antisense Genotype B-
specific 
279 bp 389 bp 61.8oC 
C6 5`-GGTCCTAGGAATCCTGATGTTG-3` nt186-165 Antisense Genotype C-
specific 
120 bp 230 bp 60.3oC 
Mix B 
D7 
 
5`-GCCAACAAGGTAGGAGCT-3` 
 
nt. 2979-2996 
 
Sense 
Genotype D-
specific 
 
119 bp 
 
200 bp 
 
56.0oC  
E8 5`-CACCAGAAATCCAGATTGGGACCA-3` nt. 2955-2978 Sense Genotype E-
specific 
143 bp 224 bp 62.7oC 
F9 5`-GYTACGGTCCAGGGTTACCA-3` nt. 3032-3051 Sense Genotype F-
specific 
66 bp 147 bp 60.4oC 
R10 5`-GGAGGCGGAT (C/T)TGCTGGCAA-3` nt. 3097-3078 Antisense Universal  276 bp 357 bp 62.4oC 
New 
Primers l 
B13N 
5`-AGGAAGR (A/G) M (A/C) AGCCTACK 
(G/T) CCC ±3` 
 
nt. 3139-3156 
 
Sense 
A-C 
Universal 
   
59.9oC 
R11 5`-TGCAT (G/T) GCCTG (A/T) GGATG 
(A/T) GTGT-3` 
nt. 3197- 3176 antisense Universal 
D-F 
  61.2oC 
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HBV Genome: 
Pre-S/S gene: 2848 - 833 
nt. 284                                                              3172    0                     155                                                                                      833nt 
 
 
 
 
P1        E8       D7       F9        R10     B13N     R11   B3            A4                  C6                    R5                                    S2 
2823   2955   2979    3032     3097     3139    3197   67-86     113-134          165-186            345-324                       685-704 
 
Figure 4-4: A diagram to show the binding sites of different multiplex PCR primers 
First round primers are P1 (sense), and S2 (antisense). Second round primers in two different mixes; Mix A: primersB3 
(common antisense primer), B13N (new common sense primer), A4 (antisense; genotype A-specific), R5 (antisense; genotype 
B-specific), C6 (antisense; genotype C-specific). Mix B: primers D7 (sense; genotype D-specific), E8 (sense; genotype E-
specific), F9 (sense; genotype E-specific), R10 (common antisense primer), R11 (new common antisense primer).    
         PreS1 region                                       PreS2                             S-gene 
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4.4.2.1.3.   Optimization of the first round product for sequencing 
The PCR conditions were altered to give visible product of the first round PCR by 
undergoing a second run with the same primers 
 
4.4.3.   HBV Genotyping by TRUGENE Kits  
The TRUGENE HBV genotyping kit with Open GeneTM Sequencing System (Visible 
GeneticVZDVXVHGDFFRUGLQJWRPDQXIDFWXUHU¶VLQVWUXFWLRQV7KHSULQFLSOHLVWRDPSOLI\
and sequence part of HBV S gene in gel electrophoresis tower. Then sequences are 
compared to stored database on established genotypes and mutations. 
 
4.4.4. Genotyping by restriction Fragment Length Polymorphism   
Using PCR to amplify conserved sequences that are genotype-specific, a nested PCR 
(Mizokami et al., 1999) was performed with the first-round sense primer F1, and 
antisense primer R2. The second round inner sense primer F3 and the antisense primer 
R2 (table 2-3). The reaction mix contains 0.125µl of hot start Taq polymerase (Qiagen), 
5pmol of each primer (MWG-Biotech Ltd), 2.5µl 10x buffer (containing 15 mM MgCl2, 
Qiagen), 100 nM of each of four deoxyribonucleoside triphosphates (dNTPs) (Roche)  
and 2µl DNA template giving a total volume of 25 µl in sterile distilled water (Sigma). 
The thermal cycler program was 95oC for 15 minutes; followed by 40 cycles of 94oC for 
15 seconds (denaturation), 60oC for 45 seconds (annealing) 72oC for 45 seconds 
(extension). An additional 20 cycles of 94oC for 20 seconds, 60oC for 20 seconds, 72oC 
for 30 seconds, followed by further extension at 72oC for 7 minutes, after that the product 
was kept at 4oC. 
 
Restriction digestions (RFLP) were carried out with 5µl of the second-round PCR 
product for 3.5 hours after adjustment with 10x enzyme reaction buffer according to 
manufacturer`s recommendations. Reactions were carried out with 10 units of AlwI, 
HphI, NciI, NlaIV, or EarI (New England Biolabs) and 1% bovine serum albumin (BSA), 
at 37oC, according to the scheme on graph4-2. The digested PCR products were 
electrophoresed on 3% agarose gel in 1xTBE buffer (134 mM Tris-HCl, pH 10; 68 mM  
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Figure 4-5: Scheme for restriction enzymes digestion for genotyping of HBV 
 HBV S gene  
 Second round PCR product=485 bp  
First step   
                  Cleavage with AlwI=485 bp Genotype C 
Second step   
                  Cleavage with EarI=485 bp Genotype B 
Third step   
 Cleavage with HphI and NciI=379 bp Genotype E 
                                       =485 or 438 bp Genotype F 
Final step   
                Cleavage with NlaIV=485 bp Genotype A 
                                                   =186 bp Genotype D 
 
Boric acid, 2.5 mM EDTA) containing 500 ng ethidium bromide per ml. The RFLPs 
pattern was then visualized under ultraviolet light. 
 
4.4.5.  Quantitative HBV PCR:  
See Chapter 3. 
4.4.6.  Primer Alignment Method: 
Clustal X alignment of each of the 11 primers of the multiplex genotyping PCR; P1, S2, 
B3, newB3, A4, R5, C6, R10, D7, E8, and F9, was performed with two distant isolates of 
each genotype from Gene Bank  as follows: genotype A; Z35717 and X51970, genotype 
B; X97850 and M54923, genotype C; X75665 and D50517, genotype D; X80925 and 
U95551, genotype E; X75657 and X75664, genotype F; X69798 and X75658, genotype 
G; AF 160501, genotype H; AY090457 and AY0900460. 
 
4.4.7.   HBV Genotypes Cloning: 
4.4.7.1. PCR amplification of S-gene 
Single round of PCR of a 1397 bp region using primers P1 (sense nt. 2823-2845) and 
B22 (anti-sense nt. 996-977) yielded sufficient quantities of amplification products for 
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cloning of genotypes A, B, C, and D. The genotype E control sample gave a visible band 
only after two rounds of PCR using the same primers. The PCR reaction mixture 
contained 200 µM of each primer, dNTP mix 200 µM of each, 2 µL template DNA, 
buffer with MgCl2 and Taq polymerase 0.125µL per tube. Sterile water was added to 
final volume of 25µL. The PCR reaction conditions were 10 minutes at 94oC, then 55 
cycles of 45sec at 94oC, 1 minute at 55oC, and 3 minutes at 72oC. A final extension step 
at 72oC for 7 minutes was done, followed by soak at 4 oC. After gel electorphoresis, 
some bands were excised and gel was purified using QIAquick PCR purification Kit 
(QIAGEN). 
 
4.4.7.2.  Quantitation of PCR product DNA  
The relative amount of DNA in 5µl of PCR products was estimated by gel 
electrophoresis with quantitative 1kb DNA ladder (Biolabs, N3232S). 1µl of the ladder 
mixed with 4µl water and 1µl 6x gel loading buffer. The intensity of bands was compared 
to the known quantities of the ladder bands that range from 33 to 125 ng.   
 
4.4.7.3.  Ligation. 
Amplified S-gene products PCR products were cloned using the pCR3.1 (30ng/µl) vector 
by TA overhang cloning kit (Invitrogen®). This vector does not require restriction 
enzyme cleavage for subcloning. It also contains a T7 and BGH priming sites that 
facilitate the screening for incorporated DNA (inserts). Quantity of the PCR products 
used ranged from 1-2µl, with an average insert length of 1300 bp, gave a ratio of 1:2 
(vector-insert) offering the best ligation. Ligation mixture also containing T4 ligase (4 
units/µl), (10x Ligation buffer), distilled water was added to a final volume 10µl and 
incubated at 16oC overnight. This vector contains T7 promoter/priming site, BGH reverse 
priming site, ampicillin resistance gene for selection and maintenance of the insert in 
E.coli, thereby facilitating the screening for the presence and orientation of the insert.   
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4.4.7.4.   Transformation 
Ligated plasmids with the S-gene insert of each genotype were used to transform 
Escherichia coli TOP10F cells (competent cells). 2µl of each ligation mixture was 
aliquoted into 25µl of TOP10F cells; the vials were incubated on ice for 30 minutes, heat 
shock for 30 seconds in 42oC water bath and immediately placed on ice. 125µl of SOC 
medium (Invitrogen®) was added at room temperature and incubated in a shaking 
incubator at 37oC for 1 hour at 225rpm. Two different volumes of each transformation 
(100 and 25µl) were plated on Luria-Bertani agar (LB) (Invitrogen®) containing 
ampicillin 50mg/µl), to allow for selection of bacteria harbouring the pCR3.1 since the 
ampicillin resistance gene is located on the vector. These plates were incubated at 37oC 
overnight. 
 
4.4.7.5.   Screening for insert 
Individual colonies were screened for the presence of the S-gene insert, using the vector 
primers T7 (sense nt. 638-657) (0.5µM) (5`-TAATACGACTCACTATAGGG-3`) and 
BGH (antisense nt. 831-813) (5`-TAGAAGGCACAGTCGAGGCT-3`). PCR reaction 
volumes are as follows; 200µM of each primer, dNTP mix 200µM of each, buffer with 
MgCl2 1.5mM and 2.5 units Hotstar Taq polymerase (QIAGEN) per tube. Sterile water 
was added to final volume of 24µL. Individual colonies were picked and added to PCR 
tubes. The PCR reaction conditions were 10 minutes at 94oC, then 35 cycles of 1 minute 
at 94oC, 1 minute at 50oC, and 2 minutes at 72oC. A final extension step at 72oC for 7 
minutes, followed by soak at 4oC. 
 
The direction of inserts was verified for the correct orientation. The vector sense primer 
T7 and the insert specific antisense primer B22, the second reaction using vector reverse 
primer BGH and primer B22 for genotypes A, B, and C. For genotypes D and E primers 
T7 and R11 (common antisense primer for genotypes D, E and F), and BGH and R11 
were used. PCR reaction volumes are as follows; 200 µM of each primer, dNTP mix 200 
µM of each, buffer with MgCl2 1.5mM and 2.5 units Hotstar Taq polymerase per tube. 
Sterile water was added to final volume of 24µL. Individual colonies were picked and 
added to PCR tubes. The PCR reaction conditions were 10 minutes at 94oC, then 50 
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cycles of 45sec at 94oC, 45sec at 50oC, and 3 minutes at 72oC. A final extension step was 
done at 72oC for 7 minutes, followed by soak at 4oC. 
 
4.4.7.6.  Plasmid extraction 
Plasmid extraction from bacteria was done using QIA prep Kits (QIAGEN). 
  
4.4.7.7.  Quantitation of plasmid DNA 
4.4.7.7.1. Fluorometry 
Measurement of plasmid DNA using Hoechst 33258 fluorochrom was used for an 
accurate estimation of the amounts of DNA. In the presence of DNA, the fluorometer had 
an excitation spectrum that peaks at 365nm and an emission spectrum that peaks at 
458nm. Calf thymus DNA 200ng/µl (Sigma) was used as standard. All measurements 
were made in TNE buffer (10mM Tris pH 7.4, 1mM NaCl, 100mM EDTA with 1ug/ml 
Hoechst-33258 dye)  
4.4.7.7.2. Nanodrop machine 
The amount of DNA was measured using the Nanodrop® NDd-1000 UV-Vis 
spectrophotometer (NanoDrop Technologies, Inc.) according to absorbance at 
wavelength 260/280 (UV light).   
 
4.4.7.8. Calculation of plasmid copies per microLiter 
The PCR insert is 1397 bp length, and the pCR3.1 vector size is 3100 bp, both give a 
total of 4481 bp. Each base pair ( bp) weighs 662 daltons. 
A dalton weighs 1.6605655 x 10-24grams or 10-15ng (Avogadro`s constant). 
Mass of 1 plasmid in ng = (vector size bp + insert size bp) x 662 x1.6605655 x10-15 ng 
Plasmid  copies per µl =  concentration of plasmid in ng/µl 
                                              mass of 1 plasmid in ng 
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4.5. HBV Genotyping Results 
4.5.1. Studying the Alignment of the Multiplex PCR Primers 
There are several considerations to be fulfilled in primer design. Each primer/probe set of 
the multiplex must amplify well by itself. A complementarity matrix was run to ensure 
that the primers do not interfere with each other, and tested for primer dimer formation as 
well. Also melting temperature (Tm) and Mg++ concentration was matched. The sequence 
of the 12 primer binding sites from all HBV genotypes was analyzed (Table s 4-4, 4-5).   
4.5.1.1.  The first round PCR 
Primers P1 (sense nt. 2823-2845) and S2 (antisense nt. 704-685) align fully with all 
genotypes A-H at the 3`end. Nevertheless, 1 to 2 nucleotides discrepancy occurs in P1 
with genotypes B, D, E, G, and H. Only two nucleotides discrepancy was observed in 
genotypes F and H with primer S2. In conclusion, first round PCR amplify a 1097 bp 
segment from all genotypes, due to their annealing to highly conserved sequences.  
4.5.1.2.  The second round PCR 
Mix A 
Primer B3: Genotypes A-C common primer 
The old B3 primer aligns completely to genotypes A, B, C and E. Discrepancy occurs in 
genotypes D, F, G and H, thus increasing the specificity of the assay (table 4-3). The 
main reason to design the new B13N primer was that the size of the genotype-A specific 
band of 68 bp was very small, which is mixed up with primer dimers common to 
multiplex and other PCRs, giving false positive and false negative results owing to the 
size of the product. 
Primer B13N: Genotypes A-C common primer 
The new B13N primer aligned completely to genotypes A, B, and C. At the 3`end, only 
one discrepancy was found in genotypes D, E, F and H, which decreases the chances of 
priming to those genotypes, and increases this primer specificity. Although genotype G 
had 1 discrepant nucleotide, it is complementary to B13N primer 3`end. Hence, the new 
B3 primer amplifies genotypes A, B, C, G and H. This highly conserved segment aligned 
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also to the sequences of our HBV cases (see appendix A). The genotype-related variation 
G to A was also accounted for in this redundant primer. 
Primer A4 Genotype ±A specific Primer 
Primer A4 anneals completely with genotype A sequences, and has discrepancies with all 
other genotypes in the 3`end (table 4-4). In conclusion, A4 is a reliable highly specific 
primer with remote possibility of alignment with any other genotype.  
Primer R5: Genotype-B specific Primer 
Primer R5 aligns completely with one genotype-B sequence X97850, but had one 
discrepant nucleotide with other strain; M54923, 2nt. before the 5`end. This primer had 
discrepancies with other genotypes A, C, D, E, F and G. There is a remote possibility of 
annealing with genotype H. 
Primer C6: Genotype-C specific Primer 
Primer C6 anneals completely to genotype C sequences. It shows discordance with 
genotypes A, B, D, E, F, G, and H (table 4-4). Therefore it is highly specific for genotype 
C detection. Our genotype C cases show at one nucleotide before the 3` end with A to C 
change, although the primer did amplify those cases (N16, N19, and N45), it is accounted 
for by the redundant base A/C.  
Mix B: Primer R10: Genotypes D-F common primer 
Primer R10 shows complete alignment with genotypes D, E, F, and G. But one genotype 
E strain; X75664 had one discrepant nucleotide in the middle of the sequence. 
Discordance occurs with genotypes A, B, C, and H. Hence, primer R10 can amplify 
genotypes D, E, F, as well as genotype G (table 4-4). 
Primer R11: Genotypes D-F common primer 
Primer R11 shows complete alignment with genotypes B, D, E, F, and H. Only one 
nucleotide was discrepant in genotypes A, C and G. 
Primer D7: Genotype-D specific Primer 
Primer D7 had complete alignment only with genotype D. It shows discordance with all 
other genotypes at its3`end. This primer is highly specific for genotype D detection. 
Primer E8: Genotype-E specific Primer (sense nt. 2955-2978) 24 bp 
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Primer E8 aligns completely with genotype E sequences. It shows marked discrepancies 
with all other genotypes as genotype A, B, C, D, G, and H at the 3`end of those 
genotypes. There is the very slight difference in size of genotype D from genotype E 
bands reaching 24 bp only. 
 
Primer F9: Genotype-F specific Primer (sense nt. 3032-3051) 20 bp 
Complete alignment is observed with genotype F sequences, whereas it shows marked 
discordance with all other genotypes. Therefore, although this primer is specific for 
genotype F, its alignment to genotype H is possible.  
 
Generally, the specificity of all those primers was high in relation to Saudi and UK 
samples as proved after sequencing HBV isolates from UK and Saudi patients. Primers 
were also examined by software for secondary structure and for specificity and for 
primer-dimer formation. 
 
4.5.2.  Analysis of DNA sequences 
DNA sequences were further analyzed using SeqMan 2 of DNA Star software package 
(Chapter 6). Phylogenetic analysis was performed to define the HBV genotypes and 
subgroups based on >8% and >4% heterogeneity of the entire HBV genome, 
respectively. 
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Table 4-3: Discrepancy of each genotype with the second round genotyping PCR common primers. 
The sequence of the 6 primer binding sites with two distant isolates from each genotype; the number of nucleotides discrepancy of each 
sequence was calculated, with their percentage in relation to the total number of nucleotides in the relevant primer. Discrepancies at the 
3`end of the primers were also analyzed, which mostly determine the specificity and their annealing to viral genome.  
* One discrepant nt. before the 3`end. 
 
Table 4-4: Discrepancy of each genotype with the second round PCR genotype-specific primers: Mix A and B 
 
Genotype 
Discrepancy 
Primer A4 (A- 
specific) (20 bp)  
Primer R5 (B-
specific) (19 bp)  
Primer C6 (C-
specific) (20 bp)  
Primer D7 (D- 
specific) (20 bp)  
Primer E8 (E- 
specific) (19 bp)  
Primer F9 (F-
specific) (20 bp) 
 3` Total (%) 3` Total (%) 3` Total (%) 3` Total (%) 3` Total (%) 3` Total (%) 
A 0 0 1 3 (14)  2 2 (9)  2 3 (17)  2 6 (25)  1 5-6 (25-30)  
B 1 5-6 (23-27)  0 0-1 (5)  3 4-5 (15-20)  2 3-4 (17-22)  1 5-6 (20-25)  1 5-7 (25-35)  
C 1 4 (18)  1 3 (14)  0 0 (0)  1 4-5 (22-28)  2 6-7 (25-29)  1 5 (25)  
D 1 4-5 (18-23)  1 3 (14)  2 2-4 (9-14)  0 0 (0)  2 4-5 (17-20)  1 8 (40)  
E 1 3 (14)  1 2-3 (9-14)  2 2 (9)  2 2 (11)  0 0 (0)  1 5-6 (25-30)  
F 1 6-7 (27-32)  1 4 (18)  2 3 (14)  2 3 (17)  2 7-8 (29-33)  0 0 (0)  
G 1 4 (18)  1 4 (18)  2 2 (9)  2 2 (11)  2 5 (20)  1 5 (25)  
H 1 7 (32)  0 3 (14)  2 3-4 (14-18)  2 3 (17)  2 7 (29)  0 1-2 (5-10)  
Genotype Discrepancy 
Primer B3 (A-C-specific) 
(20 bp)  
Primer B13N (A-C-
specific) (19 bp)  
Primer R10 (D-F-specific) 
(20 bp)  
Primer R11 (D-F 
specific) (20 bp)  
3` Total (%) 3` Total (%) 3` Total (%) 3` Total (%) 
A 0 0 (0)  0 0 (0)  1 5 (25)  1 1 (5)  
B 0 0 (0)  0 0 (0)  1 3-4 (15-20)  0 0 (0)  
C 0 0 (0)  0 0 (0)  1 4-5 (20-25)  1 1 (5)  
D 0-1 0-1 (0-5)  1 2 (10)  0 0 (0)  0 0 (0)  
E 0 0 (0)  1 2 (10)  0 0-1 (0-5)  0 0 (0)  
F 2-3 3-4 (15-20)  1 5 (26)  0 0 (0)  0 0 (0)  
G 0 2 (10)  0 1 (5)  0 0 (0)  1 1 (5)  
H 2 3 (15)  1 3-4 (16-21)  1* 3-4 (15-20)  0 0 (0)  
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4.5.3. Comparison of Different Genotyping methods 
39 out of 232 sera had low or undetectable HBV DNA not permitting genotyping by any 
method. Some of the patients were genotyped by more than one assay to confirm the 
results of our multiplex PCR. 83 patients were genotyped by VISGEN kits. The multiplex 
PCR had genotyped a total of 188 out of 232 patients (81%). Only two patients had false 
negative genotype and another two patients had different genotype than S-gene 
sequencing. The VISGEN genotyped 70 out of 86 (81.4%). Virus from two patients did 
not genotype by this method. One case was not genotyped by both methods, due to very 
low HBV DNA as measured by real-time PCR (table 4-5). Using the results obtained by 
direct sequencing and phylogenetic analysis of the S-gene as the reference method, the 
accuracy and specificity of HBV genotyping by multiplex PCR was high at 31/33 (94%).  
 
The levels of concordance of the multiplex PCR with the results obtained by single 
genotype-specific primers, were 98% for single infection, 100% of multiple genotypes 
from the same as mix A for genotypes A, B, and C, and for double infections from 
different mixes A for genotypes A, B, and C, or mix B for genotypes D, E, and F. The 
multiplex PCR was superior to all other methods as sequencing and Visgen Kits in 
detecting double or multiple HBV genotypes infections as expected. 
 
                 M       1        2        3        4         5        6        7         8      9        10      11 
 
Figure 4-6: First round of Multiplex nested genotyping PCR:  
Lane M: 100 bp DNA ladder, UK specimens, lane 1: specimen N1, lane 2: N2, lane3: N3, lane 4: 
N4, lane 5: N5, lane 6: N6, lane 7: N7, lane 8: N8, lane 9: N9, lane 10: N10, lane 11: Negative 
control.
1000 bp 
1097 bp 
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Table 4-5: Detection by different HBV genotyping methods in sera from UK patients.  
Concordance of HBV genotyping results between multiplex PCR, S-gene sequencing and core 
gene sequencing results with Visgen (p: 0.01). 
Genotype Multiplex 
PCR  
S-gene 
sequencing 
Core promoter 
sequencing 
Visgen Kits RFLPs 
  (concordance with Visgen) 
A ^ 17/18  17/17  11/13  17/18*  6  
B 11/11  6/6  7/9  11/11  2  
C 6/8  6/6  5/7  *6/8  3  
D 14/14  7/7  7/8  13/14  7 
E 4/4  3/3  2/2 4/4  1  
Multiple 
genotypes  
2/0  0 0 0 0 
Ungenotypable  9/11 3/3 3/3 9/11 0 
Not done  0 31 27 0  0 
Total 64 64 64  64 19 
Note: Multiple genotypes were also counted with single genotype patients 
*One case not genotyped by Visgen. 
^Two patients showed bigger bands by multiplex PCR (p: 0.01)  
 
Table 4-6: Comparison of genotyping techniques for HBV 
Features Multiplex  
PCR 
S-gene  
sequencing 
Core gene 
sequencing 
Visgen  
Kits 
RFLPs Probe  
Hybridization 
Principle Genotype 
specific 
primers 
Phylogenetic 
analysis  
Phylogenetic 
analysis  
Sequencing Genotype 
specific 
restriction 
sites 
Hybridization 
to genotype 
specific probes 
Detection 
method 
PCR PCR, 
sequencing  
PCR, 
sequencing 
PCR,  
sequencing  
PCR, RFLP PCR, 
hybridization to 
labelled probes 
Sensitivity 95.7%  80%   94 %  97.1%  94 % 99.3%  
Specificity 98.5%  100%  91.7%  97.8%  100% * 100% 
Detection 
limit 
103 
copies/ml 
103 -104 
copies/ml 
103 copies/ml 103 104 
copies/ml 
104 copies/ml 
Multiple 
genotypes 
Detected No No No No Detected 
Comment Rapid Standard need 
experience 
Tedious, need 
experience 
Reliable, 
expensive 
Need high 
HBV DNA 
level 
Reliable, 
expensive 
*Only 19 cases done 
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Another 19 patients were genotyped by a restriction fragment length polymorphism 
(RFLP) based method (Colindale). 14/19 (73 %) gave the correct genotype by multiplex 
PCR, another 4 patients were genotyped correctly after increasing the input DNA to 4µl 
giving a total yield of 18/19 (94.7%). On the other hand, our multiplex PCR correctly 
identified 3 patients infected with double genotypes and one case with triple HBV 
genotypes, which were not detected by the RFLPs-based assay.  
4.5.3.1. Optimization of the multiplex PCR. 
The multiplex genotyping PCR was done, but several problems were encountered at the 
beginning; the first round product of the PreS/S gene size 1097 bp using universal 
primers P1 and S2 (fig.4-6), was also used for sequencing of the S gene and phylogenetic 
analysis to confirm the HBV genotype and to verify the specificity and consistency of the 
primer-binding sites (Chapter 6). 
 
The second round PCR bands were very faint to be visualized by gel electrophoresis 
despite the loading of 9 µl of the PCR products in each well. The PCR conditions were 
altered to give visible product, this further increased the band intensity, and improved the 
sensitivity of the reaction. Several nonspecific bands were seen in the second round with 
variable sizes and those could be due to multiple non-specific priming sites. The addition 
of Q-solution (QIAGEN) 5 µl per reaction had increased the stringency of the PCR, and 
diminished those nonspecific bands considerably.  
 
The common primers B3 for mix A: genotypes A, B and C, and primer R10 for mix B: D, 
E, F respectively, were initially employed in the second round PCR. The band of 
genotype A was very small 68 bp and was easily missed because it was faint, and can be 
dismissed as primer dimer (fig.3-9), or the other way round giving false positive results 
as genotype A were interpreted in negative samples. 
 
Consequently we modified the PCR products by altering the common A-C sense B3 
primer to primer B13N (sense nt. 3139-3157), which solved the problem and significantly  
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                                                       M       1       2       3       4      5 
 
Figure 4-7: Multiplex genotype PCR; old primers: 
M: 100- bp DNA ladder, lane1: genotype A, lane 2: genotype B, lane 3: genotype C, lanes 4 : mix 
B, 5: Negative control.  
 
 
                                                      M              1                2              3 
 
 
Figure 4-8: Multiplex genotyping PCR using new common primer B13N. 
Lane M: 50- bp DNA ladder, lane 1: Genotype A, Mix A using primer old B3 primer, lane 2: 
genotype A control, Mix A using new B13N primer, lane 3: genotype A in Mix B showing primer 
dimers indistinguishable from the old 67- bp genotype A band.     
 
 
 
300 bp 
100 bp 
200 bp 
300 bp 
200 bp 
100 bp 
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improved the detection of genotype A by eliminating false positive results (fig.4-8). 
Although the drawback was the smaller difference between genotype A and C bands 
which increase to 178 bp and 230 bp respectively, necessitating the presence of both 
controls in each gel. Replacement of the common anti-sense primer R10 with primer R11 
(anti-sense) had changed the proposed size of genotype F band is 66 bp which can go 
unnoticeable to 147 bp. Alternatively, genotype F±specific primer can be changed to 
(AGCACCTCTCTCAACGACA nt. 2840-2856) to better detect this genotype. However, 
we neither had a control genotype F stain, nor detected any case having this genotype. 
To verify the avidity of genotype-specific primers in multiplex mixtures, pure plasmid 
genotype controls (cloning section) were used. No difference in the genotyping results of 
the multiplex PCR was found using single, different combinations or multiplex primer 
pairs together.  
Originally, the detection limit of the genotyping PCR was 104HBV DNA copies/ml, but 
that was improved to103 copies/ml after optimization of the first round PCR conditions as 
mentioned in the methods chapter. The test was done on serial dilutions of the WHO 
HBV standard and plasmid preparations with known HBV DNA concentrations (see 
Chapter 2: Detection limits of different HBV PCRs).  
Genotyping results of UK and Saudi specimens: 
Genotyping 105 specimens from UK patients and 130 Saudi patients was done (fig.4-9), 
results are shown in tables4-8, 4-9.The first round PCR product covering the S gene was 
visible only in specimens with high HBV DNA measurment. Confirmation of genotypes 
was done by sequencing of the S-gene, and by Visgen HBV genotyping kits. Results 
showed the following fig4-8 and 4-9, table 4-7; No samples were detected in genotypes 
F, H, or G. Sample N2 was cloned into plasmid pCR 3.1 giving clone pEn2 whose 
sequencing shown genotype E. Overall, the high concordance between these results and 
sequencing results proved the reliability of our optimized multiplex genotyping PCR. 
Genotyping by VISGEN Kit had further confirmed our multiplex PCR results. 
Some UK specimens showed an aberrant genotype A band (fig.4-8, lane 5 in mix A), that 
was reproducible as samples N5 and N13 come from the same patient. 
 Chapter 4ȂHBV Genotypes 
100 
 
 
 
 
                        Mix A:   M       A      1       2       3      4       5      B       M 
 
                          Mix B:   M      D      1       2      3       4      5       E     M    
Figure 4-9: Modified multiplex HBV genotyping PCR on UK specimens  
M:100 bp DNA ladder, Genotype controls A: genotype A, B: genotype B, D: genotype D, and E: 
genotype E. Specimens in mix A (above) and mix B (below) lane 1: N1: genotype C (230 bp mix 
A), lane 2: N2: genotype E (143 bp mix B), lane 3: N3: genotype C, lane 4: N4: genotype A (178 
bp mix A), lane 5: N5: genotype A with slightly bigger sized band (200 bp mix A). 
 
 
 
 
 
 
200 bp 
400 bp 
 
200 bp 
  100 bp 
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Figure 4-10: 2% Gel electrophoresis of multiplex genotyping PCR of specimen N9 genotype 
B  
 
 
 
Mix A: showing double bands 389 bp and 400 bp were separated. 
 
                        1          2         3           4          5         6           7        8           9          M         
 
 
Figure 4-11: Cloning of specimen N9; giving two different clones;  
Lanes 1-4 dilutions of plasmid pB10 bands sized 389 bp, and Lanes 5-8 dilutions of plasmid 
pB11 bands sized 400 bp, Lane 9: negative control, M: 100 bp-DNA ladder. 
 
 
 
500 bp 
400 bp 
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The band exhibited a size around 200 bp, between that of genotype A (178 bp) and 
genotype C (230 bp), sequencing did not show any aberrant primer binding site, and the 
phylogenetic analysis of the S-gene aligned it to genotype A. That was also confirmed by 
VISGEN Kit.  
 
Another case had double genotype B bands, that consistently showed two different 
genotype B bands in all the three specimens collected from the same patient (N8, N9, and 
N10), thereby confirming the reproducibility of these results. Bands were excised and gel 
was purified using QIAquick PCR purification Kit (QIAGEN). One band was specific for 
genotype B (389 bp), while the other exhibited a size around 400 bp. Those bands were 
separated by prolonged gel electrophoresis (fig.4-10) and cloned into plasmids pB10 and 
pB11 (fig.4-11). Each clone had different genotype B band on genotyping PCR. The 
sequence of both pB10 and pB11 showed complete alignment with the original strain 
(N9) with genotype B. and both were genotype B.The reason for this is not clear. A 
possible explanation is that either there is another non-specific binding site for the primer, 
or the presence of single stranded DNA because the common sense primer B13N was a 
redundant primer, as we doubled its amount in the mix A reaction to provide sufficient 
quantity of each variety of this primer. A change in restriction site by polymorphism was 
shown upon computer analysis of one Gene Bank HBV isolate. 
4.5.3.2. Double and multiple genotypes 
Patients with double genotypes were not revealed by direct sequencing as expected. 
Several genotyping results of UK and patients showed multiple bands (4-12). Other 
genotyping methods did not reveal any case with multiple genotypes. 
 
4.5.3.3. HBV genotypes in UK and Saudi patients 
In UK, HBV genotype A was the most common, genotype D was less frequent followed 
by genotypes B and C (table 4-7). Genotype E was rare. Some genotypes B and C in UK 
patients had Chinese ethnicity, while most genotype D patients were Asian.  In Saudi 
patients, genotype A and D were most frequent genotypes. Genotypes B, C and E had 
low frequency.  
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Table 4-7: The distribution of HBV genotypes in UK and Saudi populations. HBeAg status of different HBV genotypes in UK (p: 
0.003) and Saudi patients (p: 0.001) including age of patients (p: 0.07). 
Genotypes  UK Saudi 
HBeAg  
Positive 
HBeAg  
Negative  
Total  
 (% within 
nationality) 
Mean Age 
(years)  
HBeAg 
Positive 
HBeAg 
Negative   
Total  
 (% within 
nationality) 
Age  
 (mean in 
years)  
 (% within genotype)  (% within genotype) 
A  8 (27%) 22 (%) 30 (30%) 45 2 (9%) 20 (%) 22 (22%) 42 
B   8 (42%) 11 (%) 19 (19%) 38 0 (0%) 1 (%) 1 (1%) 42 
C  5 (38%) 8 (%) 13 (13%) 31 1 (25%) 3 (%) 4 (4%) 34 
D  6 (22%) 21 (%) 27 (27%) 31 12 (19%) 50 (%) 62 (62%) 41 
E  0 (0%) 6 (%) 6 (5.5%) 46 0 (0%) 6 (%) 6 (6%) 47 
Multiple genotypes 0 (0%) 6 (%) 6 (5.5%) 44 0 (0%) 5 (%) 5 (5%) 47 
Ungenotypable   0 (0%) 4 (%) 4  52 0 (0%) 30 (%) 30 42 
Total (valid %) 27 (26.7%) 78 (%) 105 40 15 (11.5%) 115 (%) 130 41 
 
 
Table 4-8: HBV DNA level (by quantitative real-time PCR) of different HBV genotypes by 
multiplex PCR in all Saudi and UK patients (p: 0.001). 
HBV 
Genotype 
No. of Saudi Patients in each 
viral load group (log10 
copies/ml) 
Mean 
HBV 
DNA 
(patients 
no.) 
No. of UK Patients 
in each HBV DNA group (log10 
copies/ml) 
Mean HBV 
DNA 
(patients 
no.) <=3  >3-<5  =>5  <=3  >3-<5  =>5  
A 3 5 6 4.22 (14) - 8 14 5.53 (22) 
B - - - - 2 3 13 5.65 (18) 
C 1 - 2 5.01 (3) - 4 6 6.13 (10) 
D 8 11 28 5.10 (47) 3 4 10 6.10 (17) 
E 1 2 3 6.09 (6) - 3 1 4.69 (4) 
Multiple 
genotypes 
- 1 1 4.73 (2) - - - - 
Ungenotyp-
able 
13 5 - 2.38 (18) 9 2 - 1.33 (11) 
Total 26(29%) 24(27%) 40 (44%)  (90) 14 (17%) 24 (29%) 44 (54%)  (82) 
 
 
 
Table 4-9: The correlation of HBV genotypes with clinical presentation of liver disease in 
UK and Saudi patients P: 0.192. 
 Genotype Inactive 
Hepatitis 
Total Liver 
Disease 
Acute 
Hepatitis 
Chronic 
Hepatitis 
Cirrhosis HCC 
UK 
patients 
A 3 16 (84%) 1 15   
B 3 12 (80%) 1 11   
C 2 12 (86%)  8 4  
D 3 17 (85%) 3 10 4  
E 1 3 (75%)  3   
Multiple 1 0 (0%)     
Ungenotyp
able 
7 2 (22%)   1 1 
Saudi 
patients 
A 12 12 (50%) 2 9  1 
B 0 0 (%)  0   
C 2 2 (100%)  2   
D 12 50 (81%) 13 33 6 2 
E 2 5 (71%)  2 3  
Multiple 1 2 (67%)    2 
Ungenotyp
able 
8 13 (62%)  10 2 1 
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In UK, HBeAg positivity is more in genotypes B, C than genotypes A and D, 42% , 38%, 
and 27% , 22% , respectively (table 4-7). Saudi genotype D had comparable number of 
patients with HBeAg to UK genotype D patients. Generally, HBeAg is higher in UK than 
in Saudi HBV patients at 26.7% and 11.5%, respectively.  
High HBV DNA was seen in HBV genotypes A, B, C and D in UK patients, A and D in 
Saudi patients (table 4-8). Low HBV DNAs were mostly ungenotypable.  In UK patients, 
genotypes C and D showed higher mean HBV DNA than genotypes A or B. Saudi cases 
had also higher mean  
HBV DNA in genotypes D than genotypes A, but only 6 genotype E showed the highest 
mean HBV DNA. Genotype D had higher HBV DNAs in UK patients than in Saudi 
patients at 6.10 and 5.10 log10 IU/ml, respectively. Patients with HBV genotype A had 
low and intermediate HBV DNAs (table 4-8). Although most genotype A patients with 
high HBV DNAs were from UK. 
 
Regarding the clinical presentation of HBV in UK patients, genotypes A and D had equal 
proportion of inactive hepatitis and liver disease (table 4-9). Patients with acute hepatitis 
had genotypes A and D. Cirrhosis is present in genotypes C and D patients. 
 
Saudi liver disease patients showed all spectrum of liver disease from acute hepatitis to 
HCC and had mainly HBV genotype D, and less proportion of genotype A. 
 
4.5.3.4. Cloning of HBV genotypes A to E  
4.5.3.5. PCR amplification of S-gene for cloning 
The amplification of the S/pol -gene with primers P1 and B22 mapping nt. 2823 to nt. 
996 (1389 bp) using control strains for genotypes A, B, C, D and E was done (fig.4-11). 
Single band was essential for cloning, because the smaller, unwanted products are easier 
to be incorporated into the vector. Genotype E showed visible band only after a second 
round of the same PCR. This PCR product covers the target sequences of both the 
multiplex genotyping PCR, and the RFLPs genotyping assay to provide high quality 
genotype controls for both tests. Quantitation of PCR product was done before cloning  
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Graph 4-1: Viral load of different HBV genotypes in all Saudi and UK patients 
 
 
                                      1          2          3         4          5          6          7 
 
Figure 4-12: Quantitation of the extended S/pol gene PCR amplified using primers 
P1 (nt. 2823-2845) and B22 (nt. 996-977).   
Product size 1389 bp. Using patients specimens, Lane 1: genotype A (WHO), lane2: genotype B 
(N9), Lane 3: genotype C, Lane 4: genotype D (3-38), Lane 5: genotype E (N2) (2nd round PCR), 
Lane 6: Negative control, and 7: quantitative 1kb DNA ladder (BioLabs: N3232S). Genotypes B, 
C and D showed good bands. Genotype E showed visible band only after a second round of the 
same PCR.
 
1500 bp 
1000 bp 
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Figure 4-13: Gel electrophoresis of T7, BGH screening of genotype B and genotype C 
clones.  
Lane 1:Negative control, lane 2: clone B5, lane 3: clone B6, Lane 4: clone B7, Lane 5: clone B8, 
Lane 6: clone B9, Lane 7: clone B10, Lane 8: clone: B11, Lane 9: cloneB12, Lane 10:cloneB13, 
M: DNA marker (100 bp ladder), Lane 11: clone C5, Lane 12:clone C6, Lane13: clone C7, Lane 
14: clone C8, Lane15: clone C9, Lane 16: clone C10, Lane 17: cloneC11, Lane 18: clone C12, 
Lane 19: clone C13, Lane 20: Negative control. Only clones in lanes 6, 7, 11 and 18 show the 
appropriate sized inserts (1600 bp). The rest of clones show no inserts as evidenced by the small 
size (200 bp) of the PCR product. 
 
                       1           2          3          4          5          6          7           M 
 
Figure 4-14: Orientation of plasmid inserts  
Plasmid preparations were screened by PCR using plasmid primer T7 and the internal 
primer B13N (T), and another PCR using primers B13N and BGH (B). Lane1: negative 
control, Lane2: pW6-T, Lane 3: pW6-B, Lane 4: pW7-T, Lane 5: pW7-B, Lane 6: pB11-
T, Lane 7: pB11-B, M: 100- bp DNA ladder. The expected product ~ 1180 bp, which is 
shown in lanes 2, 4 and 6 from antisense1400 bp insert (T7 and B13N primers).  
800 bp 
1000 bp 
1000 bp 
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using DNA marker with known concentrations (Roche molecular weight Marker XIV 
(100 bp ladder) (11721933001). 
4.5.3.6. Ligation and transfection of PCR product 
The PCR products were ligated to plasmid pCR3.1, then transfected into competent 
Top10 E. coli. After overnight incubation, the colonies were screened for the presence of 
the appropriate insert using vector specific T7 and BGH primers with bands about 1600 
bp (fig.4-12). The transformation yield was low, as only two clones were positive out of 
the 10-15 clones screened from plasmids for each HBV genotype.          
 
Plasmids were sequenced to confirm their identification and genotypes, and were further 
analyzed using SeqMan 3 of DNA Star software package. 
4.5.3.7. Determination of insert orientation within plasmids: 
After all plasmid preparations had a confirmatory screen for the correct size (1600 bp) 
inserts using vector specific primers T7 and BGH (fig.4-13). Several clones were 
screened to obtain the correct ones. The orientation of each insert inside plasmid was 
examined, using T7 and B13N, then B13N and BGH primers. The expected product ~ 
1180 bp which is shown in lanes 2, 4 and 6 from antisense  1400 bp insert  (T7 and B13N 
primers). The second product is ~ 780 bp from a 1000 bp insert (fig.4-14).  Possible 
explanation is a second priming site for B13N or BGH within the amplified S gene of 
HBV.  
4.5.3.8. Single primer verification of individual genotype clones   
The genotype of each plasmid preparation was verified using the corresponding primer 
mix (fig.4-15). Six single primer pairs were also used separately to verify the reliability 
of the multiplex PCR with each genotype (fig.4-16). All plasmids gave positive bands in 
both the multiplex PCR and the corresponding genotype specific single primer pair. In 
addition, negative results were seen with all other genotypes to further prove the 
specificity of the genotyping. 
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Figure 4-15: Verification of plasmid preparations genotypes: 
Using multiplex genotyping PCR   to confirm the genotype of each plasmid; lane 1: negative control, 
Mix A: lane 2: pW7 genotype A, lane 3: pB11 genotype B, lane 4: pC6 genotype C. Mix B: Lane 5: 
pD5 genotype D, Lane 6: pEn2 genotype E, M: 100 bp DNA ladder. 
 
                               M        1         2          3        4         5         6          7         8         M                    
 
Figure 4-16: HBV Genotype D PCR using single primers 
Lane M:DNA ladder, lane 1: genotype A-specific primerA4 and B13N, Lane 2: genotype B-
specific primer B5 and B13N, Lane3: genotype C-specific primer C6 and B13N, Lane 4: 
multiplex PCR mix B, Lane 5: genotype D-specific primer D7 and R11, Lane6: genotype D-
specific primer E8 and R11, Lane 7: genotype D-specific primer F9 and R11, Lane 8: Negative 
control. 
 
 
200 bp 
400 bp 
200 bp 
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4.6. Discussion 
 
In molecular approach, the presence of pathogen or product cannot be demonstrated 
without searching specifically for it, unlike general virology methods as cell culture or 
electron microscopy. The concept of multiplexing molecular tests as PCR originated from 
the need to screen for large number of different viruses, genotypes or sub genotypes 
together. Multiplex PCR provides a simple, precise, sensitive, easy to use, and practical 
method to identify the different genotypes of HBV. Verification of the specificity of these 
primers was essential. Based on the alignment of complete nucleotide sequence of 
different genotypes, the specific sequence of each genotype was found. The six primers 
used were one for each of the six genotypes according to genotype-specific sequences. 
Primer pairs were used separately and in multiplex PCR. Several multiplex-PCR assays 
are described, that uses genotype-specific primer pairs for HBV genotypes A-F 
(Kirschberg, 2004). These primer pairs specifically amplified HBV DNA of the 
respective genotype, either in single genotype PCR or in multiplex.  
 
Non-specific binding of primers can occur because of the minimal difference between 
genotypes, which may cause non-specific products of multiplex PCR as well as false 
genotyping. This assumption can be verified by comparing the primer binding sites of 
each genotype, and by analyzing the PCR products and sequencing the isolates, or by 
using different genotyping method as a confirmatory assay for the multiplex PCR results 
(Gunther, 2006). 
 
Detection limit 
This modified multiplex genotyping PCR had a high percentage of valid assay runs 
(95.4%). No false-positive results detected. Sensitivity was increased after optimization.  
In multiplex PCR, careful selection of primers is needed to avoid primer interactions that 
interfere with the sensitivity of the reaction. Each separate PCR was optimized singly on 
single and mixed genotype plasmid controls, before being assessed in optimized 
multiplex PCR (data not shown). Thus, further assessing the sensitivity of the multiplex 
assay for simultaneous detection of mixed infections and low copy targets in high copy 
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backgrounds as recommended by Gunson et al., (2006). The number of cycles required 
for optimum amplification varies depending on the quantity of the starting materials and 
the efficiency of each amplification step. 
 
Many of our specimens up to 30 specimens out of 160 (18.8%) (UK and Saudi sera) were 
non-genotypable by any method. The HBV DNA assay confirmed their low <103 
copies/ml or negative HBV DNA in the serum (table 4-8). Many of those had very low or 
negative DNA, and therefore their genotyping was not feasible. Some specimens gave 
results only after increasing the input DNA to 3Pl, but this also increased the non-specific 
bands. Due to the variability of HBV, or their detection limit, some diagnostic procedures 
risk giving false-negative results as reported in other studies (Bartholomeusz and 
Schaefer; 2004), thus influencing the yield of this method.  
 
Co infection 
Different methods were used to detect co infection with more than one HBV genotype. 
The drawback of multiplex PCR is the possible interference or masking of one 
component of test with the other products as found in mixing experiments (data not 
shown). It easy to detect double genotypes if they were in separate mixes; mix A 
(genotypes A, B and C) or mix B (genotypes D, E and F). Within the same mix, multiple 
genotypes are suggested by multiple bands, which then can be confirmed by single-
genotype primer pair PCRs used separately. We used cloning and sequencing to confirm 
double infection. Genotype-specific probes assay GSPA, better identified co-infection 
with HBV genotypes than PCR-RFLP on the S region, PCR-RFLP on the pre-S region 
(Lim et al., 2007), and 28 (10.9%) by genotyping using  hybridization with type-specific 
probes, while it was suggested by ELISA in only 2 (0.8%) sera (Kato et al., 2003). 
Coinfection seems to be more frequently detected by these methods. Different genotypes 
can co-exist, for example G and A or D and A, and the predominant genotype may shift 
during infection (Gunther, 2006).  Sequencing cannot detect mixed genotype infections. 
Discrepant as well as indeterminate results can occur between the different methods 
(Osiowy et al., 2003) (Bartholomeusz and Schaefer; 2004). 
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Contradicting genotype results raises the possibility of recombination. Recombinations 
involving genotypes A/C, A/D, A/E, B/C, and B/D have been described (Kurbanov et al., 
2005). Sequencing of suspected regions of HBV genome will exclude such a possibility. 
Genotyping by RFLPs 
Among the existing HBV genotyping methods, restriction fragment length polymorphism 
(RFLP) based methods are used widely, but HBV genetic variability may lead to wrong 
results. Comparison between RFLP and the multiplex PCR described gives 4% of 
discordance results, no untypable samples by RFLP. 
 
We had done HBV genotyping using RFLP method (Mizokami et al., 1999), but that was 
unsuccessful for several reasons; first, the detection rate of the test was very low  that is 
more than 4 log10  copies/ml as found in the cut-off experiments (data not shown). This 
did not suit our samples as a high proportion had low HBV DNA that was below this 
detection limit, giving no PCR product or faint band to begin with. Secondly, high 
amount of RFLP-PCR product was needed to cover the four different RFLPs digestions 
and an undigested control. Thirdly, the RFLPs scheme used was designed primarily to 
detect HBV genotypes B and C, which were not the main genotypes prevalent in UK or 
in Saudi patients. Lastly, the digestion into several bands was difficult to interpret, unlike 
RFLPs reactions, which digest into limited products whose sizes are distinct from the 
original starting band.  In addition, a change in restriction site by polymorphism was 
shown upon computer analysis of one Gene Bank HBV isolate.  Several RFLPs 
genotyping assays had been described, including a single RFLP assay (Rodriguez-Novoa 
et al., 2004) for both genotyping and lamivudine resistance. Other groups pointed out the 
limitations of RFLPs techniques, which need PCR conditions of sufficient specificity to 
produce a clean product that is digested and unambiguously analyzed. Incomplete 
digestion of the amplicon can further complicate the interpretation (Payungporn et al., 
2004). A change in the sequences can abolish a restriction site or introduce a new one. 
 
Cloning is used in HBV genotypes for several purposes. Known concentrations of cloned 
plasmid was essential both to determine the detection limit of each PCR assay, and to 
serve as control for quantitative real time PCR, and for all genotyping experiments as 
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PCR and RFLPs. Validation of reliable genotyping multiplex PCR required pure single 
genotype controls that give reproducible results with single primers. Also used for 
confirmation of patients with double genotypes by sequencing of all strains. Cloning was 
the only way for providing good controls to validate the specificity of the primers used, 
not only because of the higher concentration that can be achieved by plasmid encoded 
HBV, but also because of the purity of plasmid preparations.  
 
Our cloning vector was TA pCR 3.1 that was generally used for rapid cloning of PCR 
products without the need for restriction enzyme step before cloning. We successfully 
cloned the S-gene and part of the overlapping Pol gene of five HBV genotypes A to E, 
for the above reasons, and as a prerequisite to study differences in proteins encoded by 
different HBV genotypes and mutants. The HBV preS domain encodes hydrophilic 
polypeptides that had been implicated in the binding of the virus to hepatocytes, and in 
the induction of virus-neutralizing antibodies. Vaccine-escape mutants may cause 
alteration of antigenicity of HBsAg and binding to anti-S antibodies. Cloning and protein 
expression has been also used to study the pathogenesis, assess the replication capacity of 
clinical HBV isolates and to analyze drug susceptibility (Cheng et al., 2003). Site-
directed mutagenesis has been used to study the effects of point mutations in cloned HBV 
strains. The majority of cloned HBV genomes is suitable for further phenotypic 
characterization and can be used in resistance surveillance, cross-resistance analyses, and 
novel drug-discovery as adefovir susceptibility (Yang et al., 2004). 
 
HBV genotypes in UK and Saudi patients 
Eight genotypes A-H of HBV are known with variations in nucleotide sequences greater 
than 8%, while intra-genotype differences are =<4% (Gunther; 2006). HBV genotypes 
may account for the heterogeneity in disease manifestations among patients with chronic 
HBV infection. Large epidemiological studies will require the availability of a practical 
system that is rapid and reliable. 
 
In Saudi, genotypes  D, A, and UK patients genotypes A, D and B were more prevalent. 
The genotype distribution of UK patients is more of genotype A and D than the less 
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common genotypes B, C and E. Patients from Nottingham had genotypes A and B more 
than C, while the samples from London (Colindale) had mainly genotypes A and D. 
Possibly reflecting a more cosmopolitan population in the London area. Another study 
from UK detected prevalence of HBV genotypes A 41% , B 12% , C 5% , D 30% and 
12% for mixed-genotype infections(Davidson et al., 2005). Non-Caucasian genotypes are 
present in the UK blood-donating population and will therefore affect the demographics 
of HBV infection. An example of changing molecular epidemiology of HBV is the 
widespread dissemination of a regional HBV strain in England, which is primarily 
associated with injection drug use (Hallett et al., 2004). A strong correlation was found 
between HBV genotypes and ethnicity. Similarly, in a study from USA, HBV genotype A 
was prevalent among white and black patients, whereas genotypes B and C were most 
common among Chinese patients (Chu et al., 2003). 
 
On the other hand, Saudi patients had higher proportions of genotype D (62%) than A 
(22%), and lower frequency of genotypes B, C and E. None of our patients had HBV 
genotypes F, G or H. Abdo et al., (2006) demonstrated higher prevalence of HBV 
genotype D (81.4%) and lower prevalence of genotype A (1.4%) but comparable rates of 
genotypes C (1.4%) and E (5.7%) from a tertiary center in Saudi Arabia. Genotype D is 
the most prevalent in the Middle East (Saudy et al., 2003). 
 
Differences in the natural history of infection with different genotypes may have affected 
the prevailing transmission route of the virus. The mean age of UK patients with 
genotypes C and D was younger at 31 years. Saudi patients have mean age of 41 to 42 in 
most genotypes. Genotype B patients were reported to be significantly younger than 
genotype C patients (mean age 29vs.37years) (Kao et al., 2004) possible due to more 
acute presentation of the disease at young age.  
 
HBV genotypes, HBsAg and HBeAg  
Excretion of HBsAg was most abundant for Ae followed by Aa, Ba, Bj/C and remotely 
by D, which was consistent with mRNA levels (Sugiyama et al., 2006). In UK patients, 
the frequency of HBeAg was much higher than the Saudi group, reaching 26.7% versus 
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11.5% (genotype), respectively. On the other hand, HBeAg-negative phenotype is 
predominant in Saudi patients. That reflects more recent acquisition, or earlier detection 
of HBV in young UK patients. In UK, HBeAg is higher in genotypes B, C than 
genotypes A and D, 42%, 38%, and 27%, 22%, respectively (table 4-7). This suggests 
that genotypes B and C run more active course, or trigger less vigorous immune 
responses against them by eliciting an immunotolerant state than genotypes A and D.  
The proportion of anti-HBe antibodies in Saudi genotypes A and D was 9% and 19%, 
which can also be explained by the high chronic carriage of HBV in Saudi Arabia. This is 
in agreement with Ganne-Carrie et al., (2006) who demonstrated an increased prevalence 
of anti-HBe antibodies in patients infected with genotype D. The differences in HBV 
genotype prevalences and, or the HLA types and immune responses may also contribute 
to this discrepancy of anti-HBe prevalence between the two populations.  
 
Several studies have demonstrated differences in HBeAg seroconversion in different 
HBV genotypes that could be due differences in viral replication, expression of HBeAg 
and severity of liver disease. In Karachi, genotype D chronic hepatitis B patients 71/109 
(65%) were HBeAg negative (Abbas et al., 2006). HBeAg was significantly higher in 
genotype C than in genotype D (Duong et al., 2004). HBeAg-seroconversion occurred 
one decade earlier in genotype B patients with a rate of 47% vs.27% compared with 
genotype C patients (Kao et al., 2004). Within genotype B, HBeAg is more prevalent in 
subgenotype-Ba 16/62 (26%) than subgenotype-Bj 5/66 (8%) (Sugauchi et al., 2003). 
 
 
HBV genotypes and viral loads  
Our results showed higher HBV DNA levels in genotype D than genotypes A (table 4-8). 
Genotype D showed higher HBV DNA than genotype A in UK and Saudi patients, at 
mean. Many of patients with inactive hepatitis were ungenotypable, perhaps because of 
their low or undetectable HBV DNA. HBeAg correlates differently with viral load in 
different genotypes; as Lindh et al., (2000) found that HBeAg positive genotype B have 
higher DNA level than genotype C at 9.1 and 7.6 log10 copies/ml. Conversely, anti-HBe 
positive genotype B has lower HBV DNA than genotype C at 4.5 and 5.5 log10 copies/ml, 
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respectively. Similarly, HBV DNA levels were the lowest for sub genotype Aa 
(Asia/Africa), followed by Bj/Ba and D/Ae, and the highest for genotype C (Sugiyama et 
al., 2006). HBV DNA levels in sub genotype Aa carriers were significantly lower than 
Ae or genotype D (median, 3.46, 6.09 and 5.48 log copies/mL), respectively (Tanaka et 
al., 2004).  
 
Clinical presentation of HBV genotypes  
In our patients, genotype D was predominant in Saudi asymptomatic carriers with 
inactive hepatitis, which is consistent with Doung et al., (2004), where most of the 413 
carriers with HBV genotype D were asymptomatic carriers (84.2%). Acute hepatitis had 
predominantly HBV genotype D both in UK and Saudi Arabia (see table 4-9). No 
fulminant hepatitis patients detected in both UK and Saudi group. In Japan, the 
occurrence of HBV genotype B in patients with acute hepatitis was significantly greater 
than in those with chronic liver disease (39.3% v 11.7%, respectively (Imamura et al., 
2003). ALT levels were lower and HBV DNA titres were significantly higher (5.90 vs. 
5.13log10copies/ml, and HBsAg persisted longer with milder clinical course in patients 
infected with genotype A than C (Yotsuyanagi et al., 2005).  
 
The proportion of HBV genotypes differs with the various clinical features of HBV 
infection. The clinical presentation of our genotype D patients ranged from inactive 
hepatitis, acute hepatitis, chronic hepatitis, cirrhosis to HCC. Saudi patients with 
advanced liver disease had high prevalence of the HBV genotype D (table 4-9), compared 
to patients with inactive hepatitis who had genotype A more than D. UK patients with 
genotype C all had HBeAg positive as a reflection of active liver disease. Researchers 
demonstrated more severe liver fibrosis and higher serum transaminases in patients 
infected with genotype A and D (Ganne-Carrie et al., (2006), while others did not (Yalcin 
et al., 2004). This can be explained by the prevalence patterns of HBV genotype rather 
than their effect on liver disease progression. Genotypes B and C reported to be more 
prevalent in cirrhosis and HCC patients (Sakamoto et al., 2006), especially subgenotype 
C2 (Kim et al., 2009). HBV Genotype B patients exhibited more severe hepatic lobular 
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necroinflammation, less portal inflammation and fibrosis than genotype C patients did 
(Watanabe et al., 2005).  
Although the clinical presentation of Saudi patients showed association of the HBeAg-
positivity with active liver disease (table 4-9). HBeAg-negative states showed no 
significant correlation with liver disease activity. Thus, parameters other than HBeAg are 
needed to evaluate HBV patients as viral load in HBeAg-negative patients. Our results 
showed the association of genotype A with inactive HBV carriage and genotype D and to 
lesser extent genotypes A and E with chronic liver disease. HBV genotypes may be 
related to severity of liver disease. Generally, large-scale longitudinal studies are needed 
to find the relationship of HBV genotypes to liver disease severity and clinical outcomes. 
4.7. Conclusion 
This multiplex PCR genotyping method is suitable for rapid, large-scale epidemiological 
screening and clinical diagnosis of those virus infections occurring alone or in 
combination, but is also rapid and cost-effective. Virological differences among HBV 
genotypes were demonstrated that might influence HBV infections in clinical and 
epidemiological settings. HBV genotypes A and D are prevalent in UK, less frequently 
are genotypes B, C. HBV genotypes D followed by D are common in Saudi HBV 
patients.  
4.8. Future Direction 
Comparative studies using panels of sera from individuals infected with different HBV 
genotypes need to be performed to assess the influence of genotype on HBsAg, and anti-
HBs determinations. 
Protein expression of genotype-specific proteins large HBsAg and HBxAg, and studying 
the variation in their antigenicity and cellular interactions in different HBV genotypes  
Study of disease progression and response to therapy in patients infected with different 
HBV genotypes. 
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Chapter Five : S gene and Pol-gene 
5.1. Introduction 
5.1.1. Genotype-related variations in S/Pol gene: 
In HBV S-gene, HBsAg functional parts (transmembrane, extracellular, major 
hydrophilic regions and antigenic variants) are nearly identical for all genotypes (Stuyver 
et al., 2001). Only the pre-S1 region has length polymorphism. Because the efficiency of 
the backwards scanning mechanism depends on the distance between the 3`end of the 
core ORF and the initiation of the polymerase ORF, which is 143 nucleotides for 
genotype B to G, 149 for genotype A, these length polymorphism might help control the 
translation of the polymerase protein from pregenomic mRNA in a genotype-dependent 
manner.  
 
Regarding pol gene, the amino terminal part of the terminal protein (tp) of genotype A 
has two additional amino acids (tpG17 and tpT18) (fig.1-7). This affects the overlapping 
ORF for HBxAg (cD153 and cR154), as this length polymorphism is located 
immediately at the carboxy terminal of the HBeAg processing site (Stuyver et al., 2001). 
According to the old continuous numbering system of the HBV polymerase (fig.1-2), the 
tyrosine-methionine-aspartate (YMDD) motif, which is related to lamivudine resistance, 
change from methionine to valine or isoleucine is genotype dependent. Thus, for 
genotype A, it is M552V/I; for genotype B, C and F, it is M550V/I; for genotype D, it is 
M539V/I; and for genotypes E and G, it is M549V/I. Corresponding to (rt) 203-206 in the 
old numbering system. Yano et al., (2006) demonstrated that the incidence of YMDD 
mutants was slightly higher in those who were younger, had BCP, higher HBV DNA 
titres, lower ALT levels and genotype C. 
 
5.1.2. S Gene Mutations 
Mutations that alter the ratio of LHBs, MHBs and SHBs during infection variants may 
affect the pathogenesis of infection. High levels of LHBs or Pre S region mutations may 
inhibit particle secretion. Very few mutations within the pre S-1 residues 21-47 alter 
HBV binding to human hepatocytes (Huang et al., 'HOHWLRQDWWKH¶ end of the pre  
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Figure 5-1: Wild type and mutant HBsAg (gly-145-arg) 
Molecular models of HBsAg showing the "a" determinant site (pink) in wild type and HBsAg 
mutation where an arginine substituted for a glycine at amino acid position 145 (purple) is the 
most common (Adapted from Chen et al., 1996) National Academy of Sciences, USA. (Norder et 
al., 2004) 
 
 
S-1 region, at the S gene promoter, results in lower S gene expression and lower virus 
production, that potentially lead to impaired viral clearance without affecting HBV 
attachment to hepatocytes and their subsequent penetration, and therefore contribute to 
the development of chronic hepatitis (Huang et al., 2004).   
 
Pre S-2 determinants are targets for virus neutralization and are much more immunogenic 
than the S region of HBsAg (Kreutz, 2002). B-cell epitope within residues 14-24, the 
amino terminal 25-30 residues and an adjacent T-cell recognition sites within pre S-2 
residues 30-55 indicate that mutations within these regions may compromise the host 
ability to eliminate acute infection. However, pre S-2 deletions are clustered around 
immunodominant epitope, indicating their selection by the immune responses against 
wild type HBsAg (Kreutz, 2002). In acute hepatitis B, recombination within the pre-S 
region emerged transiently and the pre-S deletion mutant was finally cleared. However, 
patients with progressive liver diseases have a higher frequency of pre-S deletion (Chen 
et al., 2006). PreS mutation accounts for virus retention and misassembly. Abnormal 
expression of HBV proteins can result in cytotoxicity and ground-glass appearance of 
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liver cells, complicated eventually by cirrhosis, fibrosing cholestatic cholangitis and HCC 
(Weber; 2005). 
 
Mutation or deletion of sequences 48 and 27 bases upstream from the pre S-2 translation 
initiation site or lack of the pre S2 initiation codon, resulted in lower levels of MHBs and 
SHBs compared with LHBs, suggesting that preS2 including the PHSA binding site 
(preS-2 amino acid residues 17-29) (Kondo et al., 2002) may not be crucial for viral 
persistence and replication. In some cases, the LHBs component has aberrant 
electrophoretic mobility as well. Mutations preventing pre S expression were associated 
with the accumulation blocked virus secretion (Hartmann-Stuhler; 2001).  
 
Mutations with frame shift, microdeletions or point mutations. Mutations preventing pre 
S expression were associated with the accumulation of supercoiled DNA from 
cytoplasmic core particles intervene by different mechanisms at the translational or post-
translational level, including conformational or hydrophobic changes, insertion of basic 
residues, and reduced synthesis or secretion of HBsAg.  Consequently, mutations may 
account for altered immune recognition, not recognized by vaccine-induced antibodies or 
interferes with detection by immunoassays (Weber; 2005).Lee et al., (2003) demonstrated 
that in HBsAg mutant proteins, the two N-linked glycans at Asn15 and Asn123 result in 
low titres of pre-S1 and S2-neutralizing antibodies. Several other point mutations are 
summarized in (tables 5-1 and 5-2). Mutation at nt. 551 of the HBV (adr) genome from A 
to G, leads to a substitution of methionine (Met) to valine (Val) at position 133 in the "a" 
determinant of HBsAg. Compared to the wild-type HBsAg, the binding activity of the 
mutant HBsAg to monoclonal antibodies (A6, A11 and S17) and to vaccine-raised human 
anti-HBs antibody decreased significantly (Chen et al., 2003). 
 
S gene mutations affect immunogenicity and infectivity as well, although mutant HBsAg 
can still induce protective humoral immune responses (Ge et al., 2004). The wide spread 
vaccination in the WHO extended program of childhood vaccination, and other group 
vaccinations may increase the chances of development of HBV escape mutant, though 
the benefit of the vaccine far outweighs the risks. Exploring the antigenic differences 
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between HBV genotypes may influence the improvement of current vaccines. Vaccine 
escape mutants also occur in liver transplant patients immunized, and or treated with 
prophylactic hyperimmune gamma globulin. Mutations in the `a`epitope were correlated 
with the absence of detectable anti-HBsAg (Huang et al., 2004) (fig.5-1). Acute HBV 
infection may also occur in the presence of protective levels of anti-HBs (Gerlich, 2006). 
Detailed studies and enhanced surveillance to monitor the emergence of these variants are 
essential in evaluating the current immunization strategies. 
 
HBsAg may co-exist with anti-HBs during the transition from acute to chronic infections. 
The virus continues to replicate at low levels, as evidenced by detectable HBV DNA in 
up to 27.2% of anti-HBs positive individuals (Chaudhuri et al., 2003). Here HBsAg may 
not be neutralized fully by the anti-HBs present, implying the existence of HBsAg 
variants with altered antigenicity. Hence, not all anti-HBs positive infections are 
associated with virus elimination. Mutants are also increased in amount by the selective 
pressure of therapy. 
 
Mutation occurred at codons123, 124, 126, 129, 131, 133, 137, 140, 142 134, 143, 144 
and /or 145 (Tsatsralt-Od et al., 2007 ), result in 1-2 amino acid differences at the 
`a`determinant in SHBs , reaching43% in occult hepatitis B infections including  Q101K, 
T115A, K122N, T123A, T126N, Q129N, G130R, T131I, M133T, F134L, C138Y, 
K141E, P142S, D144E with or wothout145 glycine to arginine (G145R), N146S, and 
C147F/R alone or in combinations (Hou et al., 2001). Point mutation in and around the 
³D´ GHWHUPinant of HBsAg; allow continued replication of these variants at wild type 
levels and persistence in susceptible populations. In infants of HBsAg positive mothers, 
the incidence of HBV S-gene mutants reach 23.1 % of vaccine recipients (Hsu et al., 
2004), to 51% of infants with chronic HBV infection acquired after post exposure 
prophylaxis (Nainan et al., 2002).  
 
5.1.3.  Natural HBsAg negative HBV infections  
It is not clear whether HBsAg negative infections (fig.5-2) are due to loss of the HBsAg 
or are due to HBsAg negative variants. Most of these low titer defective replication 
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variants have low pathogenicity encouraging chronicity of atypical infections. 
Nevertheless, some HBsAg-negative infections are highly pathogenic. The role of HBV 
mutants in HBsAg negative liver disease, hepatocellular carcinoma and fulminant 
hepatitis have to be elucidated. Screening of transfused blood for anti-HBc prevents post 
transfusion hepatitis and detects HBV variants negative for HBsAg. The presence of 
HBV DNA in serum and liver of HBsAg-negative or in HCV patients (Tsatsralt-Od et al., 
2007) suggests the presence of these or related variants as well. The main threat of 
HBsAg-negative mutants lies in the safety of blood transfusion system. In endemic areas, 
it is preferable to test blood donors for anti-HBc antibodies, which are positive in more 
than 95% of HBsAg-negative cases (Hsu et al., 1999). Monoclonal antibody binding tests 
revealed decreased immunoreactivity in 6 variants of HBsAg (Hou et al., 2001). 
 
The ability of polyclonal and monoclonal antibody-based HBsAg assays to detect HBV 
mutants in viraemic patients was examined by combination of such diagnostic assays. It 
is expected that their proportion may increase with higher vaccine coverage rates, but 
they are unlikely to compromise vaccination programs. Serological assays were 
developed for the detection of HBsAg-negative variants (Ijaz et al., 2001). 
 
5.1.4. HBV Polymerase mutations: 
HBV polymerase has several functions related to viral replication including DNA 
polymerase, reverse transcriptase and RNase H activity as well as having critical domains 
required for virus replication, and packaging of pregenomic RNA into core particles. The 
¶HQG RI +%9 3RO JHQH HQFRGLQJ VHTXHQFHV WKDW SULPH PLQXV VWUDQG V\QWKHVLV GXULQg 
replication. Mutation of polymerase gene altering its activity will affect the amount of 
virus produced as well as the number of templates available to encode virus proteins to 
elicit appropriate and timely immune response. Multiple pol-gene mutations occur 
(Kreutz, 2002) alone or with co-existing mutations in other regions of the genome. 
 
Though some polymerase mutations are lethal. Several lamivudine resistant polymerase 
mutations are described that evolve during therapy (Iwao et al., 2006), most commonly 
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the YMDD (tyrosine, methionine, aspartate, aspartate) mutants in the C-domain at 
position 552 (rt204). Interestingly, S gene encoding the `a` determinant of HBsAg is 
overlapped by the variable linker region between the A (nt. 410-426) and B domains (nt. 
498-528) of the rt part of pol-gene. The YMDD mutations are unlikely to affect the 
critical antigenic sites of HBsAg. In addition, valine YVDD and isoleucine YIDD 
mutants have been described, and the linked mutation FLMA (phenyl alanine, leucine, 
methionine, and alanine) of the B-region of the pol-gene, resulting in leucine to 
methionine L528M (Kim et al., 2009).  
 
Another substitutions at rt204 (ATG to AGT; T to G and G to T) lead to a methionine to 
serine change (YSDD) are associated with the rtL180M mutation can also confer 
lamivudine resistance (Bozdayi et al., 2003). The YMDD mutation confers resistance 
against a range of other cytosine analogues as FTC, and ddC, as well as the thymidine 
analogue azidovudine. In Lamivudine non-responders, replication became undetectable 
after tenofovir introduction. 'Vaccine escape' mutants exhibited rtV173L plus rtL180M 
plus M204V mutations (Roque-Afonso et al., 2003). 
 
Pol-gene mutations abolish both encapsidation and replication, while mutations of the RT 
or RNAase H domains markedly decrease DNA synthesis without affecting RNA 
packaging; this favours the reversion to wild type upon cessation of adefovir therapy 
(Werle et al., 2004). Surprisingly both replication competent and replication or packaging 
deficient variants are maintained. Complementary mutants rescue each other as core 
positive polymerase negative clone rescues core negative, polymerase positive virus in 
co-transfected cells, this mechanism may restore the wild type virus again. Replication 
efficiency of YMDD mutant is less than that of the wild type virus and, after cessation of 
therapy, the wt virus re-overtakes the mutant. However, lamivudine-resistant viruses 
remain functional and pathogenic (Besisik et al., 2003). 
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Figure 5-2: Amino acid changes of HBsAg-negative mutants. Amino acid chain in the MHL of 
HBsAg (aa 98-156): Showing the S-S bridges. The complex N-linked glycan bound to 146N.  
 
 
Table 5-1: Types and clinical relevance of HBV mutants 
HBV element Mutation Mollecular biology Clinical association References 
Pre-S/S pre-S2 
Pre-S1/     
/S-promotor 
Misassembly Fibrosing cholestatic 
hepatitis 
 
 PreS1  (aa 21-47) Hepatocytes 
binding region 
Viral persistence  
Impaired viral clearance 
 
 pre-S2 Fibronectin±binding site 
(N-terminus) 
Viral attachment to liver 
sinusoides 
Acute hepatitis  
 S Alteration of B- and T-cell 
epitopes  
Decreased viral 
replication. 
HBsAg-negative infections. 
Vaccine-escape infection. 
Diagnostic false negative 
HBsAg. Occult hepatitis 
 
Pol Pol Replication- deficieny 
Viral persistence 
Viral latency and  
chronic hepatitis 
 
 YMDD 
motif 
Resistance to antivirals 
Viral persistence  
Lamivudine therapy escape  
 
147 
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Clinically, the majority of patients with severe hepatitis exacerbations due to YMDD 
mutants had uneventful course. YMDD variants are common in occult HBV infection in 
haemodialysis patients with chronic HCV infection, and were identified in six of 12 
(50%) patients with occult HBV infection (Besisik et al., 2003). 
 
 
Missense mutations in the initiation codon of pol gene prevent viral replication. However, 
mutations at codon 652 serine to proline, and at nt. 2798 proline to threonine of the 
terminal protein (TP) segment causes diminished replication (Wen et al., 2003). Finally, a 
terminal protein sequence may decrease the targeting to pregenomic RNA, thereby 
decrease viral replication.  
 
5.1.5. Methods of detection of HBV mutants 
Currently, HBV mutations can be determined by several methods (table 5-3). The variant 
detection varies as they are usually mixed with wild type in different proportions. 
Template-directed dye-terminator incorporation reaction (TDI-FP) have been shown to 
be more sensitive than sequencing  and could detect variants as YMDD present in as little 
as 10% , 1% , 0.1% and 0.1% respectively of the virus mixture (Bai et al., 2003).   
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Table 5-2: Correlation of amino acid substitutions in HBV Pol and S ORFs 
(Wakil et al., 2002) 
Pol-ORF mutations rt Position Effect on S-ORF HBeAg +/- %  
T476I 128 P120S 14/17 
N487D 139 G130G (silent mutations) 0/10 
L528M 180 S171S (silent mutations) 29/10 
V539I 191 W182stop 14/0 
F549F (silent mutations) 201 S193L 14/0 
M552V 204 W196L I195M 43/20 
M552I 204 W196stop  
Q563S 215 S207R 14/10 
F575F (silent mutations) 227 F219S 14/0 
L577G 229 F220L and  C221G 0/10 
 
 
 
 
Table 5-3: Methods of HBV variant Detection 
Method Detection limit Reference 
High-density DNA chip Detect large number of 
mutations, deletions and 
insertion 
Tran et al., 2006) 
Real-time detection by labelled probes   
Affigene HBV mutant VL Kits Detect mixed mutants/wt Zampino et al., 2005 
5' nuclease technology   Chan et al., 2006 
Competitively differentiated PCR.   Peng et al., 2005  
Single nucleotide polymorhism (SNPs)  Park et al., ; 2004 
Amplification refractory mutation system 
(ARMS) 
 Punia et al., 2004 
Limiting dilution cloning PCR (LDC-PCR) 0.1%  Nainan et al., 2002 
Sequence-specific PCR products (SP-PCR) 1%  Nainan et al., 2002 
Line probe assay 2.5%  Wilson et al., 2003 
Ligase chain reaction assay 2.9%  Osiowy et al., 2002 
Cloning and sequencing 5%  Nainan et al., 2002 
Direct sequencing     25% , Failed to identify 70% 
of wild-type/mutant mix  
Davidson et al., 2005 
Restriction fragment length polymorphism of 
PCR products (PCR-RFLP) 
 Hadziyannis et al., 2000 
Colorimetric point mutation assay  Ballard and Boxal  1997 
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5.2. Hypothesis 
HBV genotype sequences variations, especially regions encoding proteins, can be the 
cause of differences in biological behaviour and clinical outcome between HBV 
genotypes infections. 
5.3. Aim 
To verify the accuracy and specificity of the multiplex genotyping PCR assay  
To confirm the HBV genotypes detected by multiplex assay by sequencing and 
phylogenetic analysis. 
To determine HBV genotypes and subgenotypes present in Saudi and UK patients and 
whether apparent results in multiplex genotyping had a single variant or recombinations 
from different genotypes. 
To check the patterns of mutations of HBV S-gene including the "a" determinant in Saudi 
and UK patients.  
To detect the frequency of YMDD amino acid motif of the HBV Polymerase and related 
mutations with possible lamivudine resistance in this setting. 
To analyze genotype specific variations present within HBV S and pol genes. 
To check the genotype related differences in sequences used in HBV vaccinations. 
To confirm the sequence and genotypes of the cloned plasmids and their validity as 
controls for genotyping assays. 
 
5.4. Patients and Methods 
5.4.1. Sequencing of the S-gene 
Sera from 36 chronic hepatitis patients from UK and 20 Saudi patients were used. DNA 
was extracted by QIAAmp (blood) kits (Qiagen). PreS1/PreS2/ S gene of HBV was 
amplified by polymerase chain reaction (PCR). The first-round PCR using universal 
primers P1:5`-TCACCATATTCTTGGG AACAAGA-3` nt2823-2845 (sense) and S2: 
5`-CGAACCACTGAACAAATGGC-3` nt. 685-704 (antisense), outer pair (1, 063 
bases). The first-round product of the multiplex PCR was used to for sequencing, to 
detect regions of the pre-S/S-gene (Naito et al., 2001). 
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Sequencing was done using ABI prism protocol. Sequencing primers are P1, B3: 5`-
GGCTCMAGTTCMGGAACAGT-3 nt. 67-86 sense, B13N (nt. 3139-3156) and R10 (nt. 
3097-3078) 5`-GGAGGCGGAT Y(C/T) TGCTGGCAA-3`anti-sense. The R10 was used 
for sequencing reverse sequences.  Primer concentration was 0.25 pmol in a reaction 
using ``Big Dye`` fluorescent dye-WHUPLQDWRU FKHPLVWU\ 3HUNLQ (OPHU FRQWDLQLQJ ȝO
%LJ'\HPL[DQGȝO WHPSODWHWRDILQDOYROXPHRIȝOXQGHUJRQHVHTXHQFLQJ3&5DW
94oC for 10 sec, 50oC for 5 sec, 60oC for 4 minutes for 35 cycles. Sequencing templates 
were cleaned-up and purified by removing unincorporated primers and nucleotides from 
WKH 3&5 SURGXFWV XVLQJ ȝO ([RQXFOHDVH, ZKLFK FDWDO\]HV WKH UHPRYDO RI QXFOHRWLGHV
from single-VWUDQGHG'1$LQWKHCWRCGLUHFWLRQDQGȝOVKULPSDONDOLQHSKRVSKDWDVH
preparations (Amersham International, UK), which catalyses 5` dephosphorylation of 
nucleotides, respectively, to yield a clean PCR product for proper sequencing.  The PCR 
product was incubated at 37oC for 30 minutes, followed by heat inactivation at 70oC for 
15 minutes. A final YROXPHRIȝOIRUHDFKVDPSOHZDVSUHSDUHGE\DGGLQJȝOZDWHU
DQGȝO6RGLXPDFHWDWHS+7KH'1$ZDVSUHFLSLWDWHGIURPWKLVVROXWLRQE\DGGLQJ
ȝO  HWKDQRO FHQWULIXJLQJ DW J IRU  PLQXWHV DQG DVSLUDWLQJ WKH
supernatant, leaving the pelleted DNA. Two further washes with 70% ethanol were 
performed.  The residual ethanol was removed and the DNA pellets were air dried at 
room temperature for 20 minutes. The DNA was sequenced in the immunology 
department, University of Nottingham. 
5.4.2. Phylogenetic analysis 
Phylogenetic analysis and phylogenetic trees were done by bootstrap and neighbour 
joining methods. Comparison between complete genomes from Gene Bank and our 
sequenced strains using Chromas and Clustal X packages was used for method testing. 
5.4.3. Genotype related variations 
Intragenotypic and intergenotype variations of different parts of the HBV genome 
including the S-pol gene were determined using Mega3 packages.  In addition, translation 
of HBsAg and the HBV polymerase proteins were done using the same program. 
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5.5. Results of S/Pol Sequencing 
 
5.5.1. HBV Genotyping by Phylogenetic Analysis of S gene Sequences 
Phylogenetic analysis of HBV S/Pol sequences of PCR products was done to define 
genotypes and subgroups on the basis of 8% and >4% heterogeneity of the entire HBV 
genome, respectively. Different areas were analysed of the S gene: preS1, pre S2, 
beginning of S gene encoding small HBsAg, the `a` determinant, and end of S/Pol gene 
(tables 5-4, 5-5, 5-6). Generally, there was high concordance between our multiplex 
genotyping assay and sequencing of the S gene. PreS2 region differences were not 
conclusive for genotyping comparison (table 5-4). 
 
Pre S1 region, Pre S2and beginning as well as the end of S gene overlapping the YMDD 
region of the reverse transcriptase part of pol gene showed accurate discrimination 
between genotypes. Pre S1, Pre S2, and to a lesser extent the beginning of small HBsAg, 
carried more variation between different HBV genotypes than the more conserved 
regions at the `a` determinant and the rt part of the Pol gene. According to calculations of 
genetic distances by Kimura 2-parameter method, this further confirmed the differences 
between different regions of the S and Pol genes (table 5-5).  
 
Discrimination was demonstrated between different HBV genotypes, although the latter 
region shows the YMDD motive for the detection of antiviral drug resistance as well. The 
phylogenetic analysis different regions of the S-gene has shown genotype-related 
variations (fig.5-7 to 5-11) 
 
All UK HBV genotype A had subgenotype Ae, genotype B had subgenotype Ba, and 
genotype C subgenotype C1 (Cs). HBV subgenotypes detected in Saudi Samples had 
HBV subgenotype D1, while UK had subgenotype D2 mostly in Asian patients. All 
plasmids sequences confirmed the S-gene of relevant HBV genotypes. 
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Table 5-4: Concordance of HBV genotyping by phylogenetic analysis of different regions of 
S/ pol gene of Saudi and UK HBV isolates using Mega software. 
 Genotype 
 
PreS1 
nt. 2815  
- 3084 
PreS2 nt. 
3085-154 
S-gene 
nt. 155- 424 
`a` determinant 
nt. 425 ± 694 
RT-pol 
nt. 695- 964 
A 83% (5/6) 33% (2/6) 100% (6/6) 89% (8/9) 100% (7/7) 
B 100% (4/4) 50% (2/4) 100% (4/4) 100% (4/4) 100% (5/5) 
C 100% (6/6) 33% (2/6) 100% (6/6) 100% (4/4) 100% (7/7) 
D 100% (16/16) 75% (9/12) 100% (18/18) 91% (21/23) 100% (7/7) 
E 100% (1/1) 100% (1/1) 100% (2/2) 100% (3/3) 100% (2/2) 
 
 
 
Table  5-5: Calculated mean of nucleotides distances within each genotype in 5 different 
regions of the S/pol gene by Kimura 2-parameter method 
Genotype PreS1 PreS2 HBsAg `a` determinant RT Average 
A 0.070 0.060 0.039 0.046 0.021 0.047 
B 0.026 0.034 0.025 0.072 0.007 0.033 
C 0.070 0.074 0.045 0.042 0.024 0.051 
D 0.034 0.039 0.023 0.050 0.022 0.034 
E 0.178 0.025 0.012 0.047 0.032 0.058 
Average 0.073 0.047 0.028 0.051 0.021 0.044 
 
 
 
Table 5-6: Genetic distance calculation by average difference between HBV genotype A and 
other genotypes in nucleotides (upper line) by Kimura 2-parameter, including transitions 
and transversions. Also, distance of translated amino acids between genotypes by Dayhoff 
Matrix Model for homogenous /uniform rates     
Genotype PreS1 PreS2 HBsAg `a` 
determinant 
RT 
B      nt.  0.244 /  0.543 0.171 /  0.348 0.062 / 0.138 0.102 / 0.201 0.048 /  0.069 
C 0.154/  0.325 0.140 /  0.287 0.055 / 0.120 0.121 /  0.225 0.062 / 0.097 
D 0.326 /  0.651 0.185 /  0.418 0.033/ 0.072 0.105 /  0.210 0.066 / 0.107 
E 0.242 /  0.515 0.159 /  0.351 0.053/  0.118 0.107 /  0.229 0.054/0.066 
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5.5.2. Genotype-specific variations in PreS1 region 
The pre-S1 together with pre-S2 and S-gene encode the large HBsAg protein. Within the 
pre-S region, many nucleotide exchanges are observed. These are partly correlated to the 
HBV genotypes. Genotype D exhibits several variations. All the sequenced cases (9/9) 
with genotype D, showed deletion of the naturally occurring 11 amino acid codons at the 
beginning of preS1 region as did the genotype D Gene Bank controls. Consequently, the 
preS1 starts at codon 12 as compared to genotypes B, C, F, and H. Genotype E and G 
show one aa. codon deletion at the beginning of preS1 segment. Resulting in a total of 
108 aa in pre S1 instead of the 119 aa seen in genotypes B, C and F. Other genotype 
specific variations were observed in the beginning of the preS1 gene including P19S 
(CCC to AGC) (15/17), codons 88-91 LPAN motif found in all genotype D strains 
(appendix A).  
 
Transcription activating sequence / Hepatocyte binding sites (codon 21-47) 
L30V found in 3 genotype C cases (3/5), both have genotype C, unlike Gene Bank 
controls. Genotype-related variations were seen at positions 35, 38 and 39. All our UK 
and Saudi cases showed no deletions or insertions in PreS/S gene.  
 
5.5.3. S2-promoter (nt. 3045-3180) 
S2 promoter area primes the translation of preS2. HBV genotypes also show several 
consistent variations as follows; V90A found in subgenotype C-Australia and in N16, 
N45, while V90S seen in N19.  N114D found in one genotype D Gene Bank strain 
X65258 and one Saudi case 4-27.  
5.5.4. Mutations on PreS1 
Several isolated point mutations were seen; one genotype D case (S5) has mutation at the 
initiation codon of pre S1, which could interfere with the production of large HBsAg.   
AF 62/63 SL in genotype C cases (N19 and N16) (2/5).  
5.5.5. Genotype-specific variations in pre S2 region 
Within the polymerised human serum albumin (PHSA) binding site (preS-2 aa 17-29), 
F22L was observed in A-Europe, genotype Bj subgenotypes, but all our genotype A cases 
(5/5) showed L22F unlike Gene Bank controls. V53A and T54P/L was different in  
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Figure 5-3: The phylogenetic tree of the beginning of Pre S1 gene nt. 2815-3084 showing 
genotypes and subgenotypes of UK (suffix UK) and Saudi (suffix SA) HBV isolates. Gene Bank 
(suffix_BK) sequences: A1-AY161140, A2-S50225HBsAg-, A-europV00866adw, A-afric-
AF297625, Ba-D00330adw2, Bj-AB073858, B1-AB073852, B2-AB073830, B3-D00331, B4-
AB100695, C1-AF411412, C1Cs-AB111946, C2Ce-AF533983, C3-X75656, C4aus-
AB048704ayw, D1-AY161157, D2-X80925, D3-X85254, D4-AB048702, E-X75664, F-
X69798adw4, H-AY090454, G-AF160501.   
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Figure 5-4: The phylogenetic tree of  Pre S2 gene nt. 3085-154  showing genotypes of UK 
(suffix UK) and Saudi (suffix SA) HBV isolates. Gene Bank (suffix_BK) sequences: A1-
AY161140, A2-S50225HBsAg-, A-europV00866adw, A-afric-AF297625, Ba-D00330adw2, Bj-
AB073858, B1-AB073852, B2-AB073830, B3-D00331, B4-AB100695, C1-AF411412, C1Cs-
AB111946, C2Ce-AF533983, C3-X75656, C4aus-AB048704ayw, D1-AY161157, D2-X80925, 
D3-X85254, D4-AB048702, E-X75664, F-X69798adw4, H-AY090454, G-AF160501. 
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Figure 5-5: The phylogenetic tree of the beginning of small S-gene encoding HBsAg nt. 155- 
424. UK (suffix UK) and Saudi (suffix SA) HBV isolates. Gene Bank (suffix_BK) sequences: 
A1-AY161140, A2-S50225HBsAg-, A-europV00866adw, A-afric-AF297625, Ba-D00330adw2, 
Bj-AB073858, B1-AB073852, B2-AB073830, B3-D00331, B4-AB100695, C1-AF411412, 
C1Cs-AB111946, C2Ce-AF533983, C3-X75656, C4aus-AB048704ayw, D1-AY161157, D2-
X80925, D3-X85254, D4-AB048702, E-X75664, F-X69798adw4, H-AY090454, G-AF160501.   
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Figure 5-6: The phylogenetic tree of the S/Pol gene: nt. 425 ± 694 encoding HBsAg 
`a`determinant. However, subgenotypes are not well differentiated in this tree. UK (suffix UK) 
and Saudi (suffix SA) HBV isolates. Gene Bank (suffix_BK) sequences: A1-AY161140, A2-
S50225HBsAg-, A-europV00866adw, A-afric-AF297625, Ba-D00330adw2, Bj-AB073858, B1-
AB073852, B2-AB073830, B3-D00331, B4-AB100695, C1-AF411412, C1Cs-AB111946, C2Ce-
AF533983, C3-X75656, C4aus-AB048704ayw, D1-AY161157, D2-X80925, D3-X85254, D4-
AB048702, E-X75664, F-X69798adw4, H-AY090454, G-AF160501.        
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Figure 5-7: The phylogenetic tree of the reverse transcriptase region of the S/Pol gene nt. 
695- 964. UK (suffix UK) and Saudi (suffix SA) HBV isolates. Gene Bank (suffix_BK) 
sequences: A1-AY161140, A2-S50225HBsAg-, A-europV00866adw, A-afric-AF297625, Ba-
D00330adw2, Bj-AB073858, B1-AB073852, B2-AB073830, B3-D00331, B4-AB100695, C1-
AF411412, C1Cs-AB111946, C2Ce-AF533983, C3-X75656, C4aus-AB048704ayw, D1-
AY161157, D2-X80925, D3-X85254, D4-AB048702, E-X75664, F-X69798adw4, H-AY090454, 
G-AF160501.   
     
 Chapter 5- S gene and Pol-gene 
137 
 
 
different genotypes. This area lies in N-terminus of the PreS2 in the fibronectin binding 
site to liver sinusoids. 
 
5.5.6. Mutations in PreS2 
Only few point mutations were seen in preS2 gene. The most significant was the loss of 
initiation codon M1I in case N9 and the plasmid constructed from it pB10. 
 
5.5.7. S-gene (encoding small HBsAg) 
Sequencing of the S- gene was done, within the S region. Several genotype-associated 
variations were present; these are partly correlated to the serological hepatitis B surface 
antigen subtypes. No deletions or insertions were found. Two cases (N16, N19) had 
premature stop codon at codon 34 giving a truncated HBsAg. 
 
The `a` determinant (aa. 124-147) 
The main two loop structure of the `a` determinant is maintained by four cysteine 
residues at positions 124, 137, 139 and 147. All of them were unchanged in any of Gene 
Bank HBV genotypes controls, nor in our cases. Main genotype related variations are 
T126I was seen in genotype C, T131N in genotype A, F134Y found in genotype D. 
P127L and T140S in genotype E and S143T in genotypes A and C.   
 
T-Lymphocytes epitopes in S/pol gene  
PreS1 epitopes at aa.21-28 (Class I) and aa.21-30 (Class II) (table 1-3) did not show 
significant genotype specific variations. In the pre S1 epitope associated with HBV virus 
clearance (58-100). Codon A60 found in genotypes C controls and only two cases (2/5). 
Most our genotype C cases (3/5) have A60V. E86T was seen in genotypes A, B and C, 
but E86Q in all our genotype D cases and in only one Gene Bank control X65257. Pre S2 
epitope aa.1-11 (Class I and II) shows genotype specific variation at codons 7, 11 and 13. 
Codon 7 is a SNP candidate as explained below.  
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The overlapping epitopes in small HBsAg aa.  20-29 and aa.  20-33 (Class I and II) show 
the following changes; R24K (AGA to AAA) found in genotypes B and E. Epitope aa.41-
49 (Class I) Codons 45 and 47 show several genotype related changes as explained in 
single nucleotide polymorphism (SNPs) section. No specific variation was seen in 
epitopes aa. 88-96 and aa. 97-106 (both Class I). Epitope aa.185-194 (Class I) V194A 
seen in genotypes A (7/7). 
 
In the pol gene, epitope rt107-115 (ClassI) has only L115V in genotype H and as point 
mutation L115V in N41 and N53. Epitope rt 203-211 (ClassI) This important epitope in 
the catalytic center of reverse transcriptase has genotype specific variations at codon 
rt207, immediately after the YMDD motif. V207L and epitope rt227-235 (Class I) 
L231V were not seen in our samples. 
 
In general, minimal genotype related variations are seen in T-cell epitopes within the S 
gene. Their effect on lymphocyte activation has to be sought in a detailed study.  
 
5.5.8. Mutations in S-gene 
Only one case (N4) showed 21 bp-deletions in nt. 34. Point mutations (PM) were present 
in F20V (TTC to GTC) in 1-2 and 1-49. S61L (TCA to TTA) found in some genotype C 
cases (3/ 6). L95M seen in cases N7 and N62 and stop at codon 95 in N64. P127L found 
in 3/16 genotype D cases, A128V in cases N7 and N52 (genotype D) and in N59 
(genotype A). M133L was observed in case N41 (A) as well as HBsAg-negative Gene 
Bank case (S0225) and in genotype B; Bj subgenotype. Early stop at codon 34 was seen 
in genotype C cases N16 and N19. TT45AP found in genotype D cases N7, N12. 
 
5.5.9. Analysis of the translated HBV pol gene sequences into polymerase protein  
 
Case N9 with genotype B and N41 (genotype A) have TCA to GCA in rt codon 109 S to 
A mutation.rtS78A was seen in N14, N16, N19, and 1-55 (genotype D). No UK patient 
showed mutation in the YMDD motive of rt 204 of the polymerase gene, nor is the 
associated L 180 (pol528) present. The only Saudi case (3-38) sequenced (and cloned) in 
this region, showed isolated M204I mutation (genotype D). rt  H13N in genotype C 
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controls and some of our cases (3/6), R13L in our genotype B cases (3/5). I16T (ATT to 
ACT) seen in genotype A (4/7). I91L found in subgenotypes C-Australia and our 
genotype C cases (3/5). We found two UK cases with YVDD. 
 
 
In pol-gene rt codon 103 GTT to GAT resulting V103D in UK genotype D cases (N7 and 
N62, N65) are of Asian origin. Codon L115V (TTG to GTG) found in N63 (genotype D), 
N53 (genotype E), and N41 (genotype A). H126R was seen in N7 and N52 (both are 
genotype D), M129L in N65 and 3-35.  Q130P found in N63 and 2-31, S135Y in N7, 
N52, and 2-31a (all are genotype D). V266I was seen in N15 and in subgenotype A-
Africa control strain from Gene Bank. 
 
5.5.10. Genotype-specific variations in Pol gene  
Genotype D specific variation in the pol gene comprising the deletion of 11aa was seen in 
our genotype D cases (17/17) and of 7 aa in genotype A (6/6), 1amino acid in genotypes 
E (1/1) and G. Pol codon A262P was found in all our genotype C cases (4/4), unlike 
Gene Bank controls. Pol S274T was seen in N1 and Gene Bank genotype C control while 
Pol T274A was found in our genotype C cases N16, N19, and N45.  
 
Pol-gene codons L345I and L348R show genotype specific variability. In rt I16T in N45 
(genotypes C). As well as in 2-31 (genotype D). T38A was seen in N9 (genotypes B), 
N16 (C).Pol-gene codon N288H found in genotype A L348R (6/6). 308Q found in cases 
N9 and pB10 (B). 
 
5.5.11. Single nucleotide polymorphism (SNPs) candidates  
Although there is 92% similarity in HBV genotypes, we found some point at S/pol gene 
that show considerable differences between HBV genotypes (table 5-7) and these are 
presented in the following section; 10Q (CAA) was seen in genotype C and cases (3/5). 
N39E (GAA) in genotype B controls and cases (3/4), 39H (CAC) occurred in genotype C 
controls, but our cases (6/6) showed H39N (CAC to AAC) as did the Australian 
subgenotype of genotype C.  
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Codon H51Q (CAA) found in genotype C (4/5) of our patients unlike control. A54E 
(GCG) found in genotype C controls and 2/5 of our cases. 84V found in genotype C Gene 
Bank controls, but V84I was found in all our genotype C cases (5/5). I84L was seen in 
Asian subgenotype of genotype B (Ba), as well as in most of our genotype B cases (3/4). 
A 91 was present in genotype C controls and some of our genotype C cases (3/5), while 
V91A observed in subgenotype C-Australia and our genotype C cases N16 and N45. 
 
In preS2 segment, 7/8 AL was seen in genotypes A Europe and A Africa and case N7 
(genotype D), while A7T found in both genotype B and C controls and cases 2/4 and 2/4, 
respectively. Point mutation T7N and T7I observed in genotype B cases N9, pB10 and 
N16, N19 (genotype C), respectively.  P41H was seen in only one genotype D 
controlX65257 and most our cases (6/9).  
 
Only two SNPs candidates were observed in the S-gene codons 45 and 47, whether this is 
the cause of false positive B genotype.  SNPs candidates in the Pol gene include codons 
267/268, 270, 273 and 348. L348I in cases N11, 1-49, and 4-13 of genotype D. rt 7A 
(GAC), 53/54 and 122. F122L was seen in one genotype D Gene Bank  control; X65267 
and cases N63 and 2-31.   
 
5.5.12. Verification of multiplex genotyping PCR Primer binding sites 
Samples and plasmids sequences confirmed the S-gene of relevant HBV genotypes (See 
genotyping chapter). 
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Table 5-7: Amino acid changes deduced from single nucleotide polymorphism 
(SNPs) candidates in HBV S/pol gene 
Genotype A A  
Africa 
Ba Bj C C australia D E F H G 
PreS1 
Codon 35 
G G K K G G R R R R R 
39 T 
ACA 
T E 
GAA 
E H N 
AAC 
A 
GCA 
R S 
AGC 
S 
AGC 
N 
51 H H N N H H T H S/T 
ACT/
AGT 
N P 
54 A 
GCA 
Q 
CAA 
D D E E 
GCG 
D E M 
ATG 
M E 
91 I I V A A A A N D D D D 
Pre S2 
41 
H H A A P H H L L & 
ADrc 
L H 
54 T T P K P S L P M M P 
S gene 
45 
 
S 
 
S 
 
T 
 
T 
 
A 
 
A 
 
T 
 
A 
 
L 
 
P 
 
V 
Pol gene 
267 
 
I 
 
I 
 
T 
 
T 
 
I 
 
I 
 
T 
 
A 
 
V/S 
 
S 
 
N 
268 D D H H D D T K N D N 
270 S S C C R S V/F/R T L L F 
273 N  S S S S K R R R R 
rt7 D V T A T I A T Y Y T 
rt271 H H M L Q H E D E D Q 
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5.6. Discussion 
Limitations of sequencing data 
We used direct sequencing to detect mutants. Different methods have been used to detect 
HBsAg variants alone as direct sequencing, or in mixed populations as cloning and 
sequencing, restriction fragment length polymorphism of PCR products (PCR-RFLP) 
(Lim et al., 2007).  
 
Differences in the nucleic acid sequences may be due to PCR artefacts, or reflect 
heterogeneity of the viral population, or by point mutations (PM). PM caused by 
polymerase itself ranges between 1x10-4 and 6x10-5 depending on the fidelity of the 
enzyme used. In addition, fluctuations in the intracellular [dTTP]/[dCTP] pools might 
give rise to a G to A hypermutation, which in some cases results in several Gs that are 
replaced by As throughout the entire genome (Gunther, 2006). PCR errors are most 
frequently A to G and T to C exchanges due to the rising melting temperature. The 
probability of PCR error is less likely the more clones or specimens that show the same 
mutation in parallel (Ruiz-Tachiquin et al., 2007). 
  
Phylogenetic analysis of HBV genotypes and subgenotypes 
We investigated the genotype specific variations and the prevalence of the HBV variant 
with the pre-S mutant using sera from Saudi Arabia and UK, where high and low levels 
of endemic HBV infection exists, respectively. Phylogenetic analysis of the sequences 
and correlation with multiplex and Visgen genotyping results was done (HBV 
Genotyping chapter 4). All UK HBV genotype A had subgenotype Ae, genotype B had 
subgenotype Ba, and genotype C subgenotype C1 (Cs). In genotype D, Saudi Samples 
had HBV subgenotype D1 while UK had subgenotype D2 (cases N6, N12) patients with 
Asian ethnicity. Currently, genotypes are subdivided into several subgenotypes: A1 to 
A3, B1 to B4, C1 to C4, F1 and F2 (Norder et al., 2004). The phylogenetic analysis of S-
gene of UK patients (some of whom have Chinese origin) showed HBV genotype B2 / 
Ba analogy. This was in concordance with the results by Sugauchi et al., (2003) where 
subgenotype-Ba (recombination with genotype C) occurred in all 177 HBV carriers from 
countries of an Asian ethnicity except in Japan, whereas subgenotype-Bj was detected in 
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93% of the 97 carriers from Japan. Within HBV genotype C, Cs subgroup predominantly 
found in Southeast Asia (Vietnam, Thailand, Myanmar, and southern China) including 
HCC patients (Chan et al., 2006), while Ce subgroup predominantly found in the Far East 
(Korea, Japan, and northern China) (Chan et al., 2005). Thus, genotypes can contribute to 
the monitoring of infection by new virus strains from immigrants or as an interaction 
between circulating genotypes.  
Comparison of different parts of the S-gene 
Upon comparison of different areas of the S-gene; Pre S1, Pre S2, and to a lesser extent 
the `a` determinant were discriminative between HBV genotypes than the beginning of 
small HBsAg or the rt part of the Pol gene. A high degree of genetic stability is seen in 
the stem of the HBsAg encapsidation signal (Norder et al., 2003). However, phylogenetic 
analysis of the region including the YMDD motif of the polymerase was used for both 
HBV genotype discrimination and detection of lamivudine resistant mutants (Rodriguez-
Novoa et al., 2004). The percentage of intra-genotypic distance among Afghan isolates 
was 1.05% and inter-genotypic distance with the other genotype D was 2.87% and with 
other genotypes was 7.50% -11.1% (Amini-Bavil-Olyaee et al., 2006)Our results showed 
highest distance in preS1 region between genotype A and genotypes B 0.244 /  0.543, C 
0.154/  0.325, D 0.326 /  0.651 and E 0.242 /  0.515 (table 5-6). 
Properties of the Pre-S1 gene 
Analysis of our preS1 sequences showed that we have subgenotype Ba in UK genotype B 
cases. Our genotype C cases exhibit resemblance to both reference genotype C control, as 
well as areas of analogy to subgenotype C-Australia. Further analysis of the whole 
genome is needed to establish whether this is a recombinant strain, or a new subgenotype 
.of genotype C. In preS1 codon 39, the resemblance to Australian subgenotype can arise 
from common source of infection either in Australian population or from Asian ethnicity 
in both countries.  
 
Pre S1 contains two important epitopes; one is the hepatocyte binding region (aa 21-47), 
and the other (aa.58-100) is speculated to be the epitope recognized by neutralizing 
antibodies involved in viral clearance (Park et al., 2005). The first region also claimed to 
 Chapter 5- S gene and Pol-gene 
144 
 
have transcription activating function as well. Our results showed several differences 
between genotypes in this region, mainly in codons 35 and 39. Whether genotype related 
variation within the hepatocyte binding site affect the binding of different HBV 
genotypes to liver cells has to be explored by cell binding assays.  
Viral proteins such as the truncated middle S protein and the X protein have been also 
implicated as transactivators. The transcription activating sequence was localized to the 
21 to 47 amino acids of Pre S1 protein (Park et al., 2005). The differences in the S region 
may also change between HBV genotypes, thereby affecting the replication ability or 
oncogenic potentials of HBV genotypes. Analysis of their effects on the transactivation 
properties of HBV can be explored by further research.  Blackberg and Kidd-Ljunggren 
(2003) showed that up to 50% of the patients with HCC carried HBV mutants with 
deletions or insertions in the N-terminal half of the pre-S2 region or had a point mutation 
in the start codon of pre-S2 compared to 21% of those with chronic HBV infection... 
 
We detected several point mutations, including abolition of initiation codon of preS2. 
Similarly, pre-S2 starting codon was observed in 19 (26.7%) cases. The HBV mutants 
were more frequent in patients with hepatocellular carcinoma and in genotype B (25%) 
and genotype C (24.5%) (Huy et al., (2003). The pre-S2 is highly immunogenic, it is not 
necessary for the HBV life cycle. Loss of the preS2 protein is a mechanism to escape the 
immune system. Amino acids 41 and 52 of the pre-S2 region are essential for 
transactivation. To generate the transactivating forms of the middle surface protein (pre-
S2/S), a deletion of at least 87 C-terminal amino acids is required (Blackberg and Kidd-
Ljunggren; 2003). 
 
The PHSA binding site (preS-2 aa 17-29) showed minimal changes in codon 22, which 
may be involved in the presence or intensity of HBV viraemia, binding to circulating 
serum albumin in addition to the persistence of HBsAg in circulation. In a study by Huy 
et al., (2003) HBV pre-S mutants were detected in 71 (18.3%) of 387 serum samples 
from Vietnam (36%), Nepal (27.3%), China (22.4%), more than Japan (7.7%), and 
Ghana (4.3%). Among the HBV deletion mutations, 15.5% (11 of 71) occurred in the 
pre-S1 and 46.5% (33 of 71) in the pre-S2 regions. Eight (11.3%) cases had a mutation in 
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both the pre-S1 and pre-S2 regions, in HCC and genotype B (25%) and genotype C 
(24.5%) (Huy et al., (2003). 
 
Single nucleotide polymorphism (SNPs) is gaining popularity as a specific, rapid method 
for genotyping using certain discriminative alleles to differentiate between different 
genotypes. Our analysis (table 5-6) showed several SNPs candidates that not only 
differentiate HBV genotypes, but also may reflect areas of crucial genotype-related 
changes in functional or structural proteins encoded by them. 
S-gene mutations and HBsAg negative phenotype 
The sequences encoding the `a`determinant of HBsAg were highly conserved among our 
HBV genotypes. We found minimal changes in the HBsAg. Our cases were HBsAg-
positive therefore; comparison is difficult with HBsAg-negative variants. Some mutations 
can abolish the two loop structure of the `a` determinant by changing the hydrophilicity, 
the electric charge or the acidity of the loop or altering N-glycosylation site 
(Kreutz,2002). The triple mutation V519L/L526M/M550V causes the concomitant amino 
acid substitution E164D/I195M in the overlapping S protein. This has a reduced affinity 
to anti-HBs antibodies, similar to the vaccine escape mutant G145R (Sucupira et al., 
2006). Consequently, there is an accumulation of multiple sequence variants (sequence 
evolution), some of which are selected during antiviral therapy. 
 
There is a need for complete epidemiological data on the prevalence of HBsAg mutants 
and screening strategies need to be developed and evaluated. Detection of HBsAg needs 
to be improved by the introduction of HBsAg assays able to recognize S-gene mutants 
and escape variants with high sensitivity and has to detect smallest amounts of HBsAg in 
low level carriers. 
Vaccine escape mutants 
The difference within HBV virus clearance (58-100) epitope points to a D1 subgenotype 
of genotype D to be present in Saudi cases. Vaccine escape mutant were reported in 
genotypes B and C, and these also were found to be related to the severity of liver disease 
and sensitivity to therapy (Huy, 2003) (Abe, 2004). 
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Vaccine-induced mutants may cause alteration of antigenicity of HBsAg and binding to 
anti-S antibodies. Hence, preS/S vaccines will be more immunogenic than small HBsAg 
vaccines, but the former show high genotype-specific motifs that demand tailoring the 
vaccine according the pattern of HBV genotypes prevalent in certain geographical 
regions. Whether we need a complete vaccine containing PreS1-large HBsAg protein in 
Saudi Arabia with genotype D remain to be verified. Further epitope mapping and 
immunological studies are needed to define the exact epitopes within this area, and to 
determine the target cells as natural killer cells or cytotoxic T lymphocytes. Their effect 
on antibody binding and lymphocyte activation has to be sought in a detailed study. 
Mutations of HBV polymerase and antiviral drug resistance 
We found several mutations and genotype specific-changes in the spacer region of the 
polymerase gene. The spacer region of the polymerase enzyme is not functional, so 
genotype-specific variations probably merely reflect changes in the overlapping S-gene. 
Regarding the reverse transcriptase region of the pol-gene, we found two UK cases with 
YVDD, and only one HBeAg-negative cirrhotic genotype D Saudi case with YIDD 
mutation, and had high HBV viral load of 108  copies/ml. A stop codon created by the 
M552I causing termination of the major surface protein at amino acid 196 from its wild 
type to tryptophan. No YMDD mutants were found in genotypes A, B, C, and E in UK or 
Saudi isolates sequenced. The mutation in the C domain V204I causes a convergence in 
the corresponding site in SORF codon 182 from tryptophan to a stop codon, as observed 
in our YIDD case. High rates of lamivudine resistant mutants reported ranging from 9% 
(Bai et al., 2003), to 43% and 28% (Wakil et al., 2002) of HBeAg positive patients 
developing the YM552I/VDD and L528M mutations, respectively. YVDD and YIDD 
type tended to have the opposite background with regard to age, histology, and viral load.  
 
Clinical or other virological factors may determine the rapidity of the viral breakthrough 
during therapy. In our case no 528 (rt180) mutation was present. Famciclovir resistant 
mutants are less common than lamivudine resistant mutants, and have L528M, V521L, 
V555I.The latter mutation also causes premature termination of the overlapping envelope 
protein. Nevertheless, lamivudine resistant mutants remain sensitive to adefovir and 
lobucavir. 
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5.7. Conclusion 
In conclusion, the hepatocyte binding sites show considerable HBV genotype specific 
variations mainly in codons 35, 38 and 39. This might explain the differences in the 
hepatocyte binding rates contribution to pathogenicity, and consequently the intensity of 
the infection and the rate of infected hepatocytes with possible effect on the clinical 
consequences and severity of the disease.  
The design of HBsAg assays require high sensitivity and should include diagnosis of 
escape mutants and variant sequences. PreS2 nt. 3085-154 and the `a`dereminant are the 
most variable regions within the PreS/S gene between HBV genotypes. This should be 
considered in vaccination programs in areas where the genotype is different from that of 
the recombinant vaccine.  
5.8. Future Directions 
Check genotype-specific variations in the rest of HBV genome, including the end of pol 
gene nt. 900-1500 (polymerase codons 655-824), which overlaps the beginning of HBV 
X- gene. Epitope mapping of virus clearance epitope (preS1 aa.58-100) can be explored 
for other cytotoxic or natural killer cells epitopes present. 
 
Further studies are needed to analyze the effect of genotypic variations of preS1 and 
preS2 T-cell epitopes codons 7 and 11, and small S-gene codons 20-28, 185-194 
(genotype A)  for the immunogenicity in HBV vaccines, and whether this have any 
implications on current HBV vaccines, especially in populations with HBV genotypes 
different from the vaccine. In addition to comparison with HBsAg-negative occult HBV 
patients with groups of vaccinated individuals 
 
To express the large HBsAg protein (LHB) from plasmid pB10 constructed from case 
N9, which lacks preS2 initiation codon and to check the binding affinity of this variant 
HBsAg to different antibodies and receptors  
 
Perform expression experiments on plasmid pD5 constructed from case 3-38 carrying 
YIDD mutation, to examine the antigen-antibody binding ability of the truncated HBsAg 
resulting from this mutation. 
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Hepatocyte-binding assays can be useful to exploit genotype related differences in the 
hepatocyte binding sites on initial and continuous HBV infection, and to explore their 
contribution to pathogenicity, and their effect on the intensity of the infection as reflected 
by the number of infected hepatocytes. 
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Chapter Six: Genetic Variations of HBV Basal Core Promoter, 
Precore/Core and Overlapping X-gene 
6.1. Introduction 
6.1.1.  Core promoter/ Precore/core gene mutations 
Hepadnavirus genome have high mutation rate of 2 x104 base substitutions/site/year. 
HBV mutations arise spontaneously during replication due to infidelity of the viral 
replication machinery by reverse transcription, RNA pregenome synthesis by RNA 
polymerase, editing of viral DNA by cellular cytidine deaminases resulting in G to A and 
C to T substitutions, or recombination and cleavage/ligation of DNA by topoisomerase I. 
In addition, deletions or insertions can be generated by splicing of the pregenomic RNA 
(Gunther; 2006). Mutations within the core can be a mechanism to avoid the host 
immune response, thereby maintaining viral persistence during chronic infection. 
Alterations in the epitopes in the form of amino acid (aa) substitutions are mostly 
restricted to a small segment located in the middle of the core region (nt. 2063 to 2365, 
303 bp). 
 
The stem-loop structure of the core promoter is recognized by the viral polymerase. 
Disruption of the conformational structure by mutations interferes with encapsidation and 
binding of pregenomic RNA via the arginine±rich C-terminal domain (aa 67-262) of the 
core protein, resulting in defective replication. Compensatory mutations tend to re-
establish base pairing in the hairpin loop stem and regain the secondary structure to 
permit RNA packaging (Francois et al., 2001). 1762-1764 mutations have importance at 
the level of transcription by providing four primer-binding nucleotides in DRI (fig.6b) 
rather than three (fig.6a). Further mutations at nt. 1751 to 1755 would enable the basal 
stem structure to open more easily for reverse transcription (Kidd-Lijunggren et al., 
1997). Replication could also be influenced by a point mutation at nt. 1746 in the BCP 
that is responsible for the correct initiation of precore and pregenomic message (see table 
6-1).  
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6.1.2. Mutations and HBeAg 
Double BCP mutation (T1762/A1764) is increased in the HBeAg-seroconverters than in 
the non-converters (48% vs. 28%). Seroconversion occurred in 50% of those patients 
within 1 year, 88% within 2 years, and 93% within 5 years (Pang et al., 2004).  
 
The wild type virus is predominant in HBeAg-positive stage. Prognostically, precore 
(PC) mutants mark the sustained HBeAg seroconversion, indicating that immune 
responses, specifically against HBeAg select precore stop mutants. G1896A started to 
increase 1 year before and became significantly higher at seroconversion (23 vs. 3%) than 
that in the non-converters (Yamaura et al., 2003). The precore G1896A /UGA stop codon 
aborts the translation of the soluble HBeAg, thereby causes HBeAg-negative mutants 
(Gunther; 2006). Impaired expression of HBeAg frequently arises at the chronic stage of 
infection, as exemplified by PC and BCP mutants. However, anti-HBe antibody develops 
possibly due to cryptic HBeAg that is exposed during HBcAg degradation and turnover 
in infection. 
 
Sometimes precore (PC) mutations were associated with increased viral replication, so it 
contains regulatory polypeptide suppressing viral replication. The C-terminal of the PC 
region contains most mutation sites. A1838G changing the amino acid isoleucine (ATC) 
to valine (GTC) (Gandhe et al., 2003). Such mutation may change the binding efficacy of 
transcription factors to the core promoter, as well as the production of precore and core 
messages. The hydrophobic domain of the precore peptide functions as a leader sequence 
to anchor the peptide to the membrane of the endoplasmic reticulum. The stability of the 
secondary structure formed by the precore pregenomic RNA depends on strict base-
pairing, forming two  copies of the stem-loop structure; one in the 5`forming the 
encapsidation signal H (fig.6-2), which directs the packaging of pregenomic RNA into 
immature core particles during replication (Schaefer; 2005). 
 
The frequency of anti-HBe positive chronic hepatitis B is determined by a C/U exchange 
at position 1858. An exchange of C1858 to U1858 favors the mutation of G1896 to 
A1896. This double mutation can form a stable base pairing between these two 
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nucleotides in the stem loop of the packaging signal of the hepatitis B virus pregenome. 
A1896 change codon 28 of preC to a stop codon which prevents the translation of 
HBeAg. For genotypes C and F strains have been described which show a different 
C/U1858 phenotype than indicated (see fig.6-1). 
 
Deletion and /or insertions within the DR1 region (precore codon 6-7) are replication 
deficient and multiply by the assistance of another virus strains with complementary 
mutations or by a co-existing wt virus through alternative priming of DNA synthesis 
(Laperche et al., 2006).  
 
 
Figure 6-1: Precore encapsidation signal H
Loop structure formed by folding of pregenomic HBV RNA. A U at 1850 and an exchange 
C1858U favoursthe mutation G1896A, thus forming a stable base pairing in the stem of the 
H encapsidation signal as in wild type genotypes B, C strain, D, E and F1 (Schaefer,2005). 
6.1.3. Core gene mutations: 
Core mutants may also inhibit replication by a dominant negative effect up to 95%. Since 
disulfide bond maintains the secondary structure of HBeAg. Substitution of each cysteine 
especially C-7, rendered HBeAg nearly undetectable. Replacement of C61 with arginine, 
but not alanine, aspartic acid, phenylalanine, or serine, blocked virion secretion, which 
could be overcomed by co-expression of wild type core protein, generating viable 
HBeAg-negative variants (Bang et al., 2005). The truncated C-terminal core protein was 
always accompanied by a point mutation at nt. 2112. Mutations A 2189 C and 2086C 
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HBV adr subtype genome core mutant (L97 and V60) exhibited HBV DNA replication 
activity (Chen et al., 2005). Point mutation at nt. 2414 in one of the three SPRRR motifs, 
are important for phosphorylation and nuclear localization. Deletions lead to an 
impairment of HBV capsid assembly from core protein dimers (Francois et al., 2001). 
 
6.1.4. X gene mutation  
X-gene mutations overlap the core promoter/precore or ENII region. In addition, DR2 
can down-regulate gene expression and thereby suppress HBV protein secretion. 
Mutations in X gene are related to progression to chronic disease as a consequence of the 
rescission of antiproliferative and apoptotic effects, which might produce uncontrolled 
growth and contribute to multistep hepatocarcinogenesis (Leon et al., 2005). A HBV 
mutant with fused X-C ORF caused by a single nucleotide insertion in the overlapping 
region has been identified (Francois et al., 2001).  
 
The integrated HBV genome may activate cellular genes to promote growth of liver cells. 
Various viral factors are associated with HCC development as BCP mutations, high viral 
load and HBV genotype. Chen et al., (2005) found an insert mutation AGGCCC at 
position 204, that co-exist with G260A and G/C/T264A variants. Both were associated 
with the nuclear localization of HBx protein (Preikschat et al., 2002). Whilst the  serine to 
alanine mutation at codon 31 was significantly more prevalent in cancer patients than in 
asymptomatic carriers (Chan et al., 2006). Thus, the low frequency of mutations reflects 
the absence of antiviral pressure and indicating a degree of association with disease 
progression.  
6.1.5. Genotype differences 
Genotype differences correlate to HBeAg-seroconversion and can be associated with 
mutation (tables6-2 and 6-3); HBV subgenotype Cs has a higher tendency than Ce to 
develop BCP and overlapping X-gene mutations (80% vs. 50%) (Chan et al., 2005). 
Characteristically, HBV genotype A have a 6-nucleotide insertion at the 3`end of the 
Core gene. Genotype G has a 36-nucleotide insertion at the 5`end of the core gene, and 
consequently expresses a 24-KD core protein with 12 extra amino acids at the C-terminus 
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and stop at precore codons 2 and 28 (Alvarado-Esquivel et al., 2006). Hasegawa et al., 
(2006) identified T1809/T1812 ("Kozak" sequence) and A/T1888 (encapsidation signal) 
in 18/18 (100%) and 78%, respectively/subgenotype Aa. T1809/T1812 immediately 
upstream of the precore initiation codon, which would interfere with the translation of 
HBeAg (Tanaka et al., 2004). The nucleotide polymorphism C2733A differentiates HBV 
subgenotypes Cs (Southeast Asia) from Ce (Far East) (Chan et al., 2006). 
Chapter 6- BCP/PC/Core and  X-gene 
154 
 
Table 6-1: Common mutations in the HBV core promoter and precore and X gene  
ORF* DNA  Position Cod
on 
Genotype/Association Reference 
Core 
Promoter 
1742-
1813 
1762-1764 GGG to AGG  
or TGA (double BCP 
mutant 
7, 8 Anti-HBe phenotype. Chronic HBeAg-negative 
hepatitis. Severe Liver damage, FH, HCC. 
Affecting transcriptional regulation and 
translation of precore gene. Enhanced 
replication and core expression. Interfere with 
binding of liver specific factors, X protein and 
hepatocyte nuclear factor 1.  
Chen et al., 2005 
 
1766-1768 CTT to  
TTA 
9 Advancing liver diseases. Increased 
transcription and encapsidation of pregenomic 
RNA. Carriers and chronic hepatitis B.  
Associated with T1762 and or A1764. 
Gandhe et al., 2003 
increased C1753, 
decreased  T or G1752, 
T1773, A1775G G1799 
4 
12 
17 
HBeAg negativity 
advancing liver diseases.  
Fulminant hepatitis 
Chen et al., 2005 
Imamura et al., 
2003 
Precore 
1814-
1899 
1814, T1815C  1 HBeAg negativity. Initiation codon mutation Gandhe et al., 2003 
C1817T 2 Gln to Stop codon De Castro et al., 
2001 
G1862T Missense 
mutation/  
frame shift 
17 HBeAg negativity 
Chronic hepatitis B 
HBV carriers, G1862A. T1858C 
Gandhe et al., 2003 
G1888A 25 increase stability of upper stem of the 
encapsidation signal in pregenomic RNA. 
T1858C. Chronic hepatitis B 
Gandhe et al., 2003 
G1896A 28 Trp to Stop mutation Loss or decrease of 
HBeAg associated with genotype B and D 
more than A or C. Severe HBeAg-negative 
hepatitis. 
 
G1899A 29 Gly to Asp. Enhance the pregenomic RNA 
transcription 
Gandhe et al., 2003 
De Castro 2001 
Enhancer 
I 
  Decreased replication, Chronic hepatitis Baumert and Blum; 
2000 
Core    Alteration of T-cell epitopes. Inhibit viral 
replication. Impaired capsid assembly, decrease 
pregenomic RNA binding. Viral persistence 
 
 A2339G/G2345A  Increased replication efficiency and 
accumulation of the full-length core protein 
without cleavage by furin-like protease.  
Sugiyama et al., 
2007) 
X gene L5M, Q8K, T12A, S29P, 
S31P, S33P, V37I, P40S, 
D48N, R87W, R103W, 
T106P, K130M/V131I. 
D110E,Stop codon 135aa 
 Transcriptional transactivation Leon et al., 2005 
 1768-1775 
8 bp- deletion 
9-11 Frame shift and truncation of X protein Fischer et al., 
2006,Chan et al., 
2006 
*ORF: Open reading frame 
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6.1.6. Clinical Implications of Precore/core gene mutations: 
Precore (PC) mutants are more associated with chronic than acute infections. Amino acid 
substitution rates peaks in exacerbation of hepatitis than those before and after 
exacerbations, and switching over to PC mutant was beneficial in maintaining disease 
free status (Gandhe et al., 2003). HBeAg-seroconversion was confirmed to occur earlier 
than core promoter or precore mutations in genotype D, and occur frequently in late teens 
in HBV genotype E from West Africa with very low genetic diversity (nucleotide 
homology 96.7-99.2%)(Fujiwara et al., 2005).In genotype D, severe disease is associated 
with single or double precore mutations (G1896A/G1899A) (Fujiwara et al., 2005). In 
patients with severe hepatitis-B, the mutation rate was 52.5% (12/23) (Wang and Liu, 
2003). 
 
BCP and PC mutations, higher age, elevated ALT and anti-HBe positivity are risk factors 
for severe acute hepatitis (Yotsuyanagi et al., 2005), and fulminant than acute self-limited 
hepatitis (9% vs. 53% and 17% vs. 50%). Risk factors include Age 34 years or older, 
HBeAg-negative, total bilirubin 10.0 mg/dL or greater, and HBV genotype D (Wai et al., 
2005) or Bj subgenotype (Ozasa et al., 2006).  
 
On the other hand,  chronically infected carriers with anti-HBe have increased viral 
replication at high levels, they are associated with PC mutants, enhanced pathogenicity, 
and increased core protein synthesis that eventually progress to severe chronic active 
hepatitis (CAH). However, other groups found no association between PC mutations and 
Hepatitis Activity Index (HAI) scores (Yuen et al., 2005). 
Hepatitis activity was significantly inhibited in patients with initial PC rather than initial 
BCP mutation (Hagiwara et al., 2006). BCP mutations were significantly associated with 
higher Hepatitis Activity Index (HAI) and more severe necroinflammation, but not 
fibrosis score (Yuen et al., 2005). In HCC, 62.1% of patients with BCP mutations, 
genotype C and age > or =35 years had liver cirrhosis (Chen et al., 2005), and HBV load 
> or = 105 copies/ml (Liu et al., 2006). 
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Table 6- 2: Genotype specific sequences within the precore/core gene 
 ORF   DNA  Position Codon Genotype/Association References 
 X-gene  C1653T Core 
upstream regulatory 
sequence (CURS) 
 B, C, FH  
 1726- 1730 CTGAG  B Lindh et al., 2000 
 1744  B, C (adr) Liver damage * 
Core 
Promoter 
G1752A 
G1752C 
 Genotype B, D 
Genotype A 
Lindh et al., 2000 
increased 
1762T/1764A, C1753, 
T1766, A1768, A1896 
and decreased  T or 
G1752, T1773, G1799, 
and C1858  
 Genotype C, advancing 
liver diseases 
Chen et al., 2005 
G1757A  D, E, FH De Castro et al., 
2001 
C1773T  D  
A1775G  C  
C1802T 
G1803T 
 B, C, F, H Lindh et al., 2000 
Precore A1850T 13 D, F 
Chronic hepatitis B, 
T1858C 
De Castro et al., 
2001, Gandhe et al., 
2003 
T1858C 15 Genotype A  
 C1858T 15 Non A Genotypes : B, D, 
E, F  
HBeAg-negative Chronic 
hepatitis, encapsidation 
sLJQDOİ 
De Castro et al., 
2001 
G1896A 28 Genotype B > C,  
genotype D >  A   
 
Core  2020A 
 2020G 
 2020T 
 2020-1AT 
40    
 
 
40-41 
A, D 
B, C 
D, E, F, H 
G 
Inoue et al., 2008 
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BCP/PC and antiviral therapy 
Prognostically, BCP mutants predict the response to interferon. Lamivudine therapy 
resulted in a further increase in BCP mutants in complete responders (Chen et al., 2006). 
PC stop mutation is associated with spontaneous or interferon-induced HBeAg-
seroconversion (Kuwahara et al., 2004), while low serum HBV DNA level have low 
breakthrough rate following lamivudine therapy (Shin et al., 2005). Initial ALT level of 
300 U/L or more, G1896A mutant (Chen et al., 2006), and genotype B infected patients 
treated with lamivudine (Huang et al., 2003).  In liver transplant recipients, recurrent 
graft infection by PC/BCP variants may result in fibrosing cholestatic hepatitis (Lo et al., 
2004). In addition, other mutations in nucleotides 1752, 1773, 1802, 1803, 1845, 1850, 
and 1858 was found in the non-responders during lamivudine therapy, that might 
correlate with HBeAg persistence (Chen et al., 2006).  
6.2 Aim 
The aim of this study was:  
To characterize mutations present in HBV core promoter /precore gene, and to compare 
their prevalence in patients in Saudi Arabia, and UK; including the HBeAg-negative 
mutants.  
To explore the relationship between different mutations and patient demographics, serum 
HBV DNA levels, and severity of liver disease.  
To analyze the frequency of mutations in different HBV genotypes 
To check the effect of genotypes on natural HBV sequences, and inferred core and X-
proteins structure. 
6.3 Hypothesis 
Saudi HBV infected patients are usually HBeAg-negative, and generally have low viral 
load (chapter 3). The possibility of HBV mutants exists, particularly the HBeAg-negative 
mutants. The effect of HBV genotype among other undetermined factors may contribute 
to chronicity and favour the development of mutations. 
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6.4. Patients and Methods 
Patients Details (see chapter 3; 3.5.1.1.  and 3.5.1.2.) 
DNA was extracted from HBsAg positive sera of 23 UK patients and 56 Saudi patients.  
PCR of precore (PC) was performed on all 79 sera and basal core promoter (BCP) 
regions was done on only 26 from UK and 23 sera from Saudi hepatitis B patients.  
DNA was extracted by QIAAmp (blood) kits (Qiagen).  
Amplification of Core Promoter /Precore Gene(See Chapter 2) 
Basal Core Promoter PCR 
Optimization was done using combination of primers; C1 and PC3, or C3 nt. 1611-1630 
5`-GAGACCACCGTGAAC GCCCA-3`and PC3 to cover this important region of the 
gene. Variation of primers and PCR conditions led to the development of  the 
Xgene/basal core promoter PCR (EC) PCR using primers C1 and PC3 with product size 
475 bp (data not shown) (See Chapter 2). 
Quantitative PCR (See Chapter 3). 
Nucleotide Sequencing Method: 
Sequencing the products of precore PCR reaction (nt. 1781-2075; 286 bp), and Basal core 
promoter PCR product (nt. 1601-2075; 475 bp) with ABI prism protocol (see chapter 5). 
Sequencing primers are PC1, PC3 and C1. Sequencing was done  in the immunology 
department, University of Nottingham.  
Computer Assisted Sequence Analysis 
DNA sequences were edited and aligned with reference sequences from the Gene Bank  
using Clustal X program. Sequences of the PCR products were compared and analyzed. 
Phylogenetic relationships between sequences were estimated by Neighbor-joining 
method (Saitou and Nei; 1987) applied to pairwise distances by estimated by the 2-
parameter  method (Kimura; 1980). Sites at which there was a gap in any sequence in the 
alignment were excluded from all comparisons. The reliability of the phylogenetic results 
was assessed by re-sampling using 1000 bootstrap replicates (Felsenstein; 1985). 
Associations with a bootstrap value of greater than 70% were deemed significant. These 
analyses were performed using the MEGA3 package. 
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6.5. Results: 
PCR Amplification and sequencing of HBV Pre Core and Core Promoter Regions 
The core gene was amplified by different PCR reactions spanning different regions of the 
gene. First amplification of the pre core region of genomic HBV DNA by PCR was done 
by precore polymerase chain reaction (PC PCR) primers PC1 and PC3 (fig.6-3). The 
sensitivity of precore PCR in detecting specimen with 2 log10copies/ml was higher than 
other PCR reactions, as Basal core promoter PCR (chapter 2) (data not shown). Being a 
single round, PC-PCR decreases the likelihood of contamination compared to nested 
reactions.  
Basal Core Promoter PCR 
X gene/Basal core promoter (EC) PR was done to cover basal core promoter area in 
addition to the PC region (fig.6-4).  
Sequencing of the Core Promoter region of HBV genome: 
Sequencing of basal core promoter PCR products gave an acceptable coverage of both, 
core promoter and precore regions as well as the beginning of the core gene. The results 
(table 6-4) showed basal core promoter (BCP) variants 1762-1764 were seen in 19/26 
(73%) Saudi patients compared to 9/23 (39%) in UK patients (p:0.003). The first 
possibility of BCP 1762-1764 a change of AGG to TGG, was seen in five Saudi patients. 
While the other 2 variations; 1762/1764 A/A, and the double mutant T/A were seen in 
two and seven patients, respectively. Other types of BCP variation were seen only in five 
Saudi patients; two patients had G1762/T1764, one had C1764, 1 T1764 and one case 
showed 12 bp-deletions in BCP region. All had chronic hepatitis and one case presented 
with HCC. 
 
Of the basal core promoter (BCP) variants 1762-1764 present in 9 out of 23 (39%) UK 
patients, one of them had AGT. 1762/1764 A/A, and the double mutant T/A were also 
seen in three and five patients, respectively. Some cases showed both wild type and 
mutants as the case N15, 1-50 and 1-48 (fig.6-5). C1766T, T1768A and C1773T found in 
5/8, 2/8 and 8/8 Genotype A from UK, 4/17, 4/17 and 13/17 Genotype D Saudi patients, 
respectively. C1799G was present in all genotype B patients 7/7 and in 3/17 Genotype D 
Saudi patients. C1812T in only one genotype A case from UK. 
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                               1          2           3           4           5          6           7          M 
 
Figure  6-3: HBV Pre core PCR 
Lane 1: negative control, lanes 2-7: UK specimens, 2: N1, 3: N2, 4: N3, l5: N4, 6: N5, 
7:N6, M:100 bp DNA ladder. 
 
 
               1     2     M      3      4     5       6      7       8     9     10     11    12     13   14     M 
 
Figure 6-4: Pre core and Basal core promoter PCRs 
lanes 1: Negative control, 2: precore PCR product, M: 100 bp DNA ladder, Lanes 3 -13: 
X gene/Basal core promoter (EC) PCR specimens N1-N11 respectively. 14: negative 
control.    
 
Figure 6-5: Basal core promoter mutation 
Sample N15 showing 1762-1764AGA and TGA double mutant. W: double peak of nucleotides A 
and T. 
 
295 bp 
Product 
200 bp 
300 bp 
 300 bp 500 bp 
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Sequencing of the Precore region of HBV genome: 
Upon sequencing of the HBV precore region and the beginning of the core gene (nt. 1781 
to 2075), significant proportion of Saudi patients 37/56 (66.1%) had precore mutants (p: 
0.004) (table 6-4). Of those, codon 28 mutant (G1896A) was present in 30/37 (81.1%), 
resulting in a change of tryptophan to a stop codon. Double mutants in both codons 28 
and 29 were seen in 15/37 (40.5%) of total mutants. G1899A mutation, which alters 
codon 29 from glycine to aspargine, was detected mostly in Saudi genotype D patients 
22/37 (61%) (table 6-4). In contrast, UK patients showed a much lower prevalence of 
G1896A 5/23 (21.7%), of HBV genotypes A, B and D (appendix A).  
 
Nt. C1858 was present predominantly in genotype A patients 7/9 UK and 8/9 Saudi 
genotype A. All genotype C 3/3 UK patients had TCC in nt. 1856-1858. All Saudi and 
UK patients with genotypes B and D and E had T at position 1858 regardless of their nt. 
1896 status. Other point mutations were observed. Our genotype D had G1757A in 15/20 
Saudi and 3/3 UK patients. In patients with double mutations at codons 28 and 29; eight 
patients had also mutations at position 1940 G to C. 32/40 Saudi genotype D patients 
(82%) had C1912T. This mutation was also present in genotype D1 Gene Bank control 
AY161157, and X02496. It is a non-coding mutation; thereby it does not change the 
amino acid aspargine (Asp). Nine patients from UK had T1850A, and seven patients had 
A to T at nt. 1934, which is present in genotypes Ba, C and E.  None of the patients had 
A1838G, or G1888A mutation. 
HBeAg status of core promoter/precore mutants 
BCP/PC variants were analyzed for correlation with HBeAg, HBV viral load and 
genotype. Within HBeAg-positive, UK patients had mostly wild type BCP 9/11 
(88%).Comparably, BCP mutations were present in 4 out of 5 (80%) Saudi cases. 
HBeAg-negative had predominantly BCP mutants, however, less in UK than in Saudi 
patients at 7/12 (58.3%) and 15/21 (71.4%), respectively (table 6-4).  
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Graph 6-1A: HBeAg status of HBV core promoter (BCP) (p value: 0.003). 
Graph 6-1B: HBeAg status of HBV precore (PC) mutants in UK and Saudi patients.  
Note predominantly wild type precore in UK patients compared to the high prevalence of 
precore mutants in Saudi specimens (p value by Chi-square test). More than one type of 
mutation can exist in some patients. (p value: 0.003 by Chi-square test).   
A  
B  
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Table  6-3: HBeAg status of HBV core promoter (BCP) and precore (PC) mutants in 
UK and Saudi patients. (p value by Chi-square test).   
 UK Patients SA Patients 
HBeAg + AntiHBe Total HBeAg + AntiHBe Total 
BCP Mutants 
P: 0.003 
2/11 
(22%) 
7/12 
(58.3%) 
9/23 
(39.1%) 
4/5 (80.0%) 15/21 (71.4%) 19/26 
(73.1%) 
PC mutants  
p: 0.004 
0/11 (0%) 5/12 
(41.7%) 
5/23 
(21.7%) 
4/6* 
(66.7%) 
33/50 (66.0%) 37/56 
(66.1%) 
* Two had G1899A and two had G1896A/G1899A   
 
Table 6-4: HBV core promoter (BCP) and precore (PC) mutants in UK and Saudi 
patients and their average viral loads. Different HBV X-gene mutants in Saudi and UK 
patients. More than one type of mutation can exist in some patients. PC mutations detected 
in either or both codons 28 and 29 corresponding to nt. 1896 and 1899, respectively. Note 
predominantly wild type precore in UK patients compared to the high prevalence of 
precore mutants in Saudi specimens (p value by Chi-square test).  
 
BCP/PC status 
UK Patients SA Patients p Value 
    of 
mutation 
rates 
 Mean 
HBV 
DNA ¥ 
 Mean 
HBV 
DNA ¥ 
Wild type BCP 14/23 (60.9%) 6.1  7/26 (26.9%) 4.7   
0.003 Total BCP mutants 
(corresponding HBxAg): 
9/23 (39.1%) 6  19/26 (73.1 %) 4.2  
   - A1762T alone (K130M) 1/9 (11%)  
   6  
5/19 (26%)  
4.9  
 
   - G1764A alone (V131I)  2/9 (22%) 2/19 (11%)  
   - A1762T/G1764A 
(M130/I131) 
     5/9 (56%) 5.1       7/19 (37%) 4.2   
   - Other BCP mutants      6.6  3.9   
   - (I127N)     4/9 (44%)     0/19 (0%)   
   - (F132Y)     2/9 (22%)     7/19 (36.8%)   
Wildtype PC 18/23 (78.3%) 6.1  19/56 (33.9%) 4.6  
0.004 Total precore mutants: 5/23 (21.7%) 5.9  37/56 (66.1%) 4.3 
    - G1896A alone    3/5 (60%)  5.2    15/37 (40.5%)  3.9  
    - G1899A alone    0/5 (0%)   7/37 (18.9%)  4.6  
    - G1896A /G1899A 2/5 (40%) 4.9 15/37 (40.5%) 4.4  
*  Other types of BCP mutations two patients had G1762/T1764 (K130R), one had C1764, 
one T1764. 
2QHFDVHKDGES-Deletion (nt. 1752 to 1763). 

  A1762/T1764 
¥  p value of mean HBV DNA is  0.155 
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Graph 6-2 A: Coexistence of HBV basal core promoter (BCP) mutants and precore 
(PC) mutants in UK patients. (p value: 0.003) 
 Note predominantly wild type precore present in UK patients with or without BCP 
mutants. 
Graph 6-2 B: Coexistence of HBV basal core promoter (BCP) mutants and precore 
(PC) mutants in Saudi patients. In contrast, high rate of both mutants was found in 
Saudi patients.  
A                                                                                        
 
B 
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Table 6-5: Other identified core promoter and precore gene mutations 
Open 
Reading 
Frame ORF 
DNA  
Positio
n 
Nucleotide Change Codo
n 
UK patients Saudi patients Association 
Core 
Promoter 
1742-1814 
1766-
1768 
CTT to  
TTT or 
TTA 
  
5 genotype A 
 
4-19, 3-6 
 
Precore 
1814-1899 
1858 
 
 
 
1858 
C 15 7 genotype A 
3 genotype C 
None  In genotype A; 
1858C prevent 
PC :TAG 
 T 15 6 genotype B 
2 genotype D 
9 Genotype D B, C, D, E, F 
 1862 G to T Missense 
mutation/frame shift 
17 14 (A) None   
 
Many UK patients had wild type in both BCP and PC 9/22 (40.9%) (Graph6-1). Wild 
type (normal) precore was seen in all HBeAg-positive UK patients 10/10 (100%), with 
genotypes A, B, C, D. HBeAg-negative Saudi had significantly more precore mutants  
than UK patients at 33/50 (66%) and 5/12 (41.7%), respectively. Either core promoter 
and/or precore mutants were found in most of the Saudi patients. On the other hand, 
coexisted BCP and PC mutants occurred mainly in Saudi patients 21/25 (84%) versus 
only one UK case 1/22 (4.5%) (Graph 6-1). BCP and PC coexisted mostly in Saudi 
genotypes D (10 cases).  
 
Among other core promoter mutations, four out of 20 Saudi genotype D patients had 
T1753A, two had chronic hepatitis B and one cirrhotic and one HCC. All 3 UK genotype 
C patients had G1721A and /or A1775G. Two UK patients both were genotype A (N15, 
N4), and four Saudi patients 4/25 had C1653T, all were genotype D. Another observation 
is G1719T G1in the 3 genotype D UK and Saudi patients (17/40). In all our cases nt. 
1838A was present from all genotypes including genotype B (subgenotype Ba). G1862 T 
was seen in only one genotype A case from UK (N14) with viral load of 4.49 log10  
copies/ml clinically presented with cirrhosis (table 6-6). 
 
 
HBV viral load and BCP/PC status: 
The mean HBV DNA of wild type in both BCP and PC was higher than that of BCP or 
PC mutants (table s 6-5); double mutants had lower HBV DNA than single BCP or PC 
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mutants (table 6-4). The new BCP mutants from Saudi patients have even lower viral 
load. Both Saudi and UK PC mutants were associated with lower HBV DNA than their 
wild type PC.G1896A alone has lower mean viral load at 3.9 than wild type and G1899A 
both had 4.6 log10 copies/ml. 
 
The correlation of BCP with PC status showed that within BCP mutants, the mean HBV 
DNA decreases in mutant BCP/wt PC, then mutant in both BCP and PC. While the less 
frequent wt BCP/ mutant PC showed the lowest viral load (Grph6-1). 
 
UK BCP mutants were present more in the intermediate (=>3-<5 log10 copies/ml) viral 
load group double the rate in high viral load group at 3/4 (75%) and 6/17 (35%), 
respectively (graph 6-3). However, Saudi BCP mutants were predominant both in the 
intermediate and high HBV DNA levels at 8/11 (73%) and 8/10 (80%), respectively. 
Core promoter and precore mutants were associated with different serum HBV DNA 
levels in HBeAg-negative patients.  
 
Saudi PC mutants were found at low HBV DNA levels of =<3log10 copies/ml more 
than>3 -<5, and =>5 log10 copies/ml reaching 8/10 (80%), 15/24 (63%), and 14/22 
(64%), respectively. Some of them had very high HBV viral load (=> 7 log10 copies/ml). 
The rates of UK PC mutants were lower in both>3 -<5, and =>5 log10 copies/ml at1/4 
(25%), and 3/17 (18%), respectively (table 6-6). 
 
HBV genotype and BCP/PC status: 
Core promoter mutants were highest in genotype A and genotype D at 7/9 (78%) and 
17/20 (85%), respectively (table 6-10). Genotypes B showed less BCP mutants, but their 
numbers were too small for a solid conclusion. Double basal core promoter (BCP) 
mutations were seen in genotype A and less frequently in genotypes B, D and E patients 
at high HBV DNA levels. In contrast, genotype D predominated at intermediate and low 
viral loads (p: 0.121).  
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Graph 6-3 A: HBV viral load of basal core promoter (BCP) mutants in UK and Saudi 
patients (p: 0.011) 
Graph 6-3 B: HBV viral load of precore PC mutants in UK and Saudi patients (p: 0.019) 
 
A
 
  
 
 
B
 
HBV DNA Quantity in Wild type and Core Promoter (BCP) Mutants p:0.011 
 
No. of  
Pt. 
 
 
 
Copies 
/ml 
 
 
No. of  
Pt. 
 
 
 
 
Copies
/ml 
 
HBV DNA Quantity in Wild type and Precore Mutants p:0.019 
UK Patients Saudi Patients 
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Table 6-6 : Correlation of HBV genotypes and basal core promoter (BCP) and precore (PC) 
mutants in UK and Saudi patients. 
HBV 
Genotype 
 A B C D E Multiple 
genotypes 
Untypa
ble 
BCP 
mutants 
UK 7/9 (78%) 2/7 
(29%) 
0/3 (0%) 0/3 (0%) -  - 
SA 1/1 (100%) - - 17/23 
(74%) 
2/2 
(100%) 
 - 
PC  
mutants 
UK 2/9 (22%) 2/7 
(29%) 
0/3 (0%) 1/3 (33%) -  - 
SA 0/2 (0%) -  0/1 (0%) 35/48 
(73%) 
2/2 
(100%) 
0/2 0 /1        
 
 
 
 
 
Table 6-7: Correlation of the clinical status and core promoter mutants (p: 0.033) and 
precore mutants (p: 0.019). 
Clinical condition BCP Mutant Precore Mutant 
UK SA UK SA 
Inactive hepatitis 1/2 (50%)  0/2 (0%) 1/2 (50%) 9/13 (69%) 
Liver disease  8/21 (38%) 19/24 (79%) 4/21 (19%) 28/43 (65%) 
  - Acute hepatitis     0/1 (0%)     2/2 (100%)     0/1 (0%)     4/5 (80%) 
  - Chronic hepatitis     6/18 (33%)   10/14 (71%)     4/18 (22%)    17/29 (59%) 
  - Cirrhosis     2/2 (100%)    4/5 (80%)     0/2 (0%)     5/6 (83%) 
  - HCC     -    3/3 (100%)     -     2/3 (67%) 
Total 9/23 (39%) 19/26 (73%) 5/23 (22%) 37/56 (66%) 
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Precore mutants are predominant in Saudi HBV patients especially in genotype D 35/48 
(73%) (table 6-10), one of the three UK genotype D patients had PC mutants. In contrast, 
PC mutations were less frequent in other HBV genotypes A, B, C and E. Interestingly, 
Saudi genotype D patients possessed high incidence of codon 29 mutant (G1899A) either  
alone or as double precore mutants reaching 21/48 (44%) compared to non genotype D 
cases..  
 
HBV genotype and X/core gene sequence variation: 
According to the phylogenetic analysis of the core promoter region (fig.6-7), sequences 
were grouped into six major clusters. Four of these were occupied by genotypes A-D. A 
majority of strains were homogenous in both their S and C gene trees (Genotyping 
chapter 4). Genotype E strains were the nearest to genotype D strains. Core promoter 
region sequences showed clear correlation to HBV genotypes and subgenotypes. In 
contrast, the precore region was highly conserved between genotypes and show little 
correlation if any to HBV genotypes (fig.6-6 and 6-7), the latter tree showed a large 
cluster containing genotypes A, B, C, D, E, H and G together. In addition, the short 
segment of nucleotides (200 bp) used was inconclusive to genotypes by phylogenetic 
analysis. 
 
No significant differences were found in T cell epitope encoding regions as class I (aa18-
27) nor class II (aa 1-20, 28-47)core epitopes between different HBV genotypes except 
V27I in genotypes B and C. Genotype A (adw2) and D (ayw2) sequences had amino acid 
substitutions at residues 12 and 27 which were not present in other strains.  
 
HBV mutations and clinical presentation of HBV infection  
Regarding clinical presentation, core promoter mutants (table 6-12) were present in 
patients with liver disease at 8/21 (38%) UK and 18/21 (90%) Saudi patients. Most Saudi 
patients with cirrhosis and HCC had BCP mutations. Saudi patients with cirrhosis and 
HCC had viral loads of 2 to 10.7 log10 copies/ml. 
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 C-N19 UK
 C-N45 UK
 C-N3 UK
 CausAB048704
 C-X01587adr4
 Ba-D00330adw 2
 B-N50 UK
 B-N17 UK
 B-N39 UK
 B-N9 UK
 B-N18-UK
 D-1.78 SA
 D-X65257
 D-N6 UK
 D-4.23 SA
 A1-AY161140
 Dx3.43 SA
 D-1.56 SA
 D-3.9 SA
 D-4.1 SA
 D-pCr15R UK
 D-1.46 SA
 D-4.15 SA
 B-N46 UK
 A/E-3.27 SA
 A-N34-UK
 D-3.5 SA
 A-N41 UK
 ADrecAF297621
 D-3.12 SA
 D2-X80925
 D-109 SA
 D-LEIC UK
 3-19 SA
 D-4.27 SA
 D-1.49 SA
 D-1.50 SA
 D-4.10 SA
 D-3.7 SA
 A2-S50225
 D-3.29 SA
 E-X75664
 D-2-12 SA
 D-X02496
 Dx3.1 SA
 D4-AB048702
 A-1.51 SA
 D-1.55 SA
 D-1.4 SA
 D-3.35 SA
 D-4.21 SA
 D-1.48 SA
 D-3.32 SA
 D-1.2 SA
 D1-AY161157
 Bj.AB073858
 E-4.13 SA
 D-1.60 SA
 G-AF160501
 Cx3.30 SA
 H-AY090457
 B-N47 UK
 D-3.39 SA
 D-4-22 SA
 A-3.26 SA
 E-X75657
 Ax1.63 SA
 A-3.15 SA
 D-4.3 SA
 D-3.34 SA
 Dx3.3 SA
 D-3.8 SA
 D-4.2 SA
 D-4.19 SA
 A-N15 UK
 A-N14 UK
 A-N13 UK
 A-Z35717
 A-N44 UK
 AEuropeV00866
 A-3.47 SA
 A-N4 UK
 A-N49 UK
 A-N33 UK
 F-X75658
 D-3.6 SA
 
 Figure 6-5: Phylogenetic tree of precore region/core nt. 1781-2075 showing absence of 
correlation to HBV genotypes. Gene Bank  HBV genotype reference sequences; Z35717, 
V00866, AF297625, AB073858, X01587, X02496, X80925, X75657, X75664, AY090457, 
AF160501. UK and Saudi sequences marked with suffix UK and  SA, respectively. 
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 D-4.27 SA
 D-109 SA
 D-4.23 SA
 D-4.13 SA
 D-4.3 SA
 D-1-50 SA
 N34-A
 D-4-22 SA
 D-4.15 SA
 D-4.21 SA
 D-2-12 SA
 D-X02496
 D1-AY161157
 A1-AY161140
 D-4.19 SA
 D-4.2 SA
 D4-AB048702
 D-pCore15R UK
 D-4-1 SA
 D-LEIC UK
 D-X65257
 E-X75664
 E-X75657
 D-4.1 SA
 D-4.10 SA
 AEuropeV00866
 AaAF297625
 A-N14 UK
 A-Z35717
 A-N4 UK
 A-N15 UK
 A-N13 UK
 A-3.47 SA
 A-N44 UK
 A-N33 UK
 A2-S50225
 A-N41 UK
 D2-X80925
 ADrecAF297621
 G-AF160501
 Bj.AB073858
 H-AY090457
 CausAB048704
 C-N19 UK
 C-N45 UK
 C-N3 UK
 C-X01587adr4
 Ba-D00330adw 2
 B-N46 UK
 B-N47 UK
 B-N39 UK
 B-N50 UK
 B-N17 UK
 B-N9 UK
 
Figure 6-6: Phylogenetic tree of core promoter and precore regions nt. 1600-2075 showing 
correlation to HBV genotypes using bootstrap method 1000 replicates by Mega software. 
Gene Bank  HBV genotype reference sequences; Z35717, V00866, AF297625, Doo330, 
AB073858, X01587, X02496, X80925, X75657, X75664, AY090457, AF160501  . UK and 
Saudi sequences marked with suffix UK and SA, respectively. 
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HBV X gene mutations  
In this study, lysine to methionine (K130M) was seen in a total of 6/22 UK and 11/25 
Saudi patients. Valine has changed to isoleucine (V131I) present in 8/22 UK patients and 
10/25 Saudi patients (table 6-12). This overlaps the core promoter mutation 1762 and 
1764. K130M/V131I were found in genotype A 4/7 from UK and 1/1 Saudi patients. 
Other X-gene variants; I127N and F132Y were seen.  
 
Saudi patients with inactive hepatitis had comparable rates of PC mutants 9/13 (69%) to 
liver disease 28/43 (65%) (P: 0.019); as acute hepatitis 4/5 and chronic hepatitis 17/29 
(59%) (table 6-7). Inactive hepatitis patients had low HBV DNA at or below 3.2 log10  
copies/ml. Liver disease patients as chronic hepatitis B, cirrhosis with BCP/PC mutations 
had predominantly genotype D.  
 
HBV X gene and genotypes 
F132Y was evident in two genotype A   out of 10 (20%) patients, and 6/20 (30%) 
genotype D patients. 
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6.6. Discussion 
A comparative study like ours provides new information about HBV biology and shows 
important differences in the molecular epidemiology of the virus between Saudi and UK 
hepatitis B patients as regards to genotype, prevalence of mutations and clinical status. 
HBV is endemic in Saudi Arabia with a prevalence of 4.1% HBsAg carriers in the 
general population (Al Tarif et al., 2004). However, there are very few studies on the 
local molecular epidemiology and genetic variation. Analyses studies suggest that 
mutations contribute to viral latency, pathogenesis of liver disease, immune escape, and 
resistance to antiviral therapy (Buti et al., 2005). 
 
The prevalence of HBV basal core promoter (BCP) mutants in Saudi was nearly double 
the rate in UK patients at 19/26 (73%) and 9/23 (39%), respectively (table 6-4). In 
chronic hepatitis B patients from UK, BCP existed in wild type as variants AA 2/9 
(22%), TG 1/9 (11%), and the double mutant TA 5/9 (56%). On the other hand, in USA, 
Hussain et al., (2003) reported BCP AA mutant alone or with wild type (wt) in 16/384 
(4%), TA alone 148/384 (38%) and in combination with wt in 186/384 (48%) of mutants.  
In Saudi HBV genotype D patients, all possibilities of core promoter mutations at 1762, 
1764 exist with AA 3/19 (16%), TG 4/19 (21%), TA 7/19 (37%), GT 2/19 (11%), AC 
1/19 (5%), AT 1/19 (5%) and deletion 1/19 (5%). These types of BCP mutants were not 
reported before. Their amino acid translation is 1762-1764 RL(G/T), KL(A/T), MT(A/A) 
and KM. Such new BCP mutants were observed at even lower viral load (table 6-5). 
Similarly, Amini-Bavil-Olyaee et al., 2006) detected a G1764T mutation in the core 
promoter.  
 
C1766T, T1768A detected in 5/8, 2/8 genotype A from UK and 4/19, 4/19 genotype D 
Saudi patients, respectively. Also C1766T and T1768A are usually associated with the 
double T1762/A1764 mutations (Hussain et al., 2003). The combination of  
T1764/G1766 BCP mutation was common (29.2%) and was frequent in HBeAg-negative 
patients (39.3%), and mutants exhibited lower HBV-DNA and HBV core antigen 
(HBcAg) levels than wt BCP (Elkady et al., 2008). T1766 and/or A1768 mutants and pre-
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S deletions were significantly associated with cirrhosis in HBeAg-negative patients 
(Chen et al., 2007). While other researchers (Tsai et al., 2009) blame C1766T and 
T1753C, core promoter mutations for enhanced replication and suppressed HBeAg.  
There is a striking high prevalence of precore mutants in the Saudi HBV patients where 
the rate of 37/56(66.1%) was significantly more than their incidence in UK patients 5/23 
(21.7%) (p:0.002). G1896A was 30/37 (81%) of Saudi PC mutants, this mutation 
changed codon 28 from TGG to TAG whose translation was changed from tryptophan to 
a stop codon leading to premature termination of HBeAg.  
 
Multiple peaks were seen at individual nucleotide sites. This was obvious in our cases 
N15 where AGA had an equal peak with TGA (fig.6-5). While in the case 1-50, nt.1762-
1764 AGA was present despite of majority of wt. AGG, indicating continuous evolution 
of mutations and the existence of mixture of wild type and mutant in virus population. In 
addition, case 1-48 had both wild type precore and 1896 mutant strains together as well.  
Mixed mutant strains can be separated by line probe method (Husain et al., 2003), but not 
by sequencing method (Candiotti et al., 2006). Other studied reported mutations in 
mixture with wild type virus (Ayed et al., 2007) (Hussain et al., 2003). In addition, mean 
viral load of our different BCP mutants further illustrates that mutation production is a 
dynamic process that occurs in sequential steps. The presence of G1898A only mutation 
was seen in a UK case (N45), which does not cause precore stop codon, but can cause 
indeterminate results in hybridization assays as reported by Chu et al., (2003) G1897A 
mutant gave indeterminate InnoLipa results. 
 
BCP/PC mutations and HBeAg 
HBeAg correlates significantly with BCP mutants frequencies as found in 2/11(22%) of 
UK HBeAg-positive HBV patients (table6-5). HBeAg-negative Saudi patients had higher 
rate of BCP mutants than UK patients at 15/21(71.4%) and 7/12 (58.3%), respectively. 
Rates similar  to the UK results were reported in Scottish blood donors, where the 
frequencies of mutations in the 23 HBeAg-positive were 22% each for mutations 1762 
and 1764, increasing to 26% and 35% in the 56 anti-HBe-positive, respectively 
(Davidson et al., 2005). PC variant was commonly in both HBeAg-negative and HBeAg-
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positive Tunisian patients at (94.5% vs. 87.8%), respectively (Ayed et al., 2007). Viral 
sequence diversity is 2.4-fold higher before a reduction in HBV DNA and HBeAg 
seroconversion, which could either be related to occurrence of stochastic mutations that 
lead to a break in immune tolerance or to increased immune reactivity that drives escape 
mutations. After seroconversion, there was a striking 10-fold increase in substitution rate 
and viral diversity (Lim et al., 2007). 
 
As BCP mutants express less HBeAg (Hui and Lau, 2007), most infections in the 
community are HBeAg-negative and inactive. Whether HBeAg seroconversion is the 
cause or the result of BCP mutations remains to be verified. HBeAg Seroconversion is 
associated with more double BCP mutation T1762/A1764 than in the non-converters 
(48% vs. 28%), and occurred in 50% of patients within 1 year, 88% within 2 years, and 
93% within 5 years (Pang et al., 2004). In Tunisia, HBeAg-positive patients had BCP 
mutants in 18.2% versus 65.4% in HBeAg-negative patients (Ayed et al., 2007). 
Consequently, BCP mutations greatly enhanced genome replication and suppressed 
HBeAg expression. These effects are mediated by transcriptional up regulation of 
pregenomic RNA and suppression of precore RNA (Tsai et al., 2009). Thereby such 
mutation may decrease the translation of HBeAg than wild type level (Qin et al., 2009).  
 
No precore G1896A mutants were detected in the HBeAg-positive UK patients (table6-
4). The high frequency of PC mutations in HBeAg-negative Saudi patients 33/50 (66%) 
far exceeds the rate in our small group of UK patients 5/12 (41.7%). As Saudi HBV 
infected patients are usually HBeAg-negative, and generally have low viral load, which 
further raises the possibility that HBV mutants exist, and contribute to hepatitis 
chronicity and pathogenesis. PC mutants totally stop HBeAg or express truncated 
products. HBeAg-seroconversion is caused mainly by a decrease in HBeAg production in 
the active replication group, and by a decrease in viral replication in the inactive 
replication carriers (Misawa et al., 2006). However, HBeAg negativity did not always 
correspond to the presence of precore mutants (Cheong et al., 2008). 
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Ballard and Boxall (2000) from UK, however, reported G1896A in 3/79(4%) with mixed 
wild /mutant PC population during seroconversion, raised to 44/82 (54%) in HBeAg-
negative patients. This G1896A was much higher than that of our UK results, but similar 
to the prevalence of Saudi PC stop mutants. Such difference may be explained by 
difference in the clinical presentation, genotype distribution, or bigger size of the studied 
groups.  
 
G1862T mutation was seen in only one antiHBe-positive case from UK (N14) with viral 
load of  4.49 log10copies/ml. Chauhan et al., (2006) detected G1862T more often in 
HBeAg-positive than HBeAg-negative (37% vs. 11%) patients. This mutation could 
affect HBeAg expression at two levels. It occurs close to the signal peptide cleavage site 
from the precursor of HBeAg in the endoplasmic reticulum, and might therefore abrogate 
HBeAg synthesis. Alternatively, this mutation might interfere with reverse transcription 
of pregenomic RNA through inhibition of priming of polymerase by binding to the bulge 
of İDW DQG )UDQFRLV et al., 2001), resulting in greatly impaired viral 
replication and low viraemia  (Tong et al., 2005). However, several mutations can 
modulate HBeAg translation initiation, proteolytic cleavage, and secondary structure 
maintenance. 
 
BCP/PC mutations and T or B cell epitopes 
In our results, no significant differences were found between HBV genotypes in HLA 
class I (aa18-27) nor class II (aa 1-20, 28-47) core epitopes, as those have highly 
conserved sequences except V27I in genotypes B and C. Different HLA restricted CTL/T 
helper epitopes within the core gene as reflected by variation of amino acids within the 
core antigen, are capable of inducing significant T-cell responses. HBV genotypes as well 
follow a geographical pattern, which may be influenced by ethnic background or HLA 
type. Variations of B cell epitopes may affect their antigenicity causing changes in HBV 
serological markers or their affinities (Jazayeri et al., 2004). Patients with PC mutants or 
genotype B also had a significantly greater T helper (Th1) response and higher number of 
IFN-gamma producing cells with hepatitis B core antigen (HBcAg) stimulation, and 
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lesser Th2 response lower number of IL-10 producing cells with HBeAg stimulation 
compared to wt PC or  genotype C (Yuen et al., 2007). 
 
Viral load and BCP/PC mutants  
Core promoter BCP mutants predominate in the intermediate (>3-<5 log10 copies/ml) 
viral load group in both Saudi and UK patients at 8/11 (73%) and 3/4 (75%), 
respectively. (tables 6-8 and 6-9). BCP mutants were significantly associated with high 
HBV DNA levels (Tsai et al., 2009), particularly those with high-affinity hepatocyte 
nuclear factor I (HNF I) motifs due to their enhanced replication capacity (Parekh et al., 
2003). Conversely, reduced BCP activity and viral replication or secretion lower viral 
loads, due to missense mutations in the envelope gene or BCP transcription factor 
binding sites (Tong et al., 2005). Also genotype C has a predisposition to acquire BCP 
mutations that continuously activate virus replication after sero-conversion (Kaijima et 
al., 2009). 
 
The other new BCP mutants G1762/T1764, AC and AT from Saudi patients have lowest 
viral load 3.9 log10copies/ml (Graph 6-3), suggesting their late appearance in the course 
of HBV infection. There is significantly less BCP mutations (42.5% vs. 71.4%), and 
HBV DNA levels (5.61vs. 6.18 log10 copies/ml) in HBV genotypes B than C (Du et al., 
2007).  
 
Some precore mutants were seen in UK patients 3/17(18%) with high viral load (>5 
log10 copies/ml) (table 6-9). On the other hand, G1896A alone has marginally higher 
viral load than G1899A at 3.9 and 4.6 log10 copies/ml, respectively. This is partly 
explained by either increasing duration of infection or associated genotype D, where most 
G1899A exist. Few Saudi patients with PC mutants 14/22 (64%) had high viral loads, 
some of them had very high HBV viral load (=> 7 log10 copies/ml). Thus, confirming the 
high replication ability of codon 28 stop mutations as inferred from their occurrence in 
HBeAg-negative patients with high viral load. Alternatively, acute or severe infection can 
possibly be caused by PC mutants.  
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Cis-acting elements within the precore (PC) region are highly conserved; hence, only 
selected mutations can be viable. Interestingly, Saudi HBV PC mutants were seen in all 
levels of viral load. In intermediate viral loads, PC mutants could be encouraged in 
alternating balance between active viral replication and the counteracting immune 
response, as opposed to latent virus with low viral loads that preserve their wild type 
proportion. These findings were obtained by studies demonstrated that the quantity of PC 
mutant was negatively correlated with ALT and HBV DNA levels (Gandhe et al., 2003) 
(Nakashima et al., 2004), both before and after HBeAg seroconversion (Pang et al., 
2004); but others did not (Candotti et al., 2006). Our number of patients with low viral 
load is too small to evaluate PC mutants at low viral loads.  
 
Wild type in both BCP and PC was rare in Saudi HBV patients reaching only 1/26 (5%) 
compared with UK HBV patients 10/22 (45.5%). In contrast, coexisted BCP and PC 
mutants occurred in most of Saudi patients 10/20 (50%) versus only 1/22 (5%) in UK 
patients (table: 6-6). Coexistence was generally more in HBeAg-negative (19%) than 
HBeAg-positive (4%) patients (Chu et al., 2003). Peng et al., (2005) reported coexistence 
of PC and BCP mutants in 64/165 (38.8%) of total patients, in 64/83 (77.1%) out of sera 
with double BCP mutations, and in 64/128 (50.0%) out of sera with G1896A mutation. 
Those rates were comparable to results of the Saudi HBV patients, possibly due to longer 
duration of chronic infection.  
 
Analysis of both BCP and PC status gives a clearer view, as it demonstrates the 
sequential event decreasing viral loads in mutant BCP with wt PC, then the less frequent 
wt BCP with mutant PC, finally mutant in both BCP and PC showed the lowest viral 
load. The mean viral load in coexisting BCP and PC mutation was 4.3 and 5.1log10 
copies/ml in Saudi and UK patients, respectively (tables 6- and 6-9). That was 
comparable to other studies where single BCP variants have significantly higher viral 
load above 5 log10, while those associated with PC stop mutants, have viral load below 5 
log10 (Fang et al., 2002)(Chih et al., (2002). As either the BCP or the PC mutants, can 
influence the synthesis of HBeAg. The impact of the BCP mutation on the replication of 
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HBV can also be modulated by the emergence of the PC stop codon mutations, which 
further complicates the analysis and implications of each mutation.  
BCP/PC and ethnic origin 
Our UK patients with BCP variants were mostly Caucasians and some Asian and Chinese 
ethnic origin. BCP variants were present equally in Caucasians and Asians and rare in 
Blacks (Wai et al., 2005). A contrasting high prevalence of PC mutants was seen in Saudi 
37/56 (66.1%) compared to low prevalence in UK patients 4/22 (18%). The prevalence of 
PC mutation was similar in Saudi to Mediterranean, African, and Southern Europe 
prevalence reaching up to 50% of HBV patients (Chu and Lok. 2002). PC mutants were 
more in Asians than Caucasians, and rare in Blacks (Chu et al., 2003), which could be 
related to their ethnic origin as well as to viral genotype.  
 
Viral Genotype and BCP/PC mutants 
Our results suggest a strong correlation between HBV genotypes and BCP as well as PC 
variants. In UK patients, BCP mutants were high in genotype A subtype Ae at 7/9 (78%) 
(table 6-11). Single BCP mutants occurred in genotypes A and D only. Lower prevalence 
were reported where BCP alone or with PC variants in genotypes A (41%) and D (40%), 
more in genotype C (60%) and lowest in genotype B (26%) in UK (Davidson et al., 
2005). Also in Spain, BCP mutations were similar in genotypes A and D (Jardi et al., 
2004), while Tanaka et al., (2004) shown their existence in both subgenotype Aa (50%) 
and Ae (44%) more than in genotype D isolates (25%). Patients with genotype D were 
more likely to have persistent HBV infection with PC mutants (Kar et al., 2007). It can be 
concluded from this study that the pattern of BCP and PC mutations derived from UK 
patients was contradictory in some aspects to those described by De Castro et al., (2001). 
A high frequency of BCP (78%) (table 6-10) and lower rate of PC mutants 2/9(22%) was 
noted among UK genotype A isolates. Even more in Saudi genotype D who had 17/23 
(74%) BCP or PC35/48 (73%),  
Our UK genotype B (subtype Ba) patients had double BCP variant in both patients with 
mutation 2/7(28.6%), that was in agreement with a case-control study (Sugauchi et al., 
2003), where the double BCP mutation and HBeAg were significantly more in 80 carriers 
each of subgenotype Ba than Bj (33% vs. 15% and 35% vs. 18%), respectively. Lim et 
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al., (20076) detected BCP mutants in genotypes B 24/77 (31.2%), and C 11/77 (14.3%). 
Genotype alone cannot be relied upon in interpreting mutation rates. However, the 
number of our patients of HBV genotypes B, C and E was too small to draw a 
conclusion. Higher frequencies of BCP mutants, PC mutants, genotype C, and higher 
HBV DNA levels were more frequently detected in HCC patients than that in chronic 
carriers (Tong et al., 2007). Genotype B had lower BCP mutants (41.7% versus 89.2%) 
and viral loads (3.6 +/- 0.9 versus 4.6 +/- 1.6compared with genotype C. Whereas 
HBeAg-negative genotype C patients, PC mutants had significantly higher viral loads and 
ALT levels than those with wt PC (Kawabe et al., 2009).   
 
The high incidence of BCP 17/23(74%) and PC 35/48(73%) mutants in Saudi Arabia 
could result from the predominance of genotype D in this population, similar to the rates 
of 87% reported by Ganne-Carrie et al., (2006) in anti-HBe positive patients that were 
associated with genotype D and severe liver fibrosis. The occurrence of 1896A was 
higher in genotype B (77.27%) than that in genotype C (32.26%) (Pan et al., 2007) (table 
6-11). On the other hand, UK genotypes A and B exhibited less PC variants at 2/9(22%), 
2/7(29%), respectively. Our study demonstrated that PC mutants occurred preferentially 
in genotypes D in contradiction to De Castro et al., (2001) which relates PC stop mutant 
to genotypes B, C, D and E. Usually PC mutations were most common in genotype D 
than genotype A (82 vs. 40%)(Jardi et al., 2004). This can be a reflection of chronicity or 
mere predisposition of viral genotype to mutation. Patients with genotype D were more 
likely to have persistent HBV infection with PC mutants (Kar et al., 2007). 
 
On the other hand, genotypes A, B and C subtype C1(Cs) exhibited less PC variants in 
our UK patients. In contrast, Scottish blood donors had less PC mutations in genotypes A 
and C than genotypes B and D at 10%, 25% and 88%, 74%, respectively (Davidson et al., 
2005). Wild type PC was linked strongly to genotype A (Dal Molin et al., 2006), while 
PC mutations were significantly higher in genotype B than genotype C at (69 vs. 34%) 
with HBeAg-seroconversion (Hagiwara et al., 2006). Lower prevalence of G1896A were 
seen in subgenotype Cs than Ce (5% vs. 50%) (Chan et al., 2005). HCC-related mutations 
C1165T, A1762T and G1764A, T2712C/A/G, and A/T2525C were associated with 
Chapter 6- BCP/PC/Core and  X-gene 
181 
 
genotype B; T31C, T53C, and A1499G with subgenotype Ce, and G1613A, G1899A, 
T2170C/G, and T2441C with subgenotype Cs (Sung et al., 2008).  
 
Among Saudi patients, codon 29 mutant (G1899A) was seen in 22/56(59.4%), fifteen of 
them had associated G1896A. Interestingly, Saudi genotype D patients possessed the 
highest prevalence of codon 29 mutant (G1899A) 19/48(39.6%) compared to other 
genotypes, namely genotype A and C. The high incidence of Saudi codon 29 mutants not 
found in the UK patients, could be attributed to the predominance of subgenotype D1 in 
Saudi cases (table 6-10). Conversely, in Yemen, a lower incidence of G1896A/G1899A 
variants was less frequently present at 2/12 (17%) of genotype D PC mutants (Salam et 
al., 2002). Other researcher demonstrated the presence of G1899A/G1896A in genotype 
E (Sitnik et al., 2007), genotype B patients and G1896A alone in genotype C with 
exacerbations of chronic hepatitis (Ozasa et al., 2006). Therefore the prevalence of both 
PC variants is dependent on HBV genotypes. Clinically, G1899A were detected in acute 
liver failure patients (Wai et al., 2005), and with T1753C/A in liver cirrhosis (Song et al., 
2006) and/or T1754C/G and/or A1762T/G1764A were also significantly associated with 
fulminant hepatitis (FH) (Sainokami et al., 2007).  
 
Genotype specific areas of BCP/PC 
Molecular characterization can shed light on viral properties. Although the amino acid 
sequence of the core region is relatively conserved as compared to the surface gene, 
substitutions are observed which are largely linked to the clinical or serological picture. 
This contributes to the interpretation of disease progress, and may aid in the design of 
immunotherapies specific for HBV genotype or ethnic origin (Jazayeri et al., 2004). 
Moreover, construction of phylogenetic trees of Saudi and UK HBV sequences showed 
an almost identical pattern of HBV genotype distribution. The validity of our data was 
strengthened by comparison with international gene bank databases. The genotype 
specificity of the BCP region demonstrated in fig.6-3 might have implications on both the 
core promoter and replication efficiency of different HBV genotypes. In addition, the 
differences in the overlapping X gene and consequently the transactivation function and 
carcinogenesis of HBV among different genotypes. That was consistent with those in 
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Jazayeri`s study (2004) that areas of the core gene that allows allocation of a sequence to 
specific genotype and subtype, through combinations of 24 amino acid substitutions at 
nine residues. Phylogenetic analysis of the distal-X/PC region (Chen et al., 2007), and the 
relatively conserved HBsAg gene sequences were used, but showed a smaller 
phylogenetic signal than pre-core/core sequences (Clemente et al., 2009). Similarly, 
variations within the BCP/PC region (1653-1900), allowed genotyping of HBV with 97% 
sensitivity and 99% specificity (Kramvis et al., 2008). Although being more conserved 
region, phylogenetic studies of our precore/core region was not conclusive of HBV 
genotypes as BCP region did. 
 
Analysis of our core gene sequences with those in gene bank verified that amino 
acid/nucleotide specific nucleotide/amino acid substitutions and motifs correlate with 
HBV genotype/subtype. Cheng et al., (2006) also found that of the 216 new mutations, 
some were genotype-specific. Kramvis et al., 2008) demonstrated that 1802-1803CG is 
characteristic of genotypes A, D, and E whereas 1802-1803TT are characteristic of 
genotypes B, C, and F, and might have an association with liver damage (Lindh et al., 
1999). The Haploplot method revealed high linkage between loci 1858 and 1896, but 
strong evidence of recombination between loci 1862 and 1896. 1888A was positively 
associated with subgenotype A1 and TAA at 1817 with genotype G. Loci 1809-1812, 
1862, and 1888 may have co-evolved together (Kramvis et al., 2008). 
 
According to our results, nt.C1858 was present predominantly in genotype A UK patients 
7/9, as well as in genotype C 3/3 patients. Most of those patients 5/7 (71.4%) had wild 
type (wt) PC, which forms a stable G-C pair with the second nucleotide G1896 of codon 
28 (UGG) resulting in the wt PC. 1858C is positively associated with genotypes A, F, and 
H and subgenotypes C1, F2/F3 (Kramvis et al., 2008). T1858C may thus contribute to the 
rarity of HBeAg-negative mutants in Europe and North America, where genotype A is 
more prevalent. However, the unstable G1896A in genotype A reduce the replication 
efficiency and favors the evolution towards inactive hepatitis (Weber, 2005). Double 
BCP mutation was low (20%) among isolates with C1858 (Banerjee et al., 2005). 
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In contrast, in non-genotype A strains as genotypes B, U1858 of codon 15 (CCU) forms a 
wobble U-*SDLUZLWK*LQWKHVWHPRIWKHSUHJHQRPLF51$HQFDSVLGDWLRQVLJQDOİ
This facilitates the shift from G to A in nt.1896 to form a stable U-A pair, resulting in 
enhanced replication and packaging signal to initiate DNA synthesis, and favoring the 
development of HBeAg-negative state in genotypes B, D, E and G (Watanabe et al., 
2005) and subgenotypes C2, F1/F4 (Kramvis et al., 2008). Up to 39/44 (89%) with 
genotype C and genotype D had T1858 (Banerjee et al., 2005).  
 
All our genotype C subtype C1(Cs) 3/3 UK patients had TCC in nt.1856-1858, causing 
P15S change. Chan et al., 2006) observed that all 214 genotype C patients except one 
HBV strain with TCC at nucleotides 1856 to 1858 belonged to subgroup Cs, and was 
associated with the HBeAg (58% versus 36%), G1898A mutation (64%) and liver 
cirrhosis than in CCC (18% versus 5%). However, Sakurai et al., (2004) failed to 
demonstrate significant difference in clinical characteristics between C1858 and T1858 
variants. 
 
We demonstrated that some areas of the core promoter have been found to be strongly 
linked to genotypes; nt.1726-1727/1730 CT/G are specific for genotype B and C. In all 
our 7 genotype B (Ba) patients from UK, nt.1838A was present. That was in concordance 
with Sugauchi et al., (2003) who found that all the 41 subgenotype Ba) possessed 
G1838A in contrast to 1838G in all 29 of subtype Bj. It also existed regardless of the 
HBeAg positivity or disease activity as chronic or inactive hepatitis patients.  
 
C1773T found in 8/8 Genotype A from UK and 13/17 Genotype D Saudi patients, 
respectively. C1799G was seen in all genotype B patients and in 3/17 Genotype D Saudi 
patients. Consensus genotype A has C1461, T1773, and A1850, while consensus 
genotype D had C1773, C1850 (Hannoun et al., 2002), and G1757A. Moreover, C1773T, 
C1802, G1803, T1846, A1850 mutations might have significant correlation with HBeAg 
(Chen et al., 2006).  Clinically, in HBeAg-positive 328 carriers, mutation V1753 was 
predictive for HCC among C1/Cs carriers, and T1653 among C2/Ce-carriers, and T1653 
or V1753 or double BCP mutants among HBeAg-negative C2/Ce carriers (Tanaka et al., 
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2006). Such HBV variants are genotype specific and related to viraemia levels or binding 
of several liver specific factors. However, in view of HBV heterogeneity, single 
substitutions can represent naturally occurring variants or merely an immune-selected 
mutation in particular patient. Only one of our patients (N34) has mutations at G1740 T 
and G1745T and G1746T. Replication could also be influenced by a BCP mutation at 
nt.1746 which is responsible for the correct initiation of precore and pregenomic message 
(Francois et al., 2001). In 183 chronic genotype C, substitutions at nt. 1762, 1768, 1846, 
1896, 2134, 2288, 2441 was of determinants of early non-detectable HBV-DNA, but did 
not suppress hepatocarcinogenesis in lamivudine-resistant patients with on adefovir 
(Akuta et al., 2008).  
 
This study demonstrated G1721A in 3/3 genotype C patients from UK. Our genotype D 
had G1757A frequently in 15/20 Saudi and 3/3 UK patients. G1757A was observed in 
genotype E (Fujiwara et al., 2005), in addition to C1772, T1858 and A1757 (Sitnik et al., 
2007). In genotype D, A1679 (86.96%), T1762 (39.13%), A1764 (30.43%), and T1915 
(100%) variants were detected (Ahmed et al., 2009).  
 
Laoi and Crowley (2008) 4 out of 11 patients with severe acute HBV infection harboured 
the G1896A stop codon mutation, while the remaining 21 had self-limiting illness. A 
triple mutation, T1753C/A1762T/G1764A was identified in one severe infection. The 
latter also had a mutation, A2339G, in the core gene, not previously reported in severe 
acute infection caused by genotype D (Chen et al., 2007) In HBV genotype Ba had earlier 
A1896 only before HBeAg seroconversion, while genotype C showed significantly 
earlier and persistently higher T1762/A1764 mutant than the A1896 mutant, compared to 
genotype Ba. Furthermore, HBV genotype C was associated with the development of G 
or C1753 and T1766/A1768 mutations and the reactivation of hepatitis after HBeAg 
seroconversion. In addition, the T1846 variant was an independent factor associated with 
HBeAg seroconversion.  
 
Finally, G1862 T mutation was seen in a genotype A case (N14) clinically presented with 
cirrhosis. G1862T mutant is Genotype A-specific but is not always associated with 
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HBeAg. Subgenotype Aa (African/Asian) contains unique mutations upstream of the 
precore ATG codon of genotype Aa suppressed HBeAg expression (Tong et al., 2005). 
However, G1862A mutation has been reported both in asymptomatic HBV carriers 
(Gandhe et al., 2003), and in patients with chronic hepatitis, cirrhosis, HCC, or fulminant 
hepatitis (Francois et al., 2001).  
 
One of our samples had discrepant genotype allocation based on analysis of two genes 
core and S gene. These discrepancies were not surprising. Recombination events between 
different genotypes have been described between A and C from Tibet (Cui et al., 2002) 
and between B and C from South-east Asia (Sugushi et al., 2002). Comparisons of our 
data with core gene sequences in databases strains were almost entirely consistent. 
Several variable residues have been described throughout the core gene. HBcAg codon 
V27I, T67N, N/V/G/T74s, D83E, T91V as well as F97I contained most discrepancy 
between genotypes B and C with other genotypes.  
Clinical Presentation of HBV patients with BCP/PC mutations 
The evolution of HBV mutations depends on the stage and progression of the disease. 
Thus, molecular markers could predict the clinical outcomes of HBV patients. In chronic 
hepatitis, BCP mutants existed in 11/13(85%) Saudi, and lower rates of 6/18 (33%) in 
UK patients. Considering the natural course of HBV, the early phase of HBeAg-positive 
chronic hepatitis is due to wild type HBV; while the late phase chronic hepatitis is due to 
PC or/and BCP variants. BCP and PC mutants increase starting with HBeAg-positive 
asymptomatic carrier at (30%) and 5%, inactive HBsAg carrier 65.7% and 22.5%, then 
chronic hepatitis 95% and 32.5%, and liver cirrhosis 90% and 50%, respectively Song et 
al., (2006).  
 
In the liver disease group, PC mutations were frequently present in both inactive carriers 
and chronic hepatitis at 9/13 (69%), 28/43(65%) of Saudi patients, respectively. 
Conversely, PC mutants were seen in only 4/21(19%) of UK chronic hepatitis patients. 
This suggested that the severity of liver disease was not correlated with PC mutations. 
Similar to Saudi HBV cases, Jardi et al., (2004) demonstrated high frequency of PC 
mutations in inactive carriers (65%) and even higher (80%) in chronic hepatitis patients 
Chapter 6- BCP/PC/Core and  X-gene 
186 
 
with associated elevated ALT and highest HBV DNA, regardless of BCP mutations. PC 
variants were associated with viral persistence in anti-HBe positive patients with ongoing 
chronic hepatitis. Cumulative viral mutations in response to the host immunological 
selective pressure enable the virus for continuous survival and pathogenicity. Whether 
those associations are solely caused by PC mutations, chronic infection or are due to 
other coexisting variations remains to be established.  
 
In addition, our results showed PC mutants with anti-HBe positive patients at all levels of 
viral loads especially =>5 log 10 copies/ml (table 6-7). This is consistent with the clinical 
correlation of PC variants and anti-HBe-positive chronic hepatitis. Yuan et al., (2005) 
found that within HBeAg-positive cirrhotic patients, complicated patients had 
significantly higher frequency of BCP mutations. In contrast, anti-HBe-positive patients 
with complications had significantly higher ALT and HBV DNA levels, but similar 
frequency of BCP and PC mutations. Cheong et al., (2008) demonstrated that lamivudine 
therapy induced initial reversion from PC mutants to wild-type virus, but mutants 
reappeared later. Conversely, wt PC was replaced by PC mutants, resulting in a flare-up 
of hepatitis after cessation of lamivudine.  
 
Some groups demonstrated increased prevalence of BCP and PC mutants in CLD, 
cirrhosis or HCC (Livingston et al., 2007) (Song et al., 2005), while others did not (Liu et 
al., 2006) (Tsai et al., 2009). All Saudi patients with cirrhosis and HCC had BCP 
mutations and 60-67% had PC mutations with viral loads of 2 to 10.7log10 copies/ml 
(table 6-12). However, the number of our patients is too small to draw a solid conclusion. 
Liu et al., 2006) demonstrated that double BCP mutation, and viral load >or=105 
copies/ml were independently associated with the risk of carcinogenesis in noncirrhotic 
as well as cirrhotic HCC. T1762/A1764 mutation was detected in 75.0% of HCC patients 
with high viral load (> or =5 log copies/mL). A1896 was detected in (70.8%) of HBV/D-
infected patients (Elkady et al., 2008). At HBV DNA level of at least 104 copies/mL, 
HCC incidence was higher for those with the wt precore than for those with the G1896A 
variant (955.5 vs 269.4) per 100 000 person-years, and for those with the 
A1762T/G1764A than for those with wt BCP (1149.2 vs 358.7). The hazard ratio of 
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developing HCC was less for G1896A vs wt precore 0.34 , and more for 
A1762T/G1764A 1.73 vs wild type (Yang et al., 2008), or nine single nucleotide 
polymorphisms in the EnhII/BCP regions (six of which were genotype C HBV related) 
that was evident 9 years or more before diagnosis (Chou et al., 2008).  
 
Our liver disease patients including chronic hepatitis B, cirrhosis with BCP/PC mutations 
had genotypes D and less frequently A. Genotypes A, C and D seem to be associated with 
more severe hepatic disease. In Karachi, within genotype D chronic hepatitis B patients, 
PC and BCP mutations were detected in 44/71 (62%) HBeAg-negative compared to only 
9/38 (24%) HBeAg-positive (Abbas et al., 2006). Hence, HBV genotype D correlates 
with both PC stop mutation and liver disease, including severe liver fibrosis (Ganne-
Carrie et al., 2006). In our study, BCP and PC coexisted in Saudi genotypes D and less 
frequently A and E. In early or severe patients, both the proportion of HBeAg-positive 
patients and ALT level were higher in the patients with the mutant/Wt pattern than 
mutants in both the BCP/PC regions (Hagiwara et al., 2006). Up to 50% of genotype D 
had coexistence of BCP and PC mutants (Bahri et al., 2006) and 71.0% in genotype C 
(Nakashima et al., (2004). Coexistence also correlate with high levels of HBV DNA and 
progressive liver diseases than PC mutant only (Peng et al., 2005), reflecting their higher 
pathogenicity or appearance in later stages of the disease after HBeAg seroconversion.  
 
Conversely, we detected C1653T variants can occur in genotypes A and D. So this 
position is neither genotype-specific, nor associated with fulminant hepatitis as 
previously reported (Francois et al., 2001). Li et al., (2002) found C1653T and T1753C 
more frequently in hepatic failure patients with liver cirrhosis than with chronic hepatitis 
(100% vs 50%). Kim et al., (2009) demonstrated that the prevalence of the T1653 
mutation in the box alpha region among HBeAg-negative patients, the A1689 mutation in 
between the box alpha and beta regions, and higher in coexisting T1762/A1764 BCP 
mutations was significantly higher in the HCC group compared to the non-HCC group 
(8.9% vs. 2.2%; 19.3% vs. 4.4%, and 60.7% vs. 22.2%).  
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Four of our 17genotype D patients had T1753A, two had chronic hepatitis B and one 
cirrhotic and one HCC. Salam et al., (2002) found 1753C in 8/14 (57%) of genotype D 
mostly associated with double BCP mutant. C1752 and/or V (not T) 1753 mutation was 
significantly prevalent in HCC patients (HCC vs CLD; 52.2% vs 20%) (Elkady et al., 
2008). HBeAg-negative patients had lower frequency of A1752G mutation rate and 
higher frequency of mutations at A1775G, G1799C and nt.1846 than HBeAg-positive 
patients (Ni et al., 2004) did. In advancing liver diseases, C1753, T1766 and A1768, and 
PC mutations were increased, and the frequencies of T or G1752, T1773, G1799, and 
C1858 mutations decreased (Chen et al., 2005). The T1850A found in 8/10 (80%) 
genotype A UK patients had been linked by Gandhe and colleagues (2003) to chronic 
hepatitis patients in association with double PC variant G1896A-G1899A.  
HBV-X gene mutations 
V131I 2/9(22%) was seen in UK patients as well as M130K in 4/19(24%) and V131I 
3/19(18%) in Saudi patients. M130K and V131I together in 5/9(59%) and 7/19(37%) UK 
and Saudi patients, respectively (table 6-12). Our results showed increased prevalence 
within genotype A of K130M/V131I in 4/7 patients, and single mutant V131I in another 
3/7 patients. Higher frequencies of X-gene mutations K130M/V131I were reported in 
patients with HCC than in asymptomatic carriers (Song et al., 2005), more in genotypes 
B but not C (Lin et al., 2005). Conversely, K130M/V131I mutants alone or with F132Y 
showed lower activities in genotype B only. In genotype C, K130M/V131I with F132Y 
mutant showed higher anti-proliferative activity. The sequence of the X gene showed 
A1678T and G1759A in subtype ayw and C1792T for adw (Venard et al., 2000). 
Moreover, compared with the HBsAg-positive HCC controls, occult HBV-infected (OBI) 
HCC patients had higher frequencies of M1I and Q2K in pre-S2 gene, G185R and S210N 
in surface gene, A36T and A44L in X gene, and G1721A in enhancer II gene, and had 
lower rates of pre-S deletions and A1762T/G1764A, A1846T, G1896A and G1899A in 
BCP/PC genes (Chen et al., 2009).  
 
/Other X gene mutations may exist in patients with chronic liver disease include V92L, 
H94Y, K113T I127L/N/T, F132S (Kurosaki et al., 1996). As I127T/N, T153V were 
detected in the carboxy functional region of X protein, which might be associated with 
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the transactivating function of the X protein as well as phenylalanine-132, cycteine-137 
and histidine-139, which are essential for transactivation (Kidd-Lijunggren et al., 1997). 
Tang et al., 2005) demonstrated that regions between aa 52 to 65 and 88 to 154 are 
important for the augmentation function of HBx in HBV transcription and replication as a 
HBV mutant genome with defective X gene led to decreased levels of HBV RNA and 
HBV replication intermediates. 
 
Only one Saudi HBeAg-negative chronic hepatitis case 2-12 showed a 12bp-deletion 
1752-1765 resulting in frame shift in HBxAg and had high viral load, but with wild type 
precore. The whole BCP is absent in this unusual mutation and the regulatory sequences 
located therein. 12-bp deletion at nt.1754-1765 was described by Hussein et al., (2003). 
Core promoter deletions may causes decrease in DNA replication, limited transcription of 
precore mRNA and thereby decrease HBeAg synthesis and enhance transcription of core 
mRNA and HBcAg (Fang et al., 2009). They also may cause premature termination of 
the overlapping X ORF. Such deletion mutants highlight the functional potentials of viral 
sequences activated by mutations and may be of relevance for viral persistence.  
6.7. Conclusion 
BCP is common in UK HBV patients (41%) and are associated with moderately high 
serum HBV viral loads of =>5 log10 copies/ml and with anti-HBe antibody positivity, 
unlike PC mutants which were uncommon. In Saudi HBV patients, precore mutations are 
common reaching up to 64.8%, including either G1896A stop mutation, G1899A or both. 
Such mutations might explain the intermediate HBV levels in infected Saudi population. 
These results indicate that core promoter and/or precore mutants may be under-reported. 
Physicians should be aware of the existence of these HBV mutants and the clinical 
condition of "HBeAg-negative" chronic hepatitis in such population.  
 
There is significant association of precore mutants with HBV genotype D more than 
other genotypes, and of genotype A with BCP mutations. Follow up studies and analysis 
of associated factors as viral loads and genotype are needed to investigate whether 
precore variants may predispose either singly or interacting with other factors for the 
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development of severe liver disease. Further study of the rest of the core gene is 
recommended to check for variations associated with codon 28 stop mutant.  
 
Genotype specific sequences occur in the HBV core promoter region and the core gene. 
Whether these genotype-specific variations are related to viral replication or X-gene 
function and consequently the progression of liver disease and oncogenesis remain to be 
explored. 
Basal core promoter and enhancer region C1653T Rapid disease progression and HCC 
 AS A1753T Rapid disease progressionT1762A, T1764C HCC, C1766T Fulminant 
hepatitis, X K130 M and V131I HCC development. While Pre-S Deletions has potential 
association with HCC (Pujol et al., 2009). 
 
 
 
 
6.8. Future Direction 
Further studies are needed:  
To determine whether the diversity of HBV core promoter and the overlapping X-gene 
mutations has clinical significance as disease progression and possibly carcinogensis.  
A bigger number of patients need to be tested for the possible correlation between 
different HBV genotypes and the frequency of core promoter/precore mutations, and 
what are the characteristics of coexisted core promoter and precore variants. 
x Full epidemiological studies in UK and Saudi Arabia are needed, to identify HBV 
genotypes, precore mutants and viral load in specimens representative of different 
geographical areas. 
x Extend the study to check the rest of the core gene nt. 1960-2400 (codons 20-151) 
for genotype specific differences and mutations especially in T-cell and B-cell 
epitopes. 
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Chapter Seven :  Update and Conclusion 
 
Technical issues in HBV assays  
Validation of molecular assays for hepatitis B virus is essential at low HBV DNA levels. 
Upon our assessment of eight different PCRs covering the S, X, and C genes, only two 
assays were reliable below 103 copies/ml. One PCR of the S gene, and one of the C gene,     
The precore (PC) PCR showed a sensitivity of 1.9 x 102 IU/ml (equivalent to 1.0 x 103 
copies/ml) (fig.2-2).  
 
Another factor affecting the sensitivity of the assay is the length of the PCR product. The 
S gene PCR product was 281 bp, while the C gene PCR product size was 296 bp. The 
number of cycles needed for HBV PCR is also higher than standard 35 to 38 cycles. We 
demonstrated better yield at higher cycle number. Polymerase and master mix quality 
must be validated to fit these conditions as high fidelity polymerase. Similarly most new 
tests as Cobas Taqman run 60 cycles, which further prove our finding.  Single round 
precore PCR was the most sensitive assay of the core gene, of equal sensitivity to the 
nested core PCR.  
 
Among genotyping PCRs, multiplex PCR was has lower detection limit than RFLP PCR. 
But still the lowest detection is at 104 copies/ml . Recently, WHO standards are available 
in different HBV genotypes (Chudy et al., 2012) 
 
Our real-time detection of HBV by SYBR green was practical, more accurate and has 
detection range from 102 to 1010 copies/ml. This wide detection range is needed for 
monitoring of HBV as this virus can reach very high levels in clinical specimens. During 
comparative analysis of the quantitative results of standards and sera from our SYBR 
green versus Amplicor assay, the difference in HBV DNA measurement between the two 
methods was 0.595 with a 95% CI of 0.10-1.094. The slope was slightly different from a 
value of one indicating a less linear relationship between the two assays. The Amplicor 
test showed less concordance at higher HBV DNA levels of plasmid standards than our 
optimized method. Methods differences causes such limitations of the former assay . 
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Our thermal denaturation profiles which showed peak fluorescence at 80.5 - 81.7 oC due 
to melting of the target PCR products, belonging to two different genotypes.That was 
also proved later to be due to genotype differences in HBV genome (Liu et al., 2006), and 
mutations (Yang et al., 2008). 
Occult HBV infection 
Screening of blood bank sera for occult hepatitis B infection need highly sensitive PCRs 
as low viral load is expected. The real time quantitative PCR further confirmed that these 
cases have low HBV DNA level of = or < 103 copies/ml.  
 
Detection of OBI requires standardized assays of the highest sensitivity and specificity 
with a lower limit of detection < 10 IU/mL for HBV DNA and !0.1 ng/mL for HBsAg 
(Ocana, et al., 2011) Some HBsAg tests have high analytical sensitivity of <0·13 IU/ml 
(Nick and Scheiblauer; 2007). OBI detection also depends technically on the efficiency 
of DNA extraction, genome enrichment, amount of input DNA, PCR primers and assay 
conditions (Banerjee et al., 2007). On the other hand, sensitive PCR assays may lead to 
false positive results from contamination or amplification of non-HBV-DNA targets 
(Kew et al., 2008). However, there is no standardized method to detect OBI that permit 
objective comparison of results (Fryer and Minor, 2009). 
 
It is essential to validate suitable molecular tests to detect OBI in blood transfusion 
services, such as HBV nucleic acid amplification technology (NAT) (Fryer and Minor; 
2009). Our Saudi HBV-DNA rate is still higher than that described from other endemic 
areas as 37.7 per 106 in Italy (Velati et al., 2008) and 158 of 15,721(1.01%) repository 
tubes in Japan (Satake et al., 2007). This highlights the threat where donor screening for 
anti-HBc antibodies is not implemented, though it identifies most but not all OBIs. 
Therefore, the ideal strategy is to exclude all anti-HBc positive unit (El-Zayadi et al., 
2008) by highly sensitive serological screening, although this will result in high discard 
rate of collected blood units in endemic areas without completely covering the risk of 
transfusion transmitted HBV (Dhawan et al., 2008). The NAT aids in prevention by 
detection of donors in window period of HBV infection and OBI (Velati et al., 2008). 
The former reflects the incidence of new HBV infection. The prevalence of anti-HBc 
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decreases below the age of 40 due to the implementation of massive HBV vaccination, 
with an alarming increase of HBV-DNA than older age (75.8% vs. 21.5%) (Yugi et al., 
2006). 
 
Loss of HBsAg after acute HBV infection and the appearance of anti-HBs antibodies 
signify viral clearance. In this case, the anti-HBs is neither fully neutralizing nor 
completely protective. Our data that the seroconversion to anti-HBs is not always 
accompanied by the complete elimination of HBV virus, agree with Velati, et al., (2008), 
who demonstrated HBV DNA in 68% of donors with Anti-HBs antibody, despite that 
74.5 % had concentrations considered protective (> or =10 mIU/mL). It is appropriate to 
monitor the emergence of HBsAg negative mutants in such cases.  
 
The HBV genotypes of HBsAg blood donors were genotype A 6/25 (24%), C 1/25 (4%) 
and D 18/25 (72%). 5 were ungenotypable. There is a predilection for OBI in HBV 
genotype D than genotype A2 (Candotti et al., 2008), and in subgenotypes D3 (Chandra 
et al., 2009), D5 and Aa (Banerjee et al., 2007). The reduced sensitivity and false 
negative results of some HBsAg tests for genotypes D/ayw3, E/ayw4 and F/adw4 
(Scheiblauer; 2010), together with the higher rates of HBsAg-negative precore mutants 
(data not shown) can explain this trend. Further analysis of immunogenic epitopes is 
needed to elucidate the reasons of such differences in OBI between different HBV 
genotypes. 
 
Meta analysis showed highly variable prevalence of OBI in chronic HCV patients 
ranging from 0% to 52% (Levast et al., 2010), with serum HBV-DNA in the absence of 
HBsAg. Proper follow up is needed to evaluate the effect of OBI on the progress of 
disease and outcome of therapy. Coinfection suggests a common source of infection in a 
high risk group as dialysis patients (Jain and Nijhawan; 2008), and is characterized by the 
dominance of HCV, as HCV core protein decreases HBV replication capacity (Chen et 
al., 2003). Another contributing factor to OBI is the significant increase in those who are 
HCV-RNA positive rather than negative (Said et al., 2009), with decreased emergence of 
Chapter 7- Update and Conclusion 
194 
 
HBV pre-C variants (De Mitri et al., 2007), or HIV co-infection (Rodríguez-Torres et al., 
2007).  
 
In our study, HBV-DNA was detected in two out of 15 (13.3%) archival liver biopsies 
from Saudi HCC patients. Similarly, Obika, et al., (2008) found HBV DNA in the liver 
tissue in 25 of 167 (15.0%) HCV patients with CLD, suggesting that most infection was 
contracted during childhood and superinfection by HCV may have occurred thereafter.  
However, it is not clear if HCC is the result of HBV or HCV or to their synergistic insult. 
HCC was reported in 12 of 167 HCV patients (7.2%), more in those with high amount of 
HBV DNA (Obika et al., 2008).  OBI also had significantly higher prevalence in HCC 
patients compared with controls without HCC, at 90/222 (40.5%), and 24/300 (8%) 
respectively (Chen et al., 2009). Although almost half the patients in the HALT-C Trial 
had serological evidence of previous HBV infection there was no difference in the 
prevalence of anti-HBc in serum or HBV DNA in liver between patients who did or did 
not develop HCC (Lok et al., 2011).  
 
OBI was reported in peripheral blood mononuclear cells (PBMCs), and in liver biopsy of 
6/82 (7.3%) anti-HBc-negative much less than 10/16 (62.5%) in anti-HBc positive 
individuals (Raimondo et al., 2008). Low level of HBV-DNA remains detectable in the 
serum and liver tissue in some patients who cleared HBsAg from either acute self-limited 
or chronic HBV infection or even after a successful anti-HBV therapy (Said et al., 2009). 
Examination of liver DNA extracts seems to be the more reliable methodological 
approach than serum for OBI detection (Raimondo et al., 2008; Sagnelli et al., 2008), but 
is difficult to apply in clinical practice. 
 
Quantitative HBV PCR 
Mean HBV DNA level was significantly higher in UK than Saudi patients at 5.09 (95% 
CI 1.43-8.75) and 4.52 (95% CI 0.14-8.90) log10 copies/ml, respectively (p: 0.007). Mean 
HBV DNA in patients with HBeAg was higher at 7.18 and 6.44 log10 copies/ml, while 
anti-HBe positive patients was lower at 3.84 and 4.11 log10 copies/ml in UK and Saudi 
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patients, respectively. Saudi HBeAg-negative patients had higher HBV DNA than UK 
patient. 
 
Inactive hepatitis in Saudi patients was associated with low HBV DNA, have very low or 
undetectable HBV DNA =<103 copies/ml in their sera. On the other hand, active liver 
disease was associated with wide range of low, intermediate and high HBV DNA levels. 
Within the liver disease group, 53/92 (57.6%) Saudi and 42/66 (63.6%) UK patients have 
high HBV DNA of >5 log10, whereas a much smaller proportion show moderate or low 
HBV DNA levels. Their mean HBV DNA in Saudi and UK patients was 4.9 and 5.09 
log10 copies/ml., respectively. 
 
HBV Genotyping  
HBV genotypes A, B, C and D were detected in UK patients, A and D in Saudi patients. 
Low HBV DNAs were mostly ungenotypable. In UK patients, genotypes C and D 
showed higher mean HBV DNA than genotypes A or B. Saudi cases had also higher 
mean HBV DNA in genotypes D than genotypes A or B. Within genotype D, UK patients 
had even higher HBV DNA levels than Saudi patients at 6.10 and 5.10 log10 IU/ml, 
respectively. Saudi patients with HBV genotype A had low and intermediate HBV DNA 
levels. In contrast, most genotype A patients from UK had high HBV DNA levels. 
 
Regarding the clinical presentation of HBV in UK patients, genotypes A and D had equal 
proportion of inactive hepatitis and liver disease. Similarly, patients with acute hepatitis 
had genotypes A and D. Cirrhosis patients had genotypes C and D patients.  
 
Interestingly, phylogenetic analysis showed that all UK HBV genotype A had 
subgenotype Ae, genotype B had subgenotype Ba, and genotype C subgenotype C1 (Cs). 
HBV subgenotypes detected in Saudi Samples had HBV subgenotype D1, while UK had 
subgenotype D2 mostly in Asian patients. All plasmids sequences confirmed the S-gene 
of relevant HBV genotypes . 
 
 
Phylogenetic Analysis of S gene Sequences 
Chapter 7- Update and Conclusion 
196 
 
Phylogenetic analysis of HBV S/Pol sequences of PCR products was done to define 
genotypes and subgenotypes on the basis of 8% and >4% heterogeneity of the entire 
HBV genome, respectively. Generally, there was high concordance between results of 
our multiplex genotyping assay and sequencing of the S gene.  
 
Specifically, Pre S1 region, Pre S2 and beginning as well as the end of S gene 
overlapping the YMDD region of the reverse transcriptase part of pol gene showed 
accurate discrimination between genotypes, and showed genotype-related sequence 
variations. In contrast, the more conserved regions at the `a` determinant and the rt part of 
the Pol gene were inconclusive as regard to HBV genotypes. According to calculations of 
genetic distances by Kimura 2-parameter method, that further confirmed the differences 
between different regions of the S and Pol genes. The phylogenetic analysis of different 
regions of the S-gene have shown genotype-related variations as well. The YMDD 
motive for the detection of antiviral drug resistance as well.  
 
The pre-S1 together with pre-S2 and S-gene encode the large HBsAg protein. Within the 
pre-S region, many nucleotide exchanges are observed. Clear genotype related variations 
are observed in the S gene. Genotype D exhibits several variations. All the sequenced 
cases (9/9) with genotype D, showed deletion of the naturally occurring 11 amino acid 
codons at the beginning of preS1 region as did the genotype D Gene Bank controls. 
Consequently the preS1 starts at codon 12 as compared to genotypes B, C, F, and H. 
Genotype E and G show one aa. codon deletion at the beginning of preS1 segment. 
Resulting in a total of 108 aa in pre S1 instead of the 119 aa seen in genotypes B, C and 
F. Other genotype specific variations were observed in the beginning of the preS1 gene 
including P19S (CCC to AGC) (15/17), codons 88-91 LPAN motif found in all genotype 
D strains (appendix A).  
 
S2 promoter area primes the translation of preS2. HBV genotypes also show several 
consistent variations as follows; V90A found in subgenotype C-Australia and in N16, 
N45, while V90S seen in N19. N114D found in one genotype D Gene Bank strain 
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X65258 and one Saudi case 4-27. Possibly contributing to differences in the expression 
efficiency of HBsAg between different genotypes. 
 
Several isolated point mutations were seen; one genotype D case (S5) has mutation at the 
initiation codon of pre S1, which could interfere with the production of large HBsAg.   
AF 62/63 SL in genotype C cases (N19 and N16) (2/5) were found.  
 
Genotype-specific variations were also seen in pre S2 region. Within the polymerised 
human serum albumin (PHSA) binding site (preS2 aa 17-29), F22L was observed in A-
Europe, genotype Bj subgenotypes, but all our genotype A cases (5/5) showed L22F 
unlike Gene Bank controls. V53A and T54P/L was different in different genotypes. This 
area lies in N-terminus of the PreS2 in the fibronectin binding site to liver sinusoids. This 
can be related to pathogenesis of HBV infections. 
 
Regarding PreS1 regions encoding epitopes at aa. 21-28 (Class I) and aa.21-30 (Class II) 
did not show significant genotype specific variations. In the pre S1 epitope associated 
with HBV virus clearance (58-100), codon A60 found in genotypes C controls and two 
cases (2/5). Our genotype C cases (3/5) have A60V. E86T was seen in genotypes A, B 
and C, but E86Q in all our genotype D cases and in only one Gene Bank control X65257. 
Pre S2 epitope aa.1-11 (Class I and II) shows genotype specific variation at codons 7, 11 
and 13. Codon 7 is a SNP candidate as explained below.  
 
Furthermore, the genotype-specific contribution of preS1 epitopes favours vaccination 
using the complete HBsAg (PreS1, preS2 and small HBsAg) of the prevalent HBV 
genotypes in specific geographical areas. 
 
In general, minimal genotype related variations are seen in T-cell epitopes within the S 
gene. Their effect on lymphocyte activation, the degree of inflammatory responses and 
viral clearance contributing to the pathogenesis of liver disease has to be sought in 
detailed studies.  
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In the Pol gene, we found two UK cases with YVDD and one YMDD mutation. 
 
Single nucleotide polymorphism (SNPs) candidates  
Although there is 92% similarity in HBV genotypes, we found some point at S/pol gene 
that show considerable differences between HBV genotypes and these are presented in 
table 5-7, and can be of benefit in new HBV molecular assays and DNA arrays. 
 
Sequencing of basal core promoter PCR products gave an acceptable coverage of both, 
core promoter and precore regions as well as the beginning of the core gene. Basal core 
promote (BCP) variants 1762-1764 were seen in 19/26 (73%) Saudi patients compared to 
9/23 (39%) in UK patients. (p: 0.003). All possibilities of BCP (1762-1764) mutations 
were detected. First a change of AGG to TGG, was seen in 5 Saudi patients. While the 
other two variations; 1762/1764 A/A, and the double mutant T/A were seen in 2 and 7 
patients, respectively. Other types of BCP variation were seen only in 5 Saudi patients; 
two patients had G1762/T1764, one had C1764, one T1764 and one case showed 12 bp-
deletion in BCP region. All patients had chronic hepatitis and one case presented with 
HCC. 
 
In UK patients, basal core promoter (BCP) variants 1762-1764 present in 9 out of 23 
(39%), one of them had AGT. 1762/1764 A/A, and the double mutant T/A were also seen 
in 3 and 5 patients, respectively. Some cases showed both wild type and mutants as the 
case N15, 1-50 and 1-48 (fig.6-5).  
 
C1766T, T1768A and C1773T found in 5/8, 2/8 and 8/8 Genotype A from UK, 4/17, 
4/17 and 13/17 Genotype D Saudi patients, respectively. C1799G was present in all 
genotype B patients 7/7 and in 3/17 Genotype D Saudi patients. C1812T in only one 
genotype A case from UK. 
 
Sequencing of the Precore region of HBV genome: 
Upon sequencing of the HBV precore region and the beginning of the core gene (nt. 1781 
to 2075). Significant proportion of Saudi patients 37/56 (66.1%) had precore mutants (p: 
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0.004). Of those, codon 28 mutant (G1896A) was present in 30/37 (81.1%), resulting in a 
change of tryptophan to a stop codon. Double mutants in both codons 28 and 29 were 
seen in 15/37 (40.5%) of total mutants. G1899A mutation, which alters codon 29 from 
glycine to aspargine, was detected mostly in Saudi genotype D patients 22/37 (61%) . In 
contrast, UK patients showed a much lower prevalence of G1896A 5/23 (21.7%), of 
HBV genotypes A, B and D (appendix A). The implications of codon 29 mutations need 
to be verified in detailed studies. 
 
Nt. C1858 was present predominantly in genotype A patients 7/9 UK and 8/9 Saudi 
genotype A. All genotype C 3/3 UK patients had TCC in nt. 1856-1858. All Saudi and 
UK patients with genotypes B and D and E had T at position 1858 regardless of their nt. 
1896 status. Other point mutations were observed. Our genotype D had G1757A in 15/20 
Saudi and 3/3 UK patients. In patients with double mutations at codons 28 and 29; eight 
patients had also mutations at position 1940 G to C. 32/40 Saudi genotype D patients 
(82%) had C1912T. This mutation was also present in genotype D1 Gene Bank control 
AY161157, and X02496. It is a non-coding mutation; thereby it does not change the 
amino acid aspargine (Asp). Nine patients from UK had T1850A, and seven patients had 
A to T at nt. 1934, which is present in genotypes Ba, C and E.  None of the patients had 
A1838G, or G1888A mutation. 
 
HBeAg status of core promoter/precore mutants 
BCP/PC variants were analyzed for correlation with HBeAg, HBV viral load and 
genotype. Within HBeAg-positive, UK patients had mostly wild type BCP 9/11 (88%). 
Comparably, BCP mutations were present in 4 out of 5 (80%) Saudi cases. HBeAg-
negative had predominantly BCP mutants, however, less in UK than in Saudi patients at 
7/12 (58.3%) and 15/21 (71.4%), respectively.  
 
Many UK patients had wild type in both BCP and PC 9/22 (40.9%) (Graph 6-1). Wild 
type (normal) precore was seen in all HBeAg-positive UK patients 10/10 (100%), with 
genotypes A, B, C, D. HBeAg-negative Saudi had significantly more precore mutants 
than UK patients at 33/50 (66%) and 5/12 (41.7%), respectively. Either core promoter 
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and/or precore mutants were found in most of the Saudi patients. On the other hand, 
coexisted BCP and PC mutants occurred mainly in Saudi patients 21/25 (84%) versus 
only one UK patient. There was predominance of wild type precore in UK patients with 
or without BCP mutants. 
 
Among other core promoter mutations, four out of 20 Saudi genotype D patients had 
T1753A, two had chronic hepatitis B and one cirrhotic and one HCC. All 3 UK genotype 
C patients had G1721A and /or A1775G. Two UK patients both were genotype A (N15, 
N4), and four Saudi patients 4/25 had C1653T, all were genotype D. Another observation 
is G1719T G1in the 3 genotype D UK and Saudi patients (17/40). In all our cases nt. 
1838A was present from all genotypes including genotype B (subgenotype Ba). G1862 T 
was seen in only one genotype A case from UK (N14) with viral load of 4.49 log10  
copies/ml clinically presented with cirrhosis  
 
HBV viral load and BCP/PC status: 
The mean HBV DNA of wild type in both BCP and PC was higher than that of either 
BCP or PC mutants, double mutants had even lower HBV DNA than single BCP or PC 
mutants. The new BCP mutants from Saudi patients have even lower viral load. G1896A 
alone has lower mean viral load at 3.9 than wild type and G1899A both had 4.6 log10 
copies/ml. 
 
The correlation of BCP with PC status showed that within BCP mutants. There is a 
sequential HBV DNA decrease in mutant BCP/wt PC, then mutant in both BCP and PC. 
While the less frequent wt BCP/ mutant PC showed the lowest viral load (Graph 6-1). 
 
UK BCP mutants were present more in the intermediate (=>3 -<5 log10 copies/ml) viral 
load group double the rate in high viral load group ( =>5 log10 copies/ml) at 3/4 (75%) 
and 6/17 (35%), respectively (graph 6-3). However, Saudi BCP mutants were comparably 
predominant in both intermediate and high HBV DNA levels at 8/11 (73%) and 8/10 
(80%), respectively. Core promoter and precore mutants were associated with different 
serum HBV DNA levels in HBeAg-negative patients.  
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Saudi PC mutants were found at low HBV DNA levels of  =<3 log10 copies/ml more 
than >3 -<5, and =>5 log10 copies/ml reaching  8/10 (80%), 15/24 (63%), and 14/22 
(64%), respectively. Some of them had very high HBV viral load (=> 7 log10 copies/ml). 
The HBV DNA levels of UK PC mutants were lower in both >3 -<5, and =>5 log10 
copies/ml at 1/4 (25%), and 3/17 (18%), respectively . 
 
HBV genotype and BCP/PC status: 
Core promoter mutants were highest in genotype A and genotype D at 7/9 (78%) and 
17/20 (85%), respectively.  Genotypes B showed less BCP mutants, but their numbers 
were too small for a solid conclusion. Double basal core promoter (BCP) mutations were 
seen in genotype A and less frequently in genotypes B, D and E patients at high HBV 
DNA levels. In contrast, genotype D predominated at intermediate and low viral loads (p: 
0.121).  
 
Precore mutants are predominant in Saudi HBV patients especially in genotype D 35/48 
(73%) , one of the three UK genotype D patients had PC mutants. In contrast, PC 
mutations were less frequent in other HBV genotypes A, B, C and E. Interestingly, Saudi 
genotype D patients possessed high incidence of codon 29 mutant (G1899A) either alone 
or as double precore mutants reaching 21/48 (44%) compared to non genotype D cases..  
 
HBV genotype and X/core gene sequence variation: 
According to the phylogenetic analysis of the core promoter region (fig.6-7), sequences 
were grouped into six major clusters. Four of these were occupied by genotypes A-D. 
The majority of strains were homogenous in both their S and C gene trees (Genotyping 
chapter 4). Genotype E strains were the nearest to genotype D strains. Core promoter 
region sequences showed clear correlation to HBV genotypes and subgenotypes. In 
contrast, the precore region was highly conserved between genotypes and show little 
correlation if any to HBV genotypes (fig.6-6 and 6-7). In addition, the short segment of 
nucleotides (200 bp) used was inconclusive to genotypes by phylogenetic analysis. 
 
No significant differences were found in T cell epitope encoding regions as class I (aa18-
27) nor class II (aa 1-20, 28-47) core epitopes between different HBV genotypes except 
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V27I in genotypes B and C. Genotype A (adw2) and D (ayw2) sequences had amino acid 
substitutions at residues 12 and 27 which were not present in other strains.  
 
HBV mutations and clinical presentation of HBV infection  
Regarding clinical presentation, core promoter mutants were present in patients with liver 
disease were much higher in 18/21 (90%) Saudi patients than in 8/21 (38%) UK patients. 
Most Saudi patients with cirrhosis and HCC had BCP mutations, and showed wide range 
of HBV DNA from 2 to 10.7 log10 copies/ml. 
 
Precore mutations  
Saudi patients with inactive hepatitis had comparable rates of PC mutants 9/13 (69%) to 
liver disease 28/43 (65%) (P: 0.019); as acute hepatitis 4/5 and chronic hepatitis 17/29 
(59%). Inactive hepatitis patients had low HBV DNA at or below 3.2 log10 copies/ml. 
Liver disease patients as chronic hepatitis B, cirrhosis with BCP/PC mutations had 
predominantly genotype D.  
 
HBV X gene mutations  
In this study, lysine to methionine (K130M) was seen in a total of 6/22 UK and 11/25 
Saudi patients. Valine has changed to isoleucine (V131I) present in 8/22 UK patients and 
10/25 Saudi patients. This overlaps the core promoter mutation 1762 and 1764. 
K130M/V131I were found in genotype A 4/7 from UK and 1/1 Saudi patients. Other X-
gene variants; I127N and F132Y were seen. Correlation to oncogenic potential of X gene 
in different genotypes need to be explored in future research. 
 
HBV X gene and genotypes 
F132Y was evident in two genotype A   out of 10 (20%) patients, and 6/20 (30%) 
genotype D patients. 
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Appendix A 
S/Pol-gene Sequences 
S-Promoter nt3045-3180 
HBsAg1start PreS112        Hepatocyte binding site (21-47)   51      Viral Clearance Epitope (58-100) 88      
T-cell Epitopes 
A1-AY161140_BK   YIMGGWSSKP RKGMGTNLSV PNPLGFFPDH QLDPAFKANS NNPDWDLNPI KDHWPQANQV GVGAFGPGFT PPHGGVLGWS PQAQGILATV  [ 90] 
A2-S50225_BK     .S...GT... .......... .......... ......G... ......F... .....A.... ........L. .....I.... .......T..  [ 90] 
AeuropeV00866_BK H.L.NK.YSI .......... ......L... ......G... T.....F... .....A.... ........L. .....I.... .......T..  [ 90] 
AafrcaAF297625   -.L.NK.YSI .......... .......... ......G... T.....F... .......... ........HS .......... .......T..  [ 90] 
A-N4_UK          --....P... .......... R......... ......G... ......F... .....A.... .......... ....SL.... .......T..  [ 90] 
A-gCn5_UK        --........ .Q........ .......... ......G... ......F... .....A.... ........L. .....I.... .......T..  [ 90] 
A-N5_UK          --........ .......... .......... ......G... ......F... .....A.... ........L. .....I.... .......T..  [ 90] 
A-pW7_UK         --........ .......... .......... ......G... ......F... .....A.... ........L. .....I.... .......T..  [ 90] 
A-N14_UK         --..RRP... .......... .......... ......G... ......FYR. .....AS... ........L. .....I.... .H.....T..  [ 90] 
A-N49_UK         --.....C.. ......K... .......... ......G... ......F... .....A.... ........L. .....I.... .......T..  [ 90] 
BaD00330ADW2_BK  .S........ .......... .......... .......... E........N ..N..D..K. .......... .....L.... .....L.T..  [ 90] 
Bj-AB073858_BK   .S........ .......... .......... .......... E........H ..N..D.HK. ......S... .....L.... .......TS.  [ 90] 
B1-AB073852_BK   .S........ .......... .......... .......... E........H ..N..D.RK. .......... .....L.... .......TS.  [ 90] 
B2-AB073830_BK   .S........ .......... .......... .......... E........H ..N..D..K. .........I .....L.... .......T..  [ 90] 
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Appendix 
233 
 
B-N70f_UK           ---------- ---------- -----I...H R.M....N.. ..N....... ......R.L. .......... .......... ........... [91] 
B-N71-UK            -....PS... E......R.. .....I...H R.M....N.. ..N...Y... ......R.L. .......... .......... ........... [91] 
B-N72f_UK           ---------- ---------- --------.H R.M....N.. ..N....... ......R.L. .......... .......... ........... [91] 
B-N74r-UK           -....PS... E......R.. .....I...H R.M....N.. ..N...Y... ......R.L. .......... .......... ........... [91] 
B-N73-UK            ---------- ---------- --------.H R.M....... ..N....... ......R.L. .......... .......... ..........V [91] 
B-N72-UK            -.....V... .......R.. .....I...H R.M....N.. ..N....... ......R.L. .......... .......... ........... [91] 
AB-N68-UK           -.....V... .......R.. .....I...H R.M....... .......... ......R.L. ......V... .......... ........... [91] 
C1-AF411412_BK      ......V... ..P....R.. .T..NIDY.H ..M.D..... ..N.....L. ....F.R.L. .......... .......... ........... [91] 
C1Cs-AB111946_BK    ......V... ..P....R.. .T..NI.Y.H ..M.D...T. ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
C2-AF533983_BK      ......V... ..P....R.. .T..NI.Y.H ..M.D..... ..N.....L. ....F.R.L. .......... .......... ........... [91] 
C3-X75656_BK        ......V... ..P....R.. .T..NI.Y.H ..M.D..... ..N....... ....F.R.L. .......... .......... ........... [91] 
C4-AB048704_BK      ......V... .......R.. .T....DH.H ........H. ..N....... ....F.R.L. .......... .......... ........... [91] 
C4aus-AB048704ayw_B ......V... .......R.. .T....DH.H ........H. ..N....... ....F.R.L. .......... .......... ........... [91] 
C-N1-UK             -.....V... ..P....R.. .T..NI.Y.H ..M.D..... ..N.....L. ....F.R.L. .......... .......... ........... [91] 
C-N83-UK            -.....V... ..P....R.. .T..NI.H.H .AM.D..... ..N.....L. ....F.R.L. .......... .......... ........... [91] 
C-N80-UK            -.....V... ..P....R.. .T...V.Y.H ..M.D..... ..N.....L. ....F.R.L. .......... .......... ........... [91] 
C-wclon_UK          ......V... ..P....R.. .T..NI.Y.H ..M.D..... ..N.....L. ....F.R.L. .......... .......... ........... [91] 
C-N1_UK             ......V... ..P....R.A --F.N*L.D- SCM....... ---------- ---------- ---------- ---------- ----------- [91] 
C-N16_UK            ......A... .......R.. .TC.NIY.G- .C-------- ---------- ---------- ---------- ---------- ----------- [91] 
D1-AY161157_BK      ......V... .......R.. .....F.Y.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D2-X80925_BK        ......V... .......R.. .....L.H.R ..M.....Y. ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D3-X85254_BK        ......V... .......R.. .....L.H.H ..MPH..... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D4-AB048702_BK      ......V... .......R.. .....I.H.H .......... ..N.....L. ....F...L. .......... .......... ........... [91] 
D-1.60a_SA          ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-2.23a_SA          ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-S7a_SA            ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... ..L....... .V......... [91] 
D-3.33a_SA          ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-S6a_SA            ......V... .......R.. .....V.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-3.35a_SA          ......V... .......R.. .S...F.H.H .......... ..N..E..L. ..Q.F.R.L. .......... .......... ........... [91] 
D-3.34a_SA          ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......M.. .......... ........... [91] 
D-N36_UK            ---------- ---------- ------...H .NM....... ..N.....L. ..Q.F.R.L. .......... .......... ...M....... [91] 
D-N38f_UK           ---------- ---------- ------...H .NM....... ..N.....L. ..Q.F.R.L. .......... .......... ...M....... [91] 
D-N82_UK            ---------- ---....R.. .....F.Y.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-N78_UK            ---------- ---------- -----F.H.R ..M.....Y. ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-N79_UK            -.....D... .......R.. .....F.H.H ..M....... ..N..E..L. ..Q.F.R.L. .......... .......... ........... [91] 
D-N76_UK            -.....D... .......R.. .T...F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-N77_UK            -.....V... .......R.. .T...F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-3.38_SA           ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-pD5_SA            ......V... .......R.. .....F.H.H ..M....... ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
D-N12_UK            ......V..P ......GR.A .....--.-- ---------- ---------- ---------- ---------- ---------- ----------- [91] 
D-N11_UK            ......V... .......R.. .....LHH-H ..M.D.---- ---------- ---------- ---------- ---------- ----------- [91] 
D-7.46R_SA          ......V.Y. .......R.. .....V.H*H .SM......Y ..H......- ---------- ---------- ---------- ----------- [91] 
E-X75664_BK         ......V... .......R.. .....I.H.H ...P...... ..N....... .F..F.R.L. .......M.. .......... ........... [91] 
D-2.31a_SA          ......V... .......R.. .....L.H.H ..MP....Y. ..N.....L. ..*.F.R.L. .......... .......... ........... [91] 
E-2.25a_SA          ......V... .......R.. .....I.H.. ...P...... ..N....... .F..F.R.L. .......M.. .......... ........... [91] 
E-N81r-UK           ---------- ---....R.. .....I.... R......... ..N....... ......R.L. .......M.. .......... ........... [91] 
E-En2_UK            ......V... .......R.. .....I.H.. ...P...... ..N....... .F..F.R.L. .......M.. .......... ........... [91] 
F-X69798adw4_BK     ......V... .......R.. .T...HDH.H .......N.. T.N.....L. .FQ.L.R.L. .......... .......... ........... [91] 
H-AY090454_BK       ......V... .......RV. .T...Y.H.H .S.....H.. ..N.....L. ..Q.F.R.L. .......... .......... ........... [91] 
G-AF160501_BK       ......V... .......R.. .D...LDH.. .......... .......... ....F.R.L. .......... .......... ........... [91] 
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RT 188204YMDD 
A1-AY161140         CSVVRRAFPH CLAFSYMDDV VLGAKSVQHL ESLYTAVTNF LLSLGIHLNP NKTKRWGYSL NFMGYVIGSR GHKPQDHIVQ NNKHCFRKLP ANRPIDWKV [99] 
A2-S50225HBsAg-_BK  .......... .......... .........R .A........ .......... .......... .....R...W .TL....... KI........ V........ [99] 
A-europV00866adw_BK .......... .......... .........R .......... .......... .......... .....I...W .TL....... KI........ V........ [99] 
A-afric-AF297625_BK .......... .......... .........R .......... .......... .......... .........W .TL.....I. KI........ V........ [99] 
A-N60-UK            .......... .......... .........R .......... .......... .......... .....I...W .TL....... KI........ V......-- [99] 
A-N66-UK            .......... .........I .....T.H.R .......... .......... .......... .....I...W .TL....... KI........ V..A.S.-- [99] 
A-N75-UK            .......... .......... .........R .......... .......... .......... .........W .TL....--- ---------- --------- [99] 
A-pW7_UK            .......... .........M .........R .......... .--------- ---------- ---------- ---------- ---------- --------- [99] 
Ba-D00330adw2_BK    .......... .........M .......... ....A..... .......... H......... .........W .TL..E.... KI.MW..... V........ [99] 
Bj-AB073858_BK      .......... .......... .......... .......... .......... H......... .........W .TL..E..T. KI.L...... V........ [99] 
B1-AB073852_BK      .......... .......... .......... ....A..... .......... H......... .........W .TL..E.... KI.Q...... V........ [99] 
B2-AB073830_BK      .......... .......... .......... .......... .......... H......... ........CW .TL..E.... KI.M...... V........ [99] 
B3-D00331_BK        .......... .......... .......... ....A..... .......... Q......... .........W .TL..E...L KI.Q...... V........ [99] 
B4-AB100695_BK      .......... .......... .......... ....A..... .......... H......... .........W .SL..E..G. KI.L...... V........ [99] 
B-N71-UK            .......... .......... .......... ....A..... .......... H......... .........W .TL..E.... KI.M...... V........ [99] 
B-N72f_UK           .......... .......... .......... ....A..... .......... H......... .........W .TL..E.S.. KI.------- --------- [99] 
B-N70f_UK           .......... .......... .......... ....A..... .......... H......... .........W .TL..E.... KI.M....-- --------- [99] 
B-N69_UK            .......... .......... .......... ..I.A...H. .......... H......... .........W .TL..E.... KI.T...... V.-..VR-- [99] 
B-N74r-UK           .......... .......... .......... ....A..... .......... H......... .........W .TL..E---- ---------- --------- [99] 
B-N47-UK            .......... .......... .......... ....A..... .......... H......... .........W .TL..E---- ---------- --------- [99] 
B-N73-UK            .......... .......... .......... ....A..... .......... H......... .........W ---------- ---------- --------- [99] 
AB-N68-UK           .......... .......... .........R ....A..... .......... H......... .........W .TL....... KI........ V........ [99] 
C-X01587adr4_BK     .......... .......... .......... ...F.SI... .......... .......... ........CW .TL..E...L KI.Q...... --------- [99] 
C1Cs-AB111946_BK    .......... .......... .......... ...F...... .....V.... T......... .........W .TL..E...H KI.Q...... L........ [99] 
C2Ce-AF533983_BK    .......... .......... .......... ...F.SI... .......... .......... .........W .TL..E...L KL.Q...... V........ [99] 
C3-X75656_BK        .......... .......... .......... .....SI... .......... .......... .........W .TL..E...L KI.Q...... V........ [99] 
C4aus-AB048704ayw_BK.......... .........L .......... ...F...... .M........ H......... .........W .SL..E...H KL........  V........ [99] 
C-N1-UK             .......... .......... .......... ...F.SI... .......... .......... ........CW .TL..E...L KI.Q......  V.....LE- [99] 
C-N80-UK            .......... .......... .......... ...F.SI... .......... .......... .........W .TL..E...L KI.Q..A.VV  LSNCT-*-- [99] 
C-N83-UK            .......... .......... .......... ...F.SI... .......... .......... H........W .SL..E.... KL.Q......  V......-- [99] 
D1-AY161157_BK      .......... .......... .....N.... ...F...... .......... .......... H.......CY .SL.....I. KI.E......  V........ [99] 
D2-X80925_BK        .......... ....T..... .......... ...F...... .......... .......... ........CY .SL.....I. KI.E......  V........ [99] 
D3-X85254_BK        .......... .......... .......... ...F...... .......... .......... .....I..CH .SL..E.... KI.E......  I........ [99] 
D4-AB048702_BK      .......... .......... .......... ...F...... .......... .......... .........W .SL.....IH KI.E......  VH....... [99] 
D-N36_UK            .......... ......V... .......... ...F...... .F........ .......... H........Y .SL..----- ----------  --------- [99] 
D-N38f_UK           .......... ......V... .......... ...F...... .F........ .......... H........Y .SL..----- ----------  --------- [99] 
D-N76_UK            .......... .......... .....T.... ...F...... .........T .......... H.......CY .SL.....I. KI.E......  V........ [99] 
D-N79_UK            .......... .......... .......... .......... .......... .......... H.......CY .SL..E..I. KI.E......  V..T....- [99] 
D-X02496ayw_BK      .......... .......... .......... ...F...... .......... .......... H.......CY .S-------- ----------  --------- [99] 
D-N78_UK            .......... .......... .......... ...F...... .......... .......... ........CY .SFA.----- ----------  --------- [99] 
D-N77_UK            .......... .......... .......... ...F...... .......... .......... H.......CY .SL.....I. KI.E......  V.......- [99] 
D-N82_UK            .......... .......... .......... ...F...... .......... .......... H.......CM .SL------- ----------  --------- [99] 
D-3.38_SA           .......... ......I... .......... ...F...... .......... .......--- ---------- ---------- ----------  --------- [99] 
D-pD5_SA            .......... ......I... .......... ...F...... .--------- ---------- ---------- ---------- ----------  --------- [99] 
E-X75664_BK         .......... .......... .......R.. .....S.... .......... .......... .........W .SL..E..I. KI....G...  V........ [99] 
E-N81r-UK           .......... .......... .......... .......S.. .V........ .......... .........W .SL...---- ----------  --------- [99] 
E-En2_UK            .......... .......... .......... .....S.... .......... .......... .........W .SL..G..RL KI.D------  --------- [99] 
F-X69798adw4_BK     .......... .........L .......... .......... ...V.....T S......... H........W .SL......H KI.E......  V........ [99] 
H-AY090454_BK       .......... .........L .......... .......... ...V.....T A...W..... H....I...W .TL..E.... KI.D......  V........ [99] 
G-AF160501_BK       .......... .......... .......... .......... .......... .......... .........W .TL..E..T. KI.Q......  V........ [99] 
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Appendix B  
Basal core promoter (BCP)/X-gene 
HBx protein (HbxAg)  
Alignment of last 77 amino acids sequences of HBx protein which shows genotype/subtype identification of 42 sera using Clustal X software. Amino acid 
residues presented in single-letter code. Genotype control stains from Gene Bank are included. Sequences name starting with capital letter indicating the 
genotype and suffix SA for Saudi strains and UK for UK strains. 
Amino acid       79         90        100        110        120        130        140        150     End 
AeurpeV00866_GB  MATTVNAHQI LPKVLHKRTL GLPAMSTTDL EAYFKDCVFK DWEELGEEIR LMIFVLGGCR HKLVCAPAPC NFFTSA* [ 77] 
AaAF297625_GB    .E........ .......... .......... .......... .......... .KV....... ....F..SS. ....... [ 77] 
A1-AY161140_GB   .E.......V ..R....... ..S....... .......L.R .......... .KV....... .......... ....... [ 77] 
A-N13_UK         ---------- .......... .......... .......... ........T. .MI....... .......... ....... [ 77] 
A-3.47_SA        -----..... .......... .......... .......... .......... .MT....... .......... ....... [ 77] 
A-N44_UK         ---------- .......... .......... .......... .......... .KV....... .......... ....... [ 77] 
A2-S50225_GB     .E.......S .......... .......... .......... .......... .MI....... .......... ....... [ 77] 
A-N33_UK         ---------- .......... .......... .......... .......... .KI....... .......... ....... [ 77] 
A-N41_UK         --------.. .......... .......... .......... .......... .MV....... .......... ....... [ 77] 
A-Z35717_GB      .......... .......... .......... .......... .......... .MI....... .......... ....... [ 77] 
A-N4_UK          -------... .....Y.... .......... .......... .......... .KIY...... .......V.. ....... [ 77] 
A-N15_UK         --------.. .....Y.... .......... .......... .......... .MIY...... .......... ....... [ 77] 
A-N49_UK         ---------- .......... .......... .......... .......... .KI......M ...A...P.. ....... [ 77] 
A-N14_UK         ---------- .......... ......M... .......... .......... .MI....... .......SS. ....... [ 77] 
B1-AB073852_GB   .E......RN .......... ..S....... .........T E...M...T. .MI....... .....S.... ....... [ 77] 
B2-AB073830_GB   .E......WN .......... ..S....... .........T E......... .KV....... .....S.... ....... [ 77] 
Ba-D00330adw2_GB .E......GN .......... ..S....... .........N E.......V. .KV....... .....S.... ....... [ 77] 
Bj-AB073858_GB   .E......WN .....Y.... ..S....... .........N E......... .KIY...... .....S.T.. ....... [ 77] 
B3-D00331_GB     .E......RN .......... ..S....... ..H......T E......... .KV....... .....S.... ....... [ 77] 
B4-AB100695_GB   .E......R. .S.D.RTM.. E.SGL..S.. ......R..T E......... .MI......T .T.LFS.S.. ..LN... [ 77] 
B-N17_UK         --------GN .......... ..S....... .........T E.......V. .MI....... ....RS.... ....... [ 77] 
B-N9_UK          ---------- .......... ..S....... .........T E.......V. .MI....... ....RS.... ....... [ 77] 
B-N39_UK         ---------- ...A...... ..S....... .........N E.......V. .KV....... .....S.... ....... [ 77] 
B-N50_UK         ---------- .......... ..S....... .........N E.......V. .KV....... .....S.... ....... [ 77] 
B-N47_UK         ---------- .......... ..S....... .........T E.......V. .KV....... .....S.... ....... [ 77] 
B-N46_UK         ---------- .......... ..S....... .........T E.......M. .KV....... .....S.... ....... [ 77] 
B-N18-UK         .E....T.GN .......... ..S....... .........N E.......V. .KV....... .....S.... ....... [ 77] 
C-7.48_SA        -----...SF .......... ..A.....E. .......L.. .......... .QV....... .....S.... ....... [ 77] 
C-N19_UK         ---------- .......... ..S....... .......... .......... .KV....... .....S.... ....... [ 77] 
C-N3_UK          ----...R.V .......... ..S....... .......... .........T .KV....... .....S.... ....... [ 77] 
C-N45_UK         ---------- .......... ..S....... .......... .......... .KV....... .....S.... ....... [ 77] 
C-X01587adr4_GB  .E.......V .......... ..S....... .......L.. .......... .KV....... .....S.... ....... [ 77] 
C1Cs-AB111946_GB .E.....R.V .......... ..S....... .......... ........T. .MI....... .....S.... ....... [ 77] 
C2Ce-AF533983_GB .E.......V .......... ..S....... .......L.. .......... .MI....... .....S.... ....... [ 77] 
C3-X75656_GB     .E......MV .......... ..S....... .......... .......... .KV....... .......... ....... [ 77] 
C4ausAB048704_GB .E....T.M. .......... .......I.. .......L.. .......... .KV....... .....S.... ....... [ 77] 
D-X65257_GB      .E........ .......... ..S....... .......L.. .......... .KV....... .......... ....... [ 77] 
D-X02496_GB      .E...K...F .......... ..SV...... .......L.. .......... .KV....... .......... ....... [ 77] 
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D1-AY161157_GB   .E.......F .......... ..SV...... .......L.R .......... .KV....... .......... ....... [ 77] 
D2-X80925_GB     .E......H. ........A. .......... .......... .......... .KV....... .......... ....... [ 77] 
D3-X85254_GB     .E........ .......... ..S....... .......L.. .........W .KV....... .......... D...... [ 77] 
D4-AB048702_GB   .E.......F .......... ..S....... .......L.. .......... .KV....... .......... ....... [ 77] 
D-7.80_SA        ---------F .......... ..S....... ....T..L.. ........T. .MI....... .......... ....... [ 77] 
D-3.34_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-N22_UK         ---------- ---------- ---------- --------.. .......... .KV....... .......... ....... [ 77] 
D-3.12_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.7_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-1.205_SA       ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-2.11_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------- -...... [ 77] 
D-3.3_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.1_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.43_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-4.27_SA        ---------- -......... ..SV...... .......L.. .......... .RL....... .......... ....... [ 77] 
D-109_SA         ---------- -......... ..SV...... .......L.. .......... .RL....... .......... ....... [ 77] 
D-1.46_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------- -...... [ 77] 
D-3.18_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----... [ 77] 
D-3.8_SA         ---------- ---------- ---------- ---------- ---------- ---------- -------... ....... [ 77] 
D-4.7_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-4.23_SA        ---------C .......... ..SV...... .......L.. .......... .KM....... .......V.. ....... [ 77] 
D-4.13_SA        --------.F .......... ..SV...... .......L.. E......... .KL....... .....V.... ....... [ 77] 
D-4.3_SA         --------HF ......N... ..SG...... .......L.. .......... .KV....... .......... ....... [ 77] 
D-4-22_SA        ---------- ---------- ----...... .......L.. .......... .KI....... .......... ....... [ 77] 
D-4.2_SA         -----...HC .......... ..CV..M... .......L.. ........N. .MVY...... .......... ....... [ 77] 
D-1.50_SA        ---------- .....Y.... ..SV...... .......L.. .......... .MI....... .......... ....... [ 77] 
D-4.15_SA        ---------F .....Y.... ..SV...... .......L.. .......... .KL....... .......... ....... [ 77] 
D-4.21_SA        ---------- .........I ..SV...... .......L.. .......... .KV....... .......... ....... [ 77] 
D-7.84_SA        -------DHF .....LN... ..SV...... .......L.. .......... .KV....... .......... ....... [ 77] 
D-3.26_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.36_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-1.55_SA        ---------- ---------- ---------- ---------- ---------- ---------- ------.... ....... [ 77] 
DA-1.56_SA       ---------- ---------- ---------- ---------- ---------- ---------- --------.. ....... [ 77] 
D-2.12_SA        ------...F .......... ..SV...... .......L.. ........-- ---....... .......... ....... [ 77] 
D-3.32_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.5_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.29_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ----... [ 77] 
D-1.106_SA       ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-3.9_SA         ---------- ---------- ---------- ---------- ---------- ---------- --------S. ....... [ 77] 
D-3.39_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-1.60_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-1.49_SA        ---------- ---------- ---------- ---------- ---------- ---------- --------.. ....... [ 77] 
D-LEIC_UK        ---------- -......... ..S....... .......L.. ........L. .KV....... .......... ....... [ 77] 
D-4-1_SA         ---------- .......... ..S....... .......L.. ........L. .KV....... .......... ....... [ 77] 
D-p15R_UK        .E........ ...I...... ..S....... .......L.. ........L. .KV....... .......... ....... [ 77] 
D1.48_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------- [ 77] 
D-1.78_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------- ------. [ 77] 
D-3.19_SA        ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-1.2_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
D-1.4_SA         ---------- ---------- ---------- ---------- ---------- ---------- ---------. ....... [ 77] 
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D-N12_UK         -----D...F .......... ..SV.P.... .......L.. .......... .KV.------ ---------- ------- [ 77] 
D-N6_UK          ------..HF .......... ..SV...... .......L.. .......... .KV..S.... .......... ....... [ 77] 
D-118_SA         --------.F .......... ..SV...... .......L.. ........N. .MVY...... .......... ....... [ 77] 
D-3.35_SA        --------.F .......... ..SV...... .......L.. ........N. .MVY...... .......... ....... [ 77] 
D-7.59_SA        -------DSC .....L.... ..SV...... .......L.. .......... .KVY...... ........T. ...P... [ 77] 
D-7.86_SA        -------EPF .......... ..SV...... .......L.R ........N. .MI....... .......... ....... [ 77] 
D-7.40_SA        -------DP. .....LM..S ..SV...... .......L.. .......... .KV....... .......... ....... [ 77] 
D-7.5_SA         --------PF .......... ..SV...... .......L.. ........T. .MI....... .......... ....... [ 77] 
D-4.19_SA        .E.......F .......... ..SV...... .......L.. ........N. .MVY.F.... .......... ....... [ 77] 
D-3.6_SA         ---------- .......... ..SV...... .......L.. ........N. .MVY...... .......... ....... [ 77] 
E-X75664_GB      .E........ .......... ..S....... .......L.. .......... .KV....... .......... ....... [ 77] 
E-X75657_GB      .E........ .......... ..S....... .......L.. ....S..... .KV....... .......... ....... [ 77] 
E-2.25_SA        ---------- .....Y.... ..S....... .......L.. ....S..... .MIY...... .......... ....... [ 77] 
E-4.10_SA        ---------. .....Y.... ..S....... .......L.. ....S..... .MI....... .......... ....... [ 77] 
F-X75658_GB      .E.....PWS ..T......I ..SGR.M.WI .E.I...... .......... .KV....... .......... ....... [ 77] 
G-AF160501_GB    .E.AM.TSHH ..RQ.Y.W.. ..FV....GV .K.......A E.....N.S. .MT....... .......... ....... [ 77] 
H-AY090457_GB    --------.S ..TT...... ..SPR...WI .E.I...... ....S...L. .KV....... .....S.... ....... [ 77] 
 
1startHBeAg (3rd ORF)         1StartHBcAg 
AeurpeV00866_GB  MQLFHLCLII SCTCPTVQAS KLCLGWLWGM DIDPYKEFGA TVELLSFLPS DFFPSVRDLL DTASALYR [136] 
AaAF297625_GB    .......... .......... .......... .......... .......... .......... ........ [136] 
A1-AY161140_GB   .......... ..S....... .......... ....H..... .......... .....A.... ........ [136] 
A2-S50225_GB     .......... ..S.L..... .......*.. .......... S........H .......... ........ [136] 
ADrecAF297621_GB .......... ..S....... .......*.. .........S .......... .......... ........ [136] 
A-N13_UK         .......... .......... .......... .......... .A........ ......K... ......F. [136] 
A-3.47_SA        .......... .......... .......... .......... .......... .......... ........ [136] 
A-N44_UK         .......... .......... .......... .......... .......... .......... ........ [136] 
A-N33_UK         .*........ .......... .......... .......... S........H ..Y....... ........ [136] 
A-N41_UK         .......... ..S....... .......... ...L...... S........H .....I.... ......H. [136] 
A-N4_UK          .......... .......... .......... .......... S......... .......... ........ [136] 
A-N15_UK         .......... .......... .......*.. .......... .......... .......... ........ [136] 
A-N49_UK         .......... .......... N...V..... ---------- ---------- ---------- -------- [136] 
A-N14_UK         .......... ......F... .......... .......... .......... .......... ........ [136] 
Ba-D00330adw2_GB .......... ..S....... .......... .......... S......... .......... ........ [136] 
Bj-AB073858_GB   ........V. ..S....... .......*.. .......... .A.......A ..Y....... ...T.... [136] 
B1-AB073852_GB   ........V. ..S....... .......*D. .......... ....I..... .......... ...T.... [136] 
B2-AB073830_GB   .......... ..S....... .......*.. ...T...... S......... .....I.... ........ [136] 
B3-D00331_GB     .......... ..S....... .......... .......... S......... .....I.... ........ [136] 
B4-AB100695_GB   ....EF.... ..S....... .......... .......... S......... .......E.. ........ [136] 
B-N17_UK         .......... ..S....... .......... .......... S......... .....I.... ........ [136] 
B-N9_UK          .......... ..S....... .......... ...T...... S......... .......... ........ [136] 
B-N39_UK         .......... ..S....... .......... .......... S......... .....I.... ........ [136] 
B-N50_UK         .......... ..S....... .......... .......... S......... .....I.... ........ [136] 
B-N47_UK         .......... ..S....... .......*.. ...T...... S......... .....I.... ........ [136] 
B-N46_UK         .......... ..S....... .......*.. ...T...... S......... .......... ........ [136] 
B-N18-UK         .......... ..S....... .......... .........D S......--- ---------- -------- [136] 
C-7.48_SA        .......... ..S....... .......... ...S....-- ---------- ---------- -------- [136] 
C-N19_UK         .......... ..S.S..... .......... .......... S......... .....I.... ........ [136] 
C-N3_UK          .......... *...S..... .......... .......... S......... .....I.... ........ [136] 
C-N45_UK         .......... ..S.S..... ........S. .......... S......... .....I.... ........ [136] 
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C1Cs-AB111946_GB .......... ..S....... .......... .......... S......... ....NI.... ......F. [136] 
C2Ce-AF533983_GB .......... ..S....... .......... .......... S......... .....I.... ........ [136] 
C3-X75656_GB     .......... ..S....... .......... .......... S......... .....I.... ........ [136] 
C4ausAB048704_GB .......... ..S....... .......*D. .......... S......... ....NI.... ........ [136] 
D-7.80_SA        .......... ..S...F... .......*D. .......... S......... .......... ...A.... [136] 
D-3.34_SA        .......... ..S....... ..WP...*D. .......... S......... ......P... ..P..... [136] 
D-N22_UK         .......... ..S....... .......*D. .......... S......... .......... ........ [136] 
D-3.12_SA        .......... ..S....... .......*D. .......... S......... .......... ........ [136] 
D-3.7_SA         .......... ..S....... .......*D. .......... S.Q......T .......... ...T.... [136] 
D-1.205_SA       .......... ..S....... .......*D. .......... S.Q......T .......... ...T.... [136] 
D-2.11_SA        ---....... ..S....... .......*D. .......... S.Q....... .......... ...T.... [136] 
D-3.3_SA         .......... ..S....... .......*D. .......... S.Q....... .......... ...T.... [136] 
D-3.1_SA         .......... ..S....... .......*D. .......... S.Q....... .......... ...A.... [136] 
D-3.43_SA        .......... ..S....... .......*D. .......... ..Q......A .......... ........ [136] 
D-4.27_SA        .......... ..S....... .......*.. .......... S......... .......... ........ [136] 
D-109_SA         .......... ..S....... .......*.. .......... S......... .......... ........ [136] 
D-1.46_SA        ---....... ..S....... .......*.. .......... S......... .......... ........ [136] 
D-3.18_SA        ------.... ..S....... .......*.. .......... S......... .......... ........ [136] 
D-3.8_SA         .......... ..S....... .......*.. .......... .........T .......... ......F. [136] 
D-4.7_SA         .......... ..S....... .......*.. .....N.... .........G .......... ........ [136] 
D-4.23_SA        .......... ..S....... .......... .......... S.P....... .......... .......G [136] 
D-4.13_SA        .......... ..S....... .......*.. .......... S......... .......... ........ [136] 
D-4.3_SA         .......... ..S....... .......*.. .......... S......... .......... ...T.... [136] 
D-4-22_SA        .......... ..S....... .......*D. .......... S......... .......... ........ [136] 
D-4.2_SA         .......... ..S....... ........D. .......... .......... .......... ........ [136] 
D-1.50_SA        .......... ..S....... .......*D. .......... ..Q....... .......... ...T.... [136] 
D-4.15_SA        .......... ..S....... .......*D. .......... S........T ..Y.N..... ......F. [136] 
D-4.21_SA        .......... ..S....... .......*.. .......... .......... .......... ........ [136] 
D-X02496_GB      .......... ..S....... .......... .......... .......... .......... .N...... [136] 
D-7.84_SA        .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-3.26_SA        .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-3.36_SA        .......... ..S...D... .......... .......... .......... .......... ........ [136] 
D1-AY161157_GB   ...L...... ..S....... .......... .T........ .......... .......... ........ [136] 
D-1.55_SA        .......... ..S....... .......... .......... .......... .......... ........ [136] 
DA-1.56_SA       .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-2.12_SA        .......... ..S....... .......... .......... .......... .....L.... ........ [136] 
D-3.32_SA        .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-3.5_SA         .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-3.29_SA        ------.... ..S....... ........D. .......... .A........ .......... ........ [136] 
D-1.106_SA       ..F....... ..S....... .......*D. .......... .......... .......... ........ [136] 
D-3.9_SA         .......... ..S....... ........D. .......... .......... .......... .......G [136] 
D-3.39_SA        .......... ..S....... ........D. .......... ...S...... .......... ........ [136] 
D-1.60_SA        .......... ..S....... ........D. .......... .......... .......... ........ [136] 
D-1.49_SA        .......... ..S....... ........D. .......... .......... .......... ........ [136] 
D-LEIC_UK        .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-4-1_SA         .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-p15R_UK        .......... ..S....... .......... .......... .......... .......... ......C. [136] 
D1.48_SA         ---------- -.S....... .......... .......... .......... .......... ........ [136] 
D-X65257_GB      .......... ..S....... .......... .......... .......... .......... ........ [136] 
D4-AB048702_GB   .......... ..S....... .......... .......... .......... .......... ...A.... [136] 
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D3-X85254_GB     .R........ ..S....... ....R..*.. .......... S......... .......... ........ [136] 
D-1.78_SA        -------... ..S....... .......*D. .......... S......... .......... ........ [136] 
D-3.19_SA        .......... ..S....... .......... ...H...... .......... .......... ........ [136] 
D-1.2_SA         .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-1.4_SA         .......... ..S....... .......... .......... .......... .......... ........ [136] 
D2-X80925_GB     .......... ..S....... .......... .......... .......... .......... ........ [136] 
D-N12_UK         ---------- ---------- ---------- ---------- ---------- ---------- -------- [136] 
D-N6_UK          .......... ..S....... ....AR.... .T........ S--------- ---------- -------- [136] 
D-118_SA         .......... .WS..I.... R......*.. ..-------- ---------- ---------- -------- [136] 
D-3.35_SA        .......... ..S.------ ---------- ---------- ---------- ---------- -------- [136] 
D-7.59_SA        ....P..... CV........ ........R. ..V.....-- ---------- ---------- -------- [136] 
D-7.86_SA        .......... ..S....P.. ........D. .T-------- ---------- ---------- -------- [136] 
D-7.40_SA        .......... ..S....... .......*.. ........-- ---------- ---------- -------- [136] 
D-7.5_SA         .......... ..S...F... .......*D. .......... ---------- ---------- -------- [136] 
D-4.19_SA        .......... ..Q.LI.... R....L.*.. ..V....... .......W.. ..L.....-- -------- [136] 
D-3.6_SA         .......... .WF.LI.... R....L.*.. ..V......V I......... .S...----- -------- [136] 
E-X75664_GB      .......... ..S....... .......... .......... .......... .......... ........ [136] 
E-X75657_GB      .......... ..S....... .......... .......... .......... .......... ........ [136] 
E-2.25_SA        .......... ..S....... .......*.. .......... S......... .......... ........ [136] 
E-4.10_SA        .......... ..S....... .......*.. .......... .L........ .......... ........ [136] 
F-X75658_GB      .......... ..L....... .......... .......... S...F..... .....I.... ........ [136] 
H-AY090457_GB    .......... F.S....... .......... .......... S......... .......... ........ [136] 
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AeurpeV00866_GB  EALESPEHCS PHHTALRQAI LCW [159] 
AaAF297625_GB    .......... .......ET. ... [159] 
A1-AY161140_GB   .......... .......... ... [159] 
A2-S50225_GB     .......... .........V ... [159] 
ADrecAF297621_GB .......... .......... ... [159] 
A-N13_UK         D......... .....----- --- [159] 
A-3.47_SA        .......... ....R...-- --- [159] 
A-N44_UK         .......... .....----- --- [159] 
A-N33_UK         .......... ........-- --- [159] 
A-N41_UK         .........T .......--- --- [159] 
A-N4_UK          .......... ........-- --- [159] 
A-N15_UK         .......... .N......-- --- [159] 
A-N49_UK         ---------- ---------- --- [159] 
A-N14_UK         .......... ........-- --- [159] 
Ba-D00330adw2_GB .......... .......... ... [159] 
Bj-AB073858_GB   .........T A......... ... [159] 
B1-AB073852_GB   D........T .........V ... [159] 
B2-AB073830_GB   .......... .......... ... [159] 
B3-D00331_GB     .......... .......... ... [159] 
B4-AB100695_GB   .......... .......... ... [159] 
B-N17_UK         .......... ........-- --- [159] 
B-N9_UK          .......... ....------ --- [159] 
B-N39_UK         .......... ......---- --- [159] 
B-N50_UK         .......... .....----- --- [159] 
B-N47_UK         .......... .....----- --- [159] 
B-N46_UK         .......... .....----- --- [159] 
B-N18-UK         ---------- ---------- --- [159] 
C-X01587adr4_GB  .......... .......... ... [159] 
C1Cs-AB111946_GB .........T .....I.... ... [159] 
C2Ce-AF533983_GB .......... .........V ... [159] 
C3-X75656_GB     .......... .........V ... [159] 
C4ausAB048704_GB .......... .......... ... [159] 
C-N3_UK          .......... ........-- --- [159] 
C-N19_UK         .......... .....----- --- [159] 
C-N45_UK         .......... ........-- --- [159] 
C-7.48_SA        ---------- ---------- --- [159] 
D-7.80_SA        D....S.... A.......S- --- [159] 
D-3.34_SA        D..R.....T ....TF..-- --- [159] 
D-N22_UK         .......... .........Y --- [159] 
D-3.12_SA        .......... ........-- --- [159] 
D-3.7_SA         ..*....... ........-- --- [159] 
D-1.205_SA       ..*....... ........-- --- [159] 
D-2.11_SA        .......... ........-- --- [159] 
D-3.3_SA         .T........ ........-- --- [159] 
D-3.1_SA         .......... ........-- --- [159] 
D-3.43_SA        ........W. ........-- --- [159] 
D-4.27_SA        .......... ........-- --- [159] 
D-109_SA         .......... ........-- --- [159] 
D-1.46_SA        .......... ........-- --- [159] 
D-3.18_SA        .......... ........-- --- [159] 
D-3.8_SA         .......... ........-- --- [159] 
D-4.7_SA         Q......... ........-- --- [159] 
D-4.23_SA        .......... ....------ --- [159] 
D-4.13_SA        D......... ....------ --- [159] 
D-4.3_SA         D....S.... ....------ --- [159] 
D-4-22_SA        .......... .PR.------ --- [159] 
D-4.2_SA         .......... ....------ --- [159] 
D-1.50_SA        .......... ....------ --- [159] 
D-4.15_SA        .......... ........-- --- [159] 
D-4.21_SA        .........T .......--- --- [159] 
D-X02496_GB      .......... .......... ... [159] 
D-X65257_GB      D......... .......... ... [159] 
D1-AY161157_GB   .......... .......... ... [159] 
D2-X80925_GB     D......... .......... ... [159] 
D3-X85254_GB     .........T .......... ... [159] 
D4-AB048702_GB   D......... .......... ... [159] 
D-7.84_SA        .......... ........-. --- [159] 
D-3.26_SA        .......... ........-- --- [159] 
D-3.36_SA        .......... --......-- --- [159] 
D-1.55_SA        .......... ........-- --- [159] 
DA-1.56_SA       .......... ........-- --- [159] 
D-2.12_SA        .......... .......... ... [159] 
D-3.32_SA        .......... ........-- --- [159] 
D-3.5_SA         .......... ........-- --- [159] 
D-3.29_SA        .......... ........-- --- [159] 
D-1.106_SA       .......... ........-- --- [159] 
D-3.9_SA         .......... ........-- --- [159] 
Appendix 
241 
D-3.39_SA        .......... ........-- --- [159] 
D-1.60_SA        .......... ........-- --- [159] 
D-1.49_SA        .......... ........-- --- [159] 
D-LEIC_UK        .......... .......... ... [159] 
D-4-1_SA         .......... .......... ... [159] 
D-p15R_UK        .......... .........E FHH [159] 
D1.48_SA         .......... ........-- --- [159] 
D-1.78_SA        .......... ........-- --- [159] 
D-3.19_SA        D......... ........-- --- [159] 
D-1.2_SA         .......... ........-- --- [159] 
D-1.4_SA         .......... ........-- --- [159] 
D-N12_UK         ---------- ---------- --- [159] 
D-N6_UK          ---------- ---------- --- [159] 
D-118_SA         ---------- ---------- --- [159] 
D-3.35_SA        ---------- ---------- --- [159] 
D-7.59_SA        ---------- ---------- --- [159] 
D-7.86_SA        ---------- ---------- --- [159] 
D-7.40_SA        ---------- ---------- --- [159] 
D-7.5_SA         ---------- ---------- --- [159] 
D-4.19_SA        ---------- ---------- --- [159] 
D-3.6_SA         ---------- ---------- --- [159] 
E-X75664_GB      D......... .......... ... [159] 
E-X75657_GB      D......... .......... ... [159] 
E-2.25_SA        D......... ---------- --- [159] 
E-4.10_SA        D......... ....D.---- --- [159] 
F-X75658_GB      D........T .N........ ... [159] 
H-AY090457_GB    D........T .N...----- --- [159] 
*:HBeAg stop codon 
T-cell Epitopes               
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HBV Basal Core Promoter/Precore 
nt. 1762          1896     
                 AGGTCTT       GGGGC ATG  
A1-AY161140_GB   A.G....       .... 
A2-S50225_GB     T.A....       .A..  
AeurpeV00866_GB  T.A....       .... 
AaAF297625_GB    A.G....       ....  
A-N13_UK         T.A....       ....  
A-3.47_SA        T.AC...       ....  
A-N44_UK         A.G....       ....  
A-N33_UK         A.A.T..       ....  
A-N41_UK         T.G.T..       ....  
A-N4_UK          A.T.T.A       ....  
A-N15_UK         T.A.T.A       A...  
A-N49_UK         A.A....       ....  
A-N14_UK         T.A.T..       ....  
Ba-D00330adw2_GB A.G....       .... 
Bj-AB073858_GB   A.A.T.A       A... 
B1-AB073852_GB   T.A....       A..A 
B2-AB073830_GB   A.G....       A... 
B3-D00331_GB     A.G....       .... 
B4-AB100695_GB   T.A....       ....  
B-N17_UK         T.A....       ....   
B-N9_UK          T.A....       ....  
B-N39_UK         A.G....       .... 
B-N50_UK         A.G....       .... 
B-N47_UK         A.G....       A... 
B-N46_UK         A.G....       A... 
B-N18-UK         A.G....       .... 
C1Cs-AB112348_GB A.G....       .... 
C2Ce-AY123041_GB A.G....       .... 
C3-X75656_GB     A.G....       .... 
C4aus-AB048704_GBA.G....       A..A 
C-7.48_SA        A.G....       .... 
C-N19_UK         A.G....       .... 
C-N3_UK          A.G....       .... 
C-N45_UK         A.G....       ..A. 
D1-AY161157_GB   A.G....       .... 
D2-X80925_GB     A.G....       .... 
D3-X85254_GB     A.G....       A... 
D4-AB048702_GB   A.G....       .... 
D-7.80_SA        T.A....       A..A 
D-N22_UK         A.G....       A..A 
D-4.27_SA        G.T.G..       A... 
D-109_SA         G.T.G..       A... 
D-4.23_SA        A.A.G..       .... 
D-4.13_SA        A.C.G..       A... 
D-4.3_SA         A.G....       A... 
D-4-22_SA        A.A....       A..A 
D-4.2_SA         T.G.T.A       ...A 
D-1.50_SA        T.A....       A..A 
D-4.15_SA        A.T.G..       A..A 
D-4.21_SA        A.G....       A... 
D-7.84_SA        A.G....       .... 
D-LEIC_UK        A.G....       .... 
D-4-1_SA         A.G....       .... 
D-p15R_UK        A.G....       .... 
D-N12_UK         A.G....             
D-N6_UK          A.G....       .... 
D-118_SA         T.G.T.A       A... 
D-3.35_SA        T.G.T.A               
D-7.59_SA        A.G.T.A       ..C. 
D-7.86_SA        T.A....       ...A 
D-7.40_SA        A.G....       A... 
D-7.5_SA         T.A....       A..A 
D-4.19_SA        T.G.T.A       A... 
D-3.6_SA         T.G.T.A       A... 
D-2.12_SA        ***....       .... 
D-3.34_SA                      A..A 
D-3.12_SA                      A..A 
D-3.7_SA                       A..A 
D-1.205_SA                     A..A 
D-2.11_SA                      A..A 
D-3.3_SA                       A..A 
D-3.1_SA                       A..A 
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D-3.43_SA                      A..A 
D-1.46_SA                      A... 
D-3.18_SA                      A... 
D-3.8_SA                       A... 
D-4.7_SA                       A... 
D-3.26_SA                      .... 
D-3.36_SA                      .... 
D-1.55_SA                      .... 
DA-1.56_SA                     .... 
D-3.32_SA                      .... 
D-3.5_SA                       ....  
D-3.29_SA                      ...A 
D-1.106_SA                     A..A 
D-3.9_SA                       ...A 
D-3.39_SA                      ...A 
D-1.60_SA                      ...A 
D-1.49_SA                      ...A 
D-1.48_SA                      .... 
D-1.78_SA                      A..A 
D-3.19_SA                      .... 
D-1.2_SA                       .... 
D-1.4_SA                       .... 
E-X75664_GB      A.G....       .... 
E-2.25_SA        T.A...A       A... 
E-4.10_SA        T.A....       A... 
F-X75658_GB      A.G....       .... 
H-AY090457_GB    A.G....       ....  
G-AF160501_GB    T.AC...       A... 
 
 
 
